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This figure illustrates the patent count by assignee for the patent landscape for DNA HIV 
vaccines. The top assignees include Merck, Chiron and SmithKline Beecham. 
 






















This figure illustrates the patent count by inventor for the patent landscape for DNA HIV 
vaccines. The top inventors include Shiver, Barnett and Ertl. 
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Value Added Features 
 
This Report enhances previous Pierce Law Patent Landscape Reports Series by adding 
innovative capacity building features including: 
 
1. Greater in depth technical expert-based needs assessment (open and frequent 
communication with Dr. Kerri Clark of PIPRA) from the outset of the project, in light of 
the tight project schedule, complexity of the subject and the projected used of the data as 
a Web based publically accessible HIV Vaccine Database.  
2. Sub-categorization of patent documents in the Master Spreadsheet to facilitate future 
indexing in the Web based publically accessible HIV Vaccine Database. 
3. Utilization of HIV DNA clinical trials resources to identify key non-patent literature 
leading to top inventors and assignees. 
4. Greater utilization of the Derwent World Patent Index classification system and re-
written titles and abstracts due to the obfuscation of HIV-related nomenclature in patent 
documents.  
5. Greater utilization of key inventors and assignees to yield most relevant classifications 
used in hybrid searches (e.g., combining classification codes with keywords for powerful 
coordinated search strategies). 
6. Introduced use of new patent analytic tools (e.g. IPVisions that enables building and 
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1 
 
 The project is to provide a patent literature landscape of DNA Vaccines against HIV. As 
a first step, generally, recombinant DNAs (rDNA) based on the genes from various strains of 
HIV are generated within the context of other DNAs commonly employed in vaccine 
development, and used as a vaccine by a direct administration to a host, where the injected 
DNAs are expressed and eventually produce antibodies against HIV.  The DNA vaccines are 
often optimized at the DNA sequence level or may require the use of a special delivery system 
for better efficacy as a vaccine. 
                                                 
1 3dscience: HIV, http://www.3dscience.com/3D_Images/Biology (last visited April 16, 2008); PatentDocs: DNA, 
http://patentdocs.typepad.com/patent_docs/2007/05/implications_of.html (last visited April 16, 2008); Australian 
Motor Neuron Disease DNA Bank: Antibody: http://www.dnamnd.med.usyd.edu.au/ (last visited April 16, 2008). 
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SEARCH SUMMARY 
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DISCLAIMER 
 
 This is an educational report and is neither inclusive nor comprehensive.  Rather, it is an 
informational resource to facilitate a better understanding of the international patent literature 
landscape with regard to DNA vaccines for HIV. 
 
 This report is not a list of all potentially relevant patent documents.  It is not a Freedom to 
Operate (FTO) opinion.  Furthermore, this report does not reach the level of a FTO analysis, but 
instead constitutes an educational presentation of potentially relevant information. 
 
 While the search engines utilized in this project are extensive, it is likely that the entire 
spectrum of patent documents was not obtained utilizing the various search strategies and 
methods articulated herein.  Therefore, it is not the supposition of this team that all relevant 
patent documents were discovered during the creation of this report. 
 
 As the team members are not experts in the field of DNA vaccines for HIV, it is also 
highly possible that the categorization of the patent documents found, coded and compiled are 
incomplete.  The team cannot guarantee that these patent documents were evaluated at the level 
of expert scientific sophistication. 
 
 Due to the limited time frame imposed upon this project, the number of patent documents 
evaluated was established by this constrained schedule, the overall semestrial demands, and the 
general press of business.  As such, additional patents may have been available for evaluation, 
but without the necessary time, they may not have been considered. 
 
 Again, this report should not be viewed as FTO analysis but is instead constitutes an 
educational report. 
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1. Overview of Immunology2 
 
 Immunity is the body’s biological defense against disease, infection and biological 
invasions or abnormalities.  The two mechanisms of immunity are termed nonspecific, innate 
immunity and specific, acquired immunity.  While these two mechanisms can work together to 
eliminate or prevent infectious organisms, each has its own method of accomplishing this goal.  
A specific immune response works to stop particular types of organisms; whereas, nonspecific 
protection repels all organisms in the same way. 
 
1.A. Nonspecific, Innate Immunity 
 
 Nonspecific, Innate Immunity works to provide protection through various defense 
mechanisms such as chemical barriers (i.e. antimicrobial proteins that eliminate or damage 
invaders), physical barriers (i.e. epidermis, mucous membrane linings of the respiratory, 
gastrointestinal and genitourinary tracts), and specific cells (i.e. cells which attack unfamiliar 
cells and body cells containing infectious organisms).  Each of these defense mechanisms 
operates in a specific manner to provide protection to the body. 
 
1.A.1 Barriers 
1.A.1.a. Physical Barriers 
 
 The body’s physical barriers are the first step in its defense against infectious organisms 
(refer to Figure 2 for an illustration of the body’s physical barriers).  The skin, for example, is 
constantly being shed and renewed in a process that serves as a mechanical defense to infection.  
Additionally, the skin can secrete certain disease destroying substances such as an oily matter 
containing oleic acid which can destroy some bacteria and lysozyme which can cause the outer 
wall of certain bacteria to deteriorate.  The mucus membrane linings of the respiratory, 
gastrointestinal, and genitourinary tracts also provide an example of physical barriers against 
infectious organisms.  Like the skin, these linings provide a mechanical defense against disease 
as they are constantly being renewed.  Additionally, the linings have various other mechanisms 
harmful to infectious organisms: secretion of phlegm by the respiratory tract which traps small 
particles; cilia in the respiratory tract which forces mucus and any ensnared particles up and out 
of the nose and throat; secretion of mucus by the gastrointestinal tract which ensnare potentially 
infectious particles or prevent them from connecting to cells comprising the lining of the gut; 
secretion by the gastrointestinal tract of protective antibodies; and the stomach’s secretion of 
hydrochloric acid potent enough to kill many microorganisms. 
 
1.A.1.b. Chemical Barriers 
 
 The body’s next defense against infectious organisms is the chemical barriers contained 
within it.  If the body’s physical defenses are unable to subdue the foreign particles, it is then up 
to the chemical substances to prevent their growth.  The protective chemical substances are 
chemicals whose primary duty is to damage or eliminate infections organisms, chemicals formed 
by naturally occurring bacteria, and chemicals whose shielding effect comes second to their main 
role in the body.  Chemicals whose protective duty is second to their primary function include: 
                                                 
2 The New Encyclopædia Britannica 773–88. (Chicago Encyclopaedia Britannica) (2005). 
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chemicals which hinder the harmful digestive enzymes freed from body cells that have died in 
the natural course of events and can hinder similar enzymes produced by bacteria thus inhibiting 
bacterial growth; and blood protein transferrin which when bound to the infectious organism 
prevents it from obtaining the necessary iron to grow thus stunting the growth of the organism. 
 
 Proteins are another substance which can contribute to the chemical defense system (refer 
to Figure 2 for an illustration of proteins in chemical defense system).  One example of such 
defensive proteins is, as mentioned above, interferons.  This protein group seeks to inhibit the 
replication of a large number of, though not all, viruses.  Virus-infected cells produce interferon 
which signals other cells to prevent viral growth.  Interferon seeks to accomplish this goal by 
“interfering with the transcription of viral nucleic acid,” regulating the degree to which cells 
express certain molecules on their surface membranes, and stimulating the activity of natural 
killer cells.  Different cells produce different types of interferon.  For example, lymphocytes, 
produce gamma interferon, leucocytes produce alpha interferon and fibroblasts produce beta 
interferon. Another example of defensive proteins is called complement which works in 
conjunction with other defense mechanisms in the body to help eliminate infectious organisms. 
Complement proteins operate with other cells to lyse harmful organisms which lack a protective 
coating.   
 
1.A.1.c. Cellular Barriers 
 
 If an infectious organism evades detection and destruction from the physical and 
chemical barriers, the body’s next defense against infectious organisms is cellular (refer to 
Figure 2 for an illustration of the body’s cellular barriers).  These defensive cells include 
scavenger cells and natural killer cells.  Natural killer (NK) cells indirectly attack body cells 
which contain infectious organisms.  These cells consist of granules which contain cytotoxic 
chemicals.  The NK cells attack infectious cells by binding to the infectious cell, inserting its 
granules through the cells’ outer membrane and into the cytoplasm.  The end result of this attack 
is the cells’ death.  Scavenger cells, on the other hand, attack the infectious cells directly.  The 
two main types of scavenger cells are macrophages and microphages.  Macrophages are the 
mature form of a monocyte which is created by stem cells in the bone marrow and travel through 
the blood.  Monocytes become macrophages upon differentiation.  Macrophages identify and 
consume infectious cells in a slow and incomplete method.  The second category of scavenger 
cells is microphages which can be referred to as polymorphonuclear leukoctyes or granulocytes.  
Granulocytes are continuously being produced from precursor cells in the bone marrow.  
Microphages can be grouped into three categories according to shape and dye stain.   These 
categories are neutrophils, eosinophils, and basophils (refer to Figure 1 for a illustration of the 
differences between these three categories).  These cells may have granules storing digestive 
enzymes which are able to break down proteins or bacteriocidal compounds which  kill bacteria.  
The drawbacks to granulocytes, however, are that many organisms produce toxins poisonous to 
the granulocytes and thus evade destruction.  Other infectious cells avoid death by the simple 
fact that granulocytes are unable to digest them.  
   9 
 
Figure 1:  Illustration of the Differences between Eosinophil, Basophil and Neutrophil3 
 
1.A.2 Additional Responses to Infection 
 
 In addition to protective barriers formed by the body to combat infectious organisms, 
there are also a number of nonspecific means of fighting infection termed early induced 
responses (refer to Figure 2 for an illustration of the body’s additional responses to infection).  
These responses seek to either stall or eliminate the infection and include the inflammatory 
response and acute-phase response.  The effect of these responses may not be long-term but they 
do happen in a rapid manner as compared to acquired immune responses.  These responses are 
effectuated by chemical signals called cytokines which induce fever, acute-phase response and 
inflammatory response.  The acute-phase response is a general innate defense method of the 
body which initiates the increased temperature in the body (i.e. fever).  Since most bacteria 
survive at a lower than normal body temperature, this increased temperature is effective in 
eliminating those bacteria.  In addition to fever, acute-phase proteins are secreted by the liver to 
bind to the infectious organism and thus, trigger complement proteins which eliminate the 
bacteria. 
                                                 
3 Sportron Info, http://www.sportron.info/english/health_issues/images/immune_system.jpg (last visited April 2, 
2008). 
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Figure 2: Synopsis of Non-specific, Innate Immunity4 
 
1.B. Specific, Acquired Immunity 
 
 The concept of specific, acquired immunity, also known as adaptive immunity, arose 
from the knowledge that people who have survived certain infections do not contract such 
diseases again.  This immunity is strictly dependent upon lymphocytes, specialized white blood 
cells.  The defenses acquired by contracting such an infection are specific to that disease.  Many 
diseases, however, seem to contradict the notion of acquired immunity.  Such infections as the 
common cold do not bar a person once infected from becoming infected again.  However, the 
key is this situation is to understand that there are many infectious organisms that cause the 
symptoms of the common cold.  As such, even though infection with a certain organism does 
prevent re-infection with that same organism, it does not prevent infection by a different 
organism which may cause the same symptoms. 
 
 As is mentioned above, adaptive immunity relies upon lymphocytes.  These cells are 
responsible for the body’s capacity to react and identify any number of unknown organisms.  
Lymphocytes remain dormant until called to action.  There are over 2 trillion lymphocytes in the 
body of an adult human with only a small fraction of that number found in the bloodstream.  The 
                                                 
4 Indian River Community College, http://faculty.ircc.edu/faculty/tfischer/images/non%20specific%20defenses%20 
summary.jpg (last visited April 2, 2008). 
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rest of these cells are located throughout the body’s lymphatic system.  Organs or tissues 
containing large qualities of lymphocytes are termed lymphoid.  These lymphocytes are 
restricted in movement to the lymph capillaries located in connective tissues which guide the 
lymphocytes into contact with other cells (i.e. macrophages). 
 
1.B.1. T cells and B cells 
 
 Lymphocytes are created from stem cells in the bone marrow and continue to divide.  
This division causes the release of immature lymphocytes into the blood stream where they can 
travel to various organs.  Those immature lymphocytes which travel to the thymus to multiply 
and divide are termed T cells.  Upon leaving the thymus, these mature T cells continue to 
multiply and divide as they circulate through the bloodstream to other lymphoid organs.  The 
second type of lymphocytes is termed a B cell.  B cells are lymphocytes which remain in the 
bone marrow during differentiation and then travel directly to the lymphoid organs.  B and T 
cells each perform separate functions to identify and destroy unknown particles.  T cells directly 
attack the infectious organisms.  This type of immunity is termed cell-mediated immunity.  T 
cells can only identify infectious organisms which have entered body cells.  On the other hand, B 
cells secrete antibodies.  This type of immunity is termed humoral immunity.  B cells, with their  
antibody secretion, only attack cells which remain outside the cells of the body. 
 
 One of the important features of lymphocytes is their ability to identify unknown 
particles within the body.  Receptor molecules are located on the surface of the lymphocyte or 
secreted into fluids of the body.  These receptor molecules are responsible for the ability of 
lymphocytes to recognize foreign particles.  The shape of a receptor molecule complements a 
specific foreign molecule which allows the receptor and foreign molecule to fit together.  While 
both B and T cells have receptor molecules, only B cells produce antibodies which are 
unattached receptor molecules.  Foreign molecules that attach to these receptor sights are termed 
antigens.  Antigens include a wide range of molecules such as bacteria, viruses, fungi, dust, 
pollen, transplanted tissue and protozoans.  When the binding of an antigen to a receptor 
molecule elicits an immune response, the response is termed an immunogen. 
 
1.B.2. T cells 
 There are two main types of mature T cells: cytotoxic and helper T cells.  Cytotoxic T 
cells eliminate cells which present a threat to the individual (i.e. cells with infectious 
microorganisms and cancer cells) and primarily recognize target cells containing antigens 
associated with class I MHC molecules (molecules which are present on the surface of most 
body cells with nuclei). Helper T cells, on the other hand, activate other white bloods cells (i.e. 
lymphocytes and macrophages) and recognize unknown antigens associated with class II MHC 
molecules (molecules which are limited to the surfaces of most B cells and some T cells, 
macrophages, and macrophage-like particles).  Also, T cells have a co-receptor location on their 
surface to which the MHC molecule bind to provide added support to the bonding between T cell 
and foreign molecule.  This co-receptor location is termed CD4 for helper T cells which bind 
class II MHC molecules and CD8 for cytotoxic T cells which bind class I MHC molecules. 
 
 In addition, T cells can be divided into two subcategories, TH1 and TH2.  TH2 cells’ 
primary duty is to synthesize interleukins IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13 and aid in the 
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production of antibodies by stimulation of the B cells.  TH1 cells’ primary duty is to produce 
tumour necrosis factor-beta, interleukins (IL-2), and cytokines gamma interferon and to stimulate 
macrophages and cytotoxic T cells. 
 
1.C. Immunization through Specific Immunity 
 
 Immunization through specific immunity can be divided into two types, active and 
passive immunization.  Passive immunization refers to the transfer of preformed antibodies or 
lymphocytes from an individual whose immune system has been stimulated by the particular 
antigens.  This type of immunization is very effective in situations where a person’s immune 
system is unable to respond quickly enough to fight the infection.  Examples of situations such as 
this include snake bits, botulism and tetanus.  Active immunization, on the other hand, refers to 
the immunity protection conferred by a vaccine which stimulates the immune system to fight 
infection by production of antibodies and lymphocytes.  Vaccination seeks to front load the 
victim with a supply of antibodies or T and B cells which fight whatever infectious organism is 
encountered before infection occurs or upon interaction with the infectious organism.  The 
primary component of a vaccine is a sufficient amount and persistence of antigens to produce an 
immune response analogous to the natural infection.  Killed vaccines (vaccines which comprise 
an entire microbe which has been killed without altering it significantly) have been effective in 
situations such as influenza, typhoid, and the plague.  Attenuated vaccines (vaccines which 
comprise a weakened strain of bacteria or virus) may cause a number of symptoms of the disease 
it is seeking to eliminate; however, the introduced infectious organism never becomes virulent.  
This type of vaccine has been useful against yellow fever, measles and tuberculosis. 
 
2. HIV Overview 
 
2.A. HIV Biology 
 
 HIV/AIDS is a pandemic. The figures are overwhelming.  As of 2006, 39.5 million 
people worldwide are estimated to live with HIV.5  The World Health Organizaton (WHO) 
projects that worldwide deaths from HIV will rise from 2.8 million in 2002 to 6.5 million in 
2030 and be among the 4 top causes of death in 2030.6  Since its identification in 1981, AIDS 
has claimed the lives of more than 25 million people.7 
 
 Human Immunodeficiency Virus (HIV) adversely affects the immune system of the host 
it infects by specifically infecting cells expressing CD4 molecules which are found in immune 
cells for both cellular and innate immunity – T cells and macrophages, respectively.8 
 
 HIV belongs to a group of viruses called retrovirus and a subgroup called lentiviruses, or 
“slow” viruses.  It contains 2 copies of single stranded (+) RNA as a genome from which it 
synthesizes DNA, and then the DNA gets integrated into the host genome, becoming part of the 
                                                 
5 WORLD HEALTH STATISTICS 11 (2007), available at  http://www.who.int/whosis/en/index.html. 
6 Id. at 12. 
7 HIV/AIDS Factssheets Introduction, http://oversight.house.gov/features/hivaids (last visited April 17, 2008). 
8 National Institute of Allergy and Infectious Diseases, How HIV cause AIDS, available at 
http://www.niaid.nih.gov/factsheets/howhiv.htm (last visited April 22, 2008). 
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host system.  This is exactly the reverse of normal cellular process, which is reflected in part of 
its name “retro~.”  Another very notable feature of HIV is that it is highly error prone when 
replicating, i.e., synthesizing a DNA copy of its RNA genome and therefore highly 
mutagenic/variable.  This leads to high strain variability among different hosts and regions, and 
even within an infected host.   
 
2.B. HIV Phylogeny 
 
 The HIV strains may be classified into types, groups and subtypes based on its genetic 
makeup.9  There are two types of HIV: HIV-1 and HIV-2.  Despite their divergent genetic 
sequences, they share many similar characteristics including mode of transmission (by sexual 
contact, through blood and from mother to child) and clinically indistinguishable symptoms– 
AIDS.  However, HIV-2 is less infective, particularly early in the course of disease.  Thus, it is 
less easily transmitted and the latent period is longer than HIV-1.  Geographically, HIV-2 is 
rarely found except in West Africa and the predominant type is HIV-1.10 
 
 HIV-1 strains are further classified into three groups based on the envelope gene: M 
(major), N (new) and O (outlier) (see Figure 3).  M group is most prevalent and responsible for 
more than 90% of reported HIV/AIDS cases, while O and N groups are found very rarely.  
Group M is further divided into 9 distinct subtypes (or clades) based on HIV’s whole genome: A, 
B, C, D, F, G, H, J and K.  Each subtype is geographically distinct (see Figure 4).  Group N and 
O also have subtypes; however, they do not give distinct clades like group M group using a 
similar method to the M group.  Intersubtype recombinants known as "circulating recombinant 
forms" or “CRFs”– new hybrid viruses created by a genetic recombination of different subtypes- 
have also been identified.11 
                                                 
9 Avert, http://www.avert.org/hivtypes.htm (last visited April 3, 2008). 
10 Centers for Disease Control and Prevention, CDC Fact sheet HIV Type 2, available at 
http://www.cdc.gov/hiv/resources/Factsheets/hiv2.htm (last visited April 22, 2008). 
11 Marcia L. Kalish et al., Recombinant Viruses and Early Global HIV-1 Epidemic  available at 
http://www.cdc.gov/ncidod/eid/vol10no7/03-0904.htm ( last visited April 22, 2008).  See Avert, supra note 9. 
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Figure 3: Phylogeny of HIV12 
 
 
Figure 4: Geographic spread of HIV-1 Group M subtypes13 
                                                 
12 Luigi Buonaguro et al., Genetic and Phylogenetic Evolution of HIV-1 in a Low Subtype Heterogeneity Epidemic: 
the Italian Example, 4 Retrovirology 34 (2007), available at http://www.retrovirology.com/content/pdf/1742-4690-
4-34.pdf. 
13 Shalom Spira et al., Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug 
resistance, 51 J. ANTIMICROBIAL CHEMOTHERAPY 229–240 (2003), available at http://jac.oxfordjournals.org/cgi/ 
content/full/51/2/229?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=prevalence&searchid=1&F
IRSTINDEX=0&volume=51&issue=2&resourcetype=HWCIT. 
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2.C. HIV Anatomy14 
 
 HIV is spherical in shape having a diameter of about 0.1 μM, and can be divided into two 
structural parts: viral membrane (envelope) and viral core (see Figure. 5).  The viral envelope is 
the outer coat of HIV enclosing viral particles.  The envelope originated from the membrane of a 
human cell which HIV infects and later buds off from.  In addition to proteins from the host 
cells, embedded in the envelope are complex HIV glycoproteins called Env, glycoprotein 
(gp)160 or “spikes.”  The spikes consist of a cap made up of three molecules called gp120, and a 
stem made up of three gp41 molecules that function as an anchor.  It is involved in the entry of 
HIV into a cell by binding and membrane fusion of the virus particle to the cell.  Thus, the 
envelope proteins have been the major focus of much of the research to develop a vaccine 
against HIV.  
 
 Encompassed by the viral envelope is the matrix, made up of the viral protein p17, and 
the viral core or capsid, made up of the viral protein p24.  Inside the viral core are 2 exact copies 
of viral RNA and viral enzymes which are required for HIV replication- reverse transcriptase, 
protease and integrase. 
 
 
Figure 5: The structure of a HIV virion.15 
 
                                                 
14 See HIV/AIDS Factssheets Introduction: How HIV cause AIDS, supra note 7. 
15 Teen Aids-PeerCorps, http://www.teenaids.org/Portals/0/Images/whatIsAIDS-pic3.gif  (last visited April 16, 
2008). 
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2.D. HIV Genes16 
 
 HIV’s RNA genome is 9 kilobases in length which contains 9 genes encoding 15 
different proteins and a control sequence called long terminal repeat (LTR) at both ends of each 
genome, which are involved in the HIV replication (Figure 6).  The HIV genes are divided into 3 
groups based on their functions–structural, regulatory, and accessory genes.  Three of the genes 
called gag, pol and env belong to the structural group; the genes called tat, rev and nef belong to 
the regulatory group; the vpr, vif and vpu genes belong to the accessory group.  The structural 
genes encode proteins for making new virus particles, which have been the major target in the 
HIV vaccine development.  The latter two groups of genes are involved in the control of various 
aspects of HIV life cycle from the ability of HIV to infect a cell, replication inside a cell or 
causing disease. 
 
 Specifically, the pol gene encodes several different proteins, reverse transciptase, 
protease, RNAseH and Integrase. The gag encodes viral capsid proteins, p27-capsid, p17-matrix 
protein, p7-nucleocapsid, and p6, which are the building blocks for the viral core. The env 
encodes envelope protein gp160. The tat encodes TAT protein essential for HIV replication of its 
genome. The nef encodes a regulatory protein that directs the host cells when to make RNA 
copies from the integrated HIV DNA to produce viral RNA. The rev encodes a regulatory 
protein which promotes the production of viral proteins. The vpr encodes VPR protein which 




Figure 6: HIV Genes and their Products17 
                                                 
16 See HIV/AIDS Factssheets Introduction: How HIV cause AIDS, supra note 7. 
17 Stanford University- Human Virology, http://www.stanford.edu/group/virus/retro/2005gongishmail/HIV-1b.jpg 
(last visited April 16, 2008). 
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2.E. Vaccines to HIV18 
 
 Scientists have been struggling to develop a vaccine against HIV since the first 
identification of HIV and its etiologic role in AIDS more than two decades ago.  Currently, no 
vaccines have been produced that can produce sterile immunity.  The biology of HIV infection 
poses the unique problems for vaccine development. 
 
 First, HIV is highly variable/mutagenic.  It has a very high error rate when replicating 
viral genome coupled with a high replication rate (~109 – 1010 virions per day) results in many 
variants of the initial infecting HIV within a host.  
 
 Second, HIV infects immune cells central to the immune system, CD4+ cells and 
macrophages and thus, depletes them.  
 
 Third is the latency. HIV infects the CD4+ cells of a host; however, HIV only can 
replicate when the CD4+ cells become activated to divide to produce more T cell clones.  Until 
then, the HIV is essentially invisible to the immune system and thus, this pool of latently infected 
CD4+ T cells is never cleared even with antiretroviarl treatment.  
 
 Thus, an ideal HIV vaccine would need 1) to induce a sterilizing immunity including 
neutralizing antiboides and mucosal immunity to prevent infection and cyottoxic T cells to clear 
virus that has evaded the antibody, 2) to prevent infection of CD4+ cells, 3) to be cross reactive 
with all groups or clades in a group at a minimum, 4) to have a low cost for production and 
vaccination; to be safe and tolerable, 5) and to be easy to administer.  
 
3. HIV Vaccines 
 
 Several types of vaccines against HIV have been developed during the past three decades 
including live vector based vaccines, glycoprotein vaccine, peptide vaccines and DNA vaccine.  
HIV vaccines have been tested in man since late 1980.19  The earliest approach of HIV vaccine is 
attenuated live virus vaccine, such as vaccinia virus or poxvirus vaccine. 
 
 The vaccinia virus vaccines induced HIV-specific CD4+ T-cell responses.  Weak CD8+ 
CTL responses could also be generated when using a prime-boost combination of vaccinia virus 
and recombinant gp120 vaccines.  However, the viruses caused serious diseases in healthy 
testers; thereafter, the replication-competent vaccinia vectors have been replaced by replication-
deficient vectors because of safety concerns.  These replication-deficient vectors have been 
evaluated in human trials but no positive results have occurred. For example, a research plan for 
a prime/boost vaccine approach of canarypox vector priming and gp120 boosting was performed 
by HIV Vaccine Trials Network (HVTN) during year 2001 and 2002.  HVTN later decided to 
abandon its phase III trial and further study because the result showed that this kind of vaccine 
plan did not generate a high level of CD8+ T cell response.20 
                                                 
18 See HIV/AIDS Factssheets Introduction, supra note 7. 
19 Paul Spearman, Current Progress in the Development of HIV Vaccines, 12 CURRENT PHARMACEUTICAL DESIGN 
1149 (2006). 
20 Id.  
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 More studies on live vector-based vaccines continue.  The scientists never give up this 
approach because live vectors can generate strong and long-lived cellular immune responses.  
However, we have to consider the balance between virus safety and the capacity to generate 
immune response.  Wildtype viruses are no longer acceptable.  Most of these live vector 
approaches are highly attenuated or are viral vector systems that are competent for only a single 
round of infection in the host. 
 
 There are several types of live vector-based HIV vaccines used in current human trials 
including adenovirus vaccine, poxvirus vaccine, alphavirus vector vaccine, adeno-associated 
virus (AAV), vesicular stomatitis virus (VSU)- based HIV vaccine and poliovirus vector vaccine. 
None of these report good results as yet. The adenovirus vaccine is the leading CTL vaccine 
candidate.  It can produce potent cellular immune response but it won’t work for people already 
immunized from it.  Almost one-third of North American volunteers have preexisting immunity 
for adenovirus.21  The other live vector vaccines have common problems of high production cost, 
low stability and limited serotypes.  
 
 The current HIV vaccine approaches include DNA, peptide and glycoprotein vaccines.  
Usually these vaccines are not used in isolation; they instead would be arranged in a prime/boost 
regime such as DNA prime and protein boost.22  The primarily goal for these vaccine approaches 
is to elicit HIV-specific CD8+ CTL responses and to generate a population of supportive HIV-
specific CD4+ T cells.  
 
 Monomeric gp120-based vaccine was another form HIV vaccine in the early study. This 
vaccine was safe and could generate neutralizing antibodies to gp120.  However, this kind of 
vaccine behaved differently for laboratory-adapted HIV isolates and naturally occurring HIV 
isolates.  Results of two phase III trials showed that this approach did not produce relevant 
antibodies in human subjects.  Scientists then stopped pursing this approach. 
 
 More studies show that the monomeric gp-120-based vaccine would fail because the 
native structure of HIV envelope glycoprotein is in a trimeric conformation.  The new approach 
of glycoprotein vaccine is to generate neutralizing antibodies against HIV virus by using the 
glycoprotein which maintains its native conformation of the trimeric complex.  See Figure 7. 
 
                                                 
21 Id. at 1157. 
22 Id. at 1154. 
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Figure 7: Trimeric Conformation of the HIV gp120 Envelop Glycoprotein23 
 
 As of yet, no positive results occurred for the trimer glycoprotein approach.  One 
approach using an oligomeric gp140 vaccine is being investigated at Chiron.  Progenics 
Pharmaceuticals and Cornell University are also pursuing a disulfide-stabilized, modified 
trimeric protein vaccine.  
 
 The other two HIV vaccine approaches are DNA vaccine and peptide vaccine.  These two 
approaches share several common characteristics: they all have great potential, they have 
achieved good results in animal trials and all are safe in human trials.  However, studies so far 
have reported that these approaches only generate weak immune response in humans.  
 
 DNA vaccines use a plasmid DNA vector to generate HIV proteins or protein subunits 
within host cells.24  The HIV proteins are antigens and induce immunization response against the 
HIV virus.  The first step of DNA vaccine is to allow the plasmid DNA vector being taken up by 
host cells.  This might be procured by simply intramuscular injection.  However, there will not 
be enough antigens if the cellular uptake is inefficient.  Ways to improve the cellular uptake 
include the use of gene guns, formulation into micro-particles and the use of adjuvants that may 
increase uptake by antigen presenting cells (APCs).25  Some data shows DNA vaccines for HIV 
can generate cellular and humoral immune responses.  Several reports indicated DNA vaccines 
                                                 
23 National Institute of Allergy and Infectious Diseases: How HIV causes AIDS, available at 
http://www.niaid.nih.gov/factsheets/howhiv.htm.  
24 See Spearman, supra note 18, at 1154. 
25 Id.  
   20 
elicit reasonable levels of HIV-specific immune responses in mice and one report showed that a 
DNA/MVA vaccination approach provided longstanding protection from SHIV 89.6P.26  
However, there were no convincing conclusions resulting from human trials of DNA vaccines 
against HIV.  Only weak CD8+ CTL responses were reported.  
 
 The concept of the peptide vaccine is simple- using the peptides presented on major 
histocompatibility complex (MHC) class I or class II molecules as the antigens to trigger the 
immunization responses against HIV virus.  See Figure 8. 
 
 
Figure 8: Structure of a MHC Molecule27 
 
 The peptide vaccine can be designed to produce particular immunogens for a special 
target which may produce combinations of T-helper and CTL epitopes representing specific 
conserved regions of HIV.28  Another advantage of peptide vaccines is that it can direct the 
immune response toward subdominant epitopes that may not elicit responses of viral infection or 
other broad immune responses.29  Positive results were reported in small animals.  However, a 
human trial using a live virus prime/peptide boost vaccine showed only weak and transit cellular 
immune responses were generated inside these healthy volunteers.  How the scientists could 




                                                 
26 Id. at 1155. 
27 Tao, Mi-Hua,免疫世界的戰士 at .26, available at http://www.sinica.edu.tw/~hispj/program/doc/tao-mi-hua.pdf.  
28 Spearman, Paul, Current Progress in the Development of HIV Vaccines, Current Pharmaceutical Design, 2006, 
12, at p. 1155 
29 Id. 
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4. DNA Vaccines for HIV 
 
4.A. Vaccine Overview 
 A vaccine may be defined in basic terms as a preparation which is used to improve 
immunity to a particular disease.  The term is derived from Edward Jenner's use of cowpox 
("vacca" means cow in Latin), which, when administered to humans, provided them protection 
against smallpox, the work which Louis Pasteur and others carried on.  Vaccines are based on the 
concept of variolation originating in China, in which a person is deliberately infected with a 
weak form of smallpox.  Jenner realized that milkmaids who had contact with cowpox did not 
get smallpox.  The process of distributing and administrating vaccines is referred to as 
vaccination.  Since vaccination was much safer, smallpox inoculation fell into disuse and was 
eventually banned in England in 1848. 
 Vaccines can be prophylactic (e.g. to prevent or ameliorate the effects of a future 
infection by any natural or "wild" pathogen), or therapeutic (e.g. vaccines against cancer are also 
being investigated). 
 Over the years of research, various types of vaccines have been researched, discovered 
and used for preventing and curing diseases.  Different types of vaccines are discussed below: 
Traditionally, there are four types of vaccines: 
• Vaccines containing killed microorganisms - these are previously virulent micro-
organisms that have been killed with chemicals or heat.  Examples are vaccines against 
flu, cholera, bubonic plague, and hepatitis A. 
• Vaccines containing live, attenuated virus microorganisms - these are live micro-
organisms that have been cultivated under conditions that disable their virulent properties 
or which use closely-related but less dangerous organisms to produce a broad immune 
response.  They typically provoke more durable immunological responses and are the 
preferred type for healthy adults.  Examples include yellow fever, measles, rubella, and 
mumps. The live tuberculosis vaccine is not the contagious strain, but a related strain 
called "BCG". 
• Toxoids are inactivated toxic compounds in cases where these (rather than the micro-
organism itself) cause illness.  Examples of toxoid-based vaccines include tetanus and 
diptheria.  Not all toxoids are for micro-organisms; for example, Crotalis atrox toxoid is 
used to vaccinate dogs against rattlesnake bites. 
• Subunit vaccines, rather than introducing an inactivated or attenuated micro-organism to 
an immune system (which would constitute a "whole-agent" vaccine), a fragment of it 
can create an immune response.  Characteristic examples include the subunit vaccine 
against HBV that is composed of only the surface proteins of the virus (produced in 
yeast) and the virus like particles (VLP) vaccine against human papilloma virus (HPV) 
that is composed of the viral major capsid protein.30 
 Other than these four traditional vaccines, new and modern vaccines have also been 
discovered which are in various stages of development but have been put to application as well.  
These are: 
• Conjugate vaccines are those wherein, certain bacteria have polysaccharide outer coats 
that are poorly immunogenic.  By linking these outer coats to proteins (e.g. toxins), the 
immune system can be led to recognize the polysaccharide as if it were a protein antigen.  
This approach is used in the Haemophilus influenzae type B vaccine. 
                                                 
30 R.Wolfe et al., Anti-vaccinationists: Past and Present, BRITISH MEDICAL J., Aug. 24, 2002, at 430–432. 
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• In Recombinant Vector vaccines, by combining the physiology of one micro-organism 
and the DNA of the other, immunity can be created against diseases that have complex 
infection processes 
• DNA Vaccination is a technique which has been developed in recent years and has been 
created from an infectious agent's naked DNA.  It works by insertion (and expression, 
triggering immune system recognition) into human or animal cells, of viral or bacterial 
DNA.  Some cells of the immune system that recognize the proteins expressed will 
mount an attack against these proteins and cells expressing them.  Because these cells 
live for a very long time, if the pathogen that normally expresses these proteins is 
encountered at a later time, they will be attacked instantly by the immune system.  One 
advantage of DNA vaccines is that they are very easy to produce and store. As of 2006, 
DNA vaccination is still experimental.31 
This report looks in detail into the third kind of innovative vaccines, i.e. the DNA vaccines. 
 
 These DNA vaccines may be defined as preparation of a portion of the pathogen's 
structure that upon administration stimulates antibody production or cellular immunity against 
the pathogen but is incapable of causing severe infection, or more specifically as DNA sequences 
that code for immunogenic proteins located in appropriately constructed plasmids which include 
strong promoters, which when injected into an animal are taken up by cells and the immunogenic 
proteins are expressed and elicit an immune response.  Simultaneously, Genetic/ DNA 
immunization may be defined as a novel technique used to efficiently stimulate humoral and 
cellular immune responses to protein antigens.  The direct injection of genetic material into a 
living host causes a small amount of its cells to produce the introduced gene products.  This 
inappropriate gene expression within the host has important immunological consequences, 
resulting in the specific immune activation of the host against the gene delivered antigen.32 
 
4.B.1. DNA Vaccine Overview 
 
 The use of genetic material to deliver genes for therapeutic purposes has been practiced 
for many years.  Experiments outlining the transfer of DNA into cells of living animals were 
reported as early as 1950.  Later experiments using purified genetic material only further 
confirmed that the direct DNA gene injection in the absence of viral vectors results in the 
expression of the inoculated genes in the host.  There have been additional experiments that 
extend these findings to recombinant DNA molecules, further illustrating the idea that purified 
nucleic acids could be directly delivered into a host and proteins would be produced.  In 1992, 
scientists Tang and Johnson reported that the delivery of human growth hormone in a expression 
cassette in vivo resulted in production of detectable levels of the growth hormone in host mice.  
They also found that these inoculated mice developed antibodies against the human growth 
hormone; they termed this immunization procedure "genetic immunization", which describes the 
ability of inoculated genes to be individual immunogens.33 
 
 Since its early applications in the 1950's, DNA-based immunization has become a novel 
approach to vaccine development.  Direct injection of naked plasmid DNA can induce strong 
                                                 
31 Wikipedia,  http://en.wikipedia.org/wiki/Vaccine. 
32 H. Koprowski et al., DNA Vaccination/ Genetic Vaccination, SPRINER-VERLAG HEIDELBERG, 1998, at 198. 
33 Id. 
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immune responses to the antigen encoded by the gene vaccine.  They offer a new opportunity to 
immunize with materials that are entirely gene-based, expressed by the recipient’s own cells.  
This means that there is greater control over the immunization process, because the investigator 
determines which antigens and co-stimulants to use, where to elicit the response (e.g., skin or 
muscle), and which cytokines or innate controls (if any) to use.  The duration of the response can 
be controlled by repeated exposure to the genes, which are expressed transiently, by a variety of 
delivery mechanisms such as: direct injection; electroporation; gene gun; mucosal delivery, etc.34  
Once the plasmid DNA construct is injected the host cells take up the foreign DNA, expressing 
the viral gene and producing the corresponding viral protein inside the cell.  This form of antigen 
presentation and processing can induce both MHC and class I and class II restricted cellular and 
humoral immune responses.35 The ability to make DNA molecules strictly by rational design 
makes it possible to bypass months of development for the production of efficacious vaccines.   
 
 In addition, numerous DNA-based biopharmaceuticals are able to control disease 
progression by induction and/or inhibition of genes.  These potent therapeutics include plasmids 
containing transgenes, antisense oligonucleotides, aptamers, ribozymes, DNAzymes and short 
interfering RNAs.  DNAzymes, which cleave RNA substrates in a sequence-specific manner, 
have been studied as potential therapeutics to target pathogenic mRNAs, and may yield drugs 
that are safer than those currently available.36 
 
4.B.2. DNA Vaccine Construction 
 
 The construction of viral/bacterial plasmids with vaccine inserts is accomplished using 
recombinant DNA technology.  Once constructed, the vaccine plasmid (see Figure 9) is 
transformed into virus/bacteria, where viral/bacterial growth produces multiple plasmid copies.  
The plasmid DNA is then purified from the virus/bacteria, by separating the circular plasmid 
from the much larger bacterial DNA and other viral/bacterial impurities.  This purified DNA acts 
as the vaccine.37  The figure given below shows an example of a sample DNA vaccine plasmid 
construct. DNA vaccines are composed of viral/bacterial plasmids.  Expression plasmids used in 
DNA-based vaccination normally contain two units: the antigen expression unit composed of 
promoter/enhancer sequences, followed by antigen-encoding and polyadenylation sequences and 
the production unit composed of viral/bacterial sequences necessary for plasmid amplification 
and selection.38 
                                                 
34 Nature Technology Corporation: Biology by Design, http://www.natx.com/DNAVaccines.html.  
35J. Encke et al., DNA Vaccines,42 INTERVIROLOGY 117–24 (1999). 
36 Y. Isaka., DNAzymes as Potential Therapeutic Molecules, CURRENT OPINION IN MOLECULAR THERAPEUTICS, 
April 9, 2007, at 132–36. 
37 American Academy of Microbiology. The Scientific Future of DNA for Immunization, 1996, available at 
http://www.asmusa.org/acasrc/Colloquia/dnareprt.pdf.  
38 R. Schirmbeck et al., Revealing the Potential of DNA-based Vaccination: Lessons Learned from the Hepatitis B 
Virus Surface Antigen, 382 BIOL. CHEM. 543–52 (2001). 
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Figure 939 
 Other factors to be kept in mind while constructing a DNA vaccine might include those 
mentioned below.  To develop a successful protein therapeutic, effective DNA delivery 
technologies are required that induce high and sustained levels of protein production in 
appropriate targets sites, whereas robust and long-lasting immune responses need to be induced 
by a DNA-based vaccine.  Vectors for gene therapy and DNA vaccines must be resistant to 
degradation and attack by the immune system, have a satisfactory safety profile, and be able to 
express the therapeutic protein for the desired period of time.  Effective non-viral vectors, which 
can express the proteins of interest at high levels, are available.  However, since most of the 
DNA delivered in vivo is degraded before it can enter the nucleus, proper formulation and 
delivery are critical to the development of effective gene-based therapeutics and vaccines.  These 
systems must be safe for human and veterinary clinical applications and yet ensure that the DNA 
survives the extra- and intracellular environment and is capable of entering the appropriate 
cellular compartments.  In experiments in several laboratories various potential and proven non-
invasive chemical, mechanical, physical and biological DNA delivery systems for therapeutic 
and vaccine applications have been explored.  A few of these approaches have been evaluated 
and proven to be promising in target species.40 
 
 
4.B.3. DNA Vaccine Mechanism 
 A plasmid vector that expresses the protein of interest (e.g. viral protein) under the 
control of an appropriate promoter is injected into the skin or muscle of the host.  After uptake of 
the plasmid, the protein is produced endogenously and intracellularly processed into small 
antigenic peptides by the host proteases.  The peptides then enter the lumen of the endoplasmic 
reticulum (E.R.) by membrane-associated transporters  In the E.R., peptides bind to MHC class I 
molecules.  These peptides are presented on the cell surface in the context of the MHC class I.  
                                                 





40 S. VAN DRUNEN. & L.V. DEN HURK, NOVEL METHODS FOR THE NON-INVASIVE ADMINISTRATION OF DNA 
THERAPEUTICS AND VACCINES 3–15 (Bentham Science Publishers 2006). 
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Subsequent CD8+ cytotoxic T cells (CTL’s) are stimulated and they evoke cell-mediated 
immunity.  CTLs inhibit viruses through both cytolysis of infected cells and noncytolysis 
mechanisms such as cytokine production41.  The foreign protein can also be presented by the 
MHC class II pathway by APCs which elicit helper T cells (CD4+) responses.  These CD4+ cells 
are able to recognize the peptides formed from exogenous proteins that were endocytosed or 
phagocytosed by APC, then degraded to peptide fragments and loaded onto MHC class II 
molecules.  Depending on the the type of CD4+ cell that binds to the complex, B cells are 
stimulated and antibody production is stimulated.  This is the same manner in which traditional 
vaccines work.42  See Figure 10. 
                                            
Figure 1043 
 The DNA vaccine, introduced into the person to be immunized, can be via injection or 
delivery by a "gene gun”, with muscle typically the targeted tissue.  Transcription and translation 
occur from the vaccine plasmids that find their way into the nucleus of the muscle cells, to make 
the pathogen-derived protein.  Some of this protein makes it outside of the cell, where it is either 
bound by antibody molecules on B cells or phagocytosed by macrophages.  Either way, the 
protein gets digested inside these cells into small peptides and placed in the binding groove of a 
cell surface protein called the class II major histocompatibility complex (MHC II)44. (See Figure 
10) 
                                                 
41 J. Encke, supra note 35. 
42 R. Schirmbeck, supra note 38. 
43Brookscole, http://www.brookscole.com/chemistry_d/templates/student_resources/0030223180_ 
garrettgrisham/images/hottopics/VaccineMechanism.gif.  
44 Brookscole: DNA Vaccines and the Gene Gun, http://images.google.com/imgres?imgurl=http://www.brookscole. 
com/chemistry_d/templates/student_resources/0030973694_garrettgrisham/images/hottopics/VaccineMechanism.gif
&imgrefurl=http://www.brookscole.com/chemistry_d/templates/student_resources/0030973694_garrettgrisham/Hot
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4.B.4. Helper T-Cell responses 
 
 DNA immunization is able to raise a range of TH responses, including 
lymphoproliferation and the generation of a variety of cytokine profiles.  A major advantage of 
DNA vaccines is the ease with which they can be manipulated to bias the type of T-cell help 
towards a TH1 or TH2 response.45  Each type of response has distinctive patterns of lymphokine 
and chemokine expression, specific types of immunoglobulins expressed, patterns of lymphocyte 
trafficking, and types of innate immune responses generated.  T cell receptors (TCRs) on the 
surface of helper T cells can recognize these peptides as being foreign to the body, and therefore 
from an invading pathogen.  The helper T cell, then, releases a variety of interleukin (IL) 
proteins to stimulate both arms of the immune system (humoral and cellular) to kick into gear.  
This IL release has a number of effects.  The first is to auto-stimulate the helper T cell that 
detected the foreign protein, so that it can proliferate to fight off the disease.  Another secreted IL 
protein ramps up humoral immunity by causing the B cells whose membrane-bound antibodies 
were able to bind the foreign protein to differentiate (multiply and change) into antibody-
secreting plasma cells for the production of massive quantities of serum antibodies reactive to 
this pathogen's protein.  The last effect of the IL release is to promote the cellular arm of the 
immune system.  The cytotoxic T lymphocytes (CTLs) are activated by the IL proteins released 
by the helper T lymphocytes, and their job is to search for and destroy any cells that have foreign 
matter inside them, such as proteins from a replicating virus.  
 
 These cells of the immune system that have become activated by introduction of foreign 
matter from an infection or vaccine, whether B cell, helper T cell, or CTL, also create "memory 
cells" when they proliferate.  It is these memory cells that protect you later in life from infection 
by the same pathogen you were once exposed to.  It is this protection that vaccines seek to offer, 
with the introduction of innocuous proteins derived from a harmful pathogen, so that they bring 
forth the cellular and molecular arsenal against the foreign matter and leave behind these 
memory cell sentries to deal with future invasion.  
 
 Different types of T cell helps may be raised.  The type of T-cell help raised is influenced 
by the method of delivery and the type of immunogen expressed, as well as the targeting of 
different lymphoid compartments.46  Generally, saline needle injections (either IM or ID) tend to 
induce TH1 responses, while gene gun delivery raises TH2 responses.  This is true for 
intracellular and plasma membrane-bound antigens, but not for secreted antigens, which seem to 
generate TH2 responses, regardless of the method of delivery.47 
 
                                                                                                                                                             
Topics/DNAVaccines.html&h=396&w=325&sz=19&hl=en&start=4&tbnid=pu3x2FkBlteZ4M:&tbnh=124&tbnw=
102&prev=/images%3Fq%3DDNA%2Bvaccines%26gbv%3D2%26hl%3Den%26sa%3DG.  
45 D.M. Feltquate., Different T Helper Cell types and Antibody Isotypes Generated by Saline and Gene Gun DNA 
Immunization, J. OF IMMUNOLOGY 1997. 
46S. Boyle et al., Role of Different Lymphoid Tissues in the Initiation and Maintenance of DNA-Raised Antibody 
Responses to the Influenza Virus H1 Glycoprotein, 70(12) J. OF VIROLOGY 9074–78 (1996). 
47 M. Sällberg et al., Characterization of Humoral and CD4+ Cellular Responses after Genetic Immunization with 
Retroviral Vectors Expressing Different Forms of the Hepatitis B Virus Core and Antigens, 71(7) J. OF 
VIROLOGY 5295–03 (1997). 
   27 
 It is not understood how these different methods of DNA immunization, or the forms of 
antigen expressed, raise different profiles of T-cell help.  It was thought that the relatively large 
amounts of DNA used in IM injection were responsible for the induction of TH1 responses.  
However, evidence has shown no differences in TH type due to dose.  It has been postulated that 
the type of T-cell help raised is determined by the differentiated state of antigen presenting cells.  
Dendritic cells can differentiate to secrete IL-12 (which supports TH1 cell development) or IL-4 
(which supports TH2 responses).48  pDNA injected by needle is endocytosed into the dendritic 
cell, which is then stimulated to differentiate for TH1 cytokine production49, while the gene gun 
bombards the DNA directly into the cell, thus bypassing TH1 stimulation. 
 
 One of the greatest advantages of DNA vaccines is that they are able to induce cytotoxic 
T lymphocytes (CTL) without the inherent risk associated with live vaccines.  CTL responses 
can be raised against immunodominant and immunorecessive CTL epitopes50, as well as 
subdominant CTL epitopes, in a manner which appears to mimic natural infection.  This may 
prove to be a useful tool in assessing CTL epitopes of an antigen, and their role in providing 
immunity. 
 
 Cytotoxic T-cells recognise small peptides complexed to MHC class I molecules.51  
These peptides are derived from endogenous cytosolic proteins which are degraded and delivered 
to the nascent MHC class I molecule within the endoplasmic reticulum (ER).  Targeting gene 
products directly to the ER (by the addition of an amino-terminal insertion sequence) should thus 
enhance CTL responses.  This has been successfully demonstrated using recombinant vaccinia 
viruses expressing influenza proteins52, but the principle should be applicable to DNA vaccines 
too.  Targeting antigens for intracellular degradation (and thus entry into the MHC class I 
pathway) by the addition of ubiquitin signal sequences, or mutation of other signal sequences, 
has also been shown to be effective at increasing CTL responses.53 
 
4.B.5. Humoral (Antibody) Response 
 
 The other type of immune response induced by DNA based vaccines is the Humoral 
response.  Antibody responses elicited by DNA vaccinations are influenced by a number of 
variables, including type of antigen encoded; location of expressed antigen (i.e. intracellular vs. 
secreted); number, frequency and dose of immunizations; site and method of antigen delivery, to 
name a few.  Humoral responses after a single DNA injection can be much longer-lived than 
after a single injection with a recombinant protein.  Antibody responses against hepatitis B virus 
                                                 
48 J. Banchereau, Dendritic Cells and the Control of Immunity, 392(6673) NATURE 245–52 (1998). 
49 T. Jakob et al., Activation of Cutaneous Dendritic Cells by CpG-Containing Oligodeoxynucleotides: A Role for 
Dendritic Cells in the Augmentation of Th1 Responses by Immunostimulatory DNA 1, 161 J. OF IMMUNLOGY 3042–
49 (1998). 
50 T.M. Fu et al., Protective Cellular Immunity: Cytotoxic T-lymphocyte Responses Against Dominant and Recessive 
Epitopes of Influenza Virus Nucleoprotein Induced by DNA Immunization, J. OF VIROLOGY, April 1997, at 2715–21. 
51 N.P. Restifo, Antigen Processing in Vivo and the Elicitation of Primary CTL Responses, J. OF IMMUNOLOGY 
(1995).  
52 Id.  
53 T.W. Tobery, Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T 
Lymphocyte (CTL) Recognition and the Induction of De Novo CTL Responses In Vivo After Immunization, J. OF 
EXPERIMENTAL MEDICINE, Mar. 3, 1997, at 909–20. 
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(HBV) envelope protein (HBsAg) have been sustained for up to 74 weeks without boost, while 
life-long maintenance of protective response to influenza haemagglutinin has been demonstrated 
in mice after gene gun delivery.  Antibody-secreting cells migrate to the bone marrow and spleen 
for long-term antibody production, and are generally localised there after one year.54 
 
 DNA immunization-induced antibodies show greater affinity to native epitopes than 
recombinant protein-induced antibodies.  In other words, DNA immunization induces a 
qualitatively superior response.  Antibody can be induced after just one vaccination with DNA, 
whereas recombinant protein vaccinations generally require a boost.  As mentioned previously, 
DNA immunization can be used to bias the TH profile of the immune response, and thus the 
antibody isotype, which is not possible with either natural infection or recombinant protein 
immunization.  Antibody responses generated by DNA are useful not just in vaccination but as a 
preparative tool, too.  For example, polyclonal and monoclonal antibodies can be generated for 
use as reagents.55 
 
4.B.6. DNA Vaccine Administration 
 
 Several possible routes of plasmid delivery have been found.  Successful immunization 
has been demonstrated after delivery of plasmids through intramuscular, intradermal and 
intravenous injection.  The skin and mucous membranes are considered the best site for 
immunization due to the high concentrations of dendritic cells (DC), macrophages and 
lymphocytes. Cutaneous gene therapy and DNA vaccination are potential applications of plasmid 
delivery methods where a gene for an antigen or a therapeutic protein is inserted in the plasmid 
and applied to the skin.  However, the delivery of the DNA plasmid is a major challenge due to 
the unusual physicochemical properties of the DNA, the tissue and cellular barriers and 
expression difficulties.  Even though the skin is the most accessible organ of the body and it is an 
ideal target for gene therapy, the delivery of plasmid DNA across the skin is very difficult due to 
the specific barrier function of the stratum corneum and the inconsistent transfection rate of 
keratinocytes and other epidermal cells.  To date there is no gene delivery system that was shown 
to be optimal for cutaneous gene therapy.  In order to develop an efficient non-viral delivery 
vehicle there is need for a system that provides the combined properties of effective DNA 
condensation, cutaneous permeation, cellular transfection and sufficiently sustained expression,  
for example, the formulation approaches and delivery methods for DNA through the skin in the 
context of the barriers both at the tissue and cellular levels for both vaccine and gene therapy 
applications56. 
 Intradermal injection of DNA-coated gold particles with a gene gun have been used, it 
leads to keratinocyte and dendritic cell transduction.  A gene gun is used to accelerate the 
transdermal passage of microscopic gold beads coated with DNA plasmids (about 600 copies per 
bead) into the epidermis, where some are taken up by resident dendritic (Langerhans’) cells.  
Alternatively, a soluble antigen together with an adjuvant, is applied to the skin (transcutaneous 
                                                 
54 D.M. Justewicz, Long-term Maintenance of B Cell Immunity to Influenza Virus Hemagglutinin in Mice Following 
DNA-Based Immunization, 224 VIROLOGY 10–17 (1996). 
55 MARGARET A. SCUDERI, DNA Vaccines for the Prevention and Treatment of Hepatitis B Vaccine, in Biology 238: 
Microbiology (2003). 
56 M. Flodvari, DNA Delivery for Vaccination and Therapeutics Through the Skin, 3(1) CURRENT DRUG DELIVERY 
17–28 (2006). 
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immunization).  Some antigen reaches the epidermis and also undergoes endocytosis by 
Langerhans’ cells. The foreign DNA is expressed, and the antigens are degraded to polypeptides, 
some of which bind to major-histocompatibility complex antigens.  These activated T cells can 
interact with an activated B cell to induce a humoral response.57  See Figure 11. 
 
Figure 1158 
 The plasmid DNA can be diluted in distilled water, saline or sucrose.  There has also 
been positive demonstration of proinjection or codelivery with various drugs.  Administration of 
DNA associated with liposomes is less efficient, but allows for delivery of DNA vaccines to 




4.B.7. DNA Vaccine Advantages 
 
 DNA vaccines may have significant advantages over standard vaccines.  They can 
express antigenic epitopes which more closely resemble native viral epitopes and could therefore 
be more effective.  With live attenuated vaccines and killed vaccines the manufacturing process 
can alter the secondary and tertiary structure of the proteins and therefore the antigenicity of the 
vaccine; with naked DNA vaccines the host cell is manufacturing the viral epitope.  DNA 
vaccines would be safer than live virus vaccines, especially in immunocompromised patients, 
such as those infected with HIV.  DNA vaccines may be constructed to include genes against 
several different pathogens, thus decreasing the number of vaccinations necessary to fully 
immunize children.  Construction and manufacture of DNA vaccines would be simple.  Finally 
DNA vaccines may hold promise in treating those already infected with chronic viral infections 
(i.e., HCV, HIV or HSV).  Rapid and large-scale production are available at costs considerably 
lower than traditional vaccines, and they are also very temperature stable making storage and 
                                                 
57 Health Professionals On-Line Resource Centre, http://www.immune.org.nz/?t=919.  
58Health Professionals On-Line Resource Centre: http://www.immune.org.nz/site_resources/ 
Making_DNA_vaccine.gif. 
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transport much easier.  The continuous expression of the viral antigen caused by gene 
vaccination in an environment containing many APCs may promote successful therapeutic 
immune response which cannot be obtained by other traditional vaccines.59 
 
4.B.8. DNA Vaccine Limitations 
 
 Although DNA can be used to raise immune responses against pathogenic proteins, 
certain microbes have outer capsids that are made up of polysaccharides.  This limits the extent 
of the usage of DNA vaccines because they cannot substitute for polysaccharide-based subunit 
vaccines.  Difficulties include identifying the antigenic peptides, the potential to develop 
autoimmune responses and selection of viral vectors.60  
 
4.C. DNA Vaccines, HIV and AIDS 
 
 Developing a vaccine to protect against HIV in attempt to gain control of the AIDS 
pandemic is a top priority for researchers throughout the world.  Extensive testing has been 
conducted with live vaccines to determine if immunization would be effective at prevention, but 
they are not suitable for human use due to the potential that the vaccine viruses could mutate and 
reacquire the ability to cause disease.  The human immunodeficiency virus (HIV) and the 
acquired immunodeficiency syndrome induce account for over 40 million deaths in the past 20 
years.  Given that the currently available treatments to prevent HIV transmission and disease are 
not effective in eradicating the virus, vaccination likely represents the only efficacious adapted 
response to the global impact of this infection.61  Faced with the challenges in developing an 
HIV vaccine, international consortia and new methodologies have been proposed in order to 
accelerate the development and screening process of new candidate HIV vaccines.  Moreover, in 
the absence of a protective vaccine, the impact of a vaccine that confers partial protection needs 
to be seriously considered. 
 
4.C.1. Difficulties in HIV development62 
 
 The development of effective human immunodeficiency virus (HIV) vaccines and 
immunotherapies has been an elusive goal ever since the virus was first identified.  There are 
several contributing factors that have resulted in the failure to generate a protective or therapeutic 
HIV vaccine. HIV is highly variable due in part to the two errors made per replication cycle by 
reverse transcriptase during the replication process. This high mutation rate facilitates the virus 
in evading the adaptive cellular and humoral immune response.  Exposed parts of the envelope 
can mutate up to 35% of their amino acids without losing their function allowing for a large 
variety of mutations that can act as decoys for immune responses.  Traditional vaccines rely on 
the generation of neutralizing antibodies to confer protection. On the other hand, viral mutations 
that allow the virus to escape detection by cytotoxic T lymphocytes (CTLs) correlates with a 
                                                 
59 Encke, supra note 35. 
60 American Academy of Microbiology. The Scientific Future of DNA for Immunization, 
http://www.asmusa.org/acasrc/Colloquia/dnareprt.pdf (last visited April 27, 2008). 
61 Z. Coutsinos, Designing an Effective AIDS Vaccine: Strategies and Current Status, LA REVUE DE MEDICINE 
INTERNE, Feb. 5, 2008. 
62David A. Hokey et al., DNA vaccines for HIV: Challenges and Opportunities, SPRINGER SEMIN. IMMUN., 2006, at 
267–79. 
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decline in health characterized by a decrease in immune function and an increase in viral 
replication, thereby concluding that antibodies playing only a very limited role in viral control 
post infection.   
 
 CTL responses are able to target internal epitopes that are not accessible to antibodies, 
resulting in the destruction of infected cells.  However, HIV is able to eventually evade these 
CTL responses through incorporation of new mutations, resulting in the selection of escape 
variants that are not recognized and survive.  The selective pressures of both antibody and CTL 
responses keep the virus in a continual state of change while the immune system is undermined 
through the destruction of CD4+ T cells both by direct lysis due to infection and through the 
destruction of infected cells by CTL.  
 
 The infection pattern of HIV is likely to play a role in hindering the development of 
effective immunotherapies.  In order for a vaccine to be effective on a global scale, it must elicit 
CTL responses directed against conserved regions of HIV.  Furthermore, immune responses 
directed against single epitopes increase the likelihood that the virus will be able to mutate and 
escape immune recognition.  Therefore, the breadth of the immune response will likely be as 
critical to developing an efficacious vaccine as the type of immune response that is elicited.  
Traditional vaccines rely on the production of antibodies through the injection of live attenuated 
virus, killed viral particles, or recombinant viral proteins.  Killed viruses and recombinant 
proteins tend elicit humoral immune responses directed toward variable regions of the virus, 
rendering them ineffective.  Live attenuated viruses are better able to induce both humoral and 
cell-mediated immunity the than their non live counterparts.  One important focus has been the 
use of recombinant viral vectors.  On the other hand, DNA-based immunizations offer 
conceptual advantages compared to recombinant viral vectors.  Unlike viral vectors, they can be 
boosted in theory infinitely, and there is no issue with preexisting serology.  DNA-based 
vaccines are inherently conceptually safe because of the absence of a live vector and simple 
quality control issues.  However their major drawback is that compared to recombinant 
adenoviral vectors, the best DNA vaccines are ½ as immune potent.   
 
 One of the more popular methods of immunization involves the use of multiple strategies 
in a heterologous prime-boost regimen.  While immunization with DNA vaccines alone has had 
limited immune potency, priming with 2-3 rounds of DNA immunizations followed by a viral 
vector boost has been demonstrated to generate enhanced immune responses over that seen with 
homologous viral vector prime-boost alone.63  In addition to heterologous prime-boost regimens 
has also been examined. These vaccines have consisted of a DNA prime, a viral boost, and a 
second boost consisting of protein mixed with adjuvant (D-V-P).  One study demonstrated the 
ability of D-V-P immunizations to induce the secretion of antibodies at mucosal surfaces, 
particularly when the protein was conjugated to mannan64, suggesting this vaccine approach may 
be particularly effective at preventing infection.  Vaccination strategies would be simpler and 
more effective if we can improve the overall potency of DNA vaccines.   
 
                                                 
63 Santra S. Seaman et al. Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and 
Humoral Responses in Nonhuman Primates, J. OF VIROLOGY, 2005, at 6516–22. 
64 J. Stanbas et al., Long Lived Multi-Isotype Anti-HIV Antibody Responses Following a Prime-Double Boost 
Immunization Strategy, 23 VACCINE 2454–64 (2005). 
   32 
4.C.2. Preclinical and Clinical Studies65 
 
 Nonhuman primates (NHP) SIV and SHIV model, while not perfect, remain the best 
models for the preclinical evaluation of HIV vaccine efficacy due to a disease progression that is 
similar to that seen in humans.  Looking at a few experimental studies reported, in 2005, Su et 
al.66 reported five conserved Gag CTL epitopes using a SHIV model in rhesus macaques.  The 
study demonstrated these epitopes are maintained long into viral infection and even appear to be 
relatively conserved in several strains of SIV.  In another clinical study, Baroch et al.67 
demonstrated the ability of DNA immunization to elicit CTL responses against both dominant 
and subdominant epitopes in an SHIV model, suggesting DNA may be useful for eliciting broad 
CTL-based immune responses which are desired for control of HIV infection.   
 
 DNA vaccines have performed poorly at inducing antibody responses. This is likely due 
to the lack of soluble antigen access to B cells.  In July 2005, Rosati et al.68 examined the use of 
a DNA vaccine encoding Gag and Env fused to either MCP3 or β-catenin to target the 
transcribed antigens to secrtory or degradation pathways, respectively, and these animals 
developed stronger antibody responses.  There has been particular interest in the use of 
heterologous prime-boost strategies for HIV/SIV.  Boyer et al.69 reported partial control of 
SIV239 after a DNA/Listeria prime-boost regimen.  The combination of DNA prime-boost and 
Listeria-boost resulted in enhanced cellular immunity to virus over that seen with either agent 
alone.  There have been many vaccine strategies designed to test elicitation of immune responses 
to HIV in humans, with more than 30 human trials currently underway. Thus far, the two 
immunization methods demonstrating the highest level of immunogenicity include the use of 
recombinant Ad5 adenoviral vectors either alone or in combination with plasmid DNA in a 
heterologous DNA/Ad5 prime-boost regimen.  This is perhaps the most efficient of all the 
methods tested do far. 
  
 In concluding we can say that thus far, no correlates of protection have been found for 
HIV. However, there is strong evidence that CD8+ T cells play an important role in controlling 
HIV infection.  Currently the most important method for assessing vaccine efficacy is the 
measurement of the number of IFN-γ-secreting T cells by ELISPOT.  Adenoviral vectors have 
performed well in primate models and can be further improved if an animal has been primed 
using a DNA vaccine. While DNA vaccines alone have proven to be relatively nonimmunogenic, 
the addition of encoded molecular adjuvants as optimized IL-15 and IL-12, has been almost as 
effective as viral vectors.  It is likely that further exploration of potential molecular adjutants 
                                                 
65 See Hokey, supra note 62. 
66 J Su et al., Novel Simian Immunodeficiency Virus CTL Epitopes Restricted by MHC Class I Molecule Mamu-B*01 
are Highly Conserved for Long Term in DNA/MVA-vaccinated, SHIV-challenged Rhesus Macaques, 17 INT. 
IMMUNOLOGY 637–48 (2005). 
67 DH Baroch et al., Elicitation of High- Frequency Cytotoxic T-lymphocyte Responses Against both Dominant and 
Subdominant Simian-Human Immunodeficiency virus Epitopes by DNA Vaccination of Rhesus Monkeys, 75 J. OF 
VIROLOGY 2462–67 (2001). 
68 M Rosati et al., DNA Vaccines Expressing Different Forms of a Simian Immunodeficiency Virus Antigens 
Decrease Viremia upon SIV mac 251 Challenge, 70 J. OF VIROLOGY 8480–92 (2005). 
69 JD Boyer et al., DNA Prime Listeria Boost Induces a Cellular Immune Response to SIV Antigens in the Rhesus 
Macaque Model that is Capable of Limited Suppression of SIV 239 Viral Replication, 333 VIROLOGY 88–101 
(2005). 
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may enhance DNA vaccines further, surpassing the immunogenicity of live viral vectors while 
maintaining a superior level of safety. Thus, further studies are clearly important and will 
continue to mold and change this evolving field. 
 
5. Patent Search Methodology and Results 
 
5.A. Patent Search Methodology 
 
 The Intellectual Property Research Tools course project started on January 17, 2008 with 
a referral from PIPRA.  Cecilia Chiham, Director Biotechnology Resources at The Public 
Intellectual Property Resources for Agriculture  (hereinafter PIPRA) was the contact and 
coordinator.  During several telephone conferences, the scope of this project was defined by 
Cecilia Chiham, Kerri Clark of PIPRA, Prof. Jon Cavicchi, and Dr. Stanley Kowalski.  Initially, 
after discussions on the topic of the project to be undertaken, the team unanimously decided to 
conduct an HIV vaccine patent landscape analysis. The team was provided with flow charts 
indicating the levels of research on the subject, and the option of choosing what level of patents 
to work on.  We chose to work on DNA Vaccines and thereafter launched into the 4 month 
pursuit of searching and coding. The goal of the team search was to find relevant patents 
encompassing construction, optimization and delivery methods of DNA vaccines for HIV.     
 
 The search methodology was devised to initially generate a broad set of patents and then 
narrow down the results using the “Iterative Approach” as promoted by Prof. Cavicchi. The 
search was divided into a preliminary search round and then subsequent 4 rounds. The searches 
utilized keywords derived from the primary search and the US Classifications and Sub-classes 
that came forth after this round were used for carrying out further searches. The main concepts 
used in the primary search were Vaccine$, DNA, recombine$, plasmid, HIV, AIDS, Human 
immune$ virus, Poxvirus, Deliver$, Prim$, boost, backbone, promoter, peptide$ for the USPTO 
search, and DNA, plasmid, Vaccine*, HIV, human immune* virus, Prim*, boost*, promoter, 
adjuvant*, protein, deliver, cytokine, lead*, sequence, electroporation, gene gun while searching 
in Delphion. This primary search on Delphion also involved searching by classes of US 
Classifications 424, 435, 536, 514, 530.  The search then utilized keywords derived from the 
Primary Search to obtain relevant United States Patent Classification Codes (herein after USPC) 
codes in the United States Patent and Trademark Office database (herein after USPTO) as well 
as broad number of patents in US & EP applications and patents, WIPO PCT publications 
through the Delphion database.  With the results obtained subsequent, four rounds of search were 
carried out. 
 
For finding patent literature, we searched the following database platforms:  
1. USPTO:  Using the list of relevant class/sub-classes obtained from the primary search 
and combining it with the initial list of key words, utilizing the USPTO Seven-Step 
Strategy (http://www.uspto.gov/go/ptdl/step7.htm), we performed a series of hybrid 
searches encompassing the keywords and class/sub-classifications. With the results from 
these searches, we started coding the patent documents and assembling the Master Sheet. 
2. GenomeQuest:  Using the DNA sequences of Gag, Pol, Nef and Env, provided to us by 
Kerri Clark at PIPRA, we performed a search using GenomeQuest database. Using this 
search result, we found patents which included the three key words “HIV, DNA 
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Vaccines, and Vaccine” and a 65% to 80% homology with the respective sequences. 
After analyzing the search results, we arranged the most relevant patents in our Master 
Sheet. 
3. Delphion:  This was the main database used by us. The relevant patents found on USPTO 
database were then searched on Delphion, where the searches were narrowed down, each 
team member created their own work files, extracted pdf’s, extracted data on excel 
sheets, etc., which were then complied into the Master Sheet.   
 
 After the Preliminary Search, we moved on to Search Round I. In this round each team 
member was given fixed US Class/Subclasses to search and the keywords to use with those class 
numbers as search strings. These were: 
 
1. Lisa  
 
Class 435/320.1 + HIV any field + vaccine in title or abstract  
Class 435/320.1 + HIV any field + vaccine in title or abstract  
 
2. Arshdeep  
 
Class 424/188.1 + vaccine in title  
Class 424/188.1 + vaccine in abstract  
Class 424/188.1 + vaccine in claims  
Class 424/188.1 + vaccine in all fields  
 
3. Weonmee  
 
Class 424/208.1 + vaccine in title  
Class 424/208.1 + vaccine in abstract  
Class 424/208.1 + vaccine in claims  
Class 424/208.1 + vaccine in all fields  
 
4. Michelle  
 
a. search the Derwent World Patent Index classes B04, D16, C06 on Delphion and mine for 
relevant U.S. patent numbers;  
b. search U.S. patents for the following assignees and add keywords as indicated for relevant 
patents on HIV vaccines:  
- Merck  
- Aventis  
- Virogenetics  
- Chiron  
- University of California  
c. search U.S. patents for class 536 and add keywords as indicated  for relevant patents on HIV 
vaccines 
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 Patent searching on these outlines gave us an outcome of nearly 2284 patent documents, 
out of which only 174 were found relevant. These documents were read by us and we coded and 
categorized each of these documents under three categories: 
1. Construction 
2. Optimization; and 
3. Delivery Method 
 
 Although the emphasis was on the title, the abstract, the specifications and the claims, we 
searched the claims more thoroughly to look for SIV/HIV, prime boost and adjuvants in the 
claims. Each stack of patents was initially coded by the student Team members. These were 
subsequently reviewed by the entire Team and Dr. Kowalski and categorized according to the 
final categories mentioned above.  The documents were coded according to their relevancy and a 
Master Sheet was prepared simultaneously containing all the information on each of these patent 
documents. At the end of the Search Round I, the number relevant patent documents on the 
Master Spread Sheet had been reduced to a more manageable number.  
 
 Search round II was carried out to round up the search in Search round I in order to locate 
any relevant patent which might have been missed in the first round. This search was mainly 
carried out in the Delphion database using Derwent World Patent Index (DWPI) Patent Database 
and US & EP applications and patents, WIPO PCT publications by employing the keywords 
Vaccine, HIV, DNA polynucleotide to locate the top 21 assignees which are listed in Table 1. 
Further, the keywords HIV, vaccine were used to locate the top 3 classes of patents which came 
out to be B04, S03 and D16. These classes were then used with the keywords HIV, vaccine, 
DNA, polynucleotide to search for patent documents. Other searches were carried out using 
keywords like ELISPOT, DNA Vaccine, HIV, human immune virus, Vaccine, Susan, Chiron, 
Human Immunodeficiency Virus, DNA Polynucleotide, AIDS, etc. in classes 530 and 536, B04, 
D16, C06 and 424/188.1. The second round resulted in 463 patent documents out of which 209 
were relevant. These 209 were then first coded by us individually and then together with Dr. 
Kowalski. The final results were inserted in the Master Spread Sheet. 
 
 Having completed an exhaustive search utilizing all the possible approaches, we then 
focused our attention to Genome Quest. Because the GenomeQuest searches were not premised 
on keywords but on native DNA sequences of Gag, Pol, Env and Nef genes the coding scheme 
was based on homology.  The patent documents were search based on 65% to 80% and above 
homology of the DNA sequences of the four genes. These searches were further narrowed down 
by using keywords along with the sequences, such as, HIV, DNA Vaccine and Vaccine, in 
various different search strings. The patent documents located in this search round again were 
first coded by each of the team members individually and then together as a team with Dr. 
Kowalski. In the end of this Search Round III, we were able to add 98 relevant patent documents 
to the Master Spread Sheet out of the 513 hits. 
 
 Round IV, was carried out on IPVision, Inc. the access and password to which were 
granted by Joseph G. Hadzima, using keywords DNA and vaccine, and then further searches 
were carried out in Delphion with Researchers listed on National Center for Biotechnology 
Information (NCBI) website as inventors, HIV, vaccine, while searching for French researchers, 
Italian researches, UC Davis Researchers, NIH researchers, Harvard researchers, US  
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researchers, Dutch researchers, etc. This round resulted in 163 patents out of which 23 were 
relevant. These were coded and then put into the Master Spread Sheet. 
 
 Finally all the searching and coding ended on April 24, 2008 with the compilation of a 
final Master Spread Sheet. 
 




Database USPTO (US applications and patents) 
Keywords Vaccine$, DNA, recombine$, plasmid 
HIV, AIDS, Human immune$ virus 


































Issued patents:  
(SPEC/DNA AND ACLM/vaccin$): 2209 
(SPEC/DNA AND ACLM/vaccine): 1611 
((SPEC/DNA AND ACLM/vaccin$) AND hiv): 675 
((SPEC/DNA AND ACLM/vaccin$) AND SPEC/HIV): 627 
((SPEC/DNA AND SPEC/(HIV OR aids)) AND ACLM/vaccine$): 541 
((SPEC/DNA AND SPEC/((HIV OR ((human$ AND immun$)  
AND virus)) OR AIDS)) AND ACLM/vaccin$): 1600 
 
SPEC/poxvirus$: 2479 
(SPEC/poxvirus$ AND SPEC/HIV): 1157 
(SPEC/poxvirus AND SPEC/HIV): 669 
(SPEC/poxvirus$ AND SPEC/(HIV OR ((human$ AND immun$) AND 
virus))): 2297 
((SPEC/poxvirus$ AND SPEC/(hiv OR ((human$ AND immun$) AND 
virus))) AND ACLM/vaccin$) 
 
(SPEC/(((human AND immun$) AND virus) OR HIV) AND 
ACLM/vaccin$): 1916 
((SPEC/(((human AND immun$) AND virus) OR HIV) AND 
ACLM/vaccin$) AND ACLM/dna): 501 
((SPEC/(((human AND immun$) AND virus) OR HIV) AND 
ACLM/vaccin$) AND ACLM/poxvirus$): 101 
((SPEC/(((human AND immun$) AND virus) OR HIV) AND 
ACLM/vaccin$) AND SPEC/peptide$): 1287 
((SPEC/(((human AND immun$) AND virus) OR HIV) AND 
ACLM/vaccin$) AND ACLM/peptide$): 351 
 
(ACLM/(((human AND immun$) AND virus) OR HIV) AND 
















((ACLM/(((human AND immun$) AND virus) OR HIV) AND 
ACLM/vaccin$) AND ACLM/DNA): 82 
 
((SPEC/(HIV OR ((human AND immun$) AND virus)) AND 
ACLM/vaccin$) AND ACLM/((DNA OR recombin$) OR plasmid)): 
866 
(((SPEC/(HIV OR ((human AND immun$) AND virus))  
AND ACLM/vaccin$) AND ACLM/((DNA OR recombin$)  
OR plasmid))  
AND SPEC/deliver$): 492 
(((SPEC/(HIV OR ((human AND immun$) AND virus))  
AND ACLM/vaccin$) AND ACLM/((DNA OR recombin$)  
OR plasmid))  
AND SPEC/(boost AND prim$)): 174 
(((SPEC/(HIV OR ((human AND immun$) AND virus))  
AND ACLM/vaccin$) AND ACLM/((DNA OR recombin$) OR 
plasmid) )  
AND SPEC/backbone$): 160 
(((SPEC/(HIV OR ((human AND immun$) AND virus))  
AND ACLM/vaccin$) AND ACLM/((DNA OR recombin$) OR 
plasmid) )  
AND SPEC/promoter$): 710 
(((SPEC/(HIV OR ((human AND immun$) AND virus))  
AND ACLM/vaccin$) AND ACLM/((DNA OR recombin$)  
OR plasmid))  
AND ACLM/promoter$): 291 
 
--------------------------------------------------------- 
US patent publish application:  
(SPEC/(((human AND immun$) AND virus) OR HIV) AND 
ACLM/vaccin$): 4721 
(SPEC/(((human AND immun$) AND virus) OR HIV)  
AND ACLM/vaccin$) and ACLM/DNA: 1539 
Result Briefly reviews patents might relates to HIV vaccines 
 
 
Database Delphion  
(US & EP applications and patents, WIPO PCT publications) 
Keywords DNA, plasmid, Vaccine*, 
HIV, human immune* virus,  
Prim*, boost*, promoter, adjuvant*, protein, deliver, cytokine,  





































Search strings  















(only search for US applications and patents) 
 
((vaccin*) <in> CLAIMS) AND  
((HIV or (human and immun* and virus)) <in> DESCRIPTION)  
AND ((DNA) <in> DESCRIPTION): 13,152 
 
((vaccin*) <in> CLAIMS) AND  
((HIV or (human and immun* and virus)) <in> DESCRIPTION)  
AND ((DNA*) <in> DESCRIPTION)  
AND ((DNA* or plasmid) <in> AB): 2,063 
 
((vaccin*) <in> TI) AND (vaccin*) <in> CLAIMS)  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION)  
AND ((DNA*) <in> DESCRIPTION)  
AND ((DNA* or plasmid) <in> AB): 693 
 
((vaccin*) <in> TI) AND (vaccin*) <in> CLAIMS)  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION)  
AND ((DNA*) <in> DESCRIPTION)  
AND ((DNA* or plasmid) <in> AB) AND ((DNA* or plasmid)  
<in> CLAIMS): 598 
 
(((vaccin*) <in> CLAIMS )  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION ) 
AND ((DNA) <in> DESCRIPTION )  
AND ((DNA or plasmid) <in> AB )  
AND ((plasmid) <in> CLAIMS)): 717 
 
((vaccin*) <in> TI) AND (vaccin*) <in> CLAIMS)  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION)  
AND ((DNA*) <in> DESCRIPTION)  
AND ((DNA* or plasmid) <in> AB) AND ((DNA* or plasmid) <in> 
CLAIMS) AND ((prim*) <in> DESCRIPTION): 544 
 
((vaccin*) <in> TI) AND (vaccin*) <in> CLAIMS)  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION)  
AND ((DNA*) <in> DESCRIPTION)  
AND ((DNA* or plasmid) <in> AB) AND ((DNA* or plasmid)  
<in> CLAIMS) AND ((prim* and boost*) <in> DESCRIPTION): 424 
 
(((((vaccin*) <in> CLAIMS )  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION ) 
AND ((DNA*) <in> DESCRIPTION )  
AND ((DNA* or plasmid) <in> AB ))) AND ((prim* and boost*)  















































<in> DESCRIPTION)): 1,061 
 
((((((vaccin*) <in> CLAIMS )  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION ) 
AND ((DNA*) <in> DESCRIPTION )  
AND ((DNA* or plasmid) <in> AB ))) AND ((prim* and boost*)  
<in> DESCRIPTION )) AND ((prim*) <in> AB)): 93 
 
((vaccin*) <in> TI) AND (vaccin*) <in> CLAIMS)  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION)  
AND ((DNA*) <in> DESCRIPTION)  
AND ((DNA* or plasmid) <in> AB) AND ((DNA* or plasmid) 
 <in> CLAIMS) AND ((promoter) <in> DESCRIPTION): 590 
 
((vaccin*) <in> TI) AND (vaccin*) <in> CLAIMS)  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION)  
AND ((DNA*) <in> DESCRIPTION)  
AND ((DNA* or plasmid) <in> AB) AND ((DNA* or plasmid)  
<in> CLAIMS) AND ((promoter) <in> CLAIMS): 242 
 
((vaccin*) <in> TI) AND (vaccin*) <in> CLAIMS)  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION)  
AND ((DNA*) <in> DESCRIPTION)  
AND ((DNA* or plasmid) <in> AB) AND ((DNA* or plasmid) 
 <in> CLAIMS) AND ((promoter) <in> AB): 59 
 
((vaccin*) <in> TI) AND (vaccin*) <in> CLAIMS)  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION)  
AND ((DNA*) <in> DESCRIPTION)  
AND ((DNA* or plasmid) <in> AB) AND ((adjuvant*) 
 <in> DESCRIPTION): 519 
 
((vaccin*) <in> TI) AND (vaccin*) <in> CLAIMS)  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION)  
AND ((DNA*) <in> DESCRIPTION)  
AND ((DNA* or plasmid) <in> AB) AND ((adjuvant* and protein) 
<in> DESCRIPTION): 511 
 
((((vaccin*) <in> CLAIMS )  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION ) 
AND ((DNA*) <in> DESCRIPTION )  
AND ((DNA* or plasmid) <in> AB )) AND ((vaccin*) <in> TI )  
AND ((deliver*) <in> DESCRIPTION)): 419 
 
((((vaccin*) <in> CLAIMS )  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION ) 
















AND ((DNA*) <in> DESCRIPTION )  
AND ((DNA* or plasmid) <in> AB )) AND ((vaccin*) <in> TI )  
AND ((cytokine*) <in> DESCRIPTION)): 297 
 
((((vaccin*) <in> CLAIMS )  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION ) 
AND ((DNA*) <in> DESCRIPTION )  
AND ((DNA* or plasmid) <in> AB )) AND ((vaccin*) <in> TI )  
AND ((lead* and sequence) <in> DESCRIPTION)): 458 
 
((((vaccin*) <in> CLAIMS )  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION ) 
AND ((DNA*) <in> DESCRIPTION )  
AND ((DNA* or plasmid) <in> AB )) AND ((vaccin*) <in> TI )  
AND ((electroporation) <in> DESCRIPTION)): 195 
 
((((vaccin*) <in> CLAIMS )  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION ) 
AND ((DNA*) <in> DESCRIPTION )  
AND ((DNA* or plasmid) <in> AB )) AND ((vaccin*) <in> TI )  
AND ((gene and gun) <in> DESCRIPTION)): 136 
 
(((((HIV or (human and immun* and virus)) <in> DESCRIPTION )  
AND ((DNA*) <in> DESCRIPTION )  
AND ((DNA* or plasmid) <in> AB )) AND ((vaccin*) <in> TI )  
AND ((gene and gun) <in> DESCRIPTION)): 392 
 
((polynucleotide or DNA* or plasmid) <in> CLAIMS)  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION)  
AND ((immun*) <in> claims): 23,308 
 
((vaccin*) <in> CLAIMS )  
AND ((HIV or (human and immun* and virus)) <in> DESCRIPTION ) 
AND ((DNA*) <in> DESCRIPTION )  
AND ((DNA* or plasmid) <in> AB )): 2090 
 
( (424???*) <in> NC) AND (HIV)): 3000 
 
(( (424* or 435* or 536* or 514* or 530*) <in> NC) AND (HIV)  
AND (vaccin*)): 2111 
Result By browsing several patents of the search results, we locate:  
1. The top 5 classes of patents relate to HIV DNA vaccines-  
424, 435, 536, 514 & 530 
2. The top 3 classes with subclassification- 424/188.1,  
424/208.1 & 435/320.1.  
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Search Round 1 
Database Delphion  
(US & EP applications and patents, WIPO PCT publications) 






Search strings (only search for US applications and patents)  
 
(((424/188.1 OR 424/208.1 OR 435/320.1) <in> NC) AND (HIV)  
AND (vaccine) <in> AB): 362 
 
(((435/320.1) <in> NC) AND (HIV) AND (vaccine) <in> AB): 175 
Result 175 patents from the class of 435/320.1;  
Locate 45 might-be relevant patents 
 
Database Delphion 








1. Vaccine in the title 
2. Vaccine in the abstract 
3. Vaccine in the claims  
4. Vaccine in all text 






Database Delphion  
(US & EP applications and patents, WIPO PCT publications) 
Keywords DNA, plasmid, Vaccine*, 
HIV, human immune* virus,  
Prim*, boost*, promoter, adjuvant*, protein, deliver, cytokine,  




Search Strings (only search for US applications and patents) 
 
(( (536???*) <in> NC ) AND (((vaccine and DNA and HIV  
or Human immunodeficiency virus)) <in> AB)): 185 
 
Results Only 20 patents considered 
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Database Delphion  
(US & EP applications and patents, WIPO PCT publications) 





Search strings (only search for US applications and patents)  
 
((424/188.1) <in> NC) AND (vaccine) <in> TI): 96 results 
 
((424/188.1) <in> NC) AND (vaccine) <in> AB): 174 results 
 
((424/188.1) <in> NC) AND (vaccine) <in> CLAIMS):81results 
 
((424/188.1) <in> NC) and (vaccine) <in> ALL FIELDS):314 
Result 665 patents from the class of 424/188.1;  
Locate 36 might-be relevant patents 
 
Search Round 2 
Database Delphion  
(US & EP applications and patents, WIPO PCT publications) 
Keywords Vaccine, HIV, DNA polynucleotide 
US Classification/ 
Subclassification 
Not in use 
Search strings (only search for US issued patents)  
 
(((HIV*) <in> CLAIMS)  
AND (Vaccin*) AND (DNA or polunucle*)): 1615 
Result Locate the top 21 assignees from this search.  
The result is listed in Table 1.  
 
Table 1  
   Assignee  
1 INSTITUT PASTEUR 
2 THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 
3 CHIRON CORPORATION 
4 MERCK & CO., INC. 
5 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 
6 CONNAUGHT LABORATORIES LIMITED 
7 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 
8 PROGENICS PHARMACEUTICALS, INC. 
9 THE GENERAL HOSPITAL CORPORATION 
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10 ABBOTT LABORATORIES 
11 EMORY UNIVERSITY 
12 UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE 
13 AGOURON PHARMACEUTICALS, INC. 
14 BRISTOL-MYERS SQUIBB COMPANY 
15 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 
16 WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 
17 DUKE UNIVERSITY 
18 VERTEX PHARMACEUTICALS INCORPORATED 
19 PARKER HUGHES INSTITUTE 
20 AVENTIS PASTEUR LIMITED 
21 DANA-FARBER CANCER INSTITUTE 
 
 
Database Delphion  
(Derwent World Patent Index (DWPI) Patent Database) 
Keywords HIV, vaccine 
Classification of  
Derwent Database 
Not in use 
Search strings ((HIV*) <in> TI) AND (vaccine*) <in> TI): 570 
Result Locate the top 3 classes of patents in this search are B04, S03 and D16. 
 
Database Delphion  
(Derwent World Patent Index (DWPI) Patent Database) 
Keywords Assignees listed in table 1, HIV, vaccine, DNA, polynucleotide 





Search strings ((B04 and (S03 or D16)) <in> DERWENTCLASS): 226, 181 
 
(((B04 and (D16 or S03)) <in> DERWENTMAINCLASS )  
AND ((HIV*) <in> TI): 3591 
 
(((B04 and (D16 or S03)) <in> DERWENTMAINCLASS )  
AND ((DNA or polynucle*) and vaccin* and hiv*)): 811 
 
((B04 and (S03 or D16)) <in> DERWENTCLASS)  
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(((B04 and (S03 or D16)) <in> DERWENTCLASS)  
and ((DNA or polynucle*) <in> AB) and ((vaccin* and HIV*) <in> 
AB) 
 and ((INSTITUT PASTEUR) or (HEALTH AND HUMAN  
SERVICES) or CHIRON or (MERCK & CO) or  
(UNIVERSITY OF CALIFORNIA) or  
(CONNAUGHT LABORATORIES) or (UNIVERSITY OF 
PENNSYLVANIA) or PROGENICS or  
(GENERAL HOSPITAL CORPORATION) or ABBOTT or  
(EMORY UNIVERSITY) or (UNIVERSITY OF  
MARYLAND) or AGOURON  
or (BRISTOL-MYERS) or (UNIVERSITY OF TEXAS)  
or (WHITEHEAD INSTITUTE) or (DUKE UNIVERSITY)  
or VERTEX or (PARKER HUGHES) or (AVENTIS PASTEUR) or  
(DANA-FARBER)) <in> PA): 84  
 
(((B04 and (S03 or D16)) <in> DERWENTCLASS)  
and ((DNA or polynucle*) and vaccin* and HIV*) and  
((INSTITUT PASTEUR) or (HEALTH AND HUMAN SERVICES)  
or CHIRON or (MERCK & CO)  
or (UNIVERSITY OF CALIFORNIA) or  
(CONNAUGHT LABORATORIES) or (UNIVERSITY OF 
PENNSYLVANIA) or PROGENICS or  
(GENERAL HOSPITAL CORPORATION)  
or ABBOTT or (EMORY UNIVERSITY) or  
(UNIVERSITY OF MARYLAND) or AGOURON or  
(BRISTOL-MYERS)  
or (UNIVERSITY OF TEXAS) or (WHITEHEAD INSTITUTE)  
or (DUKE UNIVERSITY) or VERTEX or  
(PARKER HUGHES) or (AVENTIS PASTEUR) or  
(DANA-FARBER)) <in> PA): 92 
 
Result 92 patents;  
Locate 26 might be relevant patents 
 
Database Delphion  




530 and 536 
Search strings 
 
((530*, 536*) AND (ELISPOT) AND ((HIV) <in> (TITLE)  
AND ("DNA vaccine")) 
Results Patents and Published Applications: 32 
Relevant: 17 
 
Database Delphion  
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(US & EP applications and patents, WIPO PCT publications) 
Keywords DNA, Vaccine*, 
HIV, human immune* virus,  
Search Strings (only search for US applications and patents) 
 
((((vaccine and DNA and HIV or Human immunodeficiency virus))  
<in> AB )  
AND (((Merck or Aventis or Virogenetics or Chiron  
or University of California)) <in> PA)): 34 
Results Locate 34 results might be relevant 
 
Database Westlaw 
Internal database: DWPL 




Search Strings DCLA (BO4 D16 C06) & TI (HIV & VACCINE): 401 
 
Results 87 patents considered 
Locate 78 results might be relevant 
 
Database Delphion  
(US & EP applications and patents, WIPO PCT publications) 
Keywords DNA, Vaccine*, 
HIV, human immune* virus,  
Search Strings (only search for US applications and patents) 
 
((HIV or Human Immunodeficienty Virus) <in> CLAIMS)  
AND ((vaccine or immun!) <in> CLAIMS) AND ((DNA): 464 
Results 141 patents considered; 
Locate 22 results might be relevant 
 
Database Delphion  
(US & EP applications and patents, WIPO PCT publications) 





Search strings (only search for US applications and patents)  
 
((4241881) <in> NC) AND (HIV) AND ((susan) <in> IN): 5 
 
((4241881) <in> NC) AND (HIV) AND ((chiron) <in> PA): 6 
Result 11 patents from the class of 424/188.1;  
Locate 4 might-be relevant patents 
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Database Delphion  
(US & EP applications and patents, WIPO PCT publications) 
Keywords Vaccine, Human Immunodeficiency Virus, DNA polynucleotide, AIDS 
US Classification/ 
Subclassification 
Not in use 
Search strings (only search for US issued patents)  
 
((HIV and vaccine) <in> TI) AND (AIDS) AND (DNA and vaccine): 9 
(DNA and vaccin!) AND ((HIV) <in> TI) AND  
("human immunodeficiency virus"): 67 
Result Locate 76 patents from this search. The result 28 might be relevant 
patents.  
 
Search Round 3 
Database GenomeQuest 
Keywords 1. DNA sequence of Nef listed below.  
2. 80% or greater homology 
Results Patents: 128 
Locate 45 might be relevant patents 
Note 1. The DNA sequence is provided by Kerri Clark, from PIPRA, who 
downloaded from National Center for Biotechnology Information  
(NCBI) website (http://www.ncbi.nlm.nih.gov/). 

















Database GenomeQuest/GQPAT version 2008314 
Keywords/ 
result filtering 
1. Abstract contains "HIV and Vaccine" 
2. and all text contains "DNA vaccine" 
3. Alignments with 65% or greater identity  
Note 1. The DNA sequence is provided by Kerri Clark, from PIPRA, who 
downloaded from National Center for Biotechnology Information  
(NCBI) website (http://www.ncbi.nlm.nih.gov/). 
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2. Env DNA sequence of Env from NCBI website:  





































































Keywords 3. DNA sequence of Pol listed below.  
4. 65% or greater homology 
Results Patents: 282 
Locate 10 might be relevant patents 
Note 1. The DNA sequence is provided by Kerri Clark, from PIPRA, who 
downloaded from National Center for Biotechnology Information  
(NCBI) website (http://www.ncbi.nlm.nih.gov/). 












































































Search String All text contains “HIV”: 260 
All text contains “HIV and DNA”: 181 
All text contains “HIV and DNA and vaccine”: 87 
Locate 10 might be relevant patents 
 
Database GenomeQuest 
Keywords 5. DNA sequence of Gag listed below.  
6. 80% or greater homology 
Results Patents: 770 results, 103 patents 
Locate 35 might be relevant patents 
Note 1. The DNA sequence is provided by Kerri Clark, from PIPRA, who 
downloaded from National Center for Biotechnology Information 
(NCBI) website (http://www.ncbi.nlm.nih.gov/). 









































Search Round 4 
Database IPVision, Inc. 
(access and password granted by Joseph G. Hadzima 
(US & EP applications and patents, WIPO PCT publications) 
Keywords DNA, Vaccine*, 
HIV, human immune* virus,  
Search Strings US 5420030- 9 
US 5824310- 7 
US 5869624- 1 
US 6534312- 3 
US 6649409-3 
Results 23 patents considered; 
Locate 0 results might be relevant 
 
Database Delphion  
(Derwent World Patent Index (DWPI) Patent Database) 
Keywords Researchers listed on National Center for Biotechnology Information  
(NCBI) website as inventors, HIV, vaccine 
Classification of  
Derwent Database 
Not in use 
Search strings France researchers: 
((((verrier b) or (le grand) or (ataman-onal) or (terrat c) or (guillon c)  
or durand or (hurtrel b) or aubertin or (sutter g) or (erfle v)  
or (girard m) ) <in> IN ) and ((hiv*) <in> AB ) and ((hiv*) <in> TI)): 
13 
 
((((((belliard g) or (romieu a) or (zagury jf) or (dali h) or (chalion o)  
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or (le grand) or (loret e) or briand or (roques b) or (desgranges c)  
or (muller s) <in> IN ) AND ((hiv*) <in> AB )  
AND ((hiv*) <in> TI))))): 14 
 
((((riviere y) or (le grand r) or corre or camugli or (michel ml)  
or (borgne sl)) <in> IN ) AND ((hiv*) <in> AB)): 2 
 
Italy researchers 
((((cafaro a) or (titti f) or (fracasso c) or maggiorella or  
(baroncelli s) or (caputo a) or (goletti d) or (brosetti a) or 
 (pace m) or fanales-belasio or (ridolfi b) or negri or (sernicola l) 
 or (belli r) or (corrias f) or (macchia i)  
or (leone p) or (michelini z) or (ten haaft) or (butto s) or (verani p)  
or (ensoli b)) <in> IN ) AND ((hiv*) <in> AB)): 8 
 
UC Davis researchers 
((((busch m) or (lu d) or (fritts l) or (lifson jd) or (miller cj) ) <in> IN )  
AND ((hiv*) <in> AB)): 14 
 
NIH researchers 
((((patterson lj) or (malkevitch n) or (venzon d) or (pinczewski j) or  
(gomeez-roman) or (wang l) or kalyanaraman or markham  
or (robey FA) or (robert-guroff)) <in> IN ) AND ((hiv*) <in> AB )  
AND ((hiv*) <in> TI)): 27 
 
Harvard researchers: 
Derwent Results for Query: (((korioth or lord or yu or beddall  
or gorgone or miura or philippon or manson or markham or parrish  
or gelman or panicali or barouch or fu or montefiori lewis or shiver  
or letvin or craiu or santra or egan or schmitz or kuroda or nam  
or wyatt or lifton or krivulka or nickerson or lord or moss or hirsch  
or mckay or gorgone) <in> IN ) and ((hiv*) <in> TI )  
AND ((hiv*) <in> AB) AND vaccin*): 62 
 
Results 140 patents;  
Locate 62 might be relevant patents 
 
Database Delphion  
(Derwent World Patent Index (DWPI) Patent Database) 
Keywords Researchers listed on National Center for Biotechnology Information  
(NCBI) website as inventors, HIV, vaccine 
Classification of  
Derwent Database 
Not in use 
Search strings (US & EP applications and patents, WIPO PCT publications) 
 
US researchers: 
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(((smith jm) or (amara rr) or (robinson hl) or (moss b) or  
(villinger f) or (derby nr) or (kraft z) or (stamatatos l) or (binley jm)) 




(((verschoor ej) or (davis d) or (koopman g) or (morein b) or (heeney jl) 
or barnett or (wagner r) or (mooij p)  
or (nieuwenhuis ig)) <in> IN): 3, 764 
 
((HIV) <in> AB) AND (((verschoor ej) or (davis d) or  
(koopman g) or (morein b) or (heeney jl) or barnett or (wagner r) or  
(mooij p) or (nieuwenhuis ig)) <in> IN) AND ((HIV) <in> TI): 57 
 
((HIV and DNA) <in> CLAIMS) AND ((HIV) <in> AB)  
AND (((verschoor ej) or (davis d) or (koopman g) or (morein b)  
or (heeney jl) or barnett or (wagner r) or (mooij p)  
or (nieuwenhuis ig)) <in> IN) AND ((HIV) <in> TI): 21 
Results Duplicate patents assessed 
 
 
5.C. Patent Search Results Spreadsheet Summary 
5.C.1. Categorization Summary 
 
Construction, optimization and delivery mechanism are the major three landscape tiers selected 
to subcategorize the HIV DNA Vaccine patents/applications found in this project.  
 
Construction relates to working with DNA elements constituting DNA vaccines. Included under 
this tier are inventions directed to design of DNA backbones, selection elements, HIV genes, 
leader sequence, secretary signals and promoters.  
 
Under construction, wherever SIV genomes are employed instead of and/or in addition to HIV’s, 
it is indicated on a separate column as Y (Yes) or N (No).   
 
Optimization relates to working with DNA vaccines to optimize their efficacy as a vaccine. 
Included in this tier are inventions related to codon optimization of genes utilized in the DNA 
vaccine. 
 
Adjuvants under optimization, relate to substances utilized to potentiate or increase the vaccine 
efficiency, and may take a form of a gene constituting part of the DNA structure of a DNA 
vaccine (molecular adjuvant, such as a cytokine gene incorporated into a plasmid) or a form of 
protein/peptide or other chemical forms which are usually combined later with a DNA vaccine. 
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Delivery mechanism relates to the administration of DNA vaccines to hosts or vaccination 
strategy such as prime boost. Included in this tier are inventions specifically related to deliver 
DNA vaccines to hosts through various methods such as gene gun, electroporation and lipids. 
 
Wherever, DNA vaccines are part of prime boost strategy (DNA vaccination followed by other 
methods of vaccination, or vice versa), the corresponding claims are indicated.  
 
5.C.2. Master Spreadsheet 
 
(See following pages) 
 




on  (y/n) 
Optimizat













Title Publication Date Assignee/Applicant Name
EP1279404A1 Y N N N na na 
Use of HIV-1 tat, fragments or 
derivatives thereof, to target or to 
activate antigen-presenting cells, 
to deliver cargo molecules for 
vaccination or to treat other 
diseases 
2003/1/2
9 Istituto Superiore di Sanit
EP1369427A2 Y N N N na na HIV-3 retrovirus strains and their use 
2003/12/
10 INNOGENETICS N.V. 
EP1402019A4 Y N N Y na na 
MOLECULAR CLONES WITH 
MUTATED HIV GAG/POL, SIV 
GAG AND SIV ENV GENES 
2006/4/1
9 US GOVERNMENT 
EP335635A1 Y N N N na na Mutated HIV envelope protein 1989/10/4 
THE BOARD OF 
TRUSTEES OF THE 
LELAND STANFORD 
JUNIOR UNIVERSITY 
EP449116B2 Y N N N na na 
DNA sequences encoding 
modified retroviral gag 
polypeptides and vaccines 
containing them or aggregates 
thereof 
2004/8/2
5 Geneart GmbH 
US4952499 Y N Y N na na 
Genes and their encoded proteins 
which regulate gene expression 
of the interleukin-2 receptor and 





CANCER INST INC 
(DAND:Standard 
company) 
US5100662 N Y N N na 9 Steroidal liposomes exhibiting enhanced stability 
1992/3/3
1 
LIPOSOME CO INC 
(LIPO:Standard company)
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US5130247 Y N N N na na Expression of fusion protein of HIV envelope and HBsAG 
1992/7/1
4 
MERCK & CO INC 
(MERI:Standard 
company) 
US5130248 Y N N N na na Expression of fusion protein of HIV envelope and HBsAg 
1992/7/1
4 
MERCK & CO INC 
(MERI:Standard 
company) 
US5141867 Y N N N na na 
Nucleotide sequence encoding a 




DU PONT DE 
NEMOURS & CO E I 
(DUPO:Standard 
company) 






RAD LAB INC 
(BIRA:Standard 
company)|BRISTOL-
MYERS SQUIBB CO 
(BRIM:Standard 
company) 
US5439809 Y N N N na na Non-infectious HIV particles lacking long terminal repeats 1995/8/8






US5571712 Y N N N na na 
Non-infectious, replication 
defective, immunogenic HIV 
retrovirus-like particles produced 
from a recombinant HIV genome 
devoid of long terminal repeats 
1996/11/
5 
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US5654195 Y N N Y na na 
Vectors expressing hybrid 










US5665577 Y N N N na na 
Vectors containing HIV 
packaging sequences, packaging 




CANCER INST INC 
(DAND:Standard 
company) 
US5766625 N N Y N na na Artificial viral envelopes 1998/6/16 




US5795577 Y N N N na na 
Viral vector coding for a 
glycoprotein of the virus 



















US5866131 Y N N N na na Recombinant vaccine 1999/2/2
RAMSHAW I A 
(RAMS:Individual)|COM
MONWEALTH SCI & 
IND RES ORG 
(CSIR:Standard 
company)|UNIV 




US5869313 Y N N N na na 
Molecular clones of HIV-1 viral 
strains MN-ST1 and BA-L, and 
uses thereof 
1999/2/9










US5981276 Y N N N na na 
Vectors containing HIV 
packaging sequences, packaging 





CANCER INST INC 
(DAND:Standard 
company) 
US6086891 Y N N N na na 
Bi-functional plasmid that can act 
as both a DNA vaccine and a 
recombinant virus vector 
2000/7/1
1 











US6210663 N N Y N 1,2,3,4,10 10,11 
Methods of augmenting mucosal 
immunity through systemic 
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US6348450 N N Y N na na 
Noninvasive genetic 
immunization, expression 




UAB RES FOUND 
(UABR:Non-standard 
company)|CURIEL D T 
(CURI:Individual)|KAMP
EN K R V 
(KAMP:Individual)|MAR





KAMPEN K R 
(VKAM:Individual) 
US6420545 Y N N N na na 
CD4-independent HIV envelope 









company)|DOMS R W 
(DOMS:Individual)|HOFF
MAN T L 
(HOFF:Individual)|HOXI
E J A 
(HOXI:Individual)|LABR
ANCHE C C 
(LABR:Individual) 
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US6534062 N Y N N na na 
Methods for increasing a 





















US6534312 Y Y N N na na Vaccines comprising synthetic genes 
2003/3/1
8 
DAVIES M E 
(DAVI:Individual)|FREE




Y H C 
(PERR:Individual)|SHIVE
R J W 
(SHIV:Individual)|MERC
K & CO INC 
(MERI:Standard 
company) 
US6541003 Y N N N na na Conditionally controlled, attenuated HIV vaccine 2003/4/1
INFECTIOUS DISEASES 
FOUND (INFE:Non-




S M (SMIT:Individual) 













US6586409 Y N Y N na 1 
Adjuvant compositions and 






company)|WHEELER C J 
(WHEE:Individual) 
US6635624 N N Y N na na 
Nucleotide vector composition 
containing such vector and 
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(INSP:Standard company)
US6649409 Y Y N N na na 
Method for producing a 
nucleotide sequence construct 
with optimized codons for an 
HIV genetic vaccine based on a 
primary, early HIV isolate and 










US6656706 Y N N N na na 
Molecular clones with mutated 








US6696291 Y Y N N 8 na Synthetic HIV gag genes 2004/2/24 
DAVIES M E 
(DAVI:Individual)|FREE




Y H C 
(PERR:Individual)|SHIVE
R J W 
(SHIV:Individual)|MERC
K & CO INC 
(MERI:Standard 
company) 
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US6716823 N N Y N na na 
Noninvasive genetic 
immunization, expression 
products therefrom, and uses 
thereof 
2004/4/6
UAB RES FOUND 
(UABR:Non-standard 
company)|CURIEL D T 
(CURI:Individual)|KAMP
EN K R V 
(KAMP:Individual)|MAR





KAMPEN K R 
(VKAM:Individual) 
US6783939 Y N N N na na 
Alphavirus vectors and virosomes 































US6818442 Y N N Y na na 
AIDS DNA vaccine that prevents 





















US6894152 N Y N N na na 
Cloned DNA sequences related to 
the genomic RNA of 
lymphadenopathy-associated-
virus (LAV) and proteins 
2005/5/1
7 
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encoded by said LAV genomic 
RNA 
(INSP:Standard company)
US6919318 N N N N na All claims
Enhancing immune responses to 






US6998252 Y N N N na na 
Recombinant poxviruses having 
foreign DNA expressed under the 




















US7094408 N Y N N all claims na 
Immunogenicity using a 
combination of DNA and 








TIS PASTEUR LTD 
(AVET:Standard 
company)|US DEPT 
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(ALDO:Individual) 
US7205101 Y N N N na na 
Human immunodeficiency virus 
(HIV) nucleotide sequences, 





& DIAGNOSTICS INC 
(NOVS:Standard 
company) 
US7211659 Y N N N na na 
Polynucleotides encoding 
antigenic HIV type C 










RENSBURG E J 
(VREN:Individual)|ZUR 
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F H (WOLF:Individual) 
US2001004531
A1 Y N Y Y na na 
AIDS DNA vaccine that prevents 






















A1 N N Y N 1 na 
Postinfection human 
immunodeficiency virus (HIV) 
vaccination therapy 
2002/2/7 CHIRON CORP (CHIR:Standard company)
US2002022034
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A1 N Y N N all na 




BETT A J 
(BETT:Individual)|CASI
MIRO D R 
(CASI:Individual)|CAULF
IELD M J 
(CAUL:Individual)|CHAS




I E A 
(EMIN:Individual)|SHIVE
R J W 
(SHIV:Individual)|MERC




A1 N Y N N na na 





AIDS RES CENT 
(AARO:Non-standard 
company)|BARNETT S W 
(BARN:Individual)|SRIV
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US2002141975
A1 Y N N N na na 
Alphavirus vectors and virosomes 
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US2002172683
A1 N N Y N na na 
MHC-I-restricted presentation of 
HIV-1 virion antigens without 
viral replication. Application to 
the stimulation of CTL and 
vaccination in vivo; analysis of 















NAT RECH SCI 
(CNRS:Standard 
company)|CNRS CENT 
NAT RECH SCI 
(CNRS:Standard 
company)|INSERM INST 







A1 Y N N N na Y 
Genetically engineered co-
expression DNA vaccines, 























A M T (SHAT:Individual)
US2003021800
A1 Y N N N na na 
Vaccine against infectious agents 
having an intracellular phase, 
composition for the treatment and 
prevention of HIV infections, 












RM INST NAT SANTE 
& RECH MEDICALE 
(INRM:Standard 
company)|INST NAT 





A1 Y Y N N 7 7,9,11 Synthetic HIV gag genes 
2003/3/1
3 
DAVIES M E 
(DAVI:Individual)|FREE
D D C 
(FREE:Individual)|LIU M 
A 
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(LIUM:Individual)|PERR
Y H C 
(PERR:Individual)|SHIVE
R J W 
(SHIV:Individual)|MERC




A1 Y N Y N na na 
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US2003087225
A1 Y Y N N na na Synthetic HIV genes 2003/5/8
DAVIES M E 
(DAVI:Individual)|FREE




Y H C 
(PERR:Individual)|SHIVE
R J W 
(SHIV:Individual)|MERC




A1 Y N N N na na 
CD4-independent HIV envelope 









company)|DOMS R W 
(DOMS:Individual)|HOFF
MAN T L 
(HOFF:Individual)|HOXI
E J A 
(HOXI:Individual)|LABR
ANCHE C C 
(LABR:Individual) 
US2003096778
A1 Y Y N N na 20,21 
Polynucleotide vaccines 
expressing codon optimized hiv-1 







R J W 
(SHIV:Individual)|MERC
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A1 N Y N N na 12 



















A1 Y N N N na na 























V M (USTA:Individual) 
US2003158131
A1 Y N N N na na 










A1 N Y Y N na 9,10 
Vaccine for the prophylactic or 






































A1 Y N N N na na 
Compositions and methods for 





company)|AMARA R R 
(AMAR:Individual)|BRIG
HT R A 
(BRIG:Individual)|BUTE






NBERGER D L 
(ELLE:Individual)|FOLK
S T M 
(FOLK:Individual)|HILD














T L S 
(WYAT:Individual)|US 





A1 N N N N na Y Adjuvant 
2003/10/
9 
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US2003228327
A1 Y Y N N na na 
DNA-based plasmid formulations 
and vaccines and prophylactics 
containing the same 
2003/12/
11 
PICOSCRIPT LTD LLP 
(PICO:Non-standard 
company)|KITTLE J D 
(KITT:Individual)|LASHE
R A W 
(LASH:Individual)|WIDE
N S G (WIDE:Individual)
US2004033237
A1 N N N N Y na 
Immunogenicity using a 
combination of dna and vaccinia 








TIS PASTEUR LTD 
(AVET:Standard 
company)|US DEPT 
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Year  Count 
Publication 
Year  Count 
2008   2   1999   5   
2007   18   1998   5   
2006   18   1997   4   
2005   20   1996   1   
2004   24   1995   2   
2003   32   1994   3   
2002   11   1992   4   
2001   15   1990   1   
2000   8   1989   1   
 
Figure 2. Patent counts according to publication date. DNA vaccine patents within the scope of 
present search reached maximum in 2003 and decreased thereafter. Shown in a bar graph (A) and 
a table (B). 
 
 














 Filed Year  Count  Filed Year  Count 
2007   6   1997   5   
2006   8   1996   4   
2005   16   1995   2   
2004   16   1994   8   
2003   22   1993   4   
2002   23   1992   2   
2001   20   1991   2   
2000   17   1989   1   
1999   11   1988   5   
 
Figure 3: Patent counts according to filing date. DNA vaccine patents within the scope of 
present search reached maximum in 2002 and decreased thereafter. Shown in a bar graph (A) and 
a table (B). 
 








IPC-R Code- 4 digit  Items 
A61K A — Human Necessities; Medical or Veterinary Science   151   
C07K C — Chemistry; Metallurgy; Organic Chemistry   119   
C12N C — Chemistry; Metallurgy; Biochemistry   96   
A61P A — Human Necessities; Medical or Veterinary Science   49   
C07H C — Chemistry; Metallurgy; Organic Chemistry   29   
C12Q C — Chemistry; Metallurgy; Biochemistry   24   
C12P C — Chemistry; Metallurgy; Biochemistry   21   
G01N G — Physics; Measuring (counting G06M   8   
C12R C — Chemistry; Metallurgy; Biochemistry   6   
A01N A — Human Necessities; Agriculture; Forestry   4   
A01K A — Human Necessities; Agriculture; Forestry   3   
C07D C — Chemistry; Metallurgy; Organic Chemistry   2   
 
Figure 4. Patent counts according to IPC classification. More than 60% of DNA vaccine patents 
within the scope of the present search fall under A61K followed by C12N and C07K. Shown in a 
bar graph (A), a pie chart (B) and a table (C).  
 
 
Patent Count vs. Derwent Class 
 
Class  Count 
B04 Natural products and polymers. 171 
D16 Fermentation industry. 167 
C06 Biotechnology - including plant genetics and veterinary 
vaccines. 13 
S03 Scientific Instrumentation. 10 
A96 Medical, dental, veterinary, cosmetic. 6 
P14 Animal care (A01K, L, M). 4 
B07 General. 3 
C03 Other organic compounds, inorganic compounds and multi-
component mixtures. Polymers and proteins. 1 
C07 Apparatus, formulation, general. 1 
 
Figure 5. Patent counts according to Derwent classification. DNA vaccine patents within the 




Patent Count vs. Assignee 
 
Name Count 
NOT ASSIGNED YET   52   
THE UNITED STATES OF AMERICA AS REPRESENTED BY 
THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 14 
CHIRON CORPORATION   13   
MERCK & CO., INC.   12   
GLAXO GROUP LIMITED   6   
DANA-FARBER CANCER INSTITUTE   5   
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA   4   
AARON DIAMOND AIDS RESEARCH CENTRE   3   
INSTITUT PASTEUR   3   
PROGENICS PHARMACEUTICALS, INC.   3   
SMITHKLINE BEECHAM BIOLOGICALS S.A.   3   
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA   3   
 
Figure 6. Patent counts according to assignee.  
 
Patent Count vs. Inventor 
 
Name Count 
SHIVER, JOHN 17 
BARNETT, SUSAN 14 
ERTL, PETER 12 
PERRY, HELEN C. 11 
DAVIES, MARY ELLEN 8 
FREED, DANIEL C. 8 
PAVLAKIS, GEORGE 8 
VAN WELY, CATHERINE ANN 8 
LIU, MARGARET A. 6 
CASIMIRO, DANILO R. 5 
 
Figure 7.  Patent counts according to inventor 
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1. Vaccine. 2001 Mar 21;19(17-19):2485-95. 
 
Expansion of HBV-specific memory CTL primed by dual HIV/HBV genetic immunization 
during SHIV primary infection in rhesus macaques. 
 
Borgne SL, Michel ML, Camugli S, Corre B, Le Grand R, Rivière Y. 
 
We have previously shown the induction of humoral and cytotoxic responses specific for human 
immunodeficiency virus (HIV) and hepatitis B virus (HBV) antigens, following genetic 
immunization of rhesus macaques with a plasmid encoding both the third variable domain of the 
HIV-1 external envelope glycoprotein and the pseudo-viral particle of hepatitis B surface antigen 
(HBsAg) as presenting molecules. The DNA-immunized primates and two control animals were 
then challenged with a chimeric simian/human immunodeficiency virus (SHIV). They were all 
infected. Significant frequencies of SHIV specific cytotoxic T lymphocyte precursors (CTLp) 
were detected early in peripheral blood. But, in all DNA-immunized macaques, HBV envelope 
specific CTLp were detected during the primary infection, and they were correlated with the 
peak of SHIV viremia. Furthermore, HBV or SHIV specific cytotoxicity corresponded in part to 
CD8(+) T cells presenting a memory phenotype. Several mechanisms could account for this 
cellular response. But our results suggest that an expansion of memory cytotoxic CD8(+) cells, 





2. DNA Cell Biol. 2002 Sep;21(9):653-8.  
 
Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine 
against mucosal challenge with SHIV-BX08. 
 
Verrier B, Le Grand R, Ataman-Onal Y, Terrat C, Guillon C, Durand PY, Hurtrel B, Aubertin 
AM, Sutter G, Erfle V, Girard M. 
 
Recent evidence suggests that a CD8-mediated cytotoxic T-cell response against the regulatory 
proteins of human immunodeficiency virus (HIV) or simian immunodeficiency virus (SIV) may 
control infection after pathogenic virus challenge. Here, we evaluated whether vaccination with 
Tat or Tat and Rev could significantly reduce viral load in nonhuman primates. Rhesus 
macaques were primed with Semliki forest Virus (SFV) expressing HIV-1 tat (SFV-tat) and 
HIV-1 rev (SFV-rev) and boosted with modified vaccinia virus Ankara (MVA) expressing tat 
and rev. A second group of monkey was primed with SFV-tat only and boosted with MVA-tat. A 
third group received a tat and rev DNA/MVA prime-boost vaccine regimen. Monitoring of anti-
Tat and anti-Rev antibody responses or antigen-specific IFN-gamma production, as measured by 
enzyme-linked immunospot assays revealed no clear differences between the three groups. These 
123 
 
results suggest that priming with either DNA or SFV seemed to be equivalent, but the additive or 
synergistic effect of a rev vaccine could not be clearly established. The animals were challenged 
by the rectal route 9 weeks after the last booster immunization, using 10 MID(50) of a SHIV-
BX08 stock. Postchallenge follow-up of the monkeys included testing seroconversion to Gag and 
Env antigens, measuring virus infectivity in PBMC by cocultivation with noninfected human 
cells, and monitoring of plasma viral load. None of the animals was protected from infection as 
assessed by PCR, but peak viremia was reduced more than 200-fold compared to sham controls 
in one third (6/18) of vaccinated macaques, whatever the vaccine regimen they received. 
Interestingly, among these six protected animals four did not seroconvert. Altogether, these 
results clearly indicated that the addition of early HIV proteins like Tat and Rev in a 
multicomponent preventive vaccine including structural proteins like Env or Gag may be 




3. Vaccine. 2003 Jul 4;21(23):3186-99. 
 
Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus 
macaques and HIV-infected individuals. 
 
Belliard G, Romieu A, Zagury JF, Dali H, Chaloin O, Le Grand R, Loret E, Briand JP, Roques 
B, Desgranges C, Muller S. 
 
Recent contributions have demonstrated that actively secreted Tat protein plays an important 
functional role in human immunodeficiency virus-1 (HIV-1) infection and that Tat antibodies 
might interfere with disease progression by blocking the protein extracellularly. In this context 
we have studied the recognition of several Tat mutants as well as various synthetic Tat fragments 
by anti-Tat monoclonal antibodies and by IgG antibodies from a large collection of slow and 
fast-progressor infected individuals. We have also tested the sera from simian/human 
immunodeficiency virus (SHIV)-infected macaques with these Tat peptides. Important 
differences were found between long-term non-progressors and fast-progressors, and between 
human and monkey sera in terms of antibody specificity. Rabbits and macaques were immunised 
with several Tat peptides and we found that certain antibody subsets from immunised animals 
recognised the cognate protein Tat and had the capacity to inhibit Tat-induced apoptosis of T 








4. Vaccine. 2004 Sep 3;22(25-26):3258-69. 
 





Maggiorella MT, Baroncelli S, Michelini Z, Fanales-Belasio E, Moretti S, Sernicola L, Cara A, 
Negri DR, Buttò S, Fiorelli V, Tripiciano A, Scoglio A, Caputo A, Borsetti A, Ridolfi B, Bona 
R, ten Haaft P, Macchia I, Leone P, Pavone-Cossut MR, Nappi F, Ciccozzi M, Heeney J, Titti F, 
Cafaro A, Ensoli B. 
 
Vaccination with a biologically active Tat protein or tat DNA contained infection with the highly 
pathogenic SHIV89.6P virus, preventing CD4 T-cell decline and disease onset. Here we show 
that protection was prolonged, since neither CD4 T-cell decline nor active virus replication was 
observed in all vaccinated animals that controlled virus replication up to week 104 after the 
challenge. In contrast, virus persisted and replicated in peripheral blood mononuclear cells and 
lymph nodes of infected animals, two of which died. Tat-specific antibody, CD4 and CD8 T-cell 
responses were high and stable only in the animals controlling the infection. In contrast, Gag-
specific antibody production and CD4 and CD8 T-cell responses were consistently and 
persistently positive only in the monkeys that did not control primary virus replication. These 
results indicate that vaccination with Tat protein or DNA induced long-term memory Tat-
specific immune responses and controlled primary infection at its early stages allowing a long-
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5. J Med Primatol. 2003 Aug;32(4-5):240-6. 
 
Comparison of virology and immunology in SHIV 89.6 proviral DNA and virus-inoculated 
rhesus macaques. 
 
Busch M, Lu D, Fritts L, Lifson JD, Miller CJ. 
 
Inoculation of cats, goats and monkeys with plasmids encoding full-length proviral genomes 
results in persistent lentiviral infections. This system could be used as a method for 
administration of an attenuated human immunodeficiency virus (HIV) vaccine. Here, we 
compare the virology and immunology in rhesus macaques inoculated with either simian/human 
immunodeficiency virus 89.6 (SHIV 89.6) virus or a plasmid containing the SHIV 89.6 proviral 
genome. There was a delay in appearance of systemic infection in DNA-inoculated animals 
compared with virus-inoculated animals, but otherwise the pattern of infection was similar. The 
serum immunoglobulin G anti-simian immunodeficiency virus (SIV) binding antibody response 
in DNA-inoculated animals was also delayed compared with virus-inoculated animals, but 
ultimately there was no difference between live virus and DNA-inoculation in the ability to 
induce the anti-SIV immune responses that were measured. Thus, the data support the concept 









6. J Virol. 2004 Mar;78(5):2212-21.  
 
Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using 
replicating adenovirus-SIV multigene vaccine priming and subunit boosting. 
 
Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gómez-Román VR, Wang L, 
Kalyanaraman VS, Markham PD, Robey FA, Robert-Guroff M. 
 
Whereas several recent AIDS vaccine strategies have protected rhesus macaques against a 
pathogenic simian/human immunodeficiency virus (SHIV)(89.6P) challenge, similar approaches 
have provided only modest, transient reductions in viral burden after challenge with virulent, 
pathogenic SIV, which is more representative of HIV infection of people. We show here that 
priming with replicating adenovirus recombinants encoding SIV env/rev, gag, and/or nef genes, 
followed by boosting with SIV gp120 or an SIV polypeptide mimicking the CD4 binding region 
of the envelope, protects rhesus macaques from intrarectal infection with the highly pathogenic 
SIV(mac251). Using trend analysis, significant reductions in acute-phase and set point viremia 
were correlated with anti-gp120 antibody and cellular immune responses, respectively. Within 
immunization groups exhibiting significant protection, a subset (39%) of macaques have 
exhibited either no viremia, cleared viremia, or controlled viremia at the threshold of detection, 
now more than 40 weeks postchallenge. This combination prime-boost strategy, utilizing 







7. Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11088-93. Epub 2004 Jul 16. 
 
Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory 
T lymphocyte responses. 
 
Santra S, Barouch DH, Korioth-Schmitz B, Lord CI, Krivulka GR, Yu F, Beddall MH, Gorgone 
DA, Lifton MA, Miura A, Philippon V, Manson K, Markham PD, Parrish J, Kuroda MJ, Schmitz 
JE, Gelman RS, Shiver JW, Montefiori DC, Panicali D, Letvin NL. 
 
Although a consensus has emerged that an HIV vaccine should elicit a cytotoxic T lymphocyte 
(CTL) response, the characteristics of an effective vaccine-induced T lymphocyte response 
remain unclear. We explored this issue in the simian human immunodeficiency virus/rhesus 
monkey model in the course of assessing the relative immunogenicity of vaccine regimens that 
included a cytokine-augmented plasmid DNA prime and a boost with DNA or recombinant pox 
vectors. Recombinant vaccinia virus, recombinant modified vaccinia Ankara (MVA), and 
recombinant fowlpox were comparable in their immunogenicity. Moreover, whereas the 
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magnitude of the peak vaccine-elicited T lymphocyte responses in the recombinant pox virus-
boosted monkeys was substantially greater than that seen in the monkeys immunized with 
plasmid DNA alone, the magnitudes of recombinant pox boosted CTL responses decayed rapidly 
and were comparable to those of the DNA-alone-vaccinated monkeys by the time of viral 
challenge. Consistent with these comparable memory T cell responses, the clinical protection 
seen in all groups of experimentally vaccinated monkeys was similar. This study, therefore, 
indicates that the steady-state memory, rather than the peak effector vaccine-elicited T 





8. Immunol Lett. 2001 Nov 1;79(1-2):57-61. 
 
Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus 
monkeys. 
 
Barouch DH, Fu TM, Montefiori DC, Lewis MG, Shiver JW, Letvin NL. 
 
Accumulating evidence has demonstrated the importance of cytotoxic T lymphocytes (CTLs) 
and helper T lymphocytes in controlling HIV-1 replication. We have elicited immune responses 
in rhesus monkeys utilizing DNA vaccines augmented by the administration of IL-2/Ig, a fusion 
protein consisting of interleukin-2 and the Fc portion of IgG2. These vaccine-elicited immune 
responses did not prevent infection following a high-dose intravenous challenge with 
SHIV(89.6P) but did control viremia to nearly undetectable levels and prevented 
immunodeficiency and clinical disease. In contrast, control monkeys developed high levels of 
viremia and exhibited a rapid loss of CD4(+) T cells, significant clinical disease progression, and 
death in half of the animals by day 140 following challenge. Vaccine approaches that elicit 
immune responses capable of reducing plasma viral loads, but not capable of inducing sterilizing 




9. J Virol. 2001 Mar;75(5):2462-7. 
 
Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and 
subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus 
monkeys. 
 
Barouch DH, Craiu A, Santra S, Egan MA, Schmitz JE, Kuroda MJ, Fu TM, Nam JH, Wyatt LS, 
Lifton MA, Krivulka GR, Nickerson CE, Lord CI, Moss B, Lewis MG, Hirsch VM, Shiver JW, 
Letvin NL. 
 
Increasing evidence suggests that the generation of cytotoxic T-lymphocyte (CTL) responses 
specific for a diversity of viral epitopes will be needed for an effective human immunodeficiency 
virus type 1 (HIV-1) vaccine. Here, we determine the frequencies of CTL responses specific for 
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the simian immunodeficiency virus Gag p11C and HIV-1 Env p41A epitopes in simian-human 
immunodeficiency virus (SHIV)-infected and vaccinated rhesus monkeys. The p11C-specific 
CTL response was high frequency and dominant and the p41A-specific CTL response was low 
frequency and subdominant in both SHIV-infected monkeys and in monkeys vaccinated with 
recombinant modified vaccinia virus Ankara vectors expressing these viral antigens. 
Interestingly, we found that plasmid DNA vaccination led to high-frequency CTL responses 
specific for both of these epitopes. These data demonstrate that plasmid DNA may be useful in 





10. J Immunol. 2002 Jan 1;168(1):332-7. 
 
Vaccine protection against functional CTL abnormalities in simian human immunodeficiency 
virus-infected rhesus monkeys. 
 
McKay PF, Schmitz JE, Barouch DH, Kuroda MJ, Lifton MA, Nickerson CE, Gorgone DA, 
Letvin NL. 
 
Accumulating evidence suggests that HIV-specific CD8(+) CTL are dysfunctional in HIV-
infected individuals with progressive clinical disease. In the present studies, cytokine production 
by virus-specific CTL was assessed in the rhesus monkey model for AIDS to determine its 
contribution to the functional impairment of CTL. CTL from monkeys infected with 
nonpathogenic isolates of simian and simian-human immunodeficiency virus expressed high 
levels of IFN-gamma, TNF-alpha, and IL-2 after in vitro exposure to a nonspecific mitogen or 
the optimal peptide representing a dominant virus-specific CTL epitope. However, similarly 
performed studies assessing these capabilities in CTL from monkeys infected with pathogenic 
immunodeficiency virus isolates demonstrated a significant dysfunction in the ability of the CTL 
to produce IL-2 and TNF-alpha. Importantly, CTL from vaccinated monkeys that effectively 
controlled the replication of a highly pathogenic simian-human immunodeficiency virus isolate 
following challenge demonstrated a preserved capacity to produce these cytokines. These 
experiments suggest that defects in cytokine production may contribute to CTL dysfunction in 
chronic HIV or SIV infection. Moreover, an AIDS vaccine that confers protection against 
clinical disease evolution in this experimental model also preserves the functional capacity of 







11. AIDS Res Hum Retroviruses. 2005 Feb;21(2):140-4. 
 
Studies in macaques on cross-clade T cell responses elicited by a DNA/MVA AIDS vaccine, 




Smith JM, Amara RR, Wyatt LS, Ellenberger DL, Li B, Herndon JG, Patel M, Sharma S, 
Chennareddi L, Butera S, McNicholl J, McClure HM, Moss B, Robinson HL. 
 
One of the unknowns faced by an HIV/AIDS vaccine is the ability of a single clade vaccine to 
protect against the multiple genetic subtypes and recombinant forms of HIV-1 present in the 
current pandemic. Here, we use a macaque model to investigate the ability of our clade B 
vaccine that consists of DNA priming and modified vaccinia Ankara (MVA) virus boosting to 
elicit T cell responses that recognize an A/G recombinant of HIV-1. To test for cross-reactive T 
cells, intracellular cytokine staining was conducted using five pools of Gag and six pools of Env 
peptides representing B or A/G sequences. Studies using the peptide pools revealed essentially 
complete conservation of the CD8 response but only approximately 50% conservation of the 
CD4 response. Thus, the ability of an HIV vaccine for one clade to protect against other clades 





12. J Virol. 2002 Aug;76(15):7625-31. 
 
Different patterns of immune responses but similar control of a simian-human immunodeficiency 
virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA 
vaccines. 
 
Amara RR, Villinger F, Staprans SI, Altman JD, Montefiori DC, Kozyr NL, Xu Y, Wyatt LS, 
Earl PL, Herndon JG, McClure HM, Moss B, Robinson HL. 
 
Recently we demonstrated the control of a mucosal challenge with a pathogenic chimera of 
simian and human immunodeficiency virus (SHIV-89.6P) by priming with a Gag-Pol-Env-
expressing DNA and boosting with a Gag-Pol-Env-expressing recombinant modified vaccinia 
virus Ankara (DNA/MVA) vaccine. Here we evaluate the ability of the MVA component of this 
vaccine to serve as both a prime and a boost for an AIDS vaccine. The same immunization 
schedule, MVA dose, and challenge conditions were used as in the prior DNA/MVA vaccine 
trial. Compared to the DNA/MVA vaccine, the MVA-only vaccine raised less than 1/10 the 
number of vaccine-specific T cells but 10-fold-higher titers of binding antibody for Env. 
Postchallenge, the animals vaccinated with MVA alone increased their CD8 cell numbers to 
levels that were similar to those seen in DNA/MVA-vaccinated animals. However, they 
underwent a slower emergence and contraction of antiviral CD8 T cells and were slower to 
generate neutralizing antibodies than the DNA/MVA-vaccinated animals. Despite this, by 5 
weeks postchallenge, the MVA-only-vaccinated animals had achieved as good control of the 
viral infection as the DNA/MVA group, a situation that has held up to the present time in the 
trial (48 weeks postchallenge). Thus, MVA vaccines, as well as DNA/MVA vaccines, merit 






13. AIDS Res Hum Retroviruses. 2004 Jun;20(6):654-65. 
 
Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity 
in Macaques. 
 
Smith JM, Amara RR, McClure HM, Patel M, Sharma S, Yi H, Chennareddi L, Herndon JG, 
Butera ST, Heneine W, Ellenberger DL, Parekh B, Earl PL, Wyatt LS, Moss B, Robinson HL. 
 
Recently, a simian/human immunodeficiency virus (SHIV) vaccine consisting of priming with a 
Gag-Pol-Env-expressing DNA and boosting with a Gag-Pol-Env-expressing recombinant 
modified vaccinia Ankara (rMVA) has successfully controlled a virulent SHIV challenge in a 
macaque model. In this, and the accompanying paper, we report on the construction and testing 
of a Gag-Pol-Env DNA/MVA vaccine for HIV-1/AIDS. The DNA vaccine, pGA2/JS2, 
expresses aggregates of Gag proteins and includes safety mutations that render it integration, 
reverse transcription, and packaging defective. The rMVA vaccine, MVA/HIV 48, is integration 
and reverse transcription defective and has a truncated Env to enhance expression on the plasma 
membrane. In a study in rhesus macaques, priming with pGA2/JS2 and boosting with MVA/HIV 
48 raised high frequencies of T cells for Gag and Env and lower frequencies of T cells for PR, 
RT, and Tat. Stimulations with five peptide pools for Gag and seven peptide pools for Env 
revealed epitopes for cellular immune responses throughout Gag and Env. On average, CD4 T 
cells from the vaccinated animals recognized 7.1 peptide pools and CD8 T cells, 3.2 peptide 
pools. Both the height and the breadth of the elicited cellular response provide hope that this 
multiprotein DNA/MVA vaccine will successfully control clade B isolates of HIV-1, as well as 




14. AIDS Res Hum Retroviruses. 2004 Dec;20(12):1335-47. 
 
DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of 
aggregates or virus-like particles on the immunogenicity of the DNA prime. 
 
Smith JM, Amara RR, Campbell D, Xu Y, Patel M, Sharma S, Butera ST, Ellenberger DL, Yi H, 
Chennareddi L, Herndon JG, Wyatt LS, Montefiori D, Moss B, McClure HM, Robinson HL. 
 
Recently, a vaccine consisting of DNA priming followed by boosting with modified vaccinia 
Ankara (MVA) has provided long-term protection of rhesus macaques against a virulent 
challenge with a chimera of simian and human immunodeficiency viruses. Here, we report 
studies on the development of the DNA component for a DNA/MVA HIV vaccine for humans. 
Specifically, we assess the ability of a codon-optimized Gag-expressing DNA and two 
noncodon-optimized Gag-Pol-Env-expressing DNAs to prime the MVA booster dose. The 
codon-optimized DNA expressed virus-like particles (VLPs), whereas one of the noncodon-
optimized DNAs expressed VLPs and the other expressed aggregates of HIV proteins. The MVA 
boost expressed Gag-Pol and Env and produced VLPs. Immunogenicity studies in macaques 
used one intramuscular prime with 600 microg of DNA and two intramuscular boosts with 1 x 
10(8) pfu of MVA at weeks 8 and 30. The codon-optimized and noncodon-optimized DNAs 
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proved similar in their ability to prime anti-Gag T cell responses. The aggregate and VLP-
expressing Gag-Pol-Env DNAs also showed no significant differences in their ability to prime 
anti-Env Ab responses. The second MVA booster dose did not increase the peak CD4 and CD8 
T cell responses, but increased anti-Env Ab titers by 40- to 90-fold. MVA-only immunizations 
elicited 10-100 times lower frequencies of T cells and 2-4 lower titers of anti-Env Ab than the 
Gag-Pol-Env DNA/MVA immunizations. Based on the breadth of the T cell response and a trend 
toward higher titers of anti-Env Ab, we are moving forward with human trials of the noncodon-







15. J Virol. 2006 Sep;80(17):8745-62. 
 
Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 
(HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during 
homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 
infection. 
 
Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, Srivastava IK, Binley JM, Stamatatos L. 
 
The antibody responses elicited in rhesus macaques immunized with soluble human 
immunodeficiency virus (HIV) Env gp140 proteins derived from the R5-tropic HIV-1 SF162 
virus were analyzed and compared to the broadly reactive neutralizing antibody responses 
elicited during chronic infection of a macaque with a simian/human immunodeficiency virus 
(SHIV) expressing the HIV-1 SF162 Env, SHIV(SF162P4), and humans infected with 
heterologous HIV-1 isolates. Four gp140 immunogens were evaluated: SF162gp140, 
DeltaV2gp140 (lacking the crown of the V2 loop), DeltaV3gp140 (lacking the crown of the V3 
loop), and DeltaV2DeltaV3gp140 (lacking both the V2 and V3 loop crowns). SF162gp140 and 
DeltaV2gp140 have been previously evaluated by our group in a pilot study, but here, a more 
comprehensive analysis of their immunogenic properties was performed. All four gp140 
immunogens elicited stronger anti-gp120 than anti-gp41 antibodies and potent homologous 
neutralizing antibodies (NAbs) that primarily targeted the first hypervariable region (V1 loop) of 
gp120, although SF162gp140 also elicited anti-V3 NAbs. Heterologous NAbs were elicited by 
SF162gp140 and DeltaV2gp140 but were weak in potency and narrow in specificity. No 
heterologous NAbs were elicited by DeltaV3gp140 or DeltaV2DeltaV3gp140. In contrast, the 
SHIV(SF162P4)-infected macaque and HIV-infected humans generated similar titers of anti-
gp120 and anti-gp41 antibodies and NAbs of significant breadth against primary HIV-1 isolates, 
which did not target the V1 loop. The difference in V1 loop immunogenicity between soluble 
gp140 and virion-associated gp160 Env proteins derived from SF162 may be the basis for the 
observed difference in the breadth of neutralization in sera from the immunized and infected 






16. Virology. 2006 Nov 25;355(2):138-51. Epub 2006 Aug 22. 
 
Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or 
absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies. 
 
Burke B, Derby NR, Kraft Z, Saunders CJ, Dai C, Llewellyn N, Zharkikh I, Vojtech L, Zhu T, 
Srivastava IK, Barnett SW, Stamatatos L. 
 
Macaques were immunized with SF162 Env-based gp140 immunogens and challenged 
simultaneously with the CCR5-tropic homologous SHIV(SF162P4) and the CXCR4-tropic 
heterologous SHIV(SF33A) viruses. Both mock-immunized and immunized animals became 
dually infected. Prior immunization preferentially reduced the viral replication of the 
homologous virus during primary infection but the relative replication of the two coinfecting 
viruses during chronic infection was unaffected by prior immunization, despite the fact that five 
of six immunized animals maintained a significantly lower overall viral replication that the 
control animals. Neutralizing antibodies participated in controlling the replication of 
SHIV(SF162P4), but not that of SHIV(SF33A). Dual infection resulted in the emergence and 
predominance within the circulating CCR5 virus pool, of a variant with a distinct neutralization 
phenotype. The signature of this variant was the presence of three amino acid changes in gp120, 
two of which were located in the receptor and coreceptor binding sites. Also, a significant 
fraction of the viruses circulating in the blood, as early as two weeks post-infection, was 
recombinants and prior immunization did not prevent their emergence. These findings provide 
new insights into the dynamic interaction of CCR5- and CXCR4-tropic HIV isolates that are 







17. J Virol. 1999 Apr;73(4):3292-300. 
 
Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human 
immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. 
 
Verschoor EJ, Mooij P, Oostermeijer H, van der Kolk M, ten Haaft P, Verstrepen B, Sun Y, 
Morein B, Akerblom L, Fuller DH, Barnett SW, Heeney JL. 
 
The kinetics of T-helper immune responses generated in 16 mature outbred rhesus monkeys 
(Macaca mulatta) within a 10-month period by three different human immunodeficiency virus 
type 1 (HIV-1) vaccine strategies were compared. Immune responses to monomeric recombinant 
gp120SF2 (rgp120) when the protein was expressed in vivo by DNA immunization or when it 
was delivered as a subunit protein vaccine formulated either with the MF59 adjuvant or by 
incorporation into immune-stimulating complexes (ISCOMs) were compared. Virus-neutralizing 
antibodies (NA) against HIV-1SF2 reached similar titers in the two rgp120SF2 protein-
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immunized groups, but the responses showed different kinetics, while NA were delayed and their 
levels were low in the DNA-immunized animals. Antigen-specific gamma interferon (IFN-
gamma) T-helper (type 1-like) responses were detected in the DNA-immunized group, but only 
after the fourth immunization, and the rgp120/MF59 group generated both IFN-gamma and 
interleukin-4 (IL-4) (type 2-like) responses that appeared after the third immunization. In 
contrast, rgp120/ISCOM-immunized animals rapidly developed marked IL-2, IFN-gamma (type 
1-like), and IL-4 responses that peaked after the second immunization. To determine which type 
of immune responses correlated with protection from infection, all animals were challenged 
intravenously with 50 50% infective doses of a rhesus cell-propagated, in vivo-titrated stock of a 
chimeric simian immunodeficiency virus-HIVSF13 construct. Protection was observed in the 
two groups receiving the rgp120 subunit vaccines. Half of the animals in the ISCOM group were 
completely protected from infection. In other subunit vaccinees there was evidence by multiple 
assays that virus detected at 2 weeks postchallenge was effectively cleared. Early induction of 
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Efforts to broaden HIV-1-specific immunity by boosting with heterologous peptides or envelope 
protein and the influence of prior exposure to virus. 
 
Verschoor EJ, Davis D, van Gils M, Koopman G, Mooij P, Oostermeijer H, Haaft PT, 
Verstrepen B, Rosenwirth B, Morein B, Barnett SW, Heeney JL. 
 
In two previous studies, we have demonstrated the successful protection of human 
immunodeficiency virus type 1 (HIV-1)-vaccinated rhesus macaques from challenge with 
SHIV(SF13) with envelop immunogens derived from the closely related HIV-1(SF2) strain. Here 
we report on two follow-up studies in which we aimed to broaden immunity in order to elicit 
protection from a more diverse heterologous challenge with SHIV(SF33). In the first study, 
animals were boosted once with HIV-1(SF33) V2 and V3 peptides that were cross-linked to 
influenza immune-stimulating complexes (ISCOMs). In the second study, monkeys were boosted 
twice at 12-week intervals, using a heterologous recombinant gp120 derived from HIV-1(SF33) 
that was either incorporated into ISCOMs or mixed with the MF59 adjuvant. In both studies, the 
animals were challenged with 50 monkey infectious doses of SHIV(SF33) 4 weeks after the final 
boost. All controls became readily infected with the heterologous challenge virus SHIV(SF33). 
Neither boosting with heterologous SF33 peptides or gp120 afforded protection from infection to 
SF2-vaccinated animals that had previously resisted SHIV(SF13) challenge. These results 
demonstrate the importance of developing vaccine strategies that are capable of generating broad 
immune responses early in the immunization protocol. Furthermore, these findings may illustrate 








Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced 
immunity to simian/human immunodeficiency virus infection. 
 
Mooij P, Nieuwenhuis IG, Knoop CJ, Doms RW, Bogers WM, Ten Haaft PJ, Niphuis H, 
Koornstra W, Bieler K, Köstler J, Morein B, Cafaro A, Ensoli B, Wagner R, Heeney JL. 
 
Evidence is accumulating that CD4(+) T-helper (Th) responses play a critical role in facilitating 
effector responses which are capable of controlling and even preventing human 
immunodeficiency virus (HIV) infection. The present work was undertaken to determine whether 
immunization with multiple antigens influenced individual Th responses and increased 
protection relative to a single antigen. Rhesus macaques were primed with DNA and boosted 
(immune-stimulating complex-formulated protein) with a combination of regulatory and 
structural antigens (Tat-Env-Gag) or with Tat alone. Immunization with combined antigens 
reduced the magnitude of the responses to Tat compared to the single-antigen immunization. 
Interestingly, the Th immune responses to the individual antigens were noticeably different. To 
determine whether the qualitative differences in vaccine-induced Th responses correlated with 
vaccine efficacy, animals were challenged intravenously with simian/human immunodeficiency 
virus (strain SHIV(89.6p)) 2 months following the final immunization. Animals that developed 
combined Th1- and Th2-like responses to Gag and Th2 dominant Env-specific responses were 
protected from disease progression. Interestingly, one animal that was completely protected from 
infection had the strongest IFN-gamma and interleukin-2 (IL-2) responses prior to challenge, in 
addition to very strong IL-4 responses to Gag and Env. In contrast, animals with only a marked 
vaccine-induced Tat-specific Th2 response (no IFN-gamma) were not protected from infection 
or disease. These data support the rationale that effective HIV vaccine-induced immunity 










USPTO • Patents issued from 1790 through 1975 are searchable only by patent 
number, issue date, and current U.S. classifications. 
• US Patent Classification data in the Full-Text Database (Current US 
Classification [CCL]) is frequently updated to reflect the most current 
PTO Master Classification File (MCF), and will not necessarily match 
the classification data which appears on the patent full-page images (i.e., 
the printed patent) or on the Patent Classification pages. 
• The Issued Patents Full-Text Database is a database of patent full-text as 
it was printed on the patent on the day of issue. Changes to patent 
documents contained in Certificates of Correction and Re-examinations 
Certificates are not included in the searchable full-text of the patent 
databases, but are available as additional full page images at the end of 
each patent's linked full-page images. 
• Neither assignment changes nor address changes recorded at the USPTO 
are reflected in the patent full-text or the patent full-page images. 
• These databases have limited resources, both bandwidth and computer 
systems. Therefore, to assure availability to the general public, searches 
are limited in terms of both the length of the query and the amount of 
computer time available for any single search. In particular, if the fully-
expanded parsed query, which can be estimated by looking at a resulting 
hit-list link using your browser's Right-click-Properties capability, 
exceeds 256 characters in length, the query may be rejected by the 
parser, may time out before completion, or may produce invalid results 
even though it appears to have worked correctly. 
• The fact that an invention cannot be found by searching in the Patent 
Full-Text Database does not mean that the invention is patentable. The 
USPTO's text searchable patent database begins with patents granted 
since 1976. A complete patentability search must consider all prior art, 






GenomeQuest • GenomeQuest is a web based sequence searching system designed for 
scientists and intellectual property (IP) bio-analysts. GenomeQuest 
allows investigators to quickly identify and investigate relevant records, 
create reports on select records of interest, and maintain continuous 
sequence surveillance. 
 
• Sources for GenomeQuest: 
                                                 
70 See also Bumrae Cho et al., Educational Report: Patent Landscape of Several Bacillus Thuringiensis Cry Protein 
Genes in Sweetpotato 152–61(Franklin Pierce Law Center) (Jan. 2008). 
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1. USPTO: Data fetched daily; complete coverage starting from 1980 onward. 
2. EPO feeds/INPADOC: Data fetched weekly. Patent sequences from 1979 
onward 
3. WIPO & PCT: Data fetched weekly. Electronic and paper submissions. 
Patent sequences from 1980 onwards. 
4. GenBank, DDJB, EMBL: Weekly updates patent divisions. Patent 153 
sequences from 1969 onwards. 
• GenomeQuest GQ-PAT repository has 137 million total sequences, 
among which 67 million are unique patent number-sequence pairs 
spanning 179, 083 patent documents. GenBank patent division contains 
3.7 million sequences, about 5% of the sequences contained in GQ-
PAT. 
• GenomeQuest GQ-PAT database is processed using GenomeQuest’s 
proprietary pipeline which include manual curation to make all the 
sequences and annotations searchable and browseable. 
• GenomeQuest offers a single repository for search result analysis with 
powerful filtering, grouping, and sorting capabilities giving the ability 
to generate reports quickly and easily with only the relevant 
information. 










• Most comprehensive database of international patent information 
• Approximately 19,000 patent documents from over 40 patent-issuing 
authorities are reviewed and value enhanced by experts 
• Documents are read in their native language. Titles and abstracts are 
then rewritten in English to create a DWPI record 
• Included in the record is the drawing from the patent that is most 
representative of its claims and special indexing to help search for key 
patent information. 






Westlaw • Westlaw, which is owned by the Thompson Company, and can be 
accessed at is a premium access database that is useful for patent law 
practitioners. It provides access to the Derwent World Patent Index as 
well as relevant sources, including cases and statutes, patents and patent 
treatises, and post issuance information, such as KeyCite for patents. 
• The value added services from Westlaw can be accessed off the “Patent 
Practitioner” tab of the user’s account after login. This tab includes links 
to facilitate research in patent literature, cases, statutes, and regulations, 
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court records and litigation tracking. It also provides information on 
recent developments, litigation practice guides, prosecution practice 
guides, and forms. 
• Includes a link to Delphion that includes access to the full text of US, 
European, and PCT patents and patent applications, and the patent 
abstracts from Japan 
• Includes the ability to search full-text patents and a link to display the 
full original patent, including drawings in PDF 
• The Westlaw database contains full-text information of patents before 
1972, whereas other services just have bibliographic information 
• Links to Derwent databases, including the World Patent Index 
• Citing references provide relevant previous patent literature 
• Flexible pricing plans (i.e., large company or single attorney) 
• A link to “KeyCites” that covers all patents granted by the USPTO 
beginning with 1976 utility, design, and plant patents 
1. This link also includes access to reissued patents, defensive publications, and 
statutory invention registrations  
2. Can click on the flag on the document or result list or click “Full History” or 
“Citing References” links on the “Links” tab to retrieve KeyCite information 
for the patent 
Disadvantages: 
• Using certain truncations and connectors is difficult when using the 
Westlaw database 
• Hybrid searches often generate a large number of irrelevant results 
• Citing references are U.S. only 157 
• Data manipulation is less user-friendly in Westlaw than Dialog or 
Questel/Orbit 






LexisNexis • Is a premium and user-friendly website that offers point and click access 
to prior art (or “patent searching”) information: both patent and non-
patent literature. Patent prior art information includes primary legal 
materials, analytical legal materials, indices to foreign patents, European 
patents (and classifications), and treatises. Furthermore, Lexis gives the 
patent researcher access to INPADOC patent families. Non-patent prior 
art information includes industry and news sources. 
• User-friendly website design with point and click retrieval of patent and 
non-patent prior art literature 
• FOCUS feature that allows the patent informatics specialist to restrict 
his search parameters for specific terms…the results are a subset of the 
original search results, but they are more relevant to your research needs 
• Alert feature: can elect to have Lexis alert you for events including post 
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issuance court decisions affecting patent status 
• Database is international in scope 
• Shepard’s, like KeyCite in Westlaw, provides post-issuance patent 
information, including status changes, litigation notices, re-exam 
requests, and patent expirations 
• 24 hour reference staff is available 
• A history trail of searches is available  
Disadvantages of Database: 
• Shepard’s does not provide updated information on patents, it only 
reports court decisions 
• No mapping and analysis tools on Lexis-Nexis 
• Premium database: will add to the client’s bill. (Client bill can be 
mitigated through use of history trail and knowledge of efficient search 















• United States Patents — Applications (US) 
• United States Patents — Granted (US) 
• Derwent World Patents Index (DWPI) 
• European Patents — Applications (EP-A) 
• European Patents — Granted (EP-B) 
• German Patents — Applications 
• German Patents — Granted 
• INPADOC Family and Legal Status 
• Patent Abstracts of Japan (JP) 
• Switzerland (CH) 
• WIPO PCT Publications (WO) 
 
Delphion analytical tools give different insights into data: 
• Citation Link creates graphical maps of forward and backward 
references 
• Snapshot allows quick online analysis of your results using bar charts 
• PatentLab-II supports offline analysis of results with 3D graphs and 
charts 
• Clustering performs keyword-based linguistic analysis 




The productivity tools help make the most of research efforts: 
• Data Extract exports key bibliographic fields in common formats 
• Work Files save, organize, annotate and share personalized lists of 
patents 
• Saved Searches saves queries for frequently-used searches 
• Alerts automatically notifies you of updates 
• PDF Express bulk downloads of up to 500 PDFs 
• Patent viewing options include the Delphion Integrated View, both high 
resolution and low-resolution image options, and a variety of download 







IPVision IPVision, Inc. enables you to build and extract maximum value from your 
innovations and patents. Systems, services and tools solutions: 
• Analyze patent portfolios, technologies and innovations  
• Provide new competitive intelligence insights  





APPENDIX C: Definitions of U.S. Classifications71 
 
United States Patent Classification System 
• A Patent Classification is a code which provides a method for categorizing the invention. 
• Classifications are typically expressed as "482/1".  
• The first number, 482, represents the class of invention.  
• The number following the slash is the subclass of invention within the class.  
o A Subclass definition is a complete description of the subclass.  
o The Subclass Definition can incorporate an explanation of the class, a glossary, 
search notes, references to subclasses within the class, and references to other 
classes and subclasses. 
• There are about 450 Classes of invention and about 150,000 subclasses of invention in 
the USPC.  
• Classes and subclasses have titles which provide a short description of the class or 
subclass. 
• Classes and subclasses also have definitions which provide a more detailed explanation. 
• Many Classes and subclasses have explicitly defined relationships to one another. 
Subclasses contain patents. 
• In a sense, classes also contain patents but for classification purposes patents are always 
classified at the subclass level.  
• That one or more classifications (i.e., class/subclass designations) are assigned to each 
granted patent and each published application. 
• A patent classification also represents a searchable collection of patents grouped together 
according to similarly claimed subject matter.  
• A classification is used both as a tool for finding patents (patentability searches), and for 
assisting in the assignment of patent applications to examiners for examination purposes. 
 
Classification Codes applicable for this report 
• Class 424: Drug, Bio-Affecting and Body Treating Compositions 
o Class 424/188.1: Immunodeficiency Virus (e.g. HIV, etc) 
o Class 424/208.1: Immunodeficiency Virus (e.g. HIV, etc) 
• Class 435: Chemistry- Molecular Biology and Microbiology 
o Class 435/320.1: Vector, Per Se (e.g., Plasmid, Hybrid Plasmid, Cosmid, Viral 
Vector, Bacteriophage Vector, Bacteriophage Vector, etc.) 
• Class 536: Organic Compounds- Part of the Class 532-570 Series 
• Class 530: Chemistry: Natural Resins or Derivatives; Peptides or Proteins; Lignins or 
Reaction Products Thereof 
                                                 




APPENDIX D: Derwent Classifications72 
 
Description of Derwent Patent Classifications 
- Categorizes patent documents using a simple classification system for all technologies; 
consistently applied to all patents by Thomson Scientific subject experts, enabling 
effective and precise searching in a particular area of technology 
- International Patent Classification (IPC) is an internationally recognized classification 
system, which is controlled by the World Intellectual Property Organization (WIPO) and 
assigned to patent documents by Patent Offices.  
- Where possible we indicated next to the Class the equivalent IPC in an abbreviated form 
(e.g. A47, F23-5).  
o However, this should only be taken as a guide, since there are areas where the 
DWPI  
o Classes are assigned intellectually by our subject experts, and no strict 
correspondence is claimed. 
 
Classification Codes applicable for this report 
- Class B04: Natural products and polymers. Including testing of body fluids (other than 
blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown 
structure, testing of microorganisms for pathogenicity, testing of chemicals for 
mutagenicity or human toxicity and fermentative production of DNA or RNA. General 
compositions. 
- Class D16: Fermentation industry - including fermentation equipment, brewing, yeast 
production, production of pharmaceuticals and other chemicals by fermentation, 
microbiology, production of vaccines and antibodies, cell and tissue culture and genetic 
engineering. 
- Class S03: Scientific Instrumentation (G01J, K, N, T-W) Photometry, calorimetry. 
Thermometers. Meteorology, geophysics, measurement of nuclear or X-radiation. 
Investigating chemical or physical properties. 
- Class C06: Biotechnology - including plant genetics and veterinary vaccines. 
- Class A96: Medical, dental, veterinary, cosmetic 
- Class P14: Animal care (A01K, L, M) 
- Class B07: General - tablets, dispensers, catheters (excluding drainage and angioplasty), 
encapsulation etc, but not systems for administration of blood or saline or IV feeding etc. 
- Class C03: Other organic compounds, inorganic compounds and multi-component 
mixtures. Polymers and proteins 
- Class C07: Apparatus, formulation, general. including veterinary syringes, general 
formulations where the active compound is not central to the invention (eg wettable 
powders) and analysis. 
                                                 
72 Thomas Reuters, http://scientific.thomson.com/support/patents/dwpiref/reftools/classification/.  
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    99 Clinton St. C-4, Concord, NH 
    E-mail: wpark@piercelaw.edu, molbio@hanafos.com,  
 
CAREER SUMMARY 
Associate with YOUME Patent & Law Firm as a member of the chemical, pharmaceutical and 
biotechnology group. Represent national and multinational corporate clients and technology 
start-ups in patent prosecution and related counseling work.  
 
PROFESSIONAL EXPERIENCE 
YOUME PATNET & LAW FIRM, Seoul, Korea     2005 – 2007 
One of the biggest Patent firms in Korea, has been ranked No.1 in the number of flings with the 
Korean Intellectual Property Office representing since 2002.  
 
 Patent Attorney, Associate, the chemical, pharmaceutical and biotech group  
 Represent domestic and foreign clients, responsible for legal affairs related to patent 
 prosecution and litigations, including patent validity, patent infringement, as well  as 
patent prosecution before the Korean Intellectual Property Office. Specifically,  concentrates 
on the areas of biochemistry, molecular biology and pharmacology ranging  from drafting 
original patent applications and advising international filing affairs  and intellectual property 
aspects of company acquisitions or mergers.  
 
KOREANA PATNT & LAW FIRM, Seoul, Korea              2004 – 2005 
 One of the top 3 patent firms in Korea specializing in representation of foreign clients.  
 
 Patent Attorney, Associate 
Successfully represented around 70 foreign corporate clients filing in Korea, involved in a broad 
spectrum of patent issues including patent validity, patent infringement, as well as patent 
prosecution before the Korean Intellectual Property Office. 
 
APPLIED BIOSYSTEMS, Seoul, Korea        1997 – 2002 
 Korean branch of the multinational biotech company, providing over 95% of the  world 
 supply of DNA sequencing and PCR machines, which helped the completion of Human 
 Genome Project possible.  
 
 Genetic Analysis Specialist, Genetic Analysis Group 
 Responsible for technical affairs relating to the genetic and protein analysis systems 
 provided by the company; managed a ten person genetic analysis group. 
? Anticipated problems and developed practical solutions with bottom-line 
sensitivity. 
? Successfully completed the installation and technical support of genetic analysis 
systems in more than 100 universities and research institutions.  
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? Successfully conducted technical seminars at more than 50 major universities 
and research institutions. 
 
SAMSUNG BIOMEDICAL RESEARCH INSTITUITE,  Seoul, Korea    1994 – 1997 
 Research institution affiliated with Samsung Medical Center 
 Research Scientist 
? Conducted government as well as company funded research projects: Gene 
therapy of ovarian cancer, and the interaction between genes involved in the 
regulation of expression of other genes and cell division, which resulted in the 
publication of 3 papers in major scientific journals.   
? Conducted a collaboration research project with Seoul National University, 
Genetic Engineering Center for the development of a viral vector suitable for 
gene therapy of cancer.  
? Advising and Counseling start up biotech companies.  
 
EDUCATION 
Seoul National University, Biology, B.A., 1987 
 Graduated with cum laude. 
University of Southern California, Molecular Biology, Ph.D., 1994  
 Activities: Teaching and Research Assistant.  
Pierce Law Center, Master of Intellectual Property, expected to graduate in May, 2008 
 
BAR ADMISSIONS/PROFESSIONAL ACTIVITIES 
? Member, Patent and Trademark Attorneys Association 
? Admitted to practice before Korean Intellectual Property Office, 2003.  
 
LIST OF SCIENTIFIC PUBLICATIONS 
? Park, W., Mosteller, R.D., and Broek, D. “Identification of a dominant negative mutant 
in CDC25 protein interacting with ras. Oncogene 14:pp831-836, 1997.  
? Park, W., Choi, J-J. and Lee, J.-H.  “Identification of a variant estrogen receptor lacking 
exon 4 and its coexpression with wild-type estrogen receptor in ovarian carcinomas. 
Clinical Cancer Research vol 2:pp2029-2035, 1996. 
? Park, W., Mosteller, R.D., and Broek, D.  “Amino acid residues in the CDC25 guanine 
nucleotide exchange factor critical for interaction with Ras.” Molecular and Cellular 
Biology, 14: pp.8117-8122, 1994. 
? Mosteller, R.D., Park, W., and Broek, D. “Analysis of the interaction between Ras and 
CDC25 guanine-nucleotide exchange factor using the yeast GAL4-two hybrid system. 
Methods in Enzymology, Vol. 255, pp.135-148, Academic Press, 1995. 
? Seo, J., Park,W., Kim, J.S., Hwang, E.S., Lee, J.-H., and Hong, S.H.“ Endogenous gene 
expression of p53 and regulatory subunits of cyclic AMP-dependent protein kinase in 
ovarian cancer cells. Korean Journal of Zoology, 38: pp.204-211, 1995. 
? Wei, W., Das, B., Park, W., and Broek, D. “Cloning and analysis of human cDNAs 
encoding a 140kDa brain guanine nucleotide-exchange factor, Cdc25GEF , which 
regulates the function of  Ras.” Gene, 151: pp.279-284, 1994. 
? Quilliam, A.L., Huff, S.Y., Rabun, K.M., Wei, W., Park, W., Broek, D., and Der, C.J. “ 
Membrane-targeting potentiates guanine nucleotide exchange factor CDC25 and SOS1 
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activation of Ras transforming activity.” Proceedings of National Academy of Science, 
91: pp.8512- 8516, 1994. 
 
SELECTED PATENTS AND PATENT APPLICATIONS AT YOUME 
? 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives or salts thereof, KR Patent 
No.632882. 
? Porphorymonas Gingivalis Polypeptide and Nucleotides,  KR Patent No. 603552. 
? Oily Cosmetics and Method for Preparing The Same,. KR Patent No. 583021. 
? Condensed Axepines as Vasopressin Agonists, KR Patent No. 605466. 
? A Composition of the Treatment of Metabolic Syndrome comprising Beta-Glucan and 
Folium Mori Extracts as Effective Ingredients, KR Patent 623210 
? A Novel use of Rani as an apoptosis regulator, pending application 10-2005-0110192. 
? A Method for Surface Display of Target Proteins Using Cell Surface Proteins of the 
Yeast Yarrowia, pending application 10-2005-0082706. 
? Biomembrane Devices with Elastic Energy Barriers, pending application 10-2006-
0073667 
? Polynucleotides Responsible for Innate Immune Response in Drosophila and Use 
thereof, pending application 10-2006-0084687. 
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Coursework: Patent Practice & Procedure I & II, Patent Law, Legal Writing & Research, 
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Technology Licensing. 
     Governor Student Bar Association, Member International Intellectual Property Organization. 
 
Panjab University, Department of Biotechnology, Chandigarh, India 
Master of Science (Hons.) in Biotechnology, April 2007 
Thesis: “Cloning of DapA gene of E. coli DH5α in a vector pQE 30,”   
Coursework: Animal Cell Culture, Plant Cell Culture, Bioprocess Engineering, Adv. Molecular 
Biology, Adv. Recombinant DNA Technology, Intellectual Property Rights, Bioethics & 
Biotechnology. 
 
Panjab University, Department of Biotechnology, Chandigarh, India 
Bachelor of Science (Hons.) in Biotechnology, April 2005 
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Coursework: Patenting in India, American & European Patent Regimes, International Treaties/ 
Conventions on IPR. 
 
World Intellectual Property Organization, Geneva, Switzerland: 
“General Course on Intellectual Property” (DL-101e), March 1 to April 15, 2006. 
“WIPO Summer School on Intellectual Property” held at the WIPO Worldwide Academy, 
Geneve, from July 3 to July 14, 2006. 




Franklin Pierce Law Center, Concord, NH 
Research Assistant, Worked under the guidance of Prof. Jon Russell Cavicchi and Prof. Stanley 
Kowalski on “Primary Landscape Analysis of Patents Related to HIV Vaccine Development”, to 
populate publicly available web based database in collaboration with the Public Intellectual 




Department of Biotechnology, Panjab University, Chandigarh, India 
Research Assistant, Worked on under Prof. Rupinder Tewari, on “Cloning of DapA gene of E. 
coli DH5α in a vector pQE 30,” applying principles of advanced microbiology and recombinant 
DNA technology.  2006-2007 
 
Tanya Biotech, Mohali, Punjab 
Trainee, Training Program on “Laboratory Techniques in Immunochemistry.” June 2006-July 
2006 
 
Wockhardt Life Sciences Ltd., Lalru, Punjab 
Trainee, Trained for complete functioning of plant, with specialization in Quality Control.  
June 2004-July 2004 
 
LANGUAGES: English, French, Hindi, Punjabi 
 
INTERESTS:  Participating in debates and declamation contests, Travelling, Reading, Painting, 
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Franklin Pierce Law Center, Concord NH 
Master in IP (MIP) (one semester);  
Transferred to MIP-JD joint program (will graduate in year 2009) 
1995-1998 
National Chiao Tung University, HsinChu, Taiwan ROC 
M.S. Applied Chemistry (major in Biochemistry; Protein Expression) 
1991-1995 
National Chiao Tung University, HsinChu, Taiwan ROC 
B.S. Applied Chemistry 
Work Experience 
June 2007  
to  
Aug. 2007 
Paul, Hastings, Janofsky & Walker LLP (Los Angeles office) - Summer Law Clerk  
(a) Reviewing patents and file wrappers.  
(b) Searching prior arts by US/JP classifications and preparing memo for the 
results. 




AU Optronics Corp. -- Assistant Manager, Technology Office 
Handled all aspects of US litigation support including: 
(a) Preparing, collecting and responding to discovery for all patent infringement 
lawsuits in the US, including one International Trade Commission case and 
two Federal District Court cases. 
(b) Interviewed witnesses and prepared summaries. 
(c) Assisted in preparing expert reports, claim construction briefs, summary 
judgment motions and trial briefs.  




BenQ Corp. -- Patent Engineer 
(i) Negotiation: 
(a) Attended negotiation meetings with patentees. 
(b) Responded to warning letters.  
(c) Assisted in preparing legal opinions. 
(ii) Patent prosecution: 
(a) Interviewed RD engineers and assisted in prior art searches. 




Acer Display Technology Inc. -- Patent Engineer 
(a) Built up Patent system in the company. 
(b) Drafted invention disclosures. 
(c) Revised patent application drafts prepared by outside law firms for filing in 4 
different countries (US, Taiwan, China, and Japan). 





(a) Interviewed clients.  
(b) Drafted US patent applications.  
(c) Prepared Office Action responses. 
 
Language Skills 
Chinese - Mandarin (Fluent) English (Fluent) 
 
Publication 
Purification, Characterization and Mechanistic Study of β-Glucosidase from 
Flavobacterium meningosepticum (ATCC 13253) Yaw-Kuen Li, Shi-Her Chu and Yu-Hui 
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Permanent Address:  1412 8th Street· New Orleans, LA 70115 
 
EDUCATION 
Franklin Pierce Law Center, Concord, NH 
Candidate for Juris Doctor, 2009 
Member, Pierce Law Review 
Member, Student Bar Association Finance Committee 1L Representative 
Member, Student Intellectual Property Organization 
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Masters of Intellectual Property, 2006 
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Masters of Engineering, Biomedical Engineering, 2004 
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    ·  Legal research 
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Summer  Tulane University Office of Technology Transfer 
2006   Intern  
    ·  Patent searching 
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Summer  New Orleans Depot 
2004 Data Entry Clerk 
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with a MIP.  She is interested in utilizing her science background 





JON R. CAVICCHI, J.D., LL.M. (Intellectual Property) 








MicroPatent Summary Report for Relevant Patents 
MicroPatent Report
Report Summary: 
Name of Session/Report: Patent Summary (HIV DNA vaccine)
Report Created: 2008-04-26 - 16:26 GMT
Number of records selected: 218 
Table of Contents
1. US7323557B2 C12N GENEART AG
GENOME OF THE HIV-1 INTER-SUBTYPE (C/B’) AND USE THEREOF

2. US7205101B1 C12N NOVARTIS VACCINES  DIAGNOSTIC
HUMAN IMMUNODEFICIENCY VIRUS (HIV) NUCLEOTIDE SEQUENCES, RECOMBINANT 

POLYPEPTIDES, AND APPLICATIONS THEREOF

3. US7211659B2 C07K CHIRON CORP
POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, 

POLYPEPTIDES AND USES THEREOF

4. US7122180B2 C12N CHILDRENS MEDICAL CENTER
DNA VECTORS CONTAINING MUTATED HIV PROVIRUSES

5. US7094408B2 A61K US GOVERNMENT




6. US7008784B1 C07K AVENTIS PASTEUR




7. US6998252B1 C12N US HEALTH
RECOMBINANT POXVIRUSES HAVING FOREIGN DNA EXPRESSED UNDER THE CONTROL 

OF POXVIRUS REGULATORY SEQUENCES

8. US6894152B1 C12Q CENTRE NAT RECH SCIENT
CLONED DNA SEQUENCES RELATED TO THE GENOMIC RNA OF LYMPHADENOPATHY-

ASSOCIATED-VIRUS (LAV) AND PROTEINS ENCODED BY SAID LAV GENOMIC RNA

9. US6919318B1 A61K CHIRON CORP




10. US6818442B2 C07K GENEXINE CO LTD
AIDS DNA VACCINE THAT PREVENTS SIVMAC239 VIRUS INFECTION IN MONKEYS

11. US6783939B2 C07K ALPHAVAX INC




i            © 2008 MicroPatent, LLC
MicroPatent Report
12. US6716823B1 A61K UAB RESEARCH FOUNDATION




13. US6696291B2 C07K MERCK  CO INC
SYNTHETIC HIV GAG GENES

14. US6656706B2 C12N US HEALTH
MOLECULAR CLONES WITH MUTATED HIV GAG/POL, SIV GAG AND SIV ENV GENES

15. US6649409B1 C12N STATENS SERUMINSTITUT
METHOD FOR PRODUCING A NUCLEOTIDE SEQUENCE CONSTRUCT WITH OPTIMIZED 

CODONS FOR AN HIV GENETIC VACCINE BASED ON A PRIMARY, EARLY HIV 

ISOLATE AND SYNTHETIC ENVELOPE BX08 CONSTRUCTS

16. US6635624B1 C07K PASTEUR INSTITUT




17. US6586409B1 A61K VICAL INC




18. US6544518B1 A61K SMITHKLINE BEECHAM BIOLOG
VACCINES

19. US6541003B1 C12N INFECTIOUS DISEASES FOUNDATION
CONDITIONALLY CONTROLLED, ATTENUATED HIV VACCINE

20. US6534312B1 C12N MERCK  CO INC
VACCINES COMPRISING SYNTHETIC GENES

21. US6534062B2 A61K UNIV CALIFORNIA
METHODS FOR INCREASING A CYTOTOXIC T LYMPHOCYTE RESPONSE IN VIVO

22. US6420545B1 C07H TRUSTEES OF THE UNIVERSITY OF
CD4-INDEPENDENT HIV ENVELOPE PROTEINS AS VACCINES AND THERAPEUTICS

23. US6348450B1 A61K UAB RESEARCH FOUNDATION




24. US6326007B1 A61P UNIV CALIFORNIA
ATTENUATED LENTIVIRUS VECTORS EXPRESSING INTERFERON

25. US6248721B1 C07K CHANG LUNG-JI
METHOD OF USING MOUSE MODEL FOR EVALUATION OF HIV VACCINES

26. US6210663B1 A61K WISTAR INST




ii            © 2008 MicroPatent, LLC
MicroPatent Report
27. US6168923B1 A61K WISTAR INST
COMPOSITIONS AND METHODS FOR USE OF IL-12 AS AN ADJUVANT

28. US6086891A A61K ST JUDE CHILDRENS RES HOSPITAL




29. US5981276A C07K DANA FARBER CANCER INST INC
VECTORS CONTAINING HIV PACKAGING SEQUENCES, PACKAGING DEFECTIVE HIV 

VECTORS, AND USES THEREOF

30. US5883081A C12N UNIV CALIFORNIA
ISOLATION OF NOVEL HIV-2 PROVIRUSES

31. US5869313A C07K US HEALTH




32. US5866131A C07K COMMW SCIENT IND RES ORG
RECOMBINANT VACCINE

33. US5795577A C07K TRANSGENE SA




34. US5824310A A61K US HEALTH
LIPOPPLYSACCHARIDE CONJUGATE VACCINES

35. US5766625A A61K UNIV FLORIDA
ARTIFICIAL VIRAL ENVELOPES

36. US5665577A C07K DANA FARBER CANCER INST INC
VECTORS CONTAINING HIV PACKAGING SEQUENCES, PACKAGING DEFECTIVE HIV 

VECTORS, AND USES THEREOF

37. US5654195A C12N DANA FARBER CANCER INST INC
VECTORS EXPRESSING HYBRID VIRUSES, METHODS OF USE AND NOVEL ASSAYS

38. US5571712A C07K CONNAUGHT LAB
NON-INFECTIOUS, REPLICATION DEFECTIVE, IMMUNOGENIC HIV RETROVIRUS-LIKE 





39. US5439809A C12Q CONNAUGHT LAB
NON-INFECTIOUS HIV PARTICLES LACKING LONG TERMINAL REPEATS

40. US5328835A C07K SQUIBB BRISTOL MYERS CO
EXPRESSION OF IMMUNOLOGICALLY REACTIVE HIV ENVELOPE PROTEINS

41. US5141867A C12N DU PONT
NUCLEOTIDE SEQUENCE ENCODING A HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN

iii            © 2008 MicroPatent, LLC
MicroPatent Report
42. US5130248A C07K MERCK  CO INC
EXPRESSION OF FUSION PROTEIN OF HIV ENVELOPE AND HBSAG

43. US5130247A C07K MERCK  CO INC
EXPRESSION OF FUSION PROTEIN OF HIV ENVELOPE AND HBSAG

44. US5100662A A61K LIPOSOME CO INC
STEROIDAL LIPOSOMES EXHIBITING ENHANCED STABILITY

45. US4952499A C12N DANA FARBER CANCER INST INC
GENES AND THEIR ENCODED PROTEINS WHICH REGULATE GENE EXPRESSION OF THE 

INTERLEUKIN-2 RECEPTOR AND OF HUMAN LYMPHOTROPIC RETROVIRUSES

46. US20080026071A1 A61K 
MICROPARTICLES FOR DELIVERY OF HETEROLOGOUS NUCLEIC ACIDS

47. US20070292454A1 A61K 




48. US20070292390A1 C12N 
BROADLY CROSS-REACTIVE HIV-1 NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES

49. US20070248613A1 G01N 
HUMAN ANTIBODIES INTERACTING WITH HIV GP41

50. US20070269456A1 A61K 




51. US20070248679A1 C12N GLAXO GROUP LTD
VACCINE

52. US20070190031A1 C12N 
PLASMID HAVING THREE COMPLETE TRANSCRIPTIONAL UNITS AND IMMUNOGENIC 

COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE TO HIV

53. US20070166784A1 C12P 
COMBINATION APPROACHES FOR GENERATING IMMUNE RESPONSES

54. US20070053923A1 A61K 
DNA VACCINE COMPOSITION WITH ENHANCED IMMUNOGENICITY

55. US20070015721A1 C12N 
HIV-GAG CODON-OPTIMISED DNA VACCINES

56. US20070010471A1 A61K 
HIV DNA VACCINE

57. US20070042977A1 C07H 
VACCINE

58. US20060275897A1 C07K 
HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIV

iv            © 2008 MicroPatent, LLC
MicroPatent Report
59. US20060222665A1 C12N STRATHMANN AG  CO
VIRUS VACCINE

60. US20060240042A1 C12N GOVT OF THE U S A AS REPRESENT




61. US20060216305A1 C07K 




62. US20060148750A1 A61K 




63. US20060142221A1 C07H 
VACCINE

64. US20060094049A1 C12Q AARON DIAMOND AIDS RES CT
STABILIZED VIRAL ENVELOPE PROTEINS AND USES THEREOF

65. US20060051839A1 C12P EMORY UNIVERSITY A GEORGIA COR
DNA EXPRESSION VECTORS AND METHODS OF USE

66. US20050271676A1 C07H EPIMMUNE INC
INDUCING CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODEFICIENCY VIRUS-1 

USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS

67. US20050266025A1 C12N SMITHKLINE BEECHAM BIOLOG
NOVEL USE

68. US20050287167A1 C12Q CHIRON CORP
POLYCISTRONIC HIV VECTOR CONSTRUCTS

69. US20050266024A1 C07D GLAXO GROUP LTD
ADJUVANT

70. US20050256070A1 A61K 
ADJUVANT

71. US20050220883A1 A61K 
MICROPARTICLES WITH ADSORBED POLYPEPTIDE-CONTAINING MOLECULES

72. US20050220816A1 A61K ADVANCED BIOSCIENCE LAB INC
MUTANT VIRAL NUCLEIC ACIDS AND VACCINE CONTAINING SAME

73. US20050215508A1 C07K 




74. US20050208072A1 C07K 
PREVENTIVE AND THERAPEUTIC AIDS VACCINES

v            © 2008 MicroPatent, LLC
MicroPatent Report
75. US20050175627A1 A61K OXXON THERAPEUTICS LTD
HIV PHARMACCINES

76. US20050158336A1 A61K HOPE CITY




77. US20050112102A1 C12N 
DNA VACCINE COMPOSITIONS AND METHODS OF USE

78. US20050058657A1 A61P 




79. US20040236093A1 C12N 
MHC-I-RESTRICTED PRESENTATION OF HIV-1 VIRION ANTIGENS WITHOUT VIRAL 

REPLICATION. APPLICATION TO THE STIMULATION OF CTL AND VACCINATION IN 

VIVO; ANALYSIS OF VACCINATING COMPOSITION IN VITRO

80. US20040224308A1 C12N PROGENICS PHARM INC
STABILIZED VIRAL ENVELOPE PROTEINS AND USES THEREOF

81. US20040191269A1 C07K 




82. US20040180329A1 C07K 
SYNTHETIC HIV GAG GENES

83. US20040116660A1 C07K 
PROCESS FOR THE SELECTION OF HIV-1 SUBTYPE C ISOLATES, SELECTED HIV-1 





84. US20040076636A1 C07K 
HIV IMMUNOGENIC COMPLEXES

85. US20040106105A1 C12N 
VACCINE

86. US20040106100A1 C12N 
DNA VACCINES ENCODING HIV ACCESSORY PROTEINS

87. US20040077577A1 C12N GOVERNMENT OF THE USA AS REPRE
MOLECULAR CLONES WITH MUTATED HIV GAG/POL, SIV GAG AND SIV ENV GENES

88. US20040033237A1 A61K 




89. US20040063653A1 C07K 




vi            © 2008 MicroPatent, LLC
MicroPatent Report
90. US20040034209A1 A61K 




91. US20040033487A1 C12N 




92. US20030228327A1 A61K 




93. US20030220276A1 C07K 
HIV VACCINE AND METHOD OF USE

94. US20030161834A1 A61K SMITHKLINE BEECHAM BIOLOG
VACCINES

95. US20030175292A1 C12N 
COMPOSITIONS AND METHODS FOR GENERATING AN IMMUNE RESPONSE

96. US20030158134A1 C12N 
VACCINE FOR THE PROPHYLACTIC OR THERAPEUTIC IMMUNIZATION AGAINST HIV

97. US20030190308A1 A61K 
ADJUVANT

98. US20030158131A1 C12N 
DNA VECTORS CONTAINING MUTATED HIV PROVIRUSES

99. US20030129169A1 C12N 
NOVEL EXPRESSION VECTORS AND USES THEREOF

100. US20030099934A1 C07K 
CHEMICALLY MODIFIED HIV ENVELOPE GLYCOPROTEIN

101. US20030096778A1 C07K 




102. US20030091594A1 C12N UNIV PENNSYLVANIA
CD4-INDEPENDENT HIV ENVELOPE PROTEINS AS VACCINES AND THERAPEUTICS

103. US20030087225A1 C12N 
SYNTHETIC HIV GENES

104. US20030082521A1 C07K 
POLYPEPTIDE INDUCING ANTIBODIES NEUTRALIZING HIV

105. US20030050468A1 C07K 
SYNTHETIC HIV GAG GENES

106. US20030021800A1 C07K 
VACCINE AGAINST INFECTIOUS AGENTS HAVING AN INTRACELLULAR PHASE, 

COMPOSITION FOR THE TREATMENT AND PREVENTION OF HIV INFECTIONS, 

ANTIBODIES AND METHOD OF DIAGNOSIS

vii            © 2008 MicroPatent, LLC
MicroPatent Report
107. US20020193330A1 C07K 
GENETICALLY ENGINEERED CO-EXPRESSION DNA VACCINES, CONSTRUCTION 

METHODS AND USES THEREOF

108. US20020172683A1 G01N 
MHC-I-RESTRICTED PRESENTATION OF HIV-1 VIRION ANTIGENS WITHOUT VIRAL 

REPLICATION. APPLICATION TO THE STIMULATION OF CTL AND VACCINATION IN 

VIVO; ANALYSIS OF VACCINATING COMPOSITION IN VITRO

109. US20020141975A1 C07K ALPHAVAX INC




110. US20020127238A1 C07K 
HIV-1 VACCINES AND SCREENING METHODS THEREFOR

111. US20020061517A1 C12Q 
ADENOVIRUS CARRYING GAG GENE HIV VACCINE

112. US20020022034A1 A61K 
THERAPEUTIC DNA VACCINATION

113. US20020015707A1 A61K CHIRON CORP
POSTINFECTION HUMAN IMMUNODEFICIENCY VIRUS (HIV) VACCINATION THERAPY

114. US20010004531A1 C07K GENECCIN CO LTD
AIDS DNA VACCINE THAT PREVENTS SIVMAC239 VIRUS INFECTION IN MONKEYS

115. EP449116B2 C07K GENEART GMBH
DNA SEQUENCES ENCODING MODIFIED RETROVIRAL GAG POLYPEPTIDES AND 

VACCINES CONTAINING THEM OR AGGREGATES THEREOF

116. EP1402019A4 C12N US GOVERNMENT
MOLECULAR CLONES WITH MUTATED HIV GAG/POL, SIV GAG AND SIV ENV GENES

117. EP1369427A2 C12N INNOGENETICS NV
HIV-3 RETROVIRUS STRAINS AND THEIR USE

118. EP1369427A3 C12N INNOGENETICS NV
HIV-3 RETROVIRUS STRAINS AND THEIR USE

119. EP1279404A1 A61P IST SUPERIORE SANITA
USE OF HIV-1 TAT, FRAGMENTS OR DERIVATIVES THEREOF, TO TARGET OR TO 

ACTIVATE ANTIGEN-PRESENTING CELLS, TO DELIVER CARGO MOLECULES FOR 

VACCINATION OR TO TREAT OTHER DISEASES

120. EP335635A1 A61K UNIV LELAND STANFORD JUNIOR
MUTATED HIV ENVELOPE PROTEIN

121. WO2007126788A2 A61K US GOVERNMENT




viii            © 2008 MicroPatent, LLC
MicroPatent Report
122. WO2007126788A3 A61K US GOVERNMENT




123. WO2007126959A2 A61K DANA FARBER CANCER INST INC




124. WO2007066236A2 IntC INST LA RECH POUR LE DEV IRD
CHIMERIC HIV-1 GLYCOPROTEINS AND THEIR BIOLOGICAL APPLICATIONS

125. WO2007066236A3 C07K INST LA RECH POUR LE DEV IRD
CHIMERIC HIV-1 GP120 GLYCOPROTEINS AND THEIR BIOLOGICAL APPLICATIONS

126. WO2007024976A2 C07H UNIV MARYLAND BIOTECH INST
VIRUS COAT PROTEIN/RECEPTOR CHIMERAS AND METHODS OF USE

127. WO2007004231A1 A61K SETH PRADEEP
HIV-1 VACCINOGENS WITH IMMUNOMODULATORS

128. WO2006110344A1 C07K WYETH CORP




129. WO2006085959A2 C12Q CHIRON CORP




130. WO2006050394A2 IntC CHIRON CORP
COMBINATION APPROACHES FOR GENERATING IMMUNE RESPONSES

131. WO2006050394A3 C07K CHIRON CORP
COMBINATION APPROACHES FOR GENERATING IMMUNE RESPONSES

132. WO2006020071A2 A61P US GOVERNMENT
VACCINE CONSTRUCTS AND COMBINATIONS OF VACCINES DESIGNED TO IMPROVE 





133. WO2006020071A3 A61P US GOVERNMENT
VACCINES AGAINST AIDS COMPRISING CMV/R-NUCLEIC ACID CONSTRUCTS

134. WO2006009746A2 C12N WYETH CORP
PLASMID HAVING THREE COMPLETE TRANSCRIPTIONAL UNITS AND IMMUNOGENIC 

COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE TO HIV

135. WO2006009746A3 C12N WYETH CORP
PLASMID HAVING THREE COMPLETE TRANSCRIPTIONAL UNITS AND IMMUNOGENIC 

COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE TO HIV

136. WO2006009746A9 C12N WYETH CORP
PLASMID HAVING THREE COMPLETE TRANSCRIPTIONAL UNITS AND IMMUNOGENIC 

COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE TO HIV

ix            © 2008 MicroPatent, LLC
MicroPatent Report
137. WO2005027844A2 C12N UNIV KANSAS MEDICAL CT
DNA VACCINE COMPOSITIONS AND METHODS OF USE

138. WO2005027844A3 C12N UNIV KANSAS MEDICAL CT
DNA VACCINE COMPOSITIONS AND METHODS OF USE

139. WO2005027840A2 A61K CHIRON CORP
COMBINATION APPROACHES FOR GENERATING IMMUNE RESPONSES

140. WO2005026316A2 C12N BIOPTION AB
ALPHAVIRUS VACCINES

141. WO2005026316A3 C12N BIOPTION AB
ALPHAVIRUS VACCINES

142. WO2005026316A8 C12N BIOPTION AB
ALPHAVIRUS VACCINES

143. WO2005034992A2 C07K US GOVERNMENT
MECHANISMS FOR IMPROVING THE BREADTH OF THE IMMUNE RESPONSE TO DIVERSE 

STRAINS AND CLADES OF HIV

144. WO2005034992A3 C07K US GOVERNMENT
HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIF

145. WO2005016378A1 C07K ALL INDIA INST MED




146. WO2004050856A2 C07K UNIV MASSACHUSETTS




147. WO2004050856A3 C07K UNIV MASSACHUSETTS




148. WO2004067020A1 A61K UNIV POHANG
DNA VACCINE COMPOSITION WITH ENHANCED IMMUNOGENICITY

149. WO2004037847A2 C07K CHIRON CORP
HIV ENVELOPE-CD4 COMPLEXES AND HYBRIDS

150. WO2004037847A3 C07K CHIRON CORP
HIV ENVELOPE-CD4 COMPLEXES AND HYBRIDS

151. WO2004032860A2 C12Q CHIRON CORP
HIV VACCINE FORMULATIONS

152. WO2004032860A3 C12Q CHIRON CORP
HIV VACCINE FORMULATIONS

153. WO2004041851A2 C12N GLAXO GROUP LTD
VACCINE

x            © 2008 MicroPatent, LLC
MicroPatent Report
154. WO2004041851A3 C12N GLAXO GROUP LTD
VACCINE

155. WO2004035006A2 C12N AARON DIAMOND AIDS RES CT
METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST HIV

156. WO2004035006A3 C12N AARON DIAMOND AIDS RES CT
METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST HIV

157. WO2003080112A2 A61K POWDERJECT RES LTD
ADJUVANT

158. WO2003080112A3 A61K POWDERJECT RES LTD
IMIDAZOQUINOLINEAMINES AS ADJUVANTS IN HIV DNA VACCINATION

159. WO2003076591A2 C12N UNIV EMORY
COMPOSITIONS AND METHODS FOR GENERATING AN IMMUNE RESPONSE

160. WO2003076591A3 C12N UNIV EMORY
COMPOSITIONS AND METHODS FOR GENERATING AN IMMUNE RESPONSE

161. WO2003076591A8 C12N UNIV EMORY
COMPOSITIONS AND METHODS FOR GENERATING AN IMMUNE RESPONSE

162. WO2003045304A2 C12N MAYO FOUNDATION
MUTABLE VACCINES

163. WO2003045304A3 C12N MAYO FOUNDATION
MUTABLE VACCINES

164. WO2003025003A2 C12N GLAXO GROUP LTD
VACCINES

165. WO2003025003A3 C12N GLAXO GROUP LTD
HIV-GAG CODON-OPTIMISED DNA VACCINES

166. WO2003004657A1 C07K CHIRON CORP
POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE B AND/OR TYPE C 

POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

167. WO2003037919A2 C12N SOUTH AFRICAN MEDICAL RES COUN




168. WO2003037919A3 C12N SOUTH AFRICAN MEDICAL RES COUN




169. WO2003011334A1 A61K GLAXOSMITHKLINE BIOLOG SA




170. WO2002099101A1 C07K US GOVERNMENT
MOLECULAR CLONES WITH MUTATED HIV GAG/POL, SIV GAG AND SIV ENV GENES

xi            © 2008 MicroPatent, LLC
MicroPatent Report
171. WO2002004493A2 C07K CHIRON CORP
POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, 

POLYPEPTIDES AND USES THEREOF

172. WO2002004493A3 C07K CHIRON CORP
POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, 

POLYPEPTIDES AND USES THEREOF

173. WO2001054719A2 C12N SMITHKLINE BEECHAM BIOLOG
NOVEL USE

174. WO2001054719A3 C12N SMITHKLINE BEECHAM BIOLOG
VACCINE FOR THE PROPHYLACTIC OR THERAPEUTIC IMMUNIZATION AGAINST HIV

175. WO2001045748A1 A61K MERCK  CO INC




176. WO2001082964A1 A61K US HEALTH




177. WO2001082962A2 C07K AVENTIS PASTEUR
IMMUNIZING AGAINST HIV INFECTION

178. WO2001082962A3 C07K AVENTIS PASTEUR
IMMUNIZING AGAINST HIV INFECTION

179. WO2001046408A2 C07K US HEALTH
MOLECULAR CLONES WITH MUTATED HIV GAG/POL, SIV GAG AND SIV ENV GENES

180. WO2001046408A3 C07K US HEALTH
MOLECULAR CLONES WITH MUTATED HIV GAG/POL, SIV GAG AND SIV ENV GENES

181. WO2001046408A9 C07K US GOVERNMENT
MOLECULAR CLONES WITH MUTATED HIV GAG/POL, SIV GAG AND SIV ENV GENES

182. WO2001043693A2 A61K MERCK  CO INC




183. WO2001043693A3 A61K MERCK  CO INC




184. WO2001026608A2 C12P LEDBETTER JEFFREY A
DNA VACCINES ENCODING ANTIGEN LINKED TO A DOMAIN THAT BINDS CD40

185. WO2001026608A3 C12P LEDBETTER JEFFREY A
DNA VACCINES ENCODING ANTIGEN LINKED TO A DOMAIN THAT BINDS CD40

186. WO2001000648A1 C07K PROGENICS PHARM INC
STABILIZED VIRAL ENVELOPE PROTEINS AND USES THEREOF

xii            © 2008 MicroPatent, LLC
MicroPatent Report
187. WO2001019958A2 C07K DANA FARBER CANCER INST INC
STABILIZED SOLUBLE GLYCOPROTEIN TRIMERS

188. WO2001019958A3 C07K DANA FARBER CANCER INST INC
STABILIZED SOLUBLE GLYCOPROTEIN TRIMERS

189. WO2001019958A9 C07K DANA FARBER CANCER INST INC
STABILIZED SOLUBLE GLYCOPROTEIN TRIMERS

190. WO2001002607A1 C12N MERCK  CO INC
ADENOVIRUS CARRYING GAG GENE HIV VACCINE

191. WO2000071561A1 C12N UNIV PENNSYLVANIA
CD4-INDEPENDENT HIV ENVELOPE PROTEINS AS VACCINES AND THERAPEUTICS

192. WO2000071561A9 C12N TRUSTEES OF THE UNIVERSITY OF
CD4-INDEPENDENT HIV ENVELOPE PROTEINS AS VACCINES AND THERAPEUTICS

193. WO2000039303A2 C07K CHIRON CORP
MODIFIED HIV ENV POLYPEPTIDES

194. WO2000039303A3 C07K CHIRON CORP
MODIFIED HIV ENV POLYPEPTIDES

195. WO2000047223A2 A61P STRATHMANN AG  CO
VIRAL VACCINE

196. WO2000047223A3 A61P STRATHMANN AG  CO
VIRAL VACCINE

197. WO2000034494A1 C07K US HEALTH




198. WO2000039304A2 A61P CHIRON CORP
POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, 

POLYPEPTIDES AND USES THEREOF

199. WO2000039304A3 A61P CHIRON CORP
POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, 

POLYPEPTIDES AND USES THEREOF

200. WO2000039304A9 A61P CHIRON CORP
POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, 

POLYPEPTIDES AND USES THEREOF

201. WO2000029561A2 C12N STATENS SERUMINSTITUT
METHOD FOR PRODUCING A NUCLEOTIDE CONSTRUCT WITH OPTIMISED CODONS FOR 

AN HIV GENETIC VACCINE BASED ON A PRIMARY, EARLY HIV ISOLATE AND 

SYNTHETIC ENVELOPE BX08 CONSTRUCTS

202. WO2000029561A3 C12N STATENS SERUMINSTITUT
NUCLEOTIDE CONSTRUCT WITH OPTIMISED CODONS FOR AN HIV GENETIC VACCINE 

BASED ON A PRIMARY, EARLY HIV ISOLATE AND SYNTHETIC ENVELOPE

xiii            © 2008 MicroPatent, LLC
MicroPatent Report
203. WO2000029561A8 C12N STATENS SERUMINSTITUT
METHOD FOR PRODUCING A NUCLEOTIDE SEQUENCE CONSTRUCT WITH OPTIMISED 

CODONS FOR AN HIV GENETIC VACCINE BASED ON A PRIMARY, EARLY HIV 

ISOLATE AND SYNTHETIC ENVELOPE BX08 CONSTRUCTS

204. WO2000002591A1 A61K MERCK  CO INC
POLYNUCLEOTIDE VACCINE FORMULATIONS

205. WO1999027958A2 A61P IST SUPERIORE SANITA




206. WO1999027958A3 A61P IST SUPERIORE SANITA




207. WO1999027958A9 A61P IST SUPERIORE SANITA




208. WO1998035562A1 A61K MERCK  CO INC
POLYNUCLEOTIDE VACCINE FORMULATIONS

209. WO1998034640A2 C07K MERCK  CO INC
SYNTHETIC HIV

210. WO1998034640A3 C07K MERCK  CO INC
SYNTHETIC HIV GAG GENES

211. WO1997048370A2 C12N MERCK  CO INC
VACCINES COMPRISING SYNTHETIC GENES

212. WO1997048370A3 C12N MERCK  CO INC
VACCINES COMPRISING SYNTHETIC GENES

213. WO1997031115A2 A61P MERCK  CO INC
SYNTHETIC HIV GENES

214. WO1997031115A3 A61P MERCK  CO INC
SYNTHETIC HIV GENES

215. WO1995020660A2 A61K UNIV MASSACHUSETTS MEDICAL
IMMUNIZATION BY INOCULATION OF DNA TRANSCRIPTION UNIT

216. WO1995020660A3 A61K UNIV MASSACHUSETTS MEDICAL
IMMUNIZATION BY INOCULATION OF DNA TRANSCRIPTION UNIT

217. WO1994022477A1 A61P PROGENICS PHARM INC
HIV-1 VACCINES, ANTIBODY COMPOSITIONS RELATED THERETO, AND THERAPEUTIC 

AND PROPHYLACTIC USES THEREOF

218. WO1994017825A1 C12N UNIV CALIFORNIA




xiv            © 2008 MicroPatent, LLC
MicroPatent ReportUS7323557B2




[71] Applicant: GENEART AG
[75] Inventors: Wagner, Ralf; Wolf,

 Hans; Graf,  Marcus
[21] Application No.: NA
[22] Filed:  20060519 
[43] Published:  20080129 





The present invention refers to a polynucleotide comprising the nucleic acid 

sequence as depicted in SEQ ID NO:1, 2 or 3 or the fragment or derivative thereof, 

or a polynucleotide hybridizing with the nucleic acid sequence as depicted in SEQ 

ID NO:1, 2 or 3. The present invention further refers to polypeptides encoded by 

the nucleic acid sequence or the fragment or derivative thereof as depicted in SEQ 

ID NO:1, 2 or 3. The polynucleotides and polypeptides may be used as medicaments, 

vaccines or diagnostic substances, preferably for the treatment, prevention or 

diagnostic of HIV infections.
[52] US Class: 5360231 4353201
[51] Int’l Class: C12N001511 C12N001509 C07H002104 C07K001416 C12N001563 
A61K003900 
[52] ECLA: C07K001416 K61K003900 K61K003953 M07K020300 M07K020700 

M07K021500
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[71] Applicant: NOVARTIS VACCINES 

 DIAGNOSTIC
[75] Inventors: Luciw, Paul A.; 

Dina, Dino
[21] Application No.: NA
[22] Filed:  19950517 
[43] Published:  20070417 





Polynucleotide sequences are provided for the diagnosis of the presence of 

retroviral infection in a human host associated with lymphadenopathy syndrome 

and/or acquired immune deficiency syndrome, for expression of polypeptides and use 

of the polypeptides to prepare antibodies, where both the polypeptides and 

antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and 

passive immunization. The sequences provide detection of the viral infectious 

agents associated with the indicated syndromes and can be used for expression of 

antigenic polypeptides.
[52] US Class: 435005 4350691 4350693 4352351 4353201 435948 435974 

5360231 53602372 5360243
[51] Int’l Class: C12N001548 C12N000902 C12N001581 C07K001416 C12N001585 
C12N001500 C12Q000170 C12N001509 A61K003800 
[52] ECLA: C07K001416 C12N000902M C12N001581 C12N001585 C12Q000170B2B 

K61K003800 M07K020300 M07K020700 M07K021500 M07K031900 

M07K031900E M12N083000 M12N083015 M12N083055 M12N083070A 

M12N083070A1
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[71] Applicant: CHIRON CORP
[75] Inventors: zur Megede, Jan; 

Barnett, Susan
[21] Application No.: NA
[22] Filed:  20020705 
[43] Published:  20070501 





The present invention relates to polynucleotides encoding immunogenic HIV 

polypeptides. Uses of the polynucleotides in applications including immunization, 

generation of packaging cell lines, and production of HIV polypeptides are also 

described. Polynucleotides encoding antigenic HIV polypeptides are described, as 

are uses of these polynucleotides and polypeptide products therefrom, including 

formulations of immunogenic compositions and uses thereof.
[52] US Class: 53602372 4240092 4241921 4241991 4242081 435005 435006 

4350697 4350701 5360234
[51] Int’l Class: C07K001416 C12N0015867 C12P001904 A61K003921 C07H002104 
A61K003912 C12Q000168 A61K003900 A61K003800 C12Q000170 A61K004900 
[52] ECLA: C07K001416 C12N0015867P K61K003900 K61K003953 M07K020700 

M07K022124 M12N080010E M12N083042 M12N084020A
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[71] Applicant: CHILDRENS MEDICAL 

CENTER
[75] Inventors: Aldovini, Anna
[21] Application No.: NA
[22] Filed:  20011023 
[43] Published:  20061017 





The present invention pertains to mutated, non-infectious HIV viral particles, 

vectors for production of such particles and vaccines employing such vectors. The 

non-infectious particles are obtained by introducing a number of inactivating 

mutations into a native viral genome. These mutations are designed so as to 

minimize the probability of genetic reversion to an infectious virus, while 

retaining the basic protein content and immunogenic properties of a wild-type 

virion. The altered viral genome expresses proteins that can assemble into non-

infectious particles which contain immunogenic components of the virus, but which 

are unable to infect cells. The preferred mutations are introduced in at least one 

amino acid position of the nucleocapsid (NC) protein in combination with at least 

one other mutation in an amino acid position of the reverse transcriptase (RT) 

protein or the In protein. In one embodiment, the mutations to the native HIV 

genome may also be made in at least one amino acid position of the NC protein, at 

least one position in the RT protein, and at least one position in the integrase (

In) protein. In another embodiment, the mutations to the native HIV genome may be 

introduced in clusters, where two or more mutations are made in the NC protein, the 

RT protein, the In protein, or any combinations thereof.
[52] US Class: 4240932 514044 4353201 435456 435366 5360241 53602372
[51] Int’l Class: C12N000508 C07H002104 C12N001586 A61K003921 C12N0015867 
C07K001416 A61K003170 A61K004800 C12N000100 
[52] ECLA: A61K003921 C07K001416B C12N0015867 K61K003953 M07K022124
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[71] Applicant: US GOVERNMENT
[75] Inventors: Franchini, 

Genoveffa; Hel,  Zdenek; 

Pavlakis,  George
[21] Application No.: NA
[22] Filed:  20021025 
[43] Published:  20060822 





This invention relates to improved methods of inducing an immune response for the 

prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in 

conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to 

potentiate and broaden the immune response. The present invention further provides 

a particularly effective vaccine regimen comprising a DNA vaccine used in 

combination with a poxvirus virus, especially NYVAC or ALVAC.
[52] US Class: 4241921 4241881 4242081 4352351 4353201 514044 530826 

53602372
[51] Int’l Class: A61K003921 A61K003900 
[52] ECLA: A61K003921 K61K0039525C K61K003953
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NON-INFECTIOUS, NON-REPLICATING, IMMUNOGENIC 

HUMAN IMMUNODEFICIENCY VIRUS-LIKE PARTICLES

[71] Applicant: AVENTIS PASTEUR
[75] Inventors: Haynes, Joel; 

Klein, Michel  Henri; 

Rovinski,  Benjamin; Cao, 
 . . .
[21] Application No.: NA
[22] Filed:  19990903 
[43] Published:  20060307 





The present invention is directed toward methods for the production of non-

infectious, replication-deficient, immunogenic human immunodeficiency virus (HIV)-

like particles. These particles are prepared from a recombinant expression vector 

comprising a heterologous promoter operatively connected to a DNA molecule 

comprising a modified HIV genome devoid of the long terminal repeat (LTR) 

regulatory regions but containing at least the gag and pol genes in their natural 

genomic arrangement. This vector is introduced into mammalian cells to produce the 

particles of interest. These particles should prove useful in a number of 

diagnostic, virologic, and immunologic applications.
[52] US Class: 435236 4241881 4242081 435238 4353201
[51] Int’l Class: C07K001416 C12N000704 A61K003900 
[52] ECLA: C07K001416 K61K003900 M07K020300 M07K020700
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[71] Applicant: US HEALTH
[75] Inventors: Moss, Bernard; 

Mackett, Michael;  Smith, 

Geoffrey L.
[21] Application No.: NA
[22] Filed:  19950606 
[43] Published:  20060214 





Recombinant poxviruses, such as vaccinia, are provided that comprises a segment 

comprised of (A) a first DNA sequence encoding a polypeptide that is foreign to 

poxvirus and (B) a poxvirus transcriptional regulatory sequence, wherein (i) 

said transcriptional regulatory sequence is adjacent to and exerts transcriptional 

control over said first DNA sequence and (ii) said segment is positioned within a 

nonessential genomic region of said recombinant poxvirus. Vaccines, carriers, cells,

 and media comprising recombinant poxviruses, and methods of immunization with 

recombinant poxviruses also are provided.
[52] US Class: 4350691 4350693 4350914 43509141 4352351 4353201
[51] Int’l Class: C12N000910 C07K0014035 C12N001509 C07K001402 C12N001564 
C07K001407 C12N0015863 C12N000701 A61K003900 
[52] ECLA: C07K001402 C07K0014035 C07K001407 C12N000910C1A28 

C12N0015863V K61K003900 M07K020700
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MicroPatent ReportUS6894152B1
CLONED DNA SEQUENCES RELATED TO THE GENOMIC RNA 

OF LYMPHADENOPATHY-ASSOCIATED-VIRUS (LAV) AND 

PROTEINS ENCODED BY SAID LAV GENOMIC RNA

[71] Applicant: CENTRE NAT RECH 

SCIENT
[75] Inventors: Alizon, Marc; 

Sonigo, Pierre;  Stewart, 

Cole;  Danos, Oliver;  Wain 
 . . .
[21] Application No.: NA
[22] Filed:  19940225 
[43] Published:  20050517 





This invention is in the field of lymphadenopathy virus which has been designated 

Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a 

diagnostic means and method to detect the presence of DNA, RNA or antibodies of the 

lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome 

or of the lymphadenopathy syndrome by the use of DNA fragments of the peptides 

encoded by said DNA fragments. The invention further relates to the DNA fragments, 

vectors comprising them and the proteins expressed.
[52] US Class: 5360231 435005 435006 5360243
[51] Int’l Class: C12Q000168 C07H002102 
[52] ECLA: 
8            © 2008 MicroPatent, LLC
MicroPatent ReportUS6919318B1
ENHANCING IMMUNE RESPONSES TO GENETIC 

IMMUNIZATION BY USING A CHEMOKINE

[71] Applicant: CHIRON CORP
[75] Inventors: Paliard, Xavier
[21] Application No.: NA
[22] Filed:  20001019 
[43] Published:  20050719 





The immune response to a DNA immunogen in a mammal can be enhanced by 

administration of a chemokine or a polynucleotide encoding the chemokine. This 

method can be used, for example, to immunize or vaccinate a mammal against an 

infectious disease or a tumor.
[52] US Class: 514044 4241841 4241881 4241891 4353201 514002 530350
[51] Int’l Class: A61K004800 A61K003843 C07K001400 A61K003819 A61K003800 
C12N001574 
[52] ECLA: A61K003921 A61K003819 A61K003929 K61K003953 K61K0039555B2 

M12N074003F M12N077017C
9            © 2008 MicroPatent, LLC
MicroPatent ReportUS6818442B2




[71] Applicant: GENEXINE CO LTD; 

UNIV POHANG
[75] Inventors: Sung, Young Chul; 

Suh, You Suk
[21] Application No.: NA
[22] Filed:  20001206 
[43] Published:  20041116 






The present invention relates to a plasmid carrying simian immunodeficiency virus (

SIV)-derived genes. Particularly, the present invention relates to the plasmid 

pSIV/GE which carrys gag, protease, env and rev gene, all derived from SIV, but not 

tat and nef gene and the plasmid pSIV/pol which carrys SIV-derived pol gene; the 

plasmid pHIV/GE and pHIV/pol that are substituted the SIV-derived genes in the 

plasmid pSIV/GE and pSIV/pol by human immunodeficiency virus (HIV)-derived 

corresponding genes; DNA vaccine containing the plasmid pSIV/GE and pSIV/pol; and 

DNA vaccine containing the plasmid pHIV/GE and pHIV/pol. The present invention 

offers AIDS DNA vaccines which successfully exert perfect medicinal efficacy on 

primates, giving a measure of success in developing effective AIDS DNA vaccines 

applicable to humans. The plasmid of the present invention can be effectively used 

for not only AIDS prevention by AIDS infection but also therapeutic agent for AIDS.
[52] US Class: 4353201 4240932 4240936 4241841 4241881 435325 435455 

514044
[51] Int’l Class: C07K001416 C07K0014155 C07K0014035 
[52] ECLA: C07K0014035 C07K0014155 C07K001416 C07K001416B M07K020700 

M07K031900 M61K003953
10            © 2008 MicroPatent, LLC
MicroPatent ReportUS6783939B2
ALPHAVIRUS VECTORS AND VIROSOMES WITH MODIFIED 

HIV GENES FOR USE IN VACCINES

[71] Applicant: ALPHAVAX INC; UNIV 

NORTH CAROLINA
[75] Inventors: Olmsted, Robert; 

Keith, Paula;  Dryga, Sergey;

  Caley, Ian;  Maughan, 
 . . .
[21] Application No.: NA
[22] Filed:  20011116 
[43] Published:  20040831 





The present invention provides methods and compositions comprising a population of 

alphavirus replicon particles comprising two or more isolated nucleic acids 

selected from 1) an isolated nucleic acid encoding an env gene product or an 

immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated 

nucleic acid encoding a gag gene product or an immunogenic fragment thereof of a 

human immunodeficiency virus, wherein the gag gene product or immunogenic fragment 

thereof is modified to inhibit formation of virus-like particles containing the 

gag gene product or the immunogenic fragment thereof and their release from a cell,

 and 3) an isolated nucleic acid encoding a pol gene product or an immunogenic 

fragment thereof of a human immunodeficiency virus, wherein the pol gene product or 

immunogenic fragment thereof is modified to inhibit protease, integrase, RNase H 

and/or reverse transcriptase activity, and wherein the nucleic acids are each 

contained within a separate alphavirus replicon particle.
[52] US Class: 435006 4241921 4242081 435005 4350697 4353201 4353391 

5360231 53602372
[51] Int’l Class: C07K001418 C07K001416 C12N000702 A61K003921 A61K003900 
[52] ECLA: A61K003921 C07K001416B C07K001416D C07K001418A C12N000702 

K61K003900 K61K0039525C M07K020700 M07K022100 M12N077016A
11            © 2008 MicroPatent, LLC
MicroPatent ReportUS6716823B1
NONINVASIVE GENETIC IMMUNIZATION, EXPRESSION 

PRODUCTS THEREFROM, AND USES THEREOF

[71] Applicant: UAB RESEARCH 

FOUNDATION
[75] Inventors: Tang, De chu C.; 

Marks, Donald H.;  Curiel, 

David T.;  Shi, Zhongkai
[21] Application No.: NA
[22] Filed:  20000323 
[43] Published:  20040406 






Disclosed and claimed are methods of non-invasive genetic immunization in an animal 

and/or methods of inducing a systemic immune or therapeutic response in an animal, 

products therefrom and uses for the methods and products therefrom. The methods can 

include contacting skin of the animal with a vector in an amount effective to 

induce the systemic immune or therapeutic response in the animal. The vector can 

include and express an exogenous nucleic acid molecule encoding an epitope or gene 

product of interest. The systemic immune response can be to or from the epitope or 

gene product. The nucleic acid molecule can encode an epitope of interest and/or an 

antigen of interest and/or a nucleic acid molecule that stimulates and/or modulates 

an immunological response and/or stimulates and/or modulates expression, e.g., 

transcription and/or translation, such as transcription and/or translation of an 

endogenous and/or exogenous nucleic acid molecule; e.g., one or more of influenza 

hemagglutinin, influenza nuclear protein, influenza M2, tetanus toxin C-fragment, 

anthrax protective antigen, anthrax lethal factor, rabies glycoprotein, HBV surface 

antigen, HIV gp 120, HIV gp 160, human carcinoembryonic antigen, malaria CSP, 

malaria SSP, malaria MSP, malaria pfg, and mycobacterium tuberculosis HSP; and/or a 

therapeutic, an immunomodulatory gene, such as co-stimulatory gene and/or a 

cytokine gene. The immune response can be induced by the vector expressing the 

nucleic acid molecule in the animal’s cells. The animal’s cells can be epidermal 

cells. The immune response can be against a pathogen or a neoplasm. A prophylactic 

vaccine or a therapeutic vaccine or an immunological composition can include the 

[52] US Class: 514044 42409321 4353201 435375
[51] Int’l Class: A61K004800 A61K0039145 A61K003908 A61K003900 
[52] ECLA: A61K003900 A61K003900D6 A61K003908 A61K0039145 A61K004800 

K61K003953 K61K003954A K61K003954A1 K61K003954A2
12            © 2008 MicroPatent, LLC
MicroPatent ReportUS6696291B2
SYNTHETIC HIV GAG GENES

[71] Applicant: MERCK  CO INC
[75] Inventors: Shiver, John W.; 

Freed, Daniel C.;  Davies, 

Mary Ellen;  Liu, Margaret A.
 . . .
[21] Application No.: NA
[22] Filed:  20011009 
[43] Published:  20040224 





Synthetic DNA molecules encoding HIV gag and modifications of HIV gag are provided. 

The codons of the synthetic molecules are codons preferred by the projected host 

cell. The synthetic molecules may be used as a polynucleotide vaccine which 

provides effective immunoprophylaxis against HIV infection through stimulation of 

neutralizing antibody and cell-mediated immunity. 
[52] US Class: 4353391 435005 435006 435325 5360231
[51] Int’l Class: C07K001416 A61K003900 
[52] ECLA: C07K001416B K61K003900 M07K020300 M07K020700 M07K031902
13            © 2008 MicroPatent, LLC
MicroPatent ReportUS6656706B2
MOLECULAR CLONES WITH MUTATED HIV GAG/POL, SIV 

GAG AND SIV ENV GENES

[71] Applicant: US HEALTH
[75] Inventors: Pavlakis, George N.
[21] Application No.: NA
[22] Filed:  20010601 
[43] Published:  20031202 






Nucleic acid constructs containing HIV-1 gag/pol and SIV gag or SIV env genes which 

have been mutated to remove or reduce inhibitory/instability sequences are 

disclosed. Viral particles and host cells containing these constructs and/or viral 

particles are also disclosed. The exemplified constructs and viral particles of the 

invention may be useful in gene therapy for numerous disorders, including HIV 

infection, or as a vaccine for HIV-1 immunotherapy and immunoprophylaxis.
[52] US Class: 4350691 4240932 4350914 4352523 4353201 435325 435455 

514044 5360231
[51] Int’l Class: C12N000700 C07K0014155 C12N0015867 C07K001416 A61K003921 
C12N000508 A61K004800 A61K003900 
[52] ECLA: A61K003921 C07K0014155 C07K001416B C12N000700 C12N0015867 

K61K003900 K61K003953 K61K004800 M07K020700 M12N074003F 

M12N083042 M12N083048 M12N083050 M12N084010C M12N084020
14            © 2008 MicroPatent, LLC
MicroPatent ReportUS6649409B1
METHOD FOR PRODUCING A NUCLEOTIDE SEQUENCE 

CONSTRUCT WITH OPTIMIZED CODONS FOR AN HIV 

GENETIC VACCINE BASED ON A PRIMARY, EARLY HIV 

[71] Applicant: STATENS 

SERUMINSTITUT
[75] Inventors: Fomsgaard, Anders
[21] Application No.: NA
[22] Filed:  20000329 
[43] Published:  20031118 





The present invention relates to a method for producing a nucleotide sequence 

construct with optimized codons for an HIV genetic vaccine based on a primary, 

early HIV isolate. Specific such nucleotide sequence construct are the synthetic 

envelope BX08 constructs. The invention further relates to the medical use of such 

constructs for the treatment and prophylaxis of HIV through DNA vaccine and for 

diagnostics.
[52] US Class: 4353391 4242081 4350691 435325 53602372
[51] Int’l Class: C12N000506 C12N000500 C12N000700 C07H002104 A61K003921 
C12P002106 
[52] ECLA: C12N000700 A61K003921 M12N074003F
15            © 2008 MicroPatent, LLC
MicroPatent ReportUS6635624B1
NUCLEOTIDE VECTOR COMPOSITION CONTAINING SUCH 





[71] Applicant: PASTEUR INSTITUT; 

INST NAT SANT ET  DE LA RECH 

ME;  UNIV D OTTAWA
[75] Inventors: Davis, Heather 

Lynn; Whalen,  Robert Gerald;

  Michel, Marie  Louise
[21] Application No.: NA
[22] Filed:  19980902 
[43] Published:  20031021 






The invention relates to methods of inducing an immunogenic response in a subject 

that include administering a nucleotide plasmid vector that includes a gene coding 

for a surface antigen protein derived from hepatitis B virus and a promoter for the 

expression of the gene. The invention also relates to vaccine compositions for 

protecting against hepatitis B virus.
[52] US Class: 514044 4353201
[51] Int’l Class: C07K001402 A61K003929 A61K004800 A61K003900 
[52] ECLA: A61K003929B C07K001402 K61K003900 K61K004800 M07K020700
16            © 2008 MicroPatent, LLC
MicroPatent ReportUS6586409B1
ADJUVANT COMPOSITIONS AND METHODS FOR ENHANCING 





[71] Applicant: VICAL INC
[75] Inventors: Wheeler, Carl J.
[21] Application No.: NA
[22] Filed:  20000324 
[43] Published:  20030701 






The invention provides adjuvants, immunogenic compositions, and methods useful for 

polynucleotide-based vaccination and immune response. In particular, the invention 

provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is GAP-

DMORIE.
[52] US Class: 514044 424450 435006 4353201 435455 530323 560155 560224 

560252 977802
[51] Int’l Class: A61K003939 A61K0009127 A61K000900 
[52] ECLA: A61K0009127B2 A61K003939 K61K003953 K61K0039555B




[71] Applicant: SMITHKLINE BEECHAM 

BIOLOG
[75] Inventors: Friede, Martin; 

Garcon, Nathalie;  Gerard, 

Catherine  Marie Ghislaine;  
 . . .
[21] Application No.: NA
[22] Filed:  20001018 
[43] Published:  20030408 






The present invention relates to adjuvant compositions which are suitable to be 

used in vaccines. In particular, the adjuvant compositions of the present invention 

comprises a saponin and an immunostimulatory oligonucleotide, optionally with a 

carrier. Also provided by the present invention are vaccines comprising the 

adjuvants of the present invention and an antigen. Further provided are methods of 

manufacture of the adjuvants and vaccines of the present invention and their use as 

medicaments. Methods of treating an individual susceptible to or suffering from a 

disease by the administration of the vaccines of the present invention are also 

provided.
[52] US Class: 4241841 4242081 4242281 4242291 4242311 4242491 4242781 

4242831 514025
[51] Int’l Class: A61K003921 A61P003302 A61K0039112 A61P002528 A61K003900 
A61P003500 A61K00317088 A61P003104 C12N001509 A61P003704 A61P000910 
A61K003925 A61P004300 A61K0039102 A61K003902 A61K003912 A61K0039245 
A61P003300 A61K003929 A61K003939 A61K0039118 A61K0039095 A61P003708 
A61P003112 A61K0039145 A61K003910 
[52] ECLA: A61K003900D6 A61K003939 K61K0039555A K61K0039555B5 

K61K0039555B7 K61K0039555B8 K61K0039555B13
18            © 2008 MicroPatent, LLC
MicroPatent ReportUS6541003B1
CONDITIONALLY CONTROLLED, ATTENUATED HIV VACCINE

[71] Applicant: INFECTIOUS 

DISEASES  FOUNDATION
[75] Inventors: Smith, Stephen M.
[21] Application No.: NA
[22] Filed:  20000725 
[43] Published:  20030401 






A live attenuated human immunodeficiency virus type 1 (HIV-1) whose replication 

is not constitutive but is instead conditionally regulated (such that rounds of 

reverse transcription with accompanying potential for error are strictly limited) 

might yield a paradigm that minimizes evolution to virulence and facilitate vaccine 

development. We have broached the concept of conditional control of HIV-1 through 

gain-of-function. Here, we describe the design of constitutively inactive HIV-1 

genomes (HIV-DoxT and HIV-DoxSp) which can be conditionally resuscitated to an 

active state by tetracycline or related analogues. The HIV-DoxT construct comprises 

an inactivating mutation engineered into TAR, thereby rendering the virus non-

responsive to Tat, a 302-bp DNA fragment (TetopT) which contains the tet-operator 

ligated into a position upstream of the HIV TATAA box, in both the 5’ and 3’ LTRs, 

and a reverse tetracycline-controlled activator (RTTA) coding sequence in place 

of the nef coding region. The HIV-DoxSp construct contains three additional Sp1 

sites in the TetopT promoter upstream of the TATAA box thereby generating the 

promoter TetopSp. Genotypically, HIVDoxT is tat(+)tar(-)nef(-)Sp1(-) and 

HIVDoxSp is tat(+)tar(-)nef(-)Sp1(+). Since both genomes are genetically 

tar(-), they would ordinarily be expected to be wholly defective in producing 

viral proteins and/or particles. However, following transfection into an 

appropriate cell target, both proviruses, in a doxycycline-dependent fashion, 

capably released Gag and RT from cells. In the absence of doxycycline, no 

replication competent virus could be recovered. These findings suggest that the 

[52] US Class: 4241881 4242081 435236
[51] Int’l Class: C12N001585 C12N000704 A61K003921 C12N0015867 
[52] ECLA: A61K003921 C12N000704 C12N001585 C12N0015867 K61K0039525B 

M12N074003F M12N083000A1A
19            © 2008 MicroPatent, LLC
MicroPatent ReportUS6534312B1
VACCINES COMPRISING SYNTHETIC GENES

[71] Applicant: MERCK  CO INC
[75] Inventors: Shiver, John W.; 

Davies, Mary Ellen;  Freed, 

Daniel C.;  Liu, Margaret A.;
 . . .
[21] Application No.: NA
[22] Filed:  19990628 
[43] Published:  20030318 





Synthetic polynucleotides comprising a DNA sequence encoding a peptide or protein 

are provided. The DNA sequence of the synthetic polynucleotides comprise codons 

optimized for expression in a nonhomologous host. The invention is exemplified by 

synthetic DNA molecules encoding HIV env as well as modifications of HIV env. The 

codons of the synthetic molecules include the projected host cell’s preferred 

codons. The synthetic molecules provide preferred forms of foreign genetic material.

 The synthetic molecules may be used as a polynucleotide vaccine which provides 

immunoprophylaxis against HIV infection through neutralizing antibody and cell-

mediated immunity. This invention provides polynucleotides which, when directly 

introduced into a vertebrate in vivo, including mammals such as primates and humans,

 induces the expression of encoded proteins within the animal.
[52] US Class: 435339 4242081 435005 435006 4350697 5360234
[51] Int’l Class: C12N001567 C07K001416 
[52] ECLA: C07K001416D C12N001567 K61K003951 M07K020700 M07K031900
20            © 2008 MicroPatent, LLC
MicroPatent ReportUS6534062B2




[71] Applicant: UNIV CALIFORNIA; 

US DEPT OF  VETERANS AFFAIRS
[75] Inventors: Raz, Eyal; Cho, 

Hearn Jay; Richman,  Douglas;

 Horner,  Anthony A.
[21] Application No.: NA
[22] Filed:  20010328 
[43] Published:  20030318 






The invention provides methods for T helper-independent activation of an antigen-

specific cytotoxic T lymphocyte response in an individual. The methods generally 

involve administering to an individual an immunostimulatory nucleic acid molecule 

in an amount effective to increase an antigen-specific CTL response in the 

individual. The invention further provides methods for increasing chemokine 

secretion, which can block HIV infection.
[52] US Class: 4241931 5360231 5360241
[51] Int’l Class: A61K0039385 A61K003921 A61K003900 A61K003939 C12Q000170 
[52] ECLA: A61K003900D6 A61K003921 A61K0039385 A61K003939 K61K003953 

K61K003954 K61K003954A2 K61K003955 K61K0039555B7 

K61K003957 K61K003960N M12Q000170B2B
21            © 2008 MicroPatent, LLC
MicroPatent ReportUS6420545B1




[71] Applicant: TRUSTEES OF THE 

UNIVERSITY OF;  UNIV DUKE
[75] Inventors: Hoxie, James A.; 

LaBranche, Celia C. ; Doms, 

Robert W.;  Hoffman, Trevor 
 . . .
[21] Application No.: NA
[22] Filed:  19990622 
[43] Published:  20020716 






The invention relates to novel CD4-independent HIV Envelope proteins and uses 

therefor.
[52] US Class: 53602372 4242081 4350691 4352351 4353201 5360231 5360234
[51] Int’l Class: C07H002104 
[52] ECLA: 
22            © 2008 MicroPatent, LLC
MicroPatent ReportUS6348450B1
NONINVASIVE GENETIC IMMUNIZATION, EXPRESSION 

PRODUCTS THEREFROM AND USES THEREOF

[71] Applicant: UAB RESEARCH 

FOUNDATION
[75] Inventors: Tang, De chu C.; 

Marks, Donald H.;  Curiel, 

David T.;  Shi, Zhongkai; 
 . . .
[21] Application No.: NA
[22] Filed:  20000503 
[43] Published:  20020219 






Disclosed and claimed are methods of non-invasive genetic immunization in an animal 

and/or methods of inducing a systemic immune or therapeutic response in an animal, 

products therefrom and uses for the methods and products therefrom. The methods can 

include contacting skin of the animal with a vector in an amount effective to 

induce the systemic immune or therapeutic response in the animal. The vector can 

include and express an exogenous nucleic acid molecule encoding an epitope or gene 

product of interest. The systemic immune response can be to or from the epitope or 

gene product. The nucleic acid molecule can encode an epitope of interest and/or an 

antigen of interest and/or a nucleic acid molecule that stimulates and/or modulates 

an immunological response and/or stimulates and/or modulates expression, e.g., 

transcription and/or translation, such as transcription and/or translation of an 

endogenous and/or exogenous nucleic acid molecule; e.g., one or more of influenza 

hemagglutinin, influenza nuclear protein, tetanus toxin C-fragment, anthrax 

protective antigen, HIV gp 120, human carcinoembryonic antigen, and/or a 

therapeutic, an immunomodulatory gene, such as co-stimulatory gene and/or a 

cytokine gene. The immune response can be induced by the vector expressing the 

nucleic acid molecule in the animal’s cells. The immune response can be against a 

pathogen or a neoplasm. A prophylactic vaccine or a therapeutic vaccine or an 

immunological composition can include the vector.
[52] US Class: 514044 42409321 4353201 435375
[51] Int’l Class: A61K0039145 A61K003908 A61K003900 A61K004800 
[52] ECLA: A61K003900 A61K003900D6 A61K003908 A61K0039145 A61K004800 

K61K003953 K61K003954A K61K003954A1 K61K003954A223            © 2008 MicroPatent, LLC
MicroPatent ReportUS6326007B1




[71] Applicant: UNIV CALIFORNIA
[75] Inventors: Yilma, Tilahun D.; 

Giavedoni, Luis D.;  Luciw, 

Paul A.
[21] Application No.: NA
[22] Filed:  19950720 
[43] Published:  20011204 






This invention discloses recombinant vectors and live attenuated pathogens produced 

by these vectors which are useful as vaccines and therapeutic agents. Particularly 

disclosed are live attenuated recombinant viruses that remain at very low virus 

loads, and preferably do not persist in the infected hosts. These recombinant 

viruses are useful against retroviruses such as human immunodeficiency virus and 

against acquired immunodeficiency diseases. In the recombinant vectors and 

pathogens, one or more genes, or part of the gene(s), responsible for 

pathogenesis have been completely or partially rendered nonfunctional, e. g., by 

full or partial deletion or mutagenesis. Further, the recombinant vectors and 

pathogens contain one or more genes encoding cytokine(s) and/or lymphokine(s).
[52] US Class: 4242071 4241871 4241991 4242051 4242081 4352351 435236 

4353201 514044 530350 5360231 53602372
[51] Int’l Class: A61P003118 A61K003921 C12N0015867 A61K004800 
[52] ECLA: A61K003921 C12N0015867 K61K004800
24            © 2008 MicroPatent, LLC
MicroPatent ReportUS6248721B1




[71] Applicant: CHANG LUNG-JI
[75] Inventors: Chang, Lung Ji
[21] Application No.: NA
[22] Filed:  19970501 
[43] Published:  20010619 






The present invention provides animals and methods for the evaluation of vaccines. 

In particular, the present invention provides humanized animal models for the 

evaluation of vaccines designed to confer immunity against human pathogens, 

including vaccines directed against the human immunodeficiency virus. The present 

invention further relates to HIV vaccines. In particular, the present invention 

provides attenuated replication-competent HIV vaccines and replication-defective 

HIV vaccines. In addition, the invention provides modified Leishmania cells 

expressing HIV proteins.
[52] US Class: 514044 4240092 4352351 4353201 435375 800003 800008 800011
[51] Int’l Class: C07K001416 A01K0067027 C12N000704 A61K003900 
[52] ECLA: A01K0067027B C07K001416 C12N000704 K61K003900 M07K020700 

M07K022120 M12N074003F
25            © 2008 MicroPatent, LLC
MicroPatent ReportUS6210663B1
METHODS OF AUGMENTING MUCOSAL IMMUNITY THROUGH 

SYSTEMIC PRIMING AND MUCOSAL BOOSTING

[71] Applicant: WISTAR INST
[75] Inventors: Ertl, Hildegund C. 

J.
[21] Application No.: NA
[22] Filed:  19990819 
[43] Published:  20010403 






A method for inducing and enhancing mammalian mucosal immunity includes the steps 

of first administering to a mammal via a non-mucosal route a suitable amount of a 

priming vaccine composition which comprises a DNA sequence encoding an antigen of a 

pathogen under the control of regulatory sequences directing expression thereof in 

a mammalian cell, and subsequently, administering intranasally a boosting vaccine 

composition which comprises the same antigen in protein form or a DNA sequence 

encoding the same antigen. A method to reduce the anti-viral immune response to a 

recombinant viral vaccine includes the steps of administering a similar priming DNA 

vaccine composition that lacks any viral protein and subsequently administering as 

a boosting vaccine, a recombinant virus containing a DNA sequence encoding the same 

antigen as encoded by the DNA vaccine, wherein upon said recombinant virus vaccine 

administration, the immune response to the antigen is enhanced and the immune 

response to the recombinant virus is reduced.
[52] US Class: 4240932 4241841 4242081 4242291 4242491 4353201
[51] Int’l Class: A61K0039205 A61K003912 
[52] ECLA: A61K003912 A61K0039205 K61K0039525C K61K003954A2
26            © 2008 MicroPatent, LLC
MicroPatent ReportUS6168923B1




[71] Applicant: WISTAR INST; UNIV 

PENNSYLVANIA
[75] Inventors: Scott, Phillip; 

Trinchieri,  Giorgio
[21] Application No.: NA
[22] Filed:  19990301 
[43] Published:  20010102 





Improved vaccine compositions and methods of making same are provided, which 

vaccines are characterized by an antigen from a pathogen and an effective 

adjuvanting amount of Interleukin-12. These IL-12 adjuvanted vaccines are capable 

of increasing the vaccinated host’s cell mediated immune response to provide an 

increased and protective immune response to the pathogen. Also disclosed are 

methods for vaccinating hosts by administering a vaccine containing an antigen from 

a pathogenic microorganism and co-administering an adjuvanting amount of IL-12. 

Vaccines or therapeutic compositions directed against a cancer may also be 

adjuvanted with IL-12 according to this invention.
[52] US Class: 435006 4241841 4241911 4242041 4242081 4242341 4242691 

435005 4353391 530350
[51] Int’l Class: A61K003939 
[52] ECLA: A61K003939 K61K0039555B1 K61K0039555B2L12 K61K003957
27            © 2008 MicroPatent, LLC
MicroPatent ReportUS6086891A
BI-FUNCTIONAL PLASMID THAT CAN ACT AS BOTH A DNA 

VACCINE AND A RECOMBINANT VIRUS VECTOR

[71] Applicant: ST JUDE CHILDRENS 

RES HOSPITAL
[75] Inventors: Hurwitz, Julia; 

Coleclough,  Christopher
[21] Application No.: NA
[22] Filed:  19980921 
[43] Published:  20000711 





Polyenv vaccines are provided that comprise mixtures of at least 4 to about 10,000 

different recombinant viruses that each express a different HIV env variant or a 

portion thereof containing both constant and variable regions, as well as methods 

of making and using such polyenv vaccines and viruses, including the use of the 

polyenv vaccine, in live, attenuated or inactivated form, for prophylaxis or 

treatment of HIV infection. The viral vaccines of the invention are optimally 

combined with a recombinant HIV env booster, or a recombinant HIV env gene DNA 

priming or boosting vaccine.
[52] US Class: 4242081 4242301 5360231
[51] Int’l Class: A61K003921 A61P003118 C07K001416 C12N0015863 A61K003900 
A61K003812 
[52] ECLA: A61K003921 C07K001416D C12N0015863V K61K003812 K61K003900 

M07K020700 M07K022100 M07K022104 M07K022112 M07K022120
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[71] Applicant: DANA FARBER CANCER 

INST INC
[75] Inventors: Sodroski, Joseph G.

; Haseltine,  William A.;  

Poznansky, Mark;  Lever, 
 . . .
[21] Application No.: NA
[22] Filed:  19970820 
[43] Published:  19991109 






Packaging defective and packaging proficient HIV vectors are disclosed. These 

vectors can be used to establish HIV packaging defective cell lines, and to package 

desired genes. These cell lines can be used in developing a vaccine, HIV antibodies 

and as part of a system for gene transfer. The packaging proficient vector can be 

used to target HIV target cells.
[52] US Class: 4353201 435455
[51] Int’l Class: C07K001416 C12N001549 C12N0015867 A61K003900 A61K003800 
[52] ECLA: C07K001416 C12N0015867P K61K003800 K61K003900 M07K020700
29            © 2008 MicroPatent, LLC
MicroPatent ReportUS5883081A
ISOLATION OF NOVEL HIV-2 PROVIRUSES

[71] Applicant: UNIV CALIFORNIA
[75] Inventors: Kraus, Gunter; 

Wong Staal,  Flossie; 

Talbott,  Randy; Poeschla,  
 . . .
[21] Application No.: NA
[22] Filed:  19960607 
[43] Published:  19990316 





Novel HIV-2 proviruses, molecular clones, nucleic acids, polypeptides, viruses and 

viral components are described. The use of these compositions as components of 

diagnostic assays, as immunological reagents, as vaccines, as components of 

packaging cells, cell transduction vectors, and as gene therapy vectors is also 

described.
[52] US Class: 514044 4241601 4350691 4353201 53038835 5360231
[51] Int’l Class: C12N000700 C07K001416 A61K003800 
[52] ECLA: C07K001416 C12N000700 K61K003800 M07K020300 M07K020500 

M07K020700 M12N074003
30            © 2008 MicroPatent, LLC
MicroPatent ReportUS5869313A
MOLECULAR CLONES OF HIV-1 VIRAL STRAINS MN-ST1 

AND BA-L, AND USES THEREOF

[71] Applicant: US HEALTH
[75] Inventors: Reitz, Jr., Marvin 

S.; Franchini,  Genoveffa; 

Markham,  Phillip D.; Gallo, 
 . . .
[21] Application No.: NA
[22] Filed:  19960514 
[43] Published:  19990209 






The present invention relates to the HIV-1 strains MN-ST1 and BA-L which are 

typical United States HIV-1 isotypes. The present invention relates to DNA segments 

encoding the envelope protein of MN-ST1 or BA-L, to DNA constructs containing such 

DNA segments and to host cells transformed with such constructs. The viral isolates 

and envelope proteins of the present invention are of value for use in vaccines and 

bioassays for the detection of HIV-1 infection in biological samples, such as blood 

bank samples.
[52] US Class: 4352351 435006 4350691 4350693 435239 530324 53602372
[51] Int’l Class: C07K001416 A61K003900 
[52] ECLA: C07K001416D K61K003900 M07K020300 M07K020700




[71] Applicant: COMMW SCIENT IND 

RES ORG; UNIV  AUSTRALIAN
[75] Inventors: Ramshaw, Ian 

Allister; Boyle,  David 

Bernard;  Coupar, Barbara  
 . . .
[21] Application No.: NA
[22] Filed:  19950607 
[43] Published:  19990202 






A recombinant vaccine comprises a vaccine vector which incorporates a first 

nucleotide sequence capable of being expressed as all or a part of an antigenic 

polypeptide, together with a second nucleotide sequence capable of being expressed 

as all or a part of a lymphokine effective in enhancing the immune response to the 

antigenic polypeptide. The vaccine vectors include poxvirus, herpes virus or 

adenovirus, and the lymphokine may be an interleukin, tumour necrosis factor or 

gamma-interferon. The vaccine vector may express an antigenic polypeptide which is 

foreign to the host vector.
[52] US Class: 4241861 4241881 4241991 4353201
[51] Int’l Class: C07K0014525 C07K001407 C07K001454 C07K001457 A61K003900 
[52] ECLA: C07K001407 C07K0014525 C07K001454 C07K001457 K61K003900 

M07K031900 M07K031940
32            © 2008 MicroPatent, LLC
MicroPatent ReportUS5795577A
VIRAL VECTOR CODING FOR A GLYCOPROTEIN OF THE 

VIRUS RESPONSIBLE FOR A.I.D. S.

[71] Applicant: TRANSGENE SA; 

PASTEUR INSTITUT
[75] Inventors: Kieny, Marie Paule;

 Rautmann, Guy;  Lecocq, 

Jean  Pierre; Hobson,  Simon 
 . . .
[21] Application No.: NA
[22] Filed:  19950607 
[43] Published:  19980818 






This invention relates to an immunogenic composition comprising a viral vector. The 

genome of the viral vector comprises a functional origin of replication of a 

poxvirus, a DNA fragment encoding a non-cleavable gp160, a DNA fragment encoding a 

signal peptide, and a promoter for expressing DNA fragments in mammalian cells.
[52] US Class: 4242081 4241881 4350691 4350693 4353201 530395
[51] Int’l Class: C07K0014145 C07K001416 A61K003900 A61K003800 
[52] ECLA: C07K0014145 C07K001416D K61K003800 K61K003900 M07K020700 

M07K021500 M07K022120 M07K031902




[71] Applicant: US HEALTH
[75] Inventors: Golding, Basil
[21] Application No.: NA
[22] Filed:  19950106 
[43] Published:  19981020 





The present invention relates to lipopolysaccharides from Brucella abortus and 

their use as carriers in vaccines for humans and animals. In particular, the 

present invention relates to conjugate molecules having a carrier molecule of 

purified lipopolysaccharide from B. abortus coupled to an antigenic component of an 

infectious organism.
[52] US Class: 4241931 4241941 42419611 42419711 4242081 530403 530807
[51] Int’l Class: A61K0039385 
[52] ECLA: A61K0039385 K61K003960S




[71] Applicant: UNIV FLORIDA
[75] Inventors: Schreier, Hans; 

Chander, Ramesh;  Stecenko, 

Arlene A.
[21] Application No.: NA
[22] Filed:  19950607 
[43] Published:  19980616 






The production of artificial viral envelopes by a novel double-detergent dialysis 

technique is disclosed. Specifically exemplified is the production of HIV-1 and RSV 

viral envelopes. The resulting artificial viral envelopes are essentially identical 

to the natural virus with regard to characteristics which are relevant to 

immunogenicity and intracellular transfer of encapsulated material.
[52] US Class: 424450 2640041 2640043 4241921 4242041 4242081 424812 

436829
[51] Int’l Class: A61K0009127 
[52] ECLA: A61K0009127B A61K0009127P
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VECTORS CONTAINING HIV PACKAGING SEQUENCES, 





[71] Applicant: DANA FARBER CANCER 

INST INC
[75] Inventors: Sodroski, Joseph G.

; Haseltine,  William A.;  

Poznansky, Mark;  Lever, 
 . . .
[21] Application No.: NA
[22] Filed:  19931115 
[43] Published:  19970909 






Packaging defective and packaging proficient HIV vectors are disclosed. These 

vectors can be used to establish HIV packaging defective cell lines, and to package 

desired genes. These cell lines can be used in developing a vaccine, HIV antibodies 

and as part of a system for gene transfer. The packaging proficient vector can be 

used to target HIV target cells.
[52] US Class: 435456 4240932 435236 4353201 435325 435358 435362 435364 

435367 435372 435457 435465
[51] Int’l Class: C07K001416 A61K003900 A61K003800 
[52] ECLA: C07K001416 K61K003800 K61K003900 M07K020700
36            © 2008 MicroPatent, LLC
MicroPatent ReportUS5654195A
VECTORS EXPRESSING HYBRID VIRUSES, METHODS OF 

USE AND NOVEL ASSAYS

[71] Applicant: DANA FARBER CANCER 

INST INC
[75] Inventors: Sodroski, Joseph; 

Haseltine, William  A.; 

Letvin, Norman;  Li, John
[21] Application No.: NA
[22] Filed:  19940701 
[43] Published:  19970805 






A vector which can be used to establish a hybrid SIV/HIV-1 virus is described. This 

virus can be used to infect an animal such as a monkey to establish an animal model 

for in vivo testing. This animal model can be used for purposes such as screening 

for therapeutics, adjuvants and vaccines.
[52] US Class: 4353201 4352351
[51] Int’l Class: C12N0015867 C07K0014155 A01K0067027 C12N001509 C07H002104 
A61K003921 C12N000700 C07K001416 A61K004900 C12N001549 A61P003112 
A61K003900 
[52] ECLA: A01K0067027 C07K0014155 C07K001416 C12N000700 C12N0015867 

K61K003900 M07K020700 M12N074003F
37            © 2008 MicroPatent, LLC
MicroPatent ReportUS5571712A
NON-INFECTIOUS, REPLICATION DEFECTIVE, 

IMMUNOGENIC HIV RETROVIRUS-LIKE PARTICLES 

PRODUCED FROM A RECOMBINANT HIV GENOME DEVOID OF 

[71] Applicant: CONNAUGHT LAB
[75] Inventors: Haynes, Joel; 

Klein, Michel H.;  Rovinski, 

Benjamin;  Cao, Shi X.
[21] Application No.: NA
[22] Filed:  19940506 
[43] Published:  19961105 





This invention is directed towards nucleic acid molecules capable of producing 

human immunodeficiency virus (HIV) retrovirus-like particles, which are non-

infectious, replication defective, and immunogenic. Recombinant HIV genomes were 

generated that are devoid of long terminal repeats (LTRs) but contain a 

heterologous, inducible metallothionein promoter. Additional modifications have 

been made to the primer binding site, pol, vif, and env coding regions. Upon 

transfection into a suitable host these DNA molecules are capable of producing HIV 

retrovirus-like particles that lack genomic RNA. These non-infectious particles 

will provide suitable antigens for HIV diagnostic assays and immunogenic 

preparations.
[52] US Class: 435364 4241881 4242081 4350693 4353201 435365 53602372
[51] Int’l Class: C07K001416 A61K003900 
[52] ECLA: C07K001416 K61K003900 M07K020300 M07K020700
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[71] Applicant: CONNAUGHT LAB
[75] Inventors: Haynes, Joel; 

Klein, Michel H.;  Rovinski, 

Benjamin;  Cao, Shi X.
[21] Application No.: NA
[22] Filed:  19920615 
[43] Published:  19950808 






An immunogenic HIV retrovirus-like particle which is non-infectious and non-

replicating and which is useful as a candidate vaccine component against HIV 

infection, is produced by genetic engineering. A DNA molecule comprising the HIV 

genome devoid of long terminal repeats is incorporated into an expression vector, 

which is introduced into mammalian cells for expression of the HIV retrovirus-like 

particle.
[52] US Class: 4350693 4241841 4241851 4241861 4241871 4241881 4242041 

4242071 4242081 4350691 4350701 4350711 4352351 435236 

435466 435974 514002 530350 530826 5360231 53602372
[51] Int’l Class: C12Q000170 C12N001548 A61K003921 C12N000700 G01N0033569 
C12N001509 A61P003112 C12P002100 C12N001549 C07K0014155 C12P002102 
C07K001416 A61K003900 C12R000191 
[52] ECLA: C07K001416 K61K003900 M07K020300 M07K020700
39            © 2008 MicroPatent, LLC
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[71] Applicant: SQUIBB BRISTOL 

MYERS CO
[75] Inventors: Watanabe, Suan M.; 

Cosand, Wesley L.;  McArdle, 

Susan;  Travis, Bruce M.
[21] Application No.: NA
[22] Filed:  19920824 
[43] Published:  19940712 





A method for expressing proteins which are immunologically reactive with antibodies 

to lymphadenopathy-associated virus (LAV), now known as Human Immunodeficiency 

Virus (HIV), is disclosed. The proteins are produced by bacterial host cells 

transformed with a recombinant plasmid which includes appropriate procaryotic 

transcriptional and translational signals for expression, followed in reading phase 

by a DNA sequence comprising a portion of the env region of the LAV genome. This 

portion codes for a protein which is immunologically reactive with antibodies to 

LAV, or antibodies to viruses defined to be the same as or equivalent to LAV. The 

proteins produced by the method disclosed may be used to screen for the presence of 

antibodies to LAV in a biological fluid, to determine the presence of LAV antigen 

in a biological fluid, or within a method for producing antibodies to LAV through 

the immunization of an animal with the protein.
[52] US Class: 4350693 435005 4350712 4352523 43525233 4353201 435974 

5360231 930221
[51] Int’l Class: C07K001610 C07K001416 C12N001549 C12N001566 A61K003900 
[52] ECLA: C07K001416B C07K001416D C07K001610 C12N001566 K61K003900 

M07K020300 M07K020700 M07K031900 M07K031902 M07K031940 

M07K0319735
40            © 2008 MicroPatent, LLC
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[71] Applicant: DU PONT
[75] Inventors: Ivanoff, Lucinda A.

; Petteway, Steven  R.
[21] Application No.: NA
[22] Filed:  19890504 
[43] Published:  19920825 





A nucleotide sequence encoding a recombinant peptide displaying the antigenicity of 

Human Immunodeficiency Virus (HIV) viral antigens is disclosed. The peptide 

comprises an antigenic segment having about 150 to about 400 amino acids 

corresponding to at least about 30 amino acids of the C-terminal of the gp120 

domain and at least about 120 amino acids of the N-terminal of the gp41 domain.
[52] US Class: 4352523 435005 4353201 5360231 53602372
[51] Int’l Class: C12N000121 C07K001416 C12N001549 C12N001562 A61K003900 
[52] ECLA: C07K001416D C12N001562 K61K003900 M07K020300 M07K020700 

M07K031900 M07K031940
41            © 2008 MicroPatent, LLC
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[71] Applicant: MERCK  CO INC
[75] Inventors: Kniskern, Peter J.;

 Hagopian, Arpi;  Burke, 

Pamela
[21] Application No.: NA
[22] Filed:  19890919 
[43] Published:  19920714 






The present invention relates to recombinant fusion polypeptides of HIV envelope 

and HBsAg, suitable as vaccines against AIDS and/or ARC and hepatitis, as well as 

immunogens for inducing antibodies for passive protection or treatment of AIDS 

and/or ARC.
[52] US Class: 4352542 4350691 4350693 4353201 5360234 53602372
[51] Int’l Class: C07K001416 C07K001402 A61K003900 
[52] ECLA: C07K001402 C07K001416D K61K003900 M07K020300 M07K020700 

M07K031900 M07K031902 M07K031940 M07K0319735
42            © 2008 MicroPatent, LLC
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[71] Applicant: MERCK  CO INC
[75] Inventors: Kniskern, Peter J.;

 Hagopian, Arpi;  Burke, 

Pamela
[21] Application No.: NA
[22] Filed:  19890919 
[43] Published:  19920714 






The present invention relates to recombinant fusion polypeptides of HIV envelope 

and HBsAg, suitable as vaccines against AIDS and/or ARC and hepatitis, as well as 

immunogens for inducting antibodies for passive protection or treatment of AIDS 

and/or ARC.
[52] US Class: 4352542 4350691 4350693 43525421 4353201 5360234 53602372
[51] Int’l Class: C07K001416 C07K001402 A61K003900 
[52] ECLA: C07K001402 C07K001416D K61K003900 M07K020300 M07K020700 

M07K031900 M07K031902 M07K0319735
43            © 2008 MicroPatent, LLC
MicroPatent ReportUS5100662A




[71] Applicant: LIPOSOME CO INC
[75] Inventors: Bolcsak, Lois E.; 

Boni, Lawrence;  Popescu, 

Mircea C.;  Tremblay, Paul A.
[21] Application No.: NA
[22] Filed:  19891016 
[43] Published:  19920331 






The present invention relates to novel liposomes and liposome-like structures (

vesicles) comprising an amount of a derivatized sterol either alone or in 

combination with additional liposome-forming lipids. <P> <P>Sterols such as 

cholesterol or other lipids, to which numerous charged or neutral groups are 

attached, may be used to prepare liposomes and liposome-like structures such as 

micelles, reverse micelles and hexagonal phases, suspensions of multilamellar 

vesicles or small unilamellar vesicles. The novel liposomes of the present 

invention may be prepared with or without the use of organic solvents. These 

vesicles may entrap compounds varying in polarity and solubility in water and other 

solvents. The vesicles of the present invention may function as vaccines after 

entrapment or association of an immunogen, as adjuvants, either alone or in 

combination with additional adjuvants, including, for example, Freund’s adjuvant (

and other oil emulsions), Bortedella Pertussis, aluminum salts and other metal 

salts and Mycobacterial products (including muramyldipeptides), among others. The 

present invention relates to novel liposomes and liposome-like structures (

vesicles) comprising an amount of a derivatized sterol either alone or in 

combination with additional liposome-forming lipids.
[52] US Class: 424450 4240852 4242081 4242101 4242111 4242261 4242271 

4242281 4242501 4242721 4242771 4242831 4284022
[51] Int’l Class: A61K0039145 A61K0009127 
[52] ECLA: A61K0009127B A61K0009127B2 A61K0039145 K61K0039555B5
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GENES AND THEIR ENCODED PROTEINS WHICH REGULATE 

GENE EXPRESSION OF THE INTERLEUKIN-2 RECEPTOR 

AND OF HUMAN LYMPHOTROPIC RETROVIRUSES

[71] Applicant: DANA FARBER CANCER 

INST INC
[75] Inventors: Cantor, Harvey I.; 

Patarca, Roberto
[21] Application No.: NA
[22] Filed:  19880211 
[43] Published:  19900828 






The present invention is directed to genes, termed Rpt-1 (regulatory protein T 

lymphocyte-1), which are expressed at higher levels by resting CD4.sup.+ 

helper/inducer T cells relative to activated CD4.sup. + cells. The invention also 

relates to the proteins encoded by such genes, termed rpt-1 proteins, which 

regulate gene expression directed by the promoter region of the interleukin-2 

receptor (IL-2r) alpha chain gene or by the promoter region of the long terminal 

repeat of human lymphotropic retroviruses such as the human immunodeficiency virus 

type 1 (HIV-1) human T cell leukemia virus (HTLV)-I, and HTLV-II. In particular,

 rpt-1 proteins down-regulate gene expression controlled by the promoter of the IL-

2r alpha chain gene or by the promoter of the long terminal repeat of HIV-1. The 

proteins and nucleic acids of the invention have value in diagnosis and therapy of 

immune disorders such as AIDS.<P><P> In a specific example of the present invention,

 an Rpt-1 gene and its encoded intracellular protein of approximately 41,000 

daltons molecular weight are described. The rpt-1 protein is shown to be 

selectively expressed by activated CD4.sup.+ T cells, and to down-regulate gene 

expression of the IL-2r and the HIV-1.
[52] US Class: 4350691 43525233 4353201 435358 4353723 435455 53602352 

53602372 5360241
[51] Int’l Class: C12N000121 C07K001447 C12N001509 C12P002102 C12N000510 
C12N001524 C12N001585 C12R000119 
[52] ECLA: C07K001447A1 C12N001585 M07K020700
45            © 2008 MicroPatent, LLC
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[75] Inventors: O’Hagan, Derek; 

Otten, Gillis;  Donnelly, 

John;  Polo, John;  Barnett, 
 . . .
[21] Application No.: NA
[22] Filed:  20070116 
[43] Published:  20080131 





Microparticles with adsorbent surfaces, methods of making such microparticles, and 

uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(

a-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester,

 a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic 

detergents. Also provided are microparticles in the form of submicron emulsions of 

an oil droplet emulsion having a metabolizable oil and an emulsifying agent. The 

surface of the microparticles efficiently adsorb polypeptides, such as antigens, 

and nucleic acids, such as ELVIS vectors and other vector constructs, containing 

heterologous nucleotide sequences encoding biologically active macromolecules, such 

as polypeptides, antigens, and adjuvants. Methods of stimulating an immune response,

 methods of immunizing a host animal against a viral, bacterial, or parasitic 

infection, and uses of the microparticle compositions for vaccines are also 

provided. 
[52] US Class: 424497 4241841 4242081 4242091 4242111 4242161 4242181 

4242211 4242281
[51] Int’l Class: A61K003929 A61K0039125 C12N000701 A61K000916 A61K000900 
C12N001586 A61K003921 C12N000502 A61P003104 A61K003912 A61K000950 
A61K0039155 A61K004748 A61P003300 A61P003112 A61K0039145 A61K000951 
A61K0039215 A61K003900 
[52] ECLA: C12N001586 A61K000916H6D4 A61K000951 A61K003900 A61K003921 

A61K004748W8 K61K003953 K61K0039555B5
46            © 2008 MicroPatent, LLC
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THERAPEUTIC CALCIUM PHOSPHATE PARTICLES AND 

METHODS OF MANUFACTURE AND USE

[71] Applicant: N/A
[75] Inventors: Bell, Steve, J.D.; 

Morcol, Tulin; He,  Qing
[21] Application No.: NA
[22] Filed:  20070403 
[43] Published:  20071220 





Novel calcium phosphate core particles, methods of making them, and methods of 

using them as vaccine adjuvants, as cores, as carriers of biologically active 

material, and as controlled release matrices for biologically active material are 

disclosed. The core particles may have a surface modifying agent and/or 

biologically active material, such as antigenic material or natural immunoenhancing 

factor, polynucleotide material, or therapeutic proteins or peptides, partially 

coating the particle or impregnated therein. The core particles have a diameter 

between about 300 nm and about 4000 nm, more particularly between about 300 nm and 

about 2000 nm, and even more particularly between about 300 nm and about 1000 nm, 

are substantially spherical in shape, and have a substantially smooth surface 
[52] US Class: 4242081 4240852 4241841 4242041 4242091 4242311 4242321 

4242341 4242431 4242441 4242471 4242481 4242601 4242741 

4242781 424489 424491 424493 424499 514002 514003 514770
[51] Int’l Class: A61K003921 A61K003909 A61K003802 A61K000914 A61K003900 
A61K0039275 A61K0039085 A61K003820 A61K003912 A61K0039245 A61K004702 
A61K004500 A61K0039104 A61K003904 A61K0039145 A61K003908 
[52] ECLA: A61K000950K2 A61K000916K A61K003904 A61K003939 C12N001587 

K61K003953 K61K0039555B5
47            © 2008 MicroPatent, LLC
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[75] Inventors: Dimitrov, Dimiter, 

S.; Zhang, Mei Yun
[21] Application No.: NA
[22] Filed:  20070810 
[43] Published:  20071220 






The invention provides polypeptides that bind with an epitope of the gp41 subunit 

of the HIV-1 envelope glycoprotein, as well as polypeptides comprising the 

aforementioned epitopes. The invention also provides methods of inhibiting an HIV 

infection in a mammal using the polypeptides of the invention, as well as 

compositions comprising the polypeptides, nucleic acid molecules encoding the 

polypeptides, and host cells and vectors comprising the nucleic acid molecules. A 

method of isolating antibodies that bind with an epitope of the gp41 subunit of the 

HIV-1 envelope glycoprotein using competitive antigen panning (CAP) is also 

provided. The invention also features the use of the polypeptides to detect the 

presence of HIV in a mammal, and epitopes that can be used as vaccine immunogens. 
[52] US Class: 4240852 4240854 4241601 435005 435243 4353201 436086 

53038835 5303911 5360235
[51] Int’l Class: C12N001512 A61K003820 A61K00317105 A61K003942 C12N000100 
A61K003821 G01N003353 C12N001563 A61P003118 C07K001608 
[52] ECLA: C07K001610K1D K61K0039505 M07K0316210 M07K0316550
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HUMAN ANTIBODIES INTERACTING WITH HIV GP41

[71] Applicant: N/A
[75] Inventors: Shiver, John, W.; 

Miller, Michael, D. ; 

Geleziunas,  Romas; Hazuda,  
 . . .
[21] Application No.: NA
[22] Filed:  20061130 
[43] Published:  20071025 





Human scFvs are disclosed which interact with a conformational epitope along the 

pre-hairpin, N-helix coiled coil structure within the heptad repeat 1 (HR1) 

region of gp41 of HIV. These antibodies, as well as IgG conversions, are shown to 

neutralize diverse HIV isolates. Isolated nucleic acid molecules are also disclosed 

which encode relevant portions of these antibodies, as well as the purified forms 

of the expressed antibodies or relevant antibody fragments, such as VHand 

VLchains. The antibody compositions disclosed within this specification may 

provide for a therapeutic treatment against HIV infection by reducing viral load 

levels within an infected individual, thus prolonging the asymptomatic phase of HIV 

infection. These antibodies will also be useful in assays to identify HIV antiviral 

compounds as well as allowing for the identification of candidate HIV vaccines, 

such as HIV peptide vaccines. 
[52] US Class: 4241601 4241841 424600 4350691 4353201 435326 436501 

5303871 5303879 5360231
[51] Int’l Class: G01N0033566 A61P003118 A61K003300 A61K0039395 C12P002106 
C07H002104 C07K001600 C12N001500 
[52] ECLA: G01N0033569K2 C07K001610K1D M07K0316210 M07K0316561 

M07K0316960 S01N050000
49            © 2008 MicroPatent, LLC
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DNA-BASED PLASMID FORMULATIONS AND VACCINES AND 

PROPHYLACTICS CONTAINING THE SAME

[71] Applicant: N/A
[75] Inventors: Lasher, Alfred, W.;

 Kittle, Joseph, D. ; Widen, 

Steven, G.
[21] Application No.: NA
[22] Filed:  20070306 
[43] Published:  20071122 





The invention is a general method for improving the performance of the DNA-based 

vaccines. The method utilizes a complex DNA-generated profile of antigens to extend 

the effects of DNA-based vaccines and to broaden the immune response. This 

broadened immune response in turn improves the protection of the recipient from 

divergent (but related) strains of a pathogen. In addition, it effectively 

improves the efficacy of DNA-based vaccines used for treatment of viral diseases, 

including acquired immunity disorder (AIDS). One embodiment, where the target 

viral pathogen is HIV (the causative agent for aids), the method identifies an 

orderly set of plasmids of related sequences that may be used to prime a broad and 

strong immune response to HLA-restricted viral antigens. This mixture of plasmids 

is thus capable of priming an appropriate immune response to reduce the viral 

burden in HIV infected patients or to protect uninfected patients from HIV 

infection. 
[52] US Class: 4242081 4242091 4242241 4242331 4242431 4242441 4242461 

4242571 4242581
[51] Int’l Class: A61K004800 A61K003921 A61K003900 A61P003118 A61P003104 
A61P003112 A61P003116 
[52] ECLA: A61K003921 A61K004800B2 K61K003953 M07K022104




[71] Applicant: GLAXO GROUP LTD
[75] Inventors: ERTL, PETER, Franz
[21] Application No.: NA
[22] Filed:  20070412 
[43] Published:  20071025 





The invention relates to polynucleotides for DNA vaccination which polynucleotides 

encode an HIV envelope protein or fragment or immunogenic derivative fused to an 

additional HIV protein selected from a non-structural protein or capsid protein or 

fragment or immunogenic derivative thereof. Preferably the HIV envelope molecule is 

gp120 and preferred fusions include one or more of HIV Nef, Gag, RT or Tat. 

Preferably the HIV envelope molecule is non-glycosylated in mammalian cells. 
[52] US Class: 424489 4350691 4353201 514044 530350 53602372
[51] Int’l Class: C12N001548 A61K000914 A61K0031711 C07K001900 A61P003118 
C12P002100 C12N001586 C07H002104 C07K001416 A61K003900 
[52] ECLA: C07K001416B C07K001416D C07K001416F K61K003900 K61K003953 

M07K020700 M07K031900
51            © 2008 MicroPatent, LLC
MicroPatent ReportUS20070190031A1
PLASMID HAVING THREE COMPLETE TRANSCRIPTIONAL 

UNITS AND IMMUNOGENIC COMPOSITIONS FOR INDUCING 

AN IMMUNE RESPONSE TO HIV

[71] Applicant: N/A
[75] Inventors: Sidhu, Maninder, K.

; Eldridge, John,  H.; Egan, 

Michael;  Israel, Zimra
[21] Application No.: NA
[22] Filed:  20061214 
[43] Published:  20070816 





The invention provides a DNA plasmid comprising: (a) a first transcriptional unit 

comprising a nucleotide sequence that encodes a first polypeptide operably linked 

to regulatory elements including a first promoter and a first polyadenylation 

signal; (b) a second transcriptional unit comprising a nucleotide sequence that 

encodes a second polypeptide operably linked to regulatory elements including a 

second promoter and a second polyadenylation signal; (c) a third transcriptional 

unit comprising a nucleotide sequence that encodes a third polypeptide operably 

linked to regulatory elements including a third promoter and a third 

polyadenylation signal; and wherein said first, said second and said third 

promoters are each derived from different transcriptional units; and wherein said 

first, said second and said third polyadenylation signals are each derived from 

different transcriptional units. The invention further relates to immunogenic 

compositions for inducing an immune response to HIV comprising combinations of two, 

three, or four plasmids, where each plasmid is expressing a defined antigen, which 

may be a single antigen or a fusion of two or three antigens. 
[52] US Class: 4240932 4242081 435456
[51] Int’l Class: C12N0015867 A61K004800 A61K003921 
[52] ECLA: A61K003921 C07K001416 C12N001585 K61K003953 K61K003954 

K61K0039545 M12N080010D1 M12N084060
52            © 2008 MicroPatent, LLC
MicroPatent ReportUS20070166784A1





[75] Inventors: Barnett, Susan, W.;

 Gomez Roman,  Victor, Raul; 

Lian,  Ying; Peng, Bo;  
 . . .
[21] Application No.: NA
[22] Filed:  20061212 
[43] Published:  20070719 





The present invention relates to methods, polynucleotides, and polypeptides 

encoding immunogenic HIV polypeptides derived from different strains within an HIV 

subtype and/or immunogenic HIV polypeptides from different subtypes. Uses of the 

polynucleotides and polypeptides in combination approaches for generating immune 

responses are described. The combination approaches described herein have been 

shown to induce broad and potent neutralizing activity against diverse HIV strains 

from multiple strains within a given subtype and against diverse subtypes. 

Formulations of compositions for generating immune responses and methods of use for 

such compositions are also disclosed. 
[52] US Class: 4350691 435006
[51] Int’l Class: C12P002106 C12Q000168 
[52] ECLA: 
53            © 2008 MicroPatent, LLC
MicroPatent ReportUS20070053923A1





[75] Inventors: Park, Ki Seok; 

Park, Su Hyung;  Yang, Se 

Hwan; Lee,  Chang Geun; Choi,
 . . .
[21] Application No.: NA
[22] Filed:  20050824 
[43] Published:  20070308 





Disclosed is a vaccine composition that includes a peptide adjuvant, and a DNA 

vaccine encoding an immunogenic protein. Also, the present invention discloses a 

method of enhancing immune responses, which is based on the administration of the 

vaccine composition. 
[52] US Class: 4241881 514044
[51] Int’l Class: A61K003939 A61K003921 A61K004800 
[52] ECLA: A61K003939 C07K001411 C07K001416 K61K003953 K61K0039555B1
54            © 2008 MicroPatent, LLC
MicroPatent ReportUS20070015721A1
HIV-GAG CODON-OPTIMISED DNA VACCINES

[71] Applicant: N/A
[75] Inventors: Beaton, Andrew; 

Ertl, Peter; Gough,  Gerald; 

Lear,  Andrew; Tite, John;  
 . . .
[21] Application No.: NA
[22] Filed:  20041025 
[43] Published:  20070118 





The invention provides a nucleotide sequence that encodes an HIV-1 gag protein or 

fragment thereof containing a gag epitope and a second HIV antigen or a fragment 

encoding an epitope of said second HIV antigen, operably linked to a heterologous 

promoter. Preferred polynucleotide sequences further encodes nef or a fragment 

thereof and RT or a fragment thereof. 
[52] US Class: 514044 435455 435456 5360231 977906
[51] Int’l Class: C12N001586 C07H002102 A61P003118 A61K004800 C12N001549 
C07K001416 C12N0015869 C12N001509 C12N001548 
[52] ECLA: C07K001416B A61K003921 C07K001416F K61K003953





[75] Inventors: Narayan, Opendra
[21] Application No.: NA
[22] Filed:  20060223 
[43] Published:  20070111 





A DNA vaccines or immunogenic composition for providing an immune response against 

HIV without exhibiting pathogenicity in the immunized individual because of the 

disruption of the ability of the DNA molecules to encode for viral proteins 

critical in producing pathogenicity. The DNA molecule is derived by passaging a 

SHIV in order to develop a SHIV that exhibits an increased replication efficiency 

and increased pathogenicity. Following passaging, the highly virulent SHIV virus is 

rendered safe by disrupting one or more genes, such as the rt, int, and vif genes, 

as well as the 3’ LTR. 
[52] US Class: 514044 4242081
[51] Int’l Class: A61K003921 A61K004800 
[52] ECLA: C07K001416B A61K003921 A61K0039295 C07K001416D C07K001416F 

C12N000704A K61K0039525B K61K003953 M12N074003F





[75] Inventors: Ertl, Peter, Franz
[21] Application No.: NA
[22] Filed:  20060519 
[43] Published:  20070222 





The invention relates to polynucleotides for DNA vaccination which polynucleotides 

encode an HIV envelope protein or fragment or immunogenic derivative, which is non-

glycosylated when expressed in a mammalian target cell, operably linked to a 

heterologous promoter. Preferably the HIV envelope molecule, such as gp120 or gp140 

or gp160, lacks a functional secretion signal. It may be fused to additional HIV 

proteins such as Nef, Gag, RT or Tat. 
[52] US Class: 514044 435005 4352351 435325 435456 530350 53602372 977802
[51] Int’l Class: C07H002102 A61K004800 C07K001416 C12N0015867 C12Q000170 
A61K003900 
[52] ECLA: C07K001416 C07K001416B C07K001416D C07K001416F K61K003900 

K61K003953 M07K020700 M07K031900
57            © 2008 MicroPatent, LLC
MicroPatent ReportUS20060275897A1





[75] Inventors: Nabel, Gary; 

Chakrabarti, Bimal;  Kong, 

Wing pui;  Huang, Yue; Wang, 
 . . .
[21] Application No.: NA
[22] Filed:  20060315 
[43] Published:  20061207 





In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral 

vector vaccine including components from different clades of Env (optionally Env 

chimeras) and Gag-Pol-(optionally)Nef from a singlr clade. The vaccine of the 

invention may further include V1, V2, V3, or V4 deletions or combinations thereof. 

In another embodiment, the invention provides multiclade HIV envelope immunogens. 
[52] US Class: 4353201 435006
[51] Int’l Class: C07K001416 A61K003921 C12Q000168 C12N001500 
[52] ECLA: A61K003921 C07K001416B C07K001416D K61K0039525C K61K003953 

M07K022104




[71] Applicant: STRATHMANN AG  CO
[75] Inventors: Schreiber, Michael
[21] Application No.: NA
[22] Filed:  20051114 
[43] Published:  20061005 





The present invention relates to a pharmaceutical composition or a vaccine which 

comprises a mixture of viral protein molecules which are sequence variants of a 

single viral protein or of part of same. The invention furthermore relates inter 

alia to a DNA vaccine which codes for a mixture of structurally different virus 

proteins, the vaccine containing a mixture of sequence variants of a viral DNA 

molecule or of part of same which code for sequence variants of a viral protein or 

part. According to a preferred version of the invention, the viral proteins are 

sequence variants of the GP120 protein of the human immunodeficiency virus (HIV) 

which differ from each another in their amino acid sequence in the region of the V2 

loop and/or of the V3 loop. The invention furthermore relates to the preparation of 

the virus vaccines including the intermediate stages or constructs, preparation 

processes and uses connected with them. 
[52] US Class: 4242081 514044
[51] Int’l Class: C12N000510 A61P003112 A61K003576 C12N001509 A61K004800 
C12N001549 A61K003921 A61K003800 C07K0014155 C12N001534 C12P002102 
A61P003118 A61K003900 C07K001416 A61K003912 
[52] ECLA: C07K001416D A61K003921 K61K0039505 K61K003953 M07K020700
59            © 2008 MicroPatent, LLC
MicroPatent ReportUS20060240042A1
IMMUNOGENICITY USING A COMBINATION OF DNA AND 

VACCINIA VIRUS VECTOR VACCINES

[71] Applicant: GOVT OF THE U S A 

AS REPRESENT
[75] Inventors: Franchini, 

Genoveffa; Hel,  Zdenek; 

Pavlakis,  George; Tartaglia,
 . . .
[21] Application No.: NA
[22] Filed:  20060705 
[43] Published:  20061026 





This invention relates to improved methods of inducing an immune response for the 

prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in 

conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to 

potentiate and broaden the immune response. The present invention further provides 

a particularly effective vaccine regimen comprising a DNA vaccine used in 

combination with a poxvirus virus, especially NYVAC or ALVAC. 
[52] US Class: 4242081 435456
[51] Int’l Class: C12N0015867 A61K003921 
[52] ECLA: C07K001416D A61K003921 C12N0015863A C12N0015863V 

K61K0039525C K61K003953 K61K0039545
60            © 2008 MicroPatent, LLC
MicroPatent ReportUS20060216305A1
IMMUNOGENIC HIV-1 MULTI-CLADE, MULTIVALENT 

CONSTRUCTS AND METHODS OF THEIR USE

[71] Applicant: N/A
[75] Inventors: Lal, Renu; Owen, 

Sherry
[21] Application No.: NA
[22] Filed:  20050926 
[43] Published:  20060928 





Described herein are nucleic acid molecules which encode multiple highly conserved 

epitopes from HIV-1 proteins, and optionally also epitopes from CCR5; usually also 

included sequences that encode spacers between two or more of the epitopes. Some of 

the provided nucleic acid molecules further include sequences that encode targeting 

domains, useful for targeting the encoded protein into a pathway for enhancing 

epitope presentation in a vertebrate immune system. Also described are multivalent 

proteins encoded for by these nucleic acid molecules. The disclosure also 

encompasses immunogenic compositions that comprise one or more of the nucleic acid 

molecules, and/or one or more of the proteins encoded thereby, as well as methods 

of inducing an immune response against HIV-1 in a subject by administering to the 

subject an effective amount of a composition containing one or more of these 

molecules. Also provided are cultured host cells containing within them one or more 

of the described nucleic acid molecules. 
[52] US Class: 4241881 530350 4350693 435325 435456 4353201 53602372
[51] Int’l Class: C07K001416 C07H002104 A61K003921 
[52] ECLA: C07K001416B A61K003921 C07K001416D C07K001416F K61K003964F 

M07K031906
61            © 2008 MicroPatent, LLC
MicroPatent ReportUS20060148750A1
POLYNUCLEOTIDE VACCINES EXPRESSING CODON 

OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL

[71] Applicant: N/A
[75] Inventors: Shiver, John; 

Perry, Helen;  Casimiro, 

Danilo;  Fu, Tong Ming
[21] Application No.: NA
[22] Filed:  20060201 
[43] Published:  20060706 





Pharmaceutical compositions which comprise HIV Pol DNA vaccines are disclosed, 

along with the production and use of these DNA vaccines. The pol-based DNA vaccines 

of the invention are administered directly introduced into living vertebrate tissue,

 preferably humans, and preferably express inactivated versions of the HIV Pol 

protein devoid of protease, reverse transcriptase activity, RNase H activity and 

integrase activity, inducing a cellular immune response which specifically 

recognizes human immunodeficiency virus-1 (HIV-1). The DNA molecules which 

comprise the open reading frame of these DNA vaccines are synthetic DNA molecules 

encoding codon optimized HIV-1 Pol and codon optimized inactive derivatives of 

optimized HIV-1 Pol, including DNA molecules which encode inactive Pol proteins 

which comprise an amino terminal leader peptide. 
[52] US Class: 514044
[51] Int’l Class: A61K004800 
[52] ECLA: C07K001416B K61K003953





[75] Inventors: Ertl, Peter
[21] Application No.: NA
[22] Filed:  20051123 
[43] Published:  20060629 





The invention relates to polynucleotides for DNA vaccination which polynucleotides 

encode an HIV envelope protein or fragment or immunogenic derivative fused to an 

additional HIV protein selected from a non-structural protein or capsid protein or 

fragment or immunogenic derivative thereof. Preferably the HIV envelope molecule is 

gp120 and preferred fusions include one or more of HIV Nef, Gag, RT or Tat. 

Preferably the HIV envelope molecule is non-glycosylated in mammalian cells. 
[52] US Class: 514044 435005 435006 530350 53602372
[51] Int’l Class: C07H002102 A61K004800 C12Q000170 C07K001416 C12N001548 
C12Q000168 A61K003900 
[52] ECLA: C07K001416B C07K001416D C07K001416F K61K003900 K61K003953 

M07K020700 M07K031900
63            © 2008 MicroPatent, LLC
MicroPatent ReportUS20060094049A1




[71] Applicant: AARON DIAMOND AIDS 

RES CT
[75] Inventors: Binley, James; 

Schuelke, Norbert;  Olson, 

William;  Maddon, Paul;  
 . . .
[21] Application No.: NA
[22] Filed:  20051028 
[43] Published:  20060504 





This invention provides an isolated nucleic acid which comprises a nucleotide 

segment having a sequence encoding a viral envelope protein comprising a viral 

surface protein and a corresponding viral transmembrane protein wherein the viral 

envelope protein contains one or more mutations in amino acid sequence that enhance 

the stability of the complex formed between the viral surface protein and 

transmembrane protein. This invention also provides a viral envelope protein 

comprising a viral surface protein and a corresponding viral transmembrane protein 

wherein the viral envelope protein contains one or more mutations in amino acid 

sequence that enhance the stability of the complex formed between the viral surface 

protein and transmembrane protein. This invention further provides methods of 

treating HIV-1 infection. 
[52] US Class: 435006 435005
[51] Int’l Class: C12Q000168 C12Q000170 
[52] ECLA: C07K001416D K61K003953 K61K0039545
64            © 2008 MicroPatent, LLC
MicroPatent ReportUS20060051839A1
DNA EXPRESSION VECTORS AND METHODS OF USE

[71] Applicant: EMORY UNIVERSITY A 

GEORGIA COR
[75] Inventors: Robinson, Harriet; 

Amara, Rama; Ross,  Ted; 

Bright, Rick
[21] Application No.: NA
[22] Filed:  20041209 
[43] Published:  20060309 





The present invention relates to novel plasmid constructs useful for the delivery 

of DNA vaccines. The present invention provides novel plasmids having a 

transcription cassette capable of directing the expression of a vaccine nucleic 

acid insert encoding immunogens derived from any pathogen, including fungi, 

bacteria and viruses. The present invention, however, is particularly useful for 

inducing in a patient an immune response against pathogenic viruses such as HIV, 

measles or influenza. Immunodeficiency virus vaccine inserts of the present 

invention express non-infectious HIV virus-like particles (VLP) bearing multiple 

viral epitopes. VLPs allow presentation of the epitopes to multiple 

histocompatability types, thereby reducing the possibility of the targeted virus 

escaping the immune response. Also described are methods for immunizing a patient 

by delivery of a novel plasmid of the present invention to the patient for 

expression of the vaccine insert therein. Optionally, the immunization protocol may 

include a booster vaccination that may be a live vector vaccine such as a 

recombinant pox virus or modified vaccinia Arbora vector. The booster live vaccine 

vector includes a transcription cassette expressing the same vaccine insert as the 

primary immunizing vector. 
[52] US Class: 4350691 4352523 435472 530350 5360235
[51] Int’l Class: C12P002106 C12N001567 A61K003921 C07K001416 C12N001563 
C07H002104 C12N001574 C12N001570 C07K001447 C12N001585 C12N000121 
A61K003900 
[52] ECLA: A61K003921 C07K001416B C07K001416D C07K001447A11 

C12N001563 C12N001567 C12N001570 C12N001585 K61K003900 

K61K003953 K61K0039545 M07K020700 M07K022120 M07K031900 

M12N083042 M12N084010C M12N084020
65            © 2008 MicroPatent, LLC
MicroPatent ReportUS20050271676A1
INDUCING CELLULAR IMMUNE RESPONSES TO HUMAN 





[71] Applicant: EPIMMUNE INC
[75] Inventors: Sette, Alessandro; 

Sidney, John;  Southwood, 

Scott;  Livingston, Brian;  
 . . .
[21] Application No.: NA
[22] Filed:  20050128 
[43] Published:  20051208 





This invention uses our knowledge of the mechanisms by which antigen is recognized 

by T cells to identify and prepare human immunodeficiency virus (HIV) epitopes, 

and to develop epitope-based vaccines directed towards HIV. More specifically, this 

application communicates our discovery of pharmaceutical compositions and methods 

of use in the prevention and treatment of HIV infection. 
[52] US Class: 4241851 4350693 4353201 435325 530326 530327 5360235
[51] Int’l Class: C07H002104 A61K003900 
[52] ECLA: C07K001416B C07K001416D C07K001416F K61K0039515B 

K61K003953 K61K0039545 K61K0039555B5 K61K003960L 

M12N074003F




[71] Applicant: SMITHKLINE BEECHAM 

BIOLOG
[75] Inventors: Voss, Gerald
[21] Application No.: NA
[22] Filed:  20050429 
[43] Published:  20051201 





The invention provides the use of a) an HIV Tat protein or polynucleotide; or b) 

an HIV Nef protein or polynucleotide; or c) an HIV Tat protein or polynucleotide 

linked to an HIV Nef protein or polynucleotide (Nef-Tat); and an HIV gp120 

protein or polynucleotide in the manufacture of a vaccine for the prophylactic or 

therapeutic immunisation of humans against HIV. 
[52] US Class: 4242081 530350
[51] Int’l Class: C12N001549 A61K003912 C12N001509 C07K001416 A61K003939 
A61K004800 A61P003118 A61K003900 
[52] ECLA: C07K001416D C07K001416F K61K003900 K61K003953 

K61K0039555B7 K61K003957 M07K031900
67            © 2008 MicroPatent, LLC
MicroPatent ReportUS20050287167A1
POLYCISTRONIC HIV VECTOR CONSTRUCTS

[71] Applicant: CHIRON CORP
[75] Inventors: zur Megede, Jan; 

Barnett, Susan
[21] Application No.: NA
[22] Filed:  20050505 
[43] Published:  20051229 





The present disclosure relates to vectors comprising polynucleotide sequences that 

encode HIV polypeptides. In particular, the disclosure relates polycistronic vector 

constructs comprising sequences that encode HIV polypeptides as a single 

polyprotein. Compositions comprising these vectors and sequences along with methods 

of using these vectors and sequences are also disclosed. 
[52] US Class: 4241991 4242041 435006
[51] Int’l Class: C12Q000168 C07K001416 A61K003912 
[52] ECLA: C07K001416 K61K003953




[71] Applicant: GLAXO GROUP LTD
[75] Inventors: Braun, Ralph; 

Thomsen, Lindy;  Van Wely,  

Catherine; Ertl,  Peter
[21] Application No.: NA
[22] Filed:  20050509 
[43] Published:  20051201 





The relates to certain adjuvant compositions, and to vaccine and/or nucleic acid 

immunization strategies employing such compositions. The invention in particular 

relates to DNA vaccines that are useful in the prophylaxis and treatment of HIV 

infections, more particularly when administered by particle mediated delivery. 
[52] US Class: 4242081 514291 514292
[51] Int’l Class: C07D047104 A61K004506 A61K000918 A61K000906 C12N001509 
A61K003939 A61K00314745 A61P003118 C07K001416 A61K004800 A61K003900 
A61P003704 A61K003921 
[52] ECLA: A61K00314745 A61K00314745+M A61K003921 A61K003939 

A61K004506 C07K001416B K61K003953 K61K003954 K61K0039555B5 

M07K020700





[75] Inventors: Braun, Ralph; 

Thomsen, Lindy;  Van Wely,  

Catherine; Ertl,  Peter
[21] Application No.: NA
[22] Filed:  20050106 
[43] Published:  20051117 





The present invention relates to the fields of vaccines, vaccine adjuvants, 

molecular biology and immunology, and generally adjuvants and nucleic acid 

immunization techniques. More specifically, the invention relates to certain 

adjuvant compositions, and to vaccine and/or nucleic acid immunization strategies 

employing such compositions. The invention in particular relates to DNA vaccines 

that are useful in the prophylaxis and treatment of HIV infections, more 

particularly when administered by particle mediated delivery. 
[52] US Class: 514044 514291 514292
[51] Int’l Class: A61K003939 A61K003921 A61K00314745 A61K004506 C07K001416 
[52] ECLA: A61K00314745 A61K00314745+M A61K003921 A61K003939 

A61K004506 C07K001416B K61K003953 K61K003954 K61K0039555B5 

M07K020700
70            © 2008 MicroPatent, LLC
MicroPatent ReportUS20050220883A1





[75] Inventors: O’Hagan, Derek; 

Singh, Manmohan;  Kazzaz, 

Jina
[21] Application No.: NA
[22] Filed:  20050513 
[43] Published:  20051006 





Microparticles with absorbed polypeptide-containing molecules formed without the 

use of surfactant, methods of making such microparticle compositions, and uses 

thereof, are disclosed. The microparticles comprise a polymer, such as a poly(a-

hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a 

polyanhydride, and the like. Preferred polymers are poly(D,L-lactide-co-

glycolides), more preferable those having a lactide/glycolide molar ratio ranging 

from 40:60 to 60:40 and having a molecular weight ranging from 20, 000 Daltons to 

70,000 Daltons. Preferred polypeptide containing molecules are bacterial and viral 

antigens (including HIV antigens, meningitis B antigens, streptococcus B antigens, 

and Influenza A hemagglutinin antigens). 
[52] US Class: 424489 4242081 4242341
[51] Int’l Class: A61K003902 A61K000916 A61K000914 A61K003912 A61K003921 
[52] ECLA: A61K003912 A61K000916H6D4 A61K000916P4 A61K003902 

K61K0039555B5 K61K003960Y
71            © 2008 MicroPatent, LLC
MicroPatent ReportUS20050220816A1




[71] Applicant: ADVANCED 

BIOSCIENCE LAB INC
[75] Inventors: Cristillo, Anthony;

 Kalyanaraman,  Vaniambadi; 

Pal,  Ranajit
[21] Application No.: NA
[22] Filed:  20040331 
[43] Published:  20051006 





The present invention is directed to a nucleic acid comprising a deletion mutant of 

a PTAP (SEQ ID NO:1) motif and/or PPXY (SEQ ID NO:2) and/or YXXL (SEQ ID NO:3)

 motif in the late or L domain of a viral protein, where the L domain mediates the 

budding process. Examples of such viral proteins containing L domains are the 

retroviral gag proteins and the matrix proteins of rhabdoviruses and filoviruses. 

In addition, the present invention is directed to a vector containing (a) this 

nucleic acid or (b) this nucleic acid and one or more nucleic acids encoding 

other structural and regulatory viral proteins. The present invention is further 

directed to vaccines containing the nucleic acid or vector for the purpose of 

augmenting a cellular immune response. 
[52] US Class: 4242081 435456 530350 53602372
[51] Int’l Class: A61K003921 A61K003912 C12Q000170 C07H002102 C07K0014155 
C07K001416 A61K003900 
[52] ECLA: C07K0014155 C07K001416B K61K003900 K61K003953
72            © 2008 MicroPatent, LLC
MicroPatent ReportUS20050215508A1
POLYNUCLEOTIDE VACCINES EXPRESSING CODON 

OPTIMIZED HIV-1 NEF AND MODIFIED HIV-1 NEF

[71] Applicant: N/A
[75] Inventors: Shiver, John; 

Liang, Xiaoping;  Fu, Tong 

Ming
[21] Application No.: NA
[22] Filed:  20050316 
[43] Published:  20050929 





Pharmaceutical compositions which comprise HIV Nef DNA vaccines are disclosed, 

along with the production and use of these DNA vaccines. The nef-based DNA vaccines 

of the invention are administered directly introduced into living vertebrate tissue,

 preferably humans, and express the HIV Nef protein or biologically relevant 

portions thereof, inducing a cellular immune response which specifically recognizes 

human immunodeficiency virus-1 (HIV-1). The DNA molecules which comprise the open 

reading frame of these DNA vaccines are synthetic DNA molecules encoding codon 

optimized HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef 

modifications comprising amino terminal leader peptides, removal of the amino 

terminal myristylation site, and/or modification of the Nef dileucine motif. These 

modifications may effect wild type characteristics of Nef, such as myristylation 

and down regulation of host CD4. 
[52] US Class: 514044 530350
[51] Int’l Class: C07K001416 A61K004800 
[52] ECLA: C07K001416F K61K003953
73            © 2008 MicroPatent, LLC
MicroPatent ReportUS20050208072A1
PREVENTIVE AND THERAPEUTIC AIDS VACCINES

[71] Applicant: N/A
[75] Inventors: Chen, Qun
[21] Application No.: NA
[22] Filed:  20050510 
[43] Published:  20050922 





The present invention relates to prophylactic and therapeutic acquired 

immunodeficiency syndrome vaccines. In particular, the present invention provides 

methods and compositions utilizing recombinant HIV-1, HIV-2 and/or SIV genes or 

gene products in safe vaccination approaches. 
[52] US Class: 4242081 4352351 435456
[51] Int’l Class: C07K001416 A61K003921 
[52] ECLA: A61K003921 C07K001416 K61K0039525D K61K003953 K61K0039545 

M07K020700 M07K022100




[71] Applicant: OXXON THERAPEUTICS 

LTD
[75] Inventors: Schneider, Joerg
[21] Application No.: NA
[22] Filed:  20041209 
[43] Published:  20050811 





The invention relates to a recombinant polypeptide comprising amino acid sequence 

derived from at least one of an HIV gag gene product; an HIV pol gene product; or 

an HIV nef gene product, said sequence being mutated with respect to the natural 

sequence of said gene product, and said sequence maintaining each of the naturally 

occurring CD8+ T cell epitopes of said gene product as defined in p17 and p24 (

gag), amino acids 1-440 of RT (pol) and nef shown in Example 8. Furthermore the 

invention relates to nucleic acids encoding same, and viral vectors encoding same, 

and to their use in medicine and in immunisation and vaccination. 
[52] US Class: 4241881 435005 4350693 435325 435456 514044 530350 53602372
[51] Int’l Class: A61K004800 A61K003921 C07K001416 C12Q000170 A61K003800 
[52] ECLA: C07K001416B A61K003921 C07K001416F K61K003800 K61K0039525C 

K61K003953 K61K0039545 M12N074003F
75            © 2008 MicroPatent, LLC
MicroPatent ReportUS20050158336A1
SYNTHETIC CONJUGATE OF CPG SINGLE-STRANDED DNA 

AND T-HELP/CTL FUSION PEPTIDE

[71] Applicant: HOPE CITY
[75] Inventors: Diamond, Don
[21] Application No.: NA
[22] Filed:  20041213 
[43] Published:  20050721 





Highly effective vaccine compositions are constructed according to the methods of 

this invention. The methods are amenable to use with any peptidic antigen sequence 

and involve covalent attachment of an immunostimulatory nucleotide sequence to an 

antigenic peptide sequence. Preferred antigenic peptides are fusion peptides made 

up of one or more CTL epitope peptides in sequence fused to a T helper peptide. 
[52] US Class: 4241921 514044
[51] Int’l Class: A61K004800 A61K0039385 A61K003900 
[52] ECLA: A61K0039385 A61K003939 C07K001416D K61K0039555B1 

K61K0039555B7 K61K003960N K61K003960P14
76            © 2008 MicroPatent, LLC
MicroPatent ReportUS20050112102A1
DNA VACCINE COMPOSITIONS AND METHODS OF USE

[71] Applicant: N/A
[75] Inventors: Narayan, Opendra; 

Liu, Zhenqian
[21] Application No.: NA
[22] Filed:  20040915 
[43] Published:  20050526 





The present invention is directed to a DNA vaccine for immunization against HIV. 

The invention comprises a DNA molecule that has a sequence encoding a plurality of 

viral proteins capable of stimulating an immune response against HIV. The DNA 

molecule is rendered safe for use as a vaccine by the disruption of genes encoding 

reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered 

safe by at least a partial deletion of the 3’ LTR. 
[52] US Class: 4240932 514044
[51] Int’l Class: C12N001586 A61K003921 A01N006300 A01N004304 C12N001563 
A61K004800 C07H002104 C12N001500 
[52] ECLA: A61K003921 K61K003953 K61K0039555B2 M12N074003F
77            © 2008 MicroPatent, LLC
MicroPatent ReportUS20050058657A1
VACCINE COMPRISING GP120 AND NEF AND/OR TAT FOR 

THE IMMUNISATION AGAINST HIV

[71] Applicant: N/A
[75] Inventors: Ertl, Peter, Franz;

 Tite, John,  Philip; Van 

Wely,  Catherine, Ann;  Voss,
 . . .
[21] Application No.: NA
[22] Filed:  20040922 
[43] Published:  20050317 







a) an HIV Tat protein or polynucleotide; or 

b) an HIV Nef protein or polynucleotide; or 

c) an HIV Tat protein or polynucleotide linked to an HIV Nef protein or 

polynucleotide: and an HIV gp 120 protein or polynucleotide in the manufacture of a 

vaccine suitable for a prime-boost delivery for the prophylactic or therapeutic 

immunisation of humans against HIV, wherein the protein or polynucleotide is 

delivered via a bombardment approach. 
[52] US Class: 4241881 4242081 424489 514044
[51] Int’l Class: A61P003704 A61K003921 A61K00317088 A61K000900 C12N001509 
C12N001549 A61K003900 A61K0031711 A61K004800 C07K001416 C12N001589 
A61K004702 A61K003576 A61P003118 A61K003800 
[52] ECLA: A61K003921 C07K001416D C07K001416F C12N001589B K61K003953 

M07K031900
78            © 2008 MicroPatent, LLC
MicroPatent ReportUS20040236093A1
MHC-I-RESTRICTED PRESENTATION OF HIV-1 VIRION 

ANTIGENS WITHOUT VIRAL REPLICATION. APPLICATION 

TO THE STIMULATION OF CTL AND VACCINATION IN 

[71] Applicant: N/A
[75] Inventors: Schwartz, Olivier; 

Buseyne, Florence;  Marsac, 

Delphine;  Michel, Marie  
 . . .
[21] Application No.: NA
[22] Filed:  20040526 
[43] Published:  20041125 





Dendritic cells and macrophages can process extracellular antigens for presentation 

by MHC-I molecules. HIV-1 epitopes derived from incoming virions are presented 

through the exogenous MHC-I pathway in primary human dendritic cells, and to a 

lower extent in macrophages, leading to cytotoxic T lymphocyte activation in the 

absence of viral protein neosynthesis. Exogenous antigen presentation required 

adequate virus-receptor interactions and fusion of viral and cellular membranes. 

These results provide new insights about how anti-HIV cytotoxic T lymphocytes can 

be activated and are useful for anti-HIV vaccine design. 
[52] US Class: 53602372 4240932 4241871 4241881 4242071 4242081 435005 

435006 4353201
[51] Int’l Class: C12N001574 A61K004800 A61K003921 A01N006300 C12N001570 
C07H002104 C12Q000170 C12Q000168 C12N001509 C12N001563 
[52] ECLA: C07K001416 A61K003921 K61K003957 M12N074003F
79            © 2008 MicroPatent, LLC
MicroPatent ReportUS20040224308A1




[71] Applicant: PROGENICS PHARM 

INC; AARON DIAMOND  AIDS RES 

CT
[75] Inventors: Binley, James, M.; 

Schuelke, Norbert;  Olson, 

William, C.;  Maddon, Paul, 
 . . .
[21] Application No.: NA
[22] Filed:  20040218 
[43] Published:  20041111 





This invention provides an isolated nucleic acid which comprises a nucleotide 

segment having a sequence encoding a viral envelope protein comprising a viral 

surface protein and a corresponding viral transmembrane protein wherein the viral 

envelope protein contains one or more mutations in amino acid sequence that enhance 

the stability of the complex formed between the viral surface protein and 

transmembrane protein. This invention also provides a viral envelope protein 

comprising a viral surface protein and a corresponding viral transmembrane protein 

wherein the viral envelope protein contains one or more mutations in amino acid 

sequence that enhance the stability of the complex formed between the viral surface 

protein and transmembrane protein. This invention further provides methods of 

treating HIV-1 infection. 
[52] US Class: 435005 4350693 4352351 435366 435456 530350 53602372
[51] Int’l Class: C12N000704 C07K001416 
[52] ECLA: C07K001416D C12N000704A K61K0039525D M07K020302 M07K020700 

M07K021500
80            © 2008 MicroPatent, LLC
MicroPatent ReportUS20040191269A1
POLYVALENT, PRIMARY HIV-1 GLYCOPROTEIN DNA 

VACCINES AND VACCINATION METHODS

[71] Applicant: N/A
[75] Inventors: Lu, Shan; Wang, 

Shixia; Pal,  Ranajit;  

Kalyanaraman,  Vaniambadi;  
 . . .
[21] Application No.: NA
[22] Filed:  20031203 
[43] Published:  20040930 





Polyvalent, primary isolate nucleic acid compositions for inducing an immune 

response against HIV is disclosed. The compositions and methods described herein 

are for the use of a DNA composition that encodes one or more different HIV 

envelope glycoproteins. The DNA composition can encode an HIV Gag protein. The DNAs 

encoding one or more HIV proteins are a combination of different nucleic acids, 

such as DNA plasmids, generated from primary isolate DNA of different HIV major 

group genetic clades and/or different proteins. HIV protein compositions for 

inducing an immune response against HIV are disclosed. Methods for using the 

protein compositions as boosts following administration of the DNA compositions are 

provided. 
[52] US Class: 4241881 4350693 4353201 435325 530395 53602372
[51] Int’l Class: C07K001416 A61K003921 A61K003900 
[52] ECLA: A61K003921 C07K001416B C07K001416D K61K003900 K61K003953
81            © 2008 MicroPatent, LLC
MicroPatent ReportUS20040180329A1
SYNTHETIC HIV GAG GENES

[71] Applicant: N/A
[75] Inventors: Shiver, John, W.; 

Davies, Mary,  Ellen; Freed, 

 Daniel, C.; Liu,  Margaret, 
 . . .
[21] Application No.: NA
[22] Filed:  20031005 
[43] Published:  20040916 





Synthetic DNA molecules encoding HIV gag and modifications of HIV gag are provided. 

The codons of the synthetic molecules are codons preferred by the projected host 

cell. The synthetic molecules may be used as a polynucleotide vaccine which 

provides effective immunoprophylaxis against HIV infection through stimulation of 

neutralizing antibody and cell-mediated immunity. 
[52] US Class: 435005 4350693 435325 435456 530350 53602372
[51] Int’l Class: C07K001416 A61K003900 
[52] ECLA: C07K001416B K61K003900 M07K020300 M07K020700 M07K031902
82            © 2008 MicroPatent, LLC
MicroPatent ReportUS20040116660A1
PROCESS FOR THE SELECTION OF HIV-1 SUBTYPE C 

ISOLATES, SELECTED HIV-1 SUBTYPE C ISOLATES, 

THEIR GENES AND MODIFICATIONS AND DERIVATIVES 

[71] Applicant: N/A
[75] Inventors: Johnston, Robert, 

Edward; Karim,  Salim, 

Abdool;  Morris, Lynn;  
 . . .
[21] Application No.: NA
[22] Filed:  20030912 
[43] Published:  20040617 





The invention provides a process for the selection of HIV-1 subtype (clade) C 

isolates, selected HIV-1 subtype C isolates, their genes and modifications and 

derivatives thereof for use in prophylactic and therapeutic vaccines to produce 

proteins and polypeptides for the purpose of eliciting protection against HIV 

infection or disease. The process for the selection of HIV subtype isolates 

comprises the steps of isolating viruses from recently infected subjects; 

generating a consensus sequence for at least part of at least one HIV gene by 

identifying the most common codon or amino acid among the isolated viruses; and 

selecting the isolated virus or viruses with a high sequence identity to the 

consensus sequence. HIV-1 subtype C isolates, designated Du422, Du 151 and Du 179 (

assigned Accession Numbers 01032114, 00072724 and 00072725, respectively, by the 

European Collection of Cell Cultures) are also provided. 
[52] US Class: 530350 435005 4352351 4353201 530826 53602372
[51] Int’l Class: C07K001416 A61K003921 C12N000701 C12N000702 A61K003900 
[52] ECLA: A61K003921 C07K001416B C07K001416D C12N000702 K61K003900 

M07K020700 M12N074003F





[75] Inventors: Pal, Ranajit; 

Markham, Phillip;  Keen, 

Timothy;  Whitney, Stephen;  
 . . .
[21] Application No.: NA
[22] Filed:  20030702 
[43] Published:  20040422 





The present invention is directed to a vaccine and method of neutralizing 

antibodies against HIV infection. The vaccine comprises a complex of gp120 

covalently bonded to a fragment of CD4 or a CD4 equivalent molecule. 
[52] US Class: 4241881 435005 4350691 4353201 4353391 530350 53038835 

53602372
[51] Int’l Class: C07K001416 C07H002104 A61K003921 C07K001610 C12Q000170 
[52] ECLA: 





[75] Inventors: Toran Garcia, Jose,

 Luis; Martinez  Alonso, 

Carlos
[21] Application No.: NA
[22] Filed:  20030612 
[43] Published:  20040603 





The application relates to antibodies and fragments capable of binding HIV-1 gp120 

protein, nucleic acids encoding such proteins, to the use of such proteins to 

identify active compounds, and to the use of the compounds as vaccines. 
[52] US Class: 435005 4350691 4353201 4353391 5303883 53602353
[51] Int’l Class: C12N000115 A61P003118 A61K003800 A61K003576 C12N001509 
C12N000121 A61K004800 A61K003900 C07K0014155 C12N000119 C12N001549 
C12N000510 A61P003704 A61K0039395 C07K001610 A61K004500 
[52] ECLA: C07K001610K1D K61K0039505 M07K020302 M07K021500 

M07K0316210 M07K0316550 M07K0316565
85            © 2008 MicroPatent, LLC
MicroPatent ReportUS20040106100A1
DNA VACCINES ENCODING HIV ACCESSORY PROTEINS

[71] Applicant: N/A
[75] Inventors: Weiner, David, B.; 

Ayvavoo, Velpandi
[21] Application No.: NA
[22] Filed:  20030516 
[43] Published:  20040603 





Improved vaccines and methods of using the same are disclosed. Immunosuppressive 

compositions for treating individuals who have autoimmune diseases or transplants 

and methods of using the same are disclosed. 
[52] US Class: 435005 4350691 435219 4352351 4353201 435325 53602372
[51] Int’l Class: C12N000701 C07K001416 A61K003900 C12Q000170 
[52] ECLA: C07K001416F K61K003900 K61K003953 M07K020700 M07K031950 

M12Q000170B2B
86            © 2008 MicroPatent, LLC
MicroPatent ReportUS20040077577A1
MOLECULAR CLONES WITH MUTATED HIV GAG/POL, SIV 

GAG AND SIV ENV GENES

[71] Applicant: GOVERNMENT OF THE 

USA AS REPRE
[75] Inventors: Pavlakis, George, 

N.
[21] Application No.: NA
[22] Filed:  20030819 
[43] Published:  20040422 





Nucleic acid constructs containing HIV-1 gag/pol and SIV gag or SIV env genes which 

have been mutated to remove or reduce inhibitory/instability sequences are 

disclosed. Viral particles and host cells containing these constructs and/or viral 

particles are also disclosed. The exemplified constructs and viral particles of the 

invention may be useful in gene therapy for numerous disorders, including HIV 

infection, or as a vaccine for HIV-1 immunotherapy and immunoprophylaxis. 
[52] US Class: 514044 43525233 4353201 435372 530350 53602372
[51] Int’l Class: C12N0015867 A61K003921 C12N000700 C07K0014155 C07K001416 
C12N000508 A61K004800 A61K003900 
[52] ECLA: A61K003921 C07K0014155 C07K001416B C12N000700 C12N0015867 

K61K003900 K61K003953 K61K004800 M07K020700 M12N074003F 

M12N083042 M12N083048 M12N083050 M12N084010C M12N084020
87            © 2008 MicroPatent, LLC
MicroPatent ReportUS20040033237A1
IMMUNOGENICITY USING A COMBINATION OF DNA AND 

VACCINIA VIRUS VECTOR VACCINES

[71] Applicant: N/A
[75] Inventors: Franchini, 

Genoveffa; Hel,  Zdenek; 

Pavlakis,  George
[21] Application No.: NA
[22] Filed:  20021025 
[43] Published:  20040219 





This invention relates to improved methods of inducing an immune response for the 

prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in 

conjunction with a recombinant viral vaccine, e.g. , a poxvirus vaccine, to 

potentiate and broaden the immune response. The present invention further provides 

a particularly effective vaccine regimen comprising a DNA vaccine used in 

combination with a poxvirus virus, especially NYVAC or ALVAC. 
[52] US Class: 4241991 4240932 514044
[51] Int’l Class: A61K003921 
[52] ECLA: A61K003921 K61K0039525C K61K003953
88            © 2008 MicroPatent, LLC
MicroPatent ReportUS20040063653A1
POLYNUCLEOTIDE VACCINES EXPRESSING CODON 

OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL

[71] Applicant: N/A
[75] Inventors: Shiver, John, W.; 

Perry, Helen, C.;  Casimiro, 

Danilo,  R.; Fu, Tong Ming
[21] Application No.: NA
[22] Filed:  20020930 
[43] Published:  20040401 





Pharmaceutical compositions which comprise HIV Pol DNA vaccines are disclosed, 

along with the production and use of these DNA vaccines. The pol-based DNA vaccines 

of the invention are administered directly introduced into living vertebrate tissue,

 preferably humans, and preferably express inactivated versions of the HIV Pol 

protein devoid of protease, reverse transcriptase activity, RNase H activity and 

integrase activity, inducing a cellular immune response which specifically 

recognizes human immunodeficiency virus-1 (HIV-1). The DNA molecules which 

comprise the open reading frame of these DNA vaccines are synthetic DNA molecules 

encoding codon optimized HIV-1 Pol and codon optimized inactive derivatives of 

optimized HIV-1 Pol, including DNA molecules which encode inactive Pol proteins 

which comprise an amino terminal leader peptide. 
[52] US Class: 514044 5360231
[51] Int’l Class: C07K001416 C07H002102 
[52] ECLA: C07H002102 C07K001416B K61K003953
89            © 2008 MicroPatent, LLC
MicroPatent ReportUS20040034209A1
VACCINATION OF HIV INFECTED PERSONS FOLLOWING 

HIGHLY ACTIVE ANTIRETROVIAL THERAPY

[71] Applicant: N/A
[75] Inventors: Ho, David; 

Markowitz, Martin;  KLEIN, 

MICHEL;  HABIB, RAPHAELLE,  
 . . .
[21] Application No.: NA
[22] Filed:  20021009 
[43] Published:  20040219 





The present invention provides a method of permitting cessation of antiviral 

therapy on HIV-infected subjects without virus rebound or with at least a delayed 

virus rebound or a decreased post rebound set-point. The method comprises the re-

induction of HIV-specific immune responses using a vaccination strategy to induce 

both humoral and cell-mediated immunity. The present invention achieves an 

immunological control of persistent infectious virus after discontinuation of 

antiviral therapy. The vaccine strategy according to the invention is both safe and 

immunogenic in the subject HIV-infected patient population. 
[52] US Class: 53602372 4242081 4353201
[51] Int’l Class: A61K004506 A61K003921 A61K003170 C07H002104 
[52] ECLA: A61K003921 A61K003170+M A61K004506 C07H002104 K61K0039525C 

M12N074003F M12N079902A63
90            © 2008 MicroPatent, LLC
MicroPatent ReportUS20040033487A1
MODIFICATIONS OF HIV ENV, GAG, AND POL ENHANCE 

IMMUNOGENICITY FOR GENETIC IMMUNIZATION

[71] Applicant: N/A
[75] Inventors: Nabel, Gary, J.; 

Chakrabarti, Bimal,  K.; 

Huang, Yue
[21] Application No.: NA
[22] Filed:  20030204 
[43] Published:  20040219 





Modified HIV Env, Gag, Pol, or Nef DNA with improved ability to elicit antibody and 

CTL responses to HIV antigens have been identified as prototype immunogens for the 

treatment and prevention of HIV infections. 
[52] US Class: 435005 4350693 4352351 4353201 435325 530395 53602372
[51] Int’l Class: C12N001500 C12N000500 C12Q000170 C07H002104 C07H002102 
A61K003921 C12P002102 C12N001563 C07K001700 C07K000100 C12N000700 
C12N001509 C12N001574 C12N001570 C12N000502 C07K001400 C12N000701 
C07K001416 
[52] ECLA: A61K003921 C07K001416B C07K001416D C07K001416F K61K003953 

K61K0039545 M07K031900 M12N074003F
91            © 2008 MicroPatent, LLC
MicroPatent ReportUS20030228327A1
DNA-BASED PLASMID FORMULATIONS AND VACCINES AND 

PROPHYLACTICS CONTAINING THE SAME

[71] Applicant: N/A
[75] Inventors: Lasher, Alfred, W.;

 Kittle, Joseph, D. ; Widen, 

Steven, G.
[21] Application No.: NA
[22] Filed:  20021104 
[43] Published:  20031211 





The invention is a general method for improving the performance of the DNA-based 

vaccines. The method utilizes a complex DNA-generated profile of antigens to extend 

the effects of DNA-based vaccines and to broaden the immune response. This 

broadened immune response in turn improves the protection of the recipient from 

divergent (but related) strains of a pathogen. In addition, it effectively 

improves the efficacy of DNA-based vaccines used for treatment of viral diseases, 

including acquired immunity disorder (AIDS). One embodiment, where the target 

viral pathogen is HIV (the causative agent for aids), the method identifies an 

orderly set of plasmids of related sequences that may be used to prime a broad and 

strong immune response to HLA-restricted viral antigens. This mixture of plasmids 

is thus capable of priming an appropriate immune response to reduce the viral 

burden in HIV infected patients or to protect uninfected patients from HIV 

infection. 
[52] US Class: 4241881 42409321 4242081
[51] Int’l Class: A61K004800 A61K003921 
[52] ECLA: A61K003921 A61K004800B2 K61K003953 M07K022104
92            © 2008 MicroPatent, LLC
MicroPatent ReportUS20030220276A1
HIV VACCINE AND METHOD OF USE

[71] Applicant: N/A
[75] Inventors: Narayan, Opendra
[21] Application No.: NA
[22] Filed:  20021024 
[43] Published:  20031127 





The present invention relates to a vaccine for immunization against HIV. The 

vaccine has DNA sequences encoding a plurality of viral proteins, including NEF, 

VPU and reverse transcriptase. The vaccine is rendered nonpathogenic by the 

disruption of the gene(s) encoding for at least one of these proteins. 
[52] US Class: 514044 4242081 435456
[51] Int’l Class: C07K0014155 A01K0067027 C07K001416 C12N000700 C12N000704 
A61K003900 
[52] ECLA: A01K0067027 C07K0014155 C07K001416 C12N000700 C12N000704 

K61K003900 K61K003951 M07K020700 M07K031900 M12N074003F




[71] Applicant: SMITHKLINE BEECHAM 

BIOLOG
[75] Inventors: Friede, Martin; 

Garcon, Nathalie;  Gerard, 

Catherine,  Marie Ghislaine; 
 . . .
[21] Application No.: NA
[22] Filed:  20030303 
[43] Published:  20030828 





The present invention relates to adjuvant compositions which are suitable to be 

used in vaccines. In particular, the adjuvant compositions of the present invention 

comprises a saponin and an immunostimulatory oligonucleotide, optionally with a 

carrier. Also provided by the present invention are vaccines comprising the 

adjuvants of the present invention and an antigen. Further provided are methods of 

manufacture of the adjuvants and vaccines of the present invention and their use as 

medicaments. Methods of treating an individual susceptible to or suffering from a 

disease by the administration of the vaccines of the present invention are also 

provided. 
[52] US Class: 4241841 4241861 4242041 4242081 4242261 4242271 4242281 

4242291 4242311 4242491 4242581 4242631 4242781 4242831 

424450 514025 514044
[51] Int’l Class: A61K003900 
[52] ECLA: A61K003900D6 K61K0039555A K61K0039555B5 K61K0039555B7 

K61K0039555B8 K61K0039555B13 K61K0039555B15 K61K003960P20
94            © 2008 MicroPatent, LLC
MicroPatent ReportUS20030175292A1





[75] Inventors: Robinson, Harriet, 

L.; Smith, James;  Hua, Jian
[21] Application No.: NA
[22] Filed:  20030103 
[43] Published:  20030918 





We have developed DNA and viral vectors that can be used, alone or in combination, 

as a vaccine against one HIV lade, subtype, or recombinant form of HIV or against 

multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can 

encode a variety of antigens, which may be obtained from one clade or from two or 

more different clades, and the antigens selected and/or the manner in which the 

vectors are formulated (e.g., mixed) can be manipulated to generate a protective 

immune response against a variety of clades (e.g. , the clades to which a patient 

is most likely to be exposed; with the proportions of the components of the vaccine 

tailored to the extent of the patient’s risk to a particular dade or clades). 
[52] US Class: 4241881 435456 514044
[51] Int’l Class: C12N001570 C07K001416 A61K003921 C12N001585 
[52] ECLA: A61K003921 C07K001416 C12N001570 C12N001585 K61K0039525C 

K61K003953 M07K020700 M12N083000 M12N083015 M12N083042 

M12N083060
95            © 2008 MicroPatent, LLC
MicroPatent ReportUS20030158134A1





[75] Inventors: Voss, Gerald
[21] Application No.: NA
[22] Filed:  20020731 
[43] Published:  20030821 





The invention provides the use of a) an HIV Tat protein or polynucleotide; or b) 

an HIV Nef protein or polynucleotide; or c) an HIV Tat protein or polynucleotide 

linked to an HIV Nef protein or polynucleotide (Nef-Tat); and an HIV gpl20 

protein or polynucleotide in the manufacture of a vaccine for the prophylactic or 

therapeutic immunisation of humans against HIV. 
[52] US Class: 514044 4241881
[51] Int’l Class: C12N001549 A61K003912 C12N001509 C07K001416 A61K003939 
A61K004800 A61P003118 A61K003900 
[52] ECLA: C07K001416D C07K001416F K61K003900 K61K003953 

K61K0039555B7 K61K003957 M07K031900





[75] Inventors: Braun, Ralph, P.; 

Thomsen, Lindy;  Van Wely,  

Catherine; Ertl,  Peter
[21] Application No.: NA
[22] Filed:  20020319 
[43] Published:  20031009 





The present invention relates to the fields of vaccines, vaccine adjuvants, 

molecular biology and immunology, and generally adjuvants and nucleic acid 

immunization techniques. More specifically, the invention relates to certain 

adjuvant compositions, and to vaccine and/or nucleic acid immunization strategies 

employing such compositions. The invention in particular relates to DNA vaccines 

that are useful in the prophylaxis and treatment of HIV infections, more 

particularly when administered by particle mediated delivery. 
[52] US Class: 4240932 514044 514292
[51] Int’l Class: A61K003939 A61K003921 A61K00314745 A61K004506 C07K001416 
[52] ECLA: A61K00314745 A61K00314745+M A61K003921 A61K003939 

A61K004506 C07K001416B K61K003953 K61K003954 K61K0039555B5 

M07K020700
97            © 2008 MicroPatent, LLC
MicroPatent ReportUS20030158131A1
DNA VECTORS CONTAINING MUTATED HIV PROVIRUSES

[71] Applicant: N/A
[75] Inventors: Aldovini, Anna
[21] Application No.: NA
[22] Filed:  20011023 
[43] Published:  20030821 





The present invention pertains to mutated, non-infectious HIV viral particles, 

vectors for production of such particles and vaccines employing such vectors. The 

non-infectious particles are obtained by introducing a number of inactivating 

mutations into a native viral genome. These mutations are designed so as to 

minimize the probability of genetic reversion to an infectious virus, while 

retaining the basic protein content and immunogenic properties of a wild-type 

virion. The altered viral genome expresses proteins that can assemble into non-

infectious particles which contain immunogenic components of the virus, but which 

are unable to infect cells. The preferred mutations are introduced in at least one 

amino acid position of the NC protein in combination with at least one other 

mutation in an amino acid position of the RT protein or the In protein. In one 

embodiment, the mutations to the native HIV genome may also be made in at least one 

amino acid position of the NC protein, at least one position in the RT protein, and 

at least one position in the In protein. In another embodiment, the mutations to 

the native HIV genome may be introduced in clusters, where two or more mutations 

are made in the NC protein, the RT protein, the In protein, or any combinations 

thereof. 
[52] US Class: 514044 4241881 4353201 435366 435456 53602372
[51] Int’l Class: C12N000508 C07K001416 A61K003921 C12N0015867 
[52] ECLA: A61K003921 C07K001416B C12N0015867 K61K003953 M07K022124
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The present invention relates to novel vectors, to DNA vaccines and gene 

therapeutics containing said vectors, to methods for the preparation of the vectors 

and DNA vaccines and gene therapeutics, and to therapeutic uses of said vectors. 

More specifically, the present invention relates to novel vectors comprising an 

expression cassette of a gene of a nuclear-anchoring protein, which contains a DNA 

binding domain capable of binding to a specific DNA sequence and a functional 

domain capable of binding to a nuclear component and a multimerized DNA sequence 

forming a binding site for the nuclear-anchoring protein, and optionally an 

expression cassette of a gene, genes or a DNA sequence or DNA sequences of interest.

 The present invention further relates to DNA vaccines and gene therapeutics 

containing the novel vectors, to methods for the preparation of the novel vectors 

and the DNA vaccines and gene therapeutics containing the novel vectors, and to the 

use the vectors in therapy. 
[52] US Class: 42409321 4350691 435199 4353201 435325 435456
[51] Int’l Class: C12N001585 A61K004800 
[52] ECLA: C12N001585 K61K003953 K61K004800 M12N080010E M12N083042 

M12N084020 M12N084020A
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[71] Applicant: N/A
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Jean; El  Habib, Raphaelle
[21] Application No.: NA
[22] Filed:  20021118 
[43] Published:  20030529 






The present invention relates to an envelope glycoprotein of HIV in purified form 

which can be obtained by a method comprising the following steps: (1) production 

of an envelope glycoprotein in purified form, (2) reduction of at least one 

disulfide bridge of the glycoprotein of step (1) , (3) alkylation of at least 

two free sulfhydryl groups, (4) optionally, oxidation of the remaining free 

sulfhydryl groups, (5) denaturation and (6) renaturation, and to its use in a 

vaccine against HIV which can be used for inducing antibodies which neutralize HIV 

in a human individual, therapeutically or prophylactically. 
[52] US Class: 435005 4350693 4352351 4353201 435325 530395 53602372
[51] Int’l Class: C07K001416 A61P003118 C07K001610 A61K003900 
[52] ECLA: C07K001416D C07K001610K1D K61K003900
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OPTIMIZED HIV-1 NEF AND MODIFIED HIV-1 NEF

[71] Applicant: N/A
[75] Inventors: Shiver, John, W; 

Liang, Xiaoping;  Fu, Tong 

Ming
[21] Application No.: NA
[22] Filed:  20020613 
[43] Published:  20030522 





Pharmaceutical compositions which comprise HIV Nef DNA vaccines are disclosed, 

along with the production and use of these DNA vaccines. The nef-based DNA vaccines 

of the invention are administered directly introduced into living vertebrate tissue,

 preferably humans, and express the HIV Nef protein or biologically relevant 

portions thereof, inducing a cellular immune response which specifically recognizes 

human immunodeficiency virus-1 (HIV-1). The DNA molecules which comprise the open 

reading frame of these DNA vaccines are synthetic DNA molecules encoding codon 

optimized HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef 

modifications comprising amino terminal leader peptides, removal of the amino 

terminal myristylation site, and/or modification of the Nef dileucine motif. These 

modifications may effect wild type characteristics of Nef, such as myristylation 

and down regulation of host CD4. 
[52] US Class: 514044 4241841
[51] Int’l Class: C07K001416 
[52] ECLA: C07K001416F K61K003953
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The invention relates to novel CD4-independent HIV Envelope proteins and uses 

therefor. 
[52] US Class: 4242081 4352351 4353201 435325
[51] Int’l Class: C12N000119 C12N001548 A61P003118 G01N0033569 C12N000701 
A61K003800 C12N001563 A61K003152 C12N001500 G01N003350 C12N001570 
C12N000700 C12N000500 G01N003368 G01N003315 A61K004800 A61K003821 
C07K001416 C12N000121 C12N001533 C12N000510 C12N000502 C07H002102 
A61K003921 C12N001574 C12N001509 C12N000115 A61K004500 
[52] ECLA: C07K001416D C12N000700 M12N074003F





[75] Inventors: Shiver, John, W.; 

Davies, Mary,  Ellen; Freed, 

 Daniel, C.; Liu,  Margaret, 
 . . .
[21] Application No.: NA
[22] Filed:  20020520 
[43] Published:  20030508 





Synthetic DNA molecules encoding HIV genes and modifications of HIV genes are 

provided. The codons of the synthetic molecules use codons preferred by the 

projected host cell. The synthetic molecules may be used as a polynucleotide 

vaccine which provides effective immunoprophylaxis against HIV infection through 

neutralizing antibody and cell-mediated immunity. 
[52] US Class: 435005 4350693 4352351 4353201 435366 530350 53602372
[51] Int’l Class: C12N000508 C07K001416 
[52] ECLA: C07K001416D K61K003951 M07K020700 M07K031900
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The present invention thus provides a polypeptide capable of forming a structure 

corresponding to or mimicking the intermediate of gp41 as well as its use in a 

vaccine for treating or preventing HIV infections. 
[52] US Class: 435005 4241881 4350693 435219 4353201 435325 53602372
[51] Int’l Class: C07K001416 A61K003900 
[52] ECLA: C07K001416D K61K003900 M07K020700 M07K031900
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[71] Applicant: N/A
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 . . .
[21] Application No.: NA
[22] Filed:  20011009 
[43] Published:  20030313 





Synthetic DNA molecules encoding HIV gag and modifications of HIV gag are provided. 

The codons of the synthetic molecules are codons preferred by the projected host 

cell. The synthetic molecules may be used as a polynucleotide vaccine which 

provides effective immunoprophylaxis against HIV infection through stimulation of 

neutralizing antibody and cell-mediated immunity. 
[52] US Class: 53602372 435005 435006 5360237
[51] Int’l Class: C07K001416 A61K003900 
[52] ECLA: C07K001416B K61K003900 M07K020300 M07K020700 M07K031902
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VACCINE AGAINST INFECTIOUS AGENTS HAVING AN 

INTRACELLULAR PHASE, COMPOSITION FOR THE 

TREATMENT AND PREVENTION OF HIV INFECTIONS, 

[71] Applicant: N/A
[75] Inventors: Chermann, Jean 

Claude; Le Contel,  Carole; 

Galea,  Pascale
[21] Application No.: NA
[22] Filed:  20010406 
[43] Published:  20030130 





A vaccine for treating and/or preventing infectious diseases where the infectious 

agent has at least one intracellular phase in the host during its multiplication 

cycle, is disclosed. The vaccine comprises at least one cryptic epitope of a 

cellular element that is carried along by an intracellular infectious agent as it 

leaves the cell, and revealed by said infectious agent. A composition for treating 

and/or preventing HIV infections, antibodies to a peptide of interest, and a 

diagnostic method, are also disclosed. 
[52] US Class: 4241881 4242021 4242081
[51] Int’l Class: C07K0014155 A61K003900 
[52] ECLA: C07K0014155 K61K003900 M07K020300 M07K021500
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GENETICALLY ENGINEERED CO-EXPRESSION DNA 

VACCINES, CONSTRUCTION METHODS AND USES THEREOF

[71] Applicant: N/A
[75] Inventors: Hone, David; Lewis,

 George; Fouts,  Timothy; 
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[22] Filed:  20010910 
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The present invention relates to co-expression DNA vaccines and methods for 

vaccinating animals against viral, bacterial and parasitic pathogens. In particular,

 the present invention relates to DNA vaccines that co-express antigens in 

combination with biologically-active components, such as adjuvants, 

immunoregulatory agents, antisense RNAs, and/or catalytic RNAs. 
[52] US Class: 514044 4241901
[51] Int’l Class: C07K001416 A61K003939 A61K003921 
[52] ECLA: A61K003921 A61K003939 C07K001416B C07K001416D C07K001416F 

K61K003953 K61K0039555B1 K61K0039555B2 K61K0039555B2L 

K61K0039555B3 K61K003957
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MHC-I-RESTRICTED PRESENTATION OF HIV-1 VIRION 

ANTIGENS WITHOUT VIRAL REPLICATION. APPLICATION 

TO THE STIMULATION OF CTL AND VACCINATION IN 

[71] Applicant: N/A
[75] Inventors: Schwartz, Olivier; 

Buseyne, Florence;  Marsac, 

Delphine;  Michel, Marie  
 . . .
[21] Application No.: NA
[22] Filed:  20020227 
[43] Published:  20021121 





Dendritic cells and macrophages can process extracellular antigens for presentation 

by MHC-I molecules. HIV-1 epitopes derived from incoming virions are presented 

through the exogenous MHC-I pathway in primary human dendritic cells, and to a 

lower extent in macrophages, leading to cytotoxic T lymphocyte activation in the 

absence of viral protein neosynthesis. Exogenous antigen presentation required 

adequate virus-receptor interactions and fusion of viral and cellular membranes. 

These results provide new insights about how anti-HIV cytotoxic T lymphocytes can 

be activated and are useful for anti-HIV vaccine design. 
[52] US Class: 4241861 4352351 4353201 435456
[51] Int’l Class: G01N003350 C12N000704 A61K003921 
[52] ECLA: C12N000704A A61K003921 G01N003350D2F2B K61K0039525D 

K61K003953 K61K003957
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ALPHAVIRUS VECTORS AND VIROSOMES WITH MODIFIED 

HIV GENES FOR USE IN VACCINES

[71] Applicant: ALPHAVAX INC
[75] Inventors: Olmsted, Robert; 

Keith, Paula;  Dryga, Sergey;

  Caley, Ian;  Maughan, 
 . . .
[21] Application No.: NA
[22] Filed:  20011116 
[43] Published:  20021003 





The present invention provides methods and compositions comprising a population of 

alphavirus replicon particles comprising two or more isolated nucleic acids 

selected from 1) an isolated nucleic acid encoding an env gene product or an 

immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated 

nucleic acid encoding a gag gene product or an immunogenic fragment thereof of a 

human immunodeficiency virus, wherein the gag gene product or immunogenic fragment 

thereof is modified to inhibit formation of virus-like particles containing the gag 

gene product or the immunogenic fragment thereof and their release from a cell, and 

3) an isolated nucleic acid encoding a pol gene product or an immunogenic fragment 

thereof of a human immunodeficiency virus, wherein the pol gene product or 

immunogenic fragment thereof is modified to inhibit protease, integrase, RNase H 

and/or reverse transcriptase activity, and wherein the nucleic acids are each 

contained within a separate alphavirus replicon particle. 
[52] US Class: 4240932 4241861 4241881 530350 530826 53602372
[51] Int’l Class: C07K001416 A61K003921 C07K001418 C12N000702 A61K003900 
[52] ECLA: A61K003921 C07K001416B C07K001416D C07K001418A C12N000702 

K61K003900 K61K0039525C M07K020700 M07K022100 M12N077016A
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HIV-1 VACCINES AND SCREENING METHODS THEREFOR

[71] Applicant: N/A
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[21] Application No.: NA
[22] Filed:  20010626 
[43] Published:  20020912 





Methods for immunizing, and immunogen pharmaceutical compositions for eliciting a 

heterologous immune response to HIV-1 in an animal, preferably a human, are 

provided, utilizing a modified HIV-1 envelope protein or fragment or DNA encoding a 

modified HIV-1 envelope protein or fragment, the modified protein having a HIV-1 

envelope protein V2 region deletion. A humoral response against heterologous HIV-1 

strains is achieved. 
[52] US Class: 4241881 514044
[51] Int’l Class: C07K001416 A61K003800 A61K0031711 G01N003350 A61P003118 
A61K003921 G01N003315 C12N001509 A61K0039395 G01N0033569 A61K004800 
[52] ECLA: A61K003921 C07K001416D K61K0039525 K61K003953 M07K020700
110            © 2008 MicroPatent, LLC
MicroPatent ReportUS20020061517A1
ADENOVIRUS CARRYING GAG GENE HIV VACCINE

[71] Applicant: N/A
[75] Inventors: Chen, Ling; Shiver,

 John, W.; Bett,  Andrew, J.;

  Casimiro, Danilo,  R.; 
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[21] Application No.: NA
[22] Filed:  20010327 
[43] Published:  20020523 





An adenoviral vector is described which carries a codon-optimized gag gene, along 

with a heterologous promoter and transcription terminator. This viral vaccine can 

effectively prevent HIV infection when administered to humans either alone or as 

part of a prime and boost regime also with a vaccine plasmid. 
[52] US Class: 435005 4241881 4242081 4242331 4352351 4353201 435325
[51] Int’l Class: C12Q000170 C12N0015861 C07K001416 
[52] ECLA: C07K001416B C12N0015861 C12Q000170B2B K61K0039525C 

K61K003953 M07K022104





[75] Inventors: Lisziewicz, 

Julianna; Lori,  Franco
[21] Application No.: NA
[22] Filed:  20010523 
[43] Published:  20020221 





A method for genetic immunization comprises administering a highly active 

antiretroviral therapy to control viral replication, and then administering a 

transcutaneous DNA vaccine. 
[52] US Class: 4242081 514023 514044
[51] Int’l Class: A61K004506 A61K00314353 A61K0031428 A61K003117 A61K003921 
A61K003147 C12N001587 A61K004748 A61K0031496 A61K003900 
[52] ECLA: A61K003117+M A61K0031428+M A61K00314353+M A61K003147+M 

A61K0031496+M A61K003900 A61K003921 A61K004506 

A61K004748R2T C12N001587 K61K0039515C K61K003953 

K61K003954 K61K003954A
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; Penhoet, Edward,  E.
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The invention provides for a postinfection HIV vaccination therapy having a 

therapeutic goal of eliminating HIV in the patient. The therapy directs 

administration of an agent to reduce the viral load of a patient with a measurable 

viral load of HIV, administration of an agent that induces an increase in 

production of the patient’s CD4 T-cells, and administration of a vaccine capable of 

stimulating the patient to produce CTLs targeted to HIV-infected cells. 
[52] US Class: 4241841 4353201 530351 5360231
[51] Int’l Class: A61K003921 
[52] ECLA: A61K003921 A61K003921+M
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Particularly, the present invention relates to the plasmid pSIV/GE which carrys gag,

 protease, env and rev gene, all derived from SIV, but not tat and nef gene and the 

plasmid pSIV/pol which carrys SIV-derived pol gene; the plasmid pHIV/GE and 

pHIV/pol that are substituted the SIV-derived genes in the plasmid pSIV/GE and 

pSIV/pol by human immunodeficiency virus (HIV)-derived corresponding genes; DNA 

vaccine containing the plasmid pSIV/GE and pSIV/pol; and DNA vaccine containing the 

plasmid pHIV/GE and pHIV/pol. 

The present invention offers AIDS DNA vaccines which successfully exert perfect 

medicinal efficacy on primates, giving a measure of success in developing effective 

AIDS DNA vaccines applicable to humans. The plasmid of the present invention can be 

effectively used for not only AIDS prevention by AIDS infection but also 

therapeutic agent for AIDS. 
[52] US Class: 4353201 514044
[51] Int’l Class: C07K001416 C07K0014155 C07K0014035 
[52] ECLA: C07K0014035 C07K0014155 C07K001416 C07K001416B M07K020700 

M07K031900 M61K003953
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Conventional HIV-1 vaccine strategies, based on the external part of the env 

protein gp160/120, were till now not found to induce protective immunity. In 

addition, enhancing antibodies may negatively influence disease progression. Due to 

the early appearence in infection and its particulate nature, the virus core 

protein p55-GAG seems to be a promising vaccine candidate. p55-core expression was 

assayed by recombinant vaccinia and baculo viruses. Shedding of 90-110 nm core 

particles into culture medium was observed in both expression systems and proven by 

ultrathin-section electron microscopy and sedimentation analysis. Addition of the 

protease coding sequence resulted in an efficient processing of the p55-precursor 

molecule-in the Baculo-system only. Significant protease mediated processing of the 

GAG precursor in the Vaccinia-system was only achievable by addition of the entire 

POL coding sequence. In contrast to other retroviruses (MMLV), HIV-1 protease 

mediated processing is not dependent on the myristylation of p55-GAG. As protease 

mediated processing does not complete the maturation process of the p55-precursor 

particles, but, in contrast, inhibits particle formation, further investigations 

focused on the application of premature p55-GAG-particles. To extend their 

immunological spectrum, a consensus sequence of the HIV-major neutralizing epitope 

V3 of gp120, designed in our lab, was inserted into different regions of the p55 

carrier molecule. The expression of the p55/V3 chimeric proteins in E. coli and the 

Vaccinia expression system was proven by Western blot analysis using (i) 

monoclonal antibodies directed to p55 and the inserted V3 region and (ii) 

[52] US Class: 
[51] Int’l Class: C07K001416 C12N001548 C12N001549 A61K003900 A61K003800 
[52] ECLA: C07K001416B K61K003800 K61K003900 M07K020700115            © 2008 MicroPatent, LLC
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[22] Filed:  20020531 
[43] Published:  20060419 




[52] US Class: 
[51] Int’l Class: C12N000700 C07K0014155 A61K00317052 C12N001509 A61P003704 
A61K003921 C12N000121 C12N0015867 C07K001416 A61K004800 C12N000510 
A61P003118 A61K003900 
[52] ECLA: C07K0014155 C07K001416B C12N000700 C12N0015867 K61K003900 

K61K003953 K61K004800 M07K020700 M12N083042 M12N083048 

M12N083050 M12N084010C M12N084020 K61K0039525C M12N074003F
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Described are new HIV-3 retrovirus strains comprising in their nucleic acid 

sequence a contiguous R region and an U3 region sequence showing a homology of more 

than 70% with the nucleic acid sequence as represented in SEQ ID NO 3, and provided 

that said HIV-3 retrovirus strains have at least one nucleotide difference in their 

sequence compared to the HIV-3 (ANT 70) retrovirus strain deposited under ECACC 

N° V88060301. Further described are antigens obtained from the virus, particularly 

proteins p12, p16, p25 and glycoproteins gp41 and gp120 to be used in the diagnosis 

of ARC or AIDS caused by HIV-3. Immunogenic compositions to be used as vaccines 

contain an envelope glycoprotein of HIV-3 such as gp41 or gp120. 
[52] US Class: 
[51] Int’l Class: C12N000700 C07K001610 C07K001416 C12N001549 
[52] ECLA: C07K001416 C07K001416D C07K001610K1 C07K001610K1B 

C12N000700 K61K0039505 M07K020300 M12N074003F
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Described are new HIV-3 retrovirus strains comprising in their nucleic acid 

sequence a contiguous R region and an U3 region sequence showing a homology of more 

than 70% with the nucleic acid sequence as represented in SEQ ID NO 3, and provided 

that said HIV-3 retrovirus strains have at least one nucleotide difference in their 

sequence compared to the HIV-3 (ANT 70) retrovirus strain deposited under ECACC 

N° V88060301. Further described are antigens obtained from the virus, particularly 

proteins p12, p16, p25 and glycoproteins gp41 and gp120 to be used in the diagnosis 

of ARC or AIDS caused by HIV-3. Immunogenic compositions to be used as vaccines 

contain an envelope glycoprotein of HIV-3 such as gp41 or gp120.
[52] US Class: 
[51] Int’l Class: C12N000700 C07K001610 C07K001416 C12N001549 
[52] ECLA: C07K001416 C07K001416D C07K001610K1 C07K001610K1B 

C12N000700 K61K0039505 M07K020300 M12N074003F
118            © 2008 MicroPatent, LLC
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USE OF HIV-1 TAT, FRAGMENTS OR DERIVATIVES 

THEREOF, TO TARGET OR TO ACTIVATE ANTIGEN-

PRESENTING CELLS, TO DELIVER CARGO MOLECULES FOR 

[71] Applicant: IST SUPERIORE 

SANITA
[72] Inventors: Ensoli, Barbara
[21] Application No.: NA
[22] Filed:  20010726 
[43] Published:  20030129 





The present invention concerns a method for prophylactic and/or therapeutic 

vaccination and/or treatment and/or diagnosis of HIV/AIDS, other infectious 

diseases, inflammatory and angiogenic diseases and tumours which utilizes a 

biologically active HIV-1 Tat protein, fragments or derivates thereof, as a module 

with one or more of the following features: antigen, adjuvant and targeting-

delivery system to specific antigen-presenting cells including dendritic cells, 

endothelial cells and macrophages. In particular, it is claimed that Tat can be 

used only in its biologically active form as an antigen, alone or combined with one 

or more other antigens, to prime or to boost protective immune responses against 

itself as well as other antigens and/or to deliver these antigen(s) as well as 

active compounds to dendritic cells, endothelial cells and macrophages, due to its 

capability of targeting these APC and of activating their maturation and functions 

and of increasing Th-1 type immune responses as an adjuvant. Therefore, due to 

these characteristics and to the distribution of these cells in the body (during 

physiological and pathological disorders), biologically active Tat, fragments or 

derivates thereof containing the RGD region, can be used for preventive, 

therapeutic and/or diagnostic purposes for HIV/AIDS, other infectious diseases, 

inflammatory and angiogenic diseases and tumors.
[52] US Class: 
[51] Int’l Class: A61P003112 A61P003106 A61P001500 A61K003904 A61P002500 
A61P000900 A61K003574 A61K0031711 A61P000910 A61P003100 A61P000514 
A61P002702 A61P001902 A61P002706 C07K001416 A61P001302 A61P000104 
A61P001900 A61K0039395 A61P003104 A61P003122 A61K004500 A61P001700 
C12N001509 A61P000100 A61P001706 A61P002900 A61K003902 A61P003708 
A61P003300 A61K003576 A61K003939 A61K004800 A61P000310 A61P003702 
A61K003912 A61K003800 A61P003116 A61P003500 A61P001100 A61K003900 
[52] ECLA: A61K003939 C07K001416F K61K0039515B K61K003953 

K61K0039555B1
119            © 2008 MicroPatent, LLC
MicroPatent ReportEP335635A1
MUTATED HIV ENVELOPE PROTEIN

[71] Applicant: UNIV LELAND 

STANFORD JUNIOR
[72] Inventors: McCune, Joseph 

McCrary
[21] Application No.: NA
[22] Filed:  19890328 
[43] Published:  19891004 






Novel DNA constructs and expression products are provided related to the HIV virus, 

where the gp160 encoding sequence is mutated to prevent cleavage to the mature 

protein product. The mutated protein and the virion containing the mutated protein 

may serve as vaccines to protect a host against infection and in the study of the 

maturation of gp160 and methods and compositions for inhibiting the maturation.
[52] US Class: 
[51] Int’l Class: A61K003921 C12N000704 C12P002100 C07K001400 C07K0014155 
C07K001416 C12R000191 A61K003900 C12R000192 
[52] ECLA: C07K001416D K61K003900 M07K020700
120            © 2008 MicroPatent, LLC
MicroPatent ReportWO2007126788A2
METHODS AND COMPOSITIONS FOR THE TREATMENT AND 

PREVENTION OF VIRAL INFECTION

[71] Applicant: US GOVERNMENT; YE 

ZHIPING; XIE HANG;  LIU 

TERESA M; CHEN  HONG
[72] Inventors: YE, Zhiping; XIE, 

Hang; LIU, Teresa,  M.; CHEN,


 . . .
[21] Application No.: NA
[22] Filed:  20070327 
[43] Published:  20071108 






The instant invention provides nucleic acid molecules comprising a nucleic acid 

segment encoding a viral surface protein and a nucleic acid segment encoding a 

viral matrix protein for the immunization of treatment of viral infections. The 

invention also provides compositions and methods for treating or immunizing 

subjects having or at risk of having a viral infection.
[52] US Class: 
[51] Int’l Class: A61K003900 
[52] ECLA: 
121            © 2008 MicroPatent, LLC
MicroPatent ReportWO2007126788A3
METHODS AND COMPOSITIONS FOR THE TREATMENT AND 

PREVENTION OF VIRAL INFECTION

[71] Applicant: US GOVERNMENT; YE 

ZHIPING; XIE HANG;  LIU 

TERESA M; CHEN  HONG
[72] Inventors: YE, Zhiping; XIE, 

Hang; LIU, Teresa,  M.; CHEN,


 . . .
[21] Application No.: NA
[22] Filed:  20070327 
[43] Published:  20080228 






The instant invention provides nucleic acid molecules comprising a nucleic acid 

segment encoding a viral surface protein and a nucleic acid segment encoding a 

viral matrix protein for the immunization of treatment of viral infections. The 

invention also provides compositions and methods for treating or immunizing 

subjects having or at risk of having a viral infection.
[52] US Class: 
[51] Int’l Class: A61K0039145 C12N001544 
[52] ECLA: 
122            © 2008 MicroPatent, LLC
MicroPatent ReportWO2007126959A2
METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE 

RESPONSE TO HIV AND MODELS FOR TESTING

[71] Applicant: DANA FARBER CANCER 

INST INC; RUPRECHT  RUTH
[72] Inventors: RUPRECHT, Ruth
[21] Application No.: NA
[22] Filed:  20070328 
[43] Published:  20071108 





The invention provides methods and compositions for raising an immune response in a 

subject by administering an HIV antigen. The HIV antigens include HIV clade C 

polynucleotides and polypeptides. The invention also provides for recombinant HIV 

viral particles and compositions.
[52] US Class: 
[51] Int’l Class: A61K003119 
[52] ECLA: 
123            © 2008 MicroPatent, LLC
MicroPatent ReportWO2007066236A2




[71] Applicant: INST LA RECH POUR 

LE DEV IRD;  COMMISSARIAT  

ENERGIE ATOMIQUE;  
 . . .
[72] Inventors: VEAS, Francisco; 

VITA, Claudio;  MARTIN, Loïc;

 BRAY,  Dorothy;  BENLHASSAN-
 . . .
[21] Application No.: NA
[22] Filed:  20061128 
[43] Published:  20070614 






The invention relates to chimeric HIV-1 gp120 glycoproteins, wherein at least a 

part of gp120 variable region V1 and/or V2 is replaced by a CD4-derived sequence to 

obtain the exposition of CD4 induced epitopes or CD4i capable of inducing a 

specific humoral immune response. Application for the preparation of vaccinal and 

pharmaceutical composition.
[52] US Class: 
[51] Int’l Class: IntClass:: 
[52] ECLA: C07K001416D A61K003921 K61K0039505 M07K031900 M07K031932 

M07K031935 M12N074003F
124            © 2008 MicroPatent, LLC
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[71] Applicant: INST LA RECH POUR 

LE DEV IRD;  COMMISSARIAT  

ENERGIE ATOMIQUE;  
 . . .
[72] Inventors: VEAS, Francisco; 

VITA, Claudio;  MARTIN, Loïc;

 BRAY,  Dorothy;  BENLHASSAN-
 . . .
[21] Application No.: NA
[22] Filed:  20061128 
[43] Published:  20071115 






The invention relates to chimeric HIV-1 gp120 glycoproteins, wherein at least a 

part of gp120 variable region V1 and/or V2 is replaced by a CD4-derived sequence to 

obtain the exposition of CD4 induced epitopes or CD4i capable of inducing a 

specific humoral immune response. Application for the preparation of vaccinal and 

pharmaceutical composition.
[52] US Class: 
[51] Int’l Class: C07K001610 A61K003921 C07K001416 
[52] ECLA: C07K001416D A61K003921 K61K0039505 M07K031900 M07K031932 

M07K031935 M12N074003F
125            © 2008 MicroPatent, LLC
MicroPatent ReportWO2007024976A2




[71] Applicant: UNIV MARYLAND 

BIOTECH INST;  DEVICO 

ANTHONY L;  FOUTS TIMOTHY;  
 . . .
[72] Inventors: DEVICO, Anthony, L.

; FOUTS, Timothy;  TUSKEN, 

Robert, G.
[21] Application No.: NA
[22] Filed:  20060823 
[43] Published:  20070301 





The invention relates to chimeric molecules comprising a virus coat sequence and a 

receptor sequence that can inter-act with each other to form a complex that is 

capable of binding a co-receptor. Such chimeric molecules therefore exhibit 

functional properties characteristic of a receptor-coat protein complex and are 

useful as agents that inhibit virus infection of cells due to occupancy of a co-

receptor present on the cell. In particular aspects, the chimeric polypeptide 

includes an immunodeficiency virus envelope polypeptide, such as that of HIV, SIV, 

FIV, FeLV, FPV and herpes virus. Receptor sequences suitable for use in a chimeric 

polypeptide include, for example, CD4 receptors, fragments and mimetic thereof. DNA 

vaccines comprising nucleotide sequences encoding for such chimeric molecules is 

another aspect of the present invention.
[52] US Class: 
[51] Int’l Class: C07H002102 A61K004800 
[52] ECLA: C07K001416D C07K0014705B14 K61K003800 K61K003900 

M07K031900 M07K031930 M12N074003F
126            © 2008 MicroPatent, LLC
MicroPatent ReportWO2007004231A1
HIV-1 VACCINOGENS WITH IMMUNOMODULATORS

[71] Applicant: SETH PRADEEP
[72] Inventors: SETH, Pradeep
[21] Application No.: NA
[22] Filed:  20050704 
[43] Published:  20070111 






Vaccinagens comprise recombinant plasmid vaccine constructs NK-29692CO, NK-49426CO, 

NK-49587CO, NK-IND-tat-CO and NK-IND-nef-CO and recombinant viral vector vaccine 

constructs VV-29692CO, VV 49426CO, VV 49587CO, VV-IND-tatCO and VV-IND-nefCO.
[52] US Class: 
[51] Int’l Class: A61K003921 
[52] ECLA: C07K001416 K61K0039525C M12N022120
127            © 2008 MicroPatent, LLC
MicroPatent ReportWO2006110344A1
NOVEL METHODS FOR INDUCING AN IMMUNE RESPONSE 

AGAINST HUMAN IMMUNODEFIENCY VIRUS

[71] Applicant: WYETH CORP; CHONG 

SIEWYEN; EGAN  MICHAEL ALBIN;

  ELDRIDGE JOHN  HAYWARD; 
 . . .
[72] Inventors: CHONG, SiewYen; 

EGAN, Michael  Albin; 

ELDRIDGE,  John Hayward;  
 . . .
[21] Application No.: NA
[22] Filed:  20060403 
[43] Published:  20061019 





The present invention relates to novel methods for inducing an immune response 

against human immunodeficiency virus. More particularly, the invention relates to 

the methods for inducing (or stimulating) both humoral and cellular immune 

response against HIV in a human subject.
[52] US Class: 
[51] Int’l Class: C07K001416 A61K003921 
[52] ECLA: C07K001416B C07K001416D C07K001416F K61K003900 K61K003953 

K61K0039545 K61K0039555 K61K0039555B2L12
128            © 2008 MicroPatent, LLC
MicroPatent ReportWO2006085959A2
FUSION PROTEINS COMPRISING CD4 MINIMAL MODULES 

AND METHODS OF USE THEREOF

[71] Applicant: CHIRON CORP; 

MASIGNANI VEGA;  SCARSELLI 

MARIA;  CAPECCHI BARBARA;  
 . . .
[72] Inventors: MASIGNANI, Vega; 

SCARSELLI, Maria;  CAPECCHI, 

Barbara;  SHARMA, Victoria;  
 . . .
[21] Application No.: NA
[22] Filed:  20050608 
[43] Published:  20060817 





Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in 

a non-CD4 backbone are described. Also described are complexes of these fusion 

proteins with Env as well as methods of diagnosis, treatment and prevention using 

the polynucleotides and polypeptides are also provided.
[52] US Class: 
[51] Int’l Class: C12Q000170 
[52] ECLA: C07K0014705B14 M07K031901
129            © 2008 MicroPatent, LLC
MicroPatent ReportWO2006050394A2




[71] Applicant: CHIRON CORP; 

HEALTH AND HUMAN  SERVICES 

THE;  BARNETT SUSAN W;  
 . . .
[72] Inventors: BARNETT, Susan, W.;

 GOMEZ ROMAN,  Victor, Raul 

The  Government Of The  
 . . .
[21] Application No.: NA
[22] Filed:  20051101 
[43] Published:  20060511 






The present invention relates to methods, polypeptides, and polynucleotides 

encoding immunogenic identical or analogous HIV polypeptides derived from the same 

or different strains within an HIV subtype and/or different subtypes. Uses of the 

polynucleotides and polypeptides in combination approaches for generating immune 

responses are also described. The combination approaches described herein induce 

broad and potent immune responses against diverse HIV strains from multiple strains 

within a given subtype and against diverse subtypes. Formulations of compositions 

for generating immune responses and methods of use for such compositions are also 

disclosed.
[52] US Class: 
[51] Int’l Class: IntClass:: 
[52] ECLA: A61K003921 C07K001416D K61K003900 K61K003953 M07K022100 

M07K022104
130            © 2008 MicroPatent, LLC
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[71] Applicant: CHIRON CORP; 

REPRESENTED BY THE  

SECRETARY O;  BARNETT SUSAN 
 . . .
[72] Inventors: BARNETT, Susan, W.;

 GOMEZ ROMAN,  Victor, Raul 

The  Government Of The  
 . . .
[21] Application No.: NA
[22] Filed:  20051101 
[43] Published:  20060824 






The present invention relates to methods, polypeptides, and polynucleotides 

encoding immunogenic identical or analogous HIV polypeptides derived from the same 

or different strains within an HIV subtype and/or different subtypes. Uses of the 

polynucleotides and polypeptides in combination approaches for generating immune 

responses are also described. The combination approaches described herein induce 

broad and potent immune responses against diverse HIV strains from multiple strains 

within a given subtype and against diverse subtypes. Formulations of compositions 

for generating immune responses and methods of use for such compositions are also 

disclosed.
[52] US Class: 
[51] Int’l Class: C07K001416 A61K003921 
[52] ECLA: A61K003921 C07K001416D K61K003900 K61K003953 M07K022100 

M07K022104
131            © 2008 MicroPatent, LLC
MicroPatent ReportWO2006020071A2
VACCINE CONSTRUCTS AND COMBINATIONS OF VACCINES 

DESIGNED TO IMPROVE THE BREADTH OF THE IMMUNE 

RESPONSE TO DIVERSE STRAINS AND CLADES OF HIV

[71] Applicant: US GOVERNMENT; 

GENVEC INC; NABEL  GARY J; 

HUANG YUE;  XU LING;  
 . . .
[72] Inventors: NABEL, Gary, J.; 

HUANG, Yue; XU,  Ling; 

CHAKRABARTI,  Bimal; WU, Lan;
 . . .
[21] Application No.: NA
[22] Filed:  20050715 
[43] Published:  20060223 






The present disclosure provides compositions for eliciting an immune response, 

including a prophylactic immune response, against human immunodeficiency virus. The 

composition includes nucleic acid constructs encoding HIV antigenic polypeptides of 

multiple clades or strains. Methods for eliciting an immune response by 

administering the composition to a subject are also provided.
[52] US Class: 
[51] Int’l Class: A61P003100 A61K003921 C07K001416 
[52] ECLA: A61K003921 C07K001416B C07K001416D C07K001416F K61K003900 

K61K003953
132            © 2008 MicroPatent, LLC
MicroPatent ReportWO2006020071A3




[71] Applicant: US GOVERNMENT; 

GENVEC INC; NABEL  GARY J; 

HUANG YUE;  XU LING;  
 . . .
[72] Inventors: NABEL, Gary, J.; 

HUANG, Yue; XU,  Ling; 

CHAKRABARTI,  Bimal; WU, Lan;
 . . .
[21] Application No.: NA
[22] Filed:  20050715 
[43] Published:  20060518 






The present disclosure provides compositions for eliciting an immune response, 

including a prophylactic immune response, against human immunodeficiency virus. The 

composition includes nucleic acid constructs encoding HIV antigenic polypeptides of 

multiple clades or strains. Methods for eliciting an immune response by 

administering the composition to a subject are also provided.
[52] US Class: 
[51] Int’l Class: A61P003100 A61K003921 C07K001416 
[52] ECLA: A61K003921 C07K001416B C07K001416D C07K001416F K61K003900 

K61K003953
133            © 2008 MicroPatent, LLC
MicroPatent ReportWO2006009746A2
PLASMID HAVING THREE COMPLETE TRANSCRIPTIONAL 

UNITS AND IMMUNOGENIC COMPOSITIONS FOR INDUCING 

AN IMMUNE RESPONSE TO HIV

[71] Applicant: WYETH CORP; SIDHU 

MANINDER K;  ELDRIDGE JOHN H;

  EGAN MICHAEL;  ISRAEL 
 . . .
[72] Inventors: SIDHU, Maninder, K.

; ELDRIDGE, John,  H.; EGAN, 

Michael;  ISRAEL, Zimra
[21] Application No.: NA
[22] Filed:  20050615 
[43] Published:  20060126 





The invention provides a DNA plasmid comprising: (a) a first transcriptional unit 

comprising a nucleotide sequence that encodes a first polypeptide operably linked 

to regulatory elements including a first promoter and a first polyadenylation 

signal; (b) a second transcriptional unit comprising a nucleotide sequence that 

encodes a second polypeptide operably linked to regulatory elements including a 

second promoter and a second polyadenylation signal; (c) a third transcriptional 

unit comprising a nucleotide sequence that encodes a third polypeptide operably 

linked to regulatory elements including a third promoter and a third 

polyadenylation signal; and wherein said first, said second and said third 

promoters are each derived from different transcriptional units; and wherein said 

first, said second and said third polyadenylation signals are each derived from 

different transcriptional units. The invention further relates to immunogenic 

compositions for inducing an immune response to HIV comprising combinations of two, 

three, or four plasmids, where each plasmid is expressing a defined antigen, which 

may be a single antigen or a fusion of two or three antigens.
[52] US Class: 
[51] Int’l Class: C12N001586 IntClass:: 
[52] ECLA: 
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MicroPatent ReportWO2006009746A3
PLASMID HAVING THREE COMPLETE TRANSCRIPTIONAL 

UNITS AND IMMUNOGENIC COMPOSITIONS FOR INDUCING 

AN IMMUNE RESPONSE TO HIV

[71] Applicant: WYETH CORP; SIDHU 

MANINDER K;  ELDRIDGE JOHN H;

  EGAN MICHAEL;  ISRAEL 
 . . .
[72] Inventors: SIDHU, Maninder, K.

; ELDRIDGE, John,  H.; EGAN, 

Michael;  ISRAEL, Zimra
[21] Application No.: NA
[22] Filed:  20050615 
[43] Published:  20060511 





The invention provides a DNA plasmid comprising: (a) a first transcriptional unit 

comprising a nucleotide sequence that encodes a first polypeptide operably linked 

to regulatory elements including a first promoter and a first polyadenylation 

signal; (b) a second transcriptional unit comprising a nucleotide sequence that 

encodes a second polypeptide operably linked to regulatory elements including a 

second promoter and a second polyadenylation signal; (c) a third transcriptional 

unit comprising a nucleotide sequence that encodes a third polypeptide operably 

linked to regulatory elements including a third promoter and a third 

polyadenylation signal; and wherein said first, said second and said third 

promoters are each derived from different transcriptional units; and wherein said 

first, said second and said third polyadenylation signals are each derived from 

different transcriptional units. The invention further relates to immunogenic 

compositions for inducing an immune response to HIV comprising combinations of two, 

three, or four plasmids, where each plasmid is expressing a defined antigen, which 

may be a single antigen or a fusion of two or three antigens.
[52] US Class: 
[51] Int’l Class: C12N001563 IntClass:: 
[52] ECLA: 
135            © 2008 MicroPatent, LLC
MicroPatent ReportWO2006009746A9
PLASMID HAVING THREE COMPLETE TRANSCRIPTIONAL 

UNITS AND IMMUNOGENIC COMPOSITIONS FOR INDUCING 

AN IMMUNE RESPONSE TO HIV

[71] Applicant: WYETH CORP; SIDHU 

MANINDER K;  ELDRIDGE JOHN H;

  EGAN MICHAEL;  ISRAEL 
 . . .
[72] Inventors: SIDHU MANINDER K; 

ELDRIDGE JOHN H;  EGAN 

MICHAEL;  ISRAEL ZIMRA
[21] Application No.: NA
[22] Filed:  20050615 
[43] Published:  20060302 





The invention provides a DNA plasmid comprising: (a) a first transcriptional unit 

comprising a nucleotide sequence that encodes a first polypeptide operably linked 

to regulatory elements including a first promoter and a first polyadenylation 

signal; (b) a second transcriptional unit comprising a nucleotide sequence that 

encodes a second polypeptide operably linked to regulatory elements including a 

second promoter and a second polyadenylation signal; (c) a third transcriptional 

unit comprising a nucleotide sequence that encodes a third polypeptide operably 

linked to regulatory elements including a third promoter and a third 

polyadenylation signal; and wherein said first, said second and said third 

promoters are each derived from different transcriptional units; and wherein said 

first, said second and said third polyadenylation signals are each derived from 

different transcriptional units. The invention further relates to immunogenic 

compositions for inducing an immune response to HIV comprising combinations of two, 

three, or four plasmids, where each plasmid is expressing a defined antigen, which 

may be a single antigen or a fusion of two or three antigens.
[52] US Class: 
[51] Int’l Class: C12N001563 IntClass:: 
[52] ECLA: 
136            © 2008 MicroPatent, LLC
MicroPatent ReportWO2005027844A2
DNA VACCINE COMPOSITIONS AND METHODS OF USE

[71] Applicant: UNIV KANSAS 

MEDICAL CT;  NARAYAN OPENDRA;

  LIU ZHENQIAN
[72] Inventors: NARAYAN, Opendra; 

LIU, Zhenqian
[21] Application No.: NA
[22] Filed:  20040916 
[43] Published:  20050331 





The present invention is directed to a DNA vaccine for immunization against HIV. 

The invention comprises a DNA molecule that has a sequence encoding a plurality of 

viral proteins capable of stimulating an immune response against HIV. The DNA 

molecule is rendered safe for use as a vaccine by the disruption of genes encoding 

reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered 

safe by at least a partial deletion of the 3’ LTR. 
[52] US Class: 
[51] Int’l Class: C12N001586 A61K003921 A01N006300 A01N004304 C12N001563 
A61K004800 C07H002104 C12N001500 
[52] ECLA: A61K003921 K61K003953 K61K0039555B2 M12N074003F
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DNA VACCINE COMPOSITIONS AND METHODS OF USE

[71] Applicant: UNIV KANSAS 

MEDICAL CT;  NARAYAN OPENDRA;

  LIU ZHENQIAN
[72] Inventors: NARAYAN, Opendra; 

LIU, Zhenqian
[21] Application No.: NA
[22] Filed:  20040916 
[43] Published:  20051006 





The present invention is directed to a DNA vaccine for immunization against HIV. 

The invention comprises a DNA molecule that has a sequence encoding a plurality of 

viral proteins capable of stimulating an immune response against HIV. The DNA 

molecule is rendered safe for use as a vaccine by the disruption of genes encoding 

reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered 

safe by at least a partial deletion of the 3’ LTR.
[52] US Class: 
[51] Int’l Class: C12N001586 A61K003921 A01N006300 A01N004304 C12N001563 
A61K004800 C07H002104 C12N001500 
[52] ECLA: A61K003921 K61K003953 K61K0039555B2 M12N074003F
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[71] Applicant: CHIRON CORP; NAT 

INST OF HEALTH NAT  CANCER; 

BARNETT  SUSAN W; GOMEZ- 
 . . .
[72] Inventors: BARNETT, Susan, W.;

 GÓMEZ-ROMÁN,  Victor, Raúl 

c/o  National  Institutes of 
 . . .
[21] Application No.: NA
[22] Filed:  20040915 
[43] Published:  20050331 






The present invention relates to methods, polynucleotides, and polypeptides 

encoding immunogenic HIV polypeptides derived from different strains within an HIV 

subtype and/or immunogenic HIV polypeptides from different subtypes. Uses of the 

polynucleotides and polypeptides in combination approaches for generating immune 

responses are described. The combination approaches described herein have been 

shown to induce broad and potent neutralizing activity against diverse HIV strains 

from multiple strains within a given subtype and against diverse subtypes. 

Formulations of compositions for generating immune responses and methods of use for 

such compositions are also disclosed.
[52] US Class: 
[51] Int’l Class: A61K 
[52] ECLA: A61K003921 K61K003953 M12N074003F




[71] Applicant: BIOPTION AB; 

LILJESTROEM PETER
[72] Inventors: LILJESTRÖM, Peter
[21] Application No.: NA
[22] Filed:  20040915 
[43] Published:  20050324 






The present invention is directed to recombinant alphavirus vectors and expression 

of heterologous antigens therefrom in animal cells. Recombinant alphavirus vectors 

of the present invention can be used for preparing antigenic compositions which can 

be administered as vaccines. 
[52] US Class: 
[51] Int’l Class: C12N001586 C07K001418 
[52] ECLA: C12N001586 C07K001416B C07K001416D C07K001416F 

K61K0039525C K61K003953 K61K0039545 M12N074003F 

M12N077016A




[71] Applicant: BIOPTION AB; 

LILJESTROEM PETER
[72] Inventors: LILJESTRÖM, Peter
[21] Application No.: NA
[22] Filed:  20040915 
[43] Published:  20050526 






The present invention is directed to recombinant alphavirus vectors and expression 

of heterologous antigens therefrom in animal cells. Said vectors are characterized 

by having inter alia an alphavirus 3&rsquo;-untranslated region (3&rsquo;-UTR) 

comprising a deletion of non-essential nucleotides, suitably a deletion of at least 

525 nucleotides. Recombinant alphavirus vectors of the present invention can be 

used for preparing antigenic compositions which can be administered as vaccines.
[52] US Class: 
[51] Int’l Class: C12N001586 C07K001418 
[52] ECLA: C12N001586 C07K001416B C07K001416D C07K001416F 

K61K0039525C K61K003953 K61K0039545 M12N074003F 

M12N077016A




[71] Applicant: BIOPTION AB; 

LILJESTROEM PETER
[72] Inventors: LILJESTROEM PETER
[21] Application No.: NA
[22] Filed:  20040915 
[43] Published:  20050721 






The present invention is directed to recombinant alphavirus vectors and expression 

of heterologous antigens therefrom in animal cells. Said vectors are characterized 

by having inter alia an alphavirus 3’-untranslated region (3’-UTR) comprising a 

deletion of non-essential nucleotides, suitably a deletion of at least 525 

nucleotides. Recombinant alphavirus vectors of the present invention can be used 

for preparing antigenic compositions which can be administered as vaccines.
[52] US Class: 
[51] Int’l Class: C12N001586 C07K001418 
[52] ECLA: C12N001586 C07K001416B C07K001416D C07K001416F 

K61K0039525C K61K003953 K61K0039545 M12N074003F 

M12N077016A
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[71] Applicant: US GOVERNMENT; 

NABEL GARY J;  CHAKRABARTI 

BIMAL;  KONG WING-PUI;  
 . . .
[72] Inventors: NABEL, Gary, J.; 

CHAKRABARTI, Bimal;  KONG, 

Wing-pui;  HUANG, Yue; YANG, 
 . . .
[21] Application No.: NA
[22] Filed:  20040915 
[43] Published:  20050421 





In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral 

vector vaccine including components from different clades fo Env (optionally Env 

chimeras) and Gag-Pol-(optionally)Nef from a single clade. The vaccine of the 

invention may further include V1, V2, V3, or V4 deletions or combinations thereof. 

In another embodiment, the invention provides multiclade HIV envelope immunogens. 
[52] US Class: 
[51] Int’l Class: C07K001416 A61K003921 
[52] ECLA: A61K003921 C07K001416B C07K001416D K61K0039525C K61K003953 

M07K022104
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[71] Applicant: US GOVERNMENT; 

NABEL GARY J;  CHAKRABARTI 

BIMAL;  KONG WING-PUI;  
 . . .
[72] Inventors: NABEL, Gary, J.; 

CHAKRABARTI, Bimal;  KONG, 

Wing-pui;  HUANG, Yue; YANG, 
 . . .
[21] Application No.: NA
[22] Filed:  20040915 
[43] Published:  20050909 





In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral 

vector vaccine including components from different clades fo Env (optionally Env 

chimeras) and Gag-Pol-(optionally)Nef from a single clade. The vaccine of the 

invention may further include V1, V2, V3, or V4 deletions or combinations thereof. 

In another embodiment, the invention provides multiclade HIV envelope immunogens.
[52] US Class: 
[51] Int’l Class: C07K001416 A61K003921 
[52] ECLA: A61K003921 C07K001416B C07K001416D K61K0039525C K61K003953 

M07K022104
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[22] Filed:  20030818 
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An immunodeficiency virus (HIV) DNA vaccine to cambat Indian subtype C of HIV-1 

comprising a vector and gene of virus subtype C of HIV-1 said gene being mounted on 

the vector.
[52] US Class: 
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Polyvalent, primary isolate nucleic acid compositions for inducing an immune 

response against HIV is disclosed. The compositions and methods described herein 

are for the use of a DNA composition that encodes one or more different HIV 

envelope glycoproteins. The DNA composition can encode an HIV Gag protein. The DNAs 

encoding one or more HIV proteins are a combination of different nucleic acids, 

such as DNA plasmids, generated from primary isolate DNA of different HIV major 

group genetic clades and/or different proteins. HIV protein compositions for 

inducing an immune response against HIV are disclosed. Methods for using the 

protein compositions as boosts following administration of the DNA compositions are 

provided. 
[52] US Class: 
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VACCINES AND VACCINATION METHODS
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Polyvalent, primary isolate nucleic acid compositions for inducing an immune 

response against HIV is disclosed. The compositions and methods described herein 

are for the use of a DNA composition that encodes one or more different HIV 

envelope glycoproteins. The DNA composition can encode an HIV Gag protein. The DNAs 

encoding one or more HIV proteins are a combination of different nucleic acids, 

such as DNA plasmids, generated from primary isolate DNA of different HIV major 

group genetic clades and/or different proteins. HIV protein compositions for 

inducing an immune response against HIV are disclosed. Methods for using the 

protein compositions as boosts following administration of the DNA compositions are 

provided.
[52] US Class: 
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Disclosed is a vaccine composition that includes a peptide adjuvant, and a DNA 

vaccine encoding an immunogenic protein. Also, the present invention discloses a 

method of enhancing immune responses, which is based on the administration of the 

vaccine composition.
[52] US Class: 
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Env-CD4 complexes and hybrids are disclosed that expose cryptic epitopes that are 

important in virus neutralization. Methods of diagnosis, treatment and prevention 

using the polynucleotides and polypeptides are also provided. 
[52] US Class: 
[51] Int’l Class: C07K001700 C07H002104 A61K003921 C07K001628 C07K001416 
C12N000502 C07K001473 C07K001610 A61K003900 
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C07K001628A14 K61K003900 K61K003953 M07K0316600 

M07K0316960 M07K031932 K61K003960P M12N074003F M12N079902A 

M12N079902A67 M12N080010D1
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Env-CD4 complexes and hybrids are disclosed that expose cryptic epitopes that are 

important in virus neutralization. Methods of diagnosis, treatment and prevention 

using the polynucleotides and polypeptides are also provided.
[52] US Class: 
[51] Int’l Class: C07K001700 C07H002104 A61K003921 C07K001628 C07K001416 
C12N000502 C07K001473 C07K001610 A61K003900 
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Provided herein are HIV vaccines comprising HIV polypeptide-encoding DNA adsorbed 

to PLG and/or HIV proteins. Also provided are methods of using these vaccines to 

generate immune responses in a subject. 
[52] US Class: 
[51] Int’l Class: C12Q000170 C07H002104 A61K004800 A61K003921 C12P002106 
C07K001416 C12N001500 C12N001587 
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C07K001416 C07K001416B C07K001416D C12N001587 K61K003953 

K61K0039555B8 M07K020700
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Provided herein are HIV vaccines comprising HIV polypeptide-encoding DNA adsorbed 

to PLG and/or HIV proteins. Also provided are methods of using these vaccines to 

generate immune responses in a subject.
[52] US Class: 
[51] Int’l Class: C12Q000170 C07H002104 A61K004800 A61K003921 C12P002106 
C07K001416 C12N001500 C12N001587 
[52] ECLA: A61K003921 A61K004800B4B A61K004800D A61K004800H 

C07K001416 C07K001416B C07K001416D C12N001587 K61K003953 

K61K0039555B8 M07K020700
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The invention relates to polynucleotides for DNA vaccination which polynucleotides 

encode an HIV envelope protein or fragment or immunogenic derivative fused to an 

additional HIV protein selected from a non-structural protein or capsid protein or 

fragment or immunogenic derivative thereof. Preferably the HIV envelope molecule is 

gp120 and preferred fusions include one or more of HIV Nef, Gag, RT or Tat. 

Preferably the HIV envelope molecule is non-glycosylated in mammalian cells. 
[52] US Class: 
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The invention relates to polynucleotides for DNA vaccination which polynucleotides 

encode an HIV envelope protein or fragment or immunogenic derivative fused to an 

additional HIV protein selected from a non-structural protein or capsid protein or 

fragment or immunogenic derivative thereof. Preferably the HIV envelope molecule is 

gp120 and preferred fusions include one or more of HIV Nef, Gag, RT or Tat. 

Preferably the HIV envelope molecule is non-glycosylated in mammalian cells.
[52] US Class: 
[51] Int’l Class: C12N001548 C07K001416 A61K003900 
[52] ECLA: C07K001416B C07K001416D C07K001416F K61K003900 K61K003953 

M07K020700 M07K031900
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The present invention relates to nucleic acid and attenuated vaccinia vectors for 

prophylactic use against HIV infection, as well as methods of eliciting immune 

responses in subjects susceptible to HIV infection. The prophylactic vaccine 

regimen of the invention involves immunological priming with an inoculum comprising 

two novel DNA vectors, followed by boosting with a Modified Vaccinia Ankara (MVA) 

recombinant viral vector expressing the corresponding HIV proteins. 
[52] US Class: 
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The present invention relates to nucleic acid and attenuated vaccinia vectors for 

prophylactic use against HIV infection, as well as methods of eliciting immune 

responses in subjects susceptible to HIV infection. The prophylactic vaccine 

regimen of the invention involves immunological priming with an inoculum comprising 

two novel DNA vectors, followed by boosting with a Modified Vaccinia Ankara (MVA) 

recombinant viral vector expressing the corresponding HIV proteins.
[52] US Class: 
[51] Int’l Class: C12N001563 A61K0039285 A61K00317088 A01N004304 C12N001500 
A61K004748 C12P002106 A61K004800 C12N000500 
[52] ECLA: C07K001416 A61K003921 C12N0015863V K61K003953 K61K0039545 

M07K031900 M12N071013 M12N071013A M12N074003F 

M12N079902A63 M12N079904
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The relates to certain adjuvant compositions, and to vaccine and/or nucleic acid 

immunization strategies employing such compositions. The invention in particular 

relates to DNA vaccines that are useful in the prophylaxis and treatment of HIV 

infections, more particularly when administered by particle mediated delivery. 
[52] US Class: 
[51] Int’l Class: A61K004506 A61K000918 A61K000906 A61P003704 C07D047104 
C12N001509 A61K003939 A61K00314745 A61P003118 C07K001416 A61K004800 
A61K003900 A61K003921 
[52] ECLA: A61K00314745 A61K00314745+M A61K003921 A61K003939 

A61K004506 C07K001416B K61K003953 K61K003954 K61K0039555B5 

M07K020700
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The relates to certain adjuvant compositions, and to vaccine and/or nucleic acid 

immunization strategies employing such compositions. The invention in particular 

relates to DNA vaccines that are useful in the prophylaxis and treatment of HIV 

infections, more particularly when administered by particle mediated delivery.
[52] US Class: 
[51] Int’l Class: A61K004506 A61K000918 A61K000906 A61P003704 C07D047104 
C12N001509 A61K003939 A61K00314745 A61P003118 C07K001416 A61K004800 
A61K003900 A61K003921 
[52] ECLA: A61K00314745 A61K00314745+M A61K003921 A61K003939 

A61K004506 C07K001416B K61K003953 K61K003954 K61K0039555B5 

M07K020700
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We have developed DNA and viral vectors that can be used, alone or in combination, 

as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against 

multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can 

encode a variety of antigens, which may be obtained from one clade or from two or 

more different clades, and the antigens selected and/or the manner in which the 

vectors are formulated (e.g., mixed) can be manipulated to generate a protective 

immune response against a variety of clades (e.g., the clades to which a patient 

is most likely to be exposed; with the proportions of the components of the vaccine 

tailored to the extent of the patient’s risk to a particular clade or clades). 
[52] US Class: 
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We have developed DNA and viral vectors that can be used, alone or in combination, 

as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against 

multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can 

encode a variety of antigens, which may be obtained from one clade or from two or 

more different clades, and the antigens selected and/or the manner in which the 

vectors are formulated (e.g., mixed) can be manipulated to generate a protective 

immune response against a variety of clades (e.g., the clades to which a patient 

is most likely to be exposed; with the proportions of the components of the vaccine 

tailored to the extent of the patient’s risk to a particular clade or clades).
[52] US Class: 
[51] Int’l Class: C12N0015863 A61K003921 A61K003576 C12N001509 C12N000704 
A61K004800 A61P003118 C07K001416 
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We have developed DNA and viral vectors that can be used, alone or in combination, 

as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against 

multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can 

encode a variety of antigens, which may be obtained from one clade or from two or 

more different clades, and the antigens selected and/or the manner in which the 

vectors are formulated (e.g., mixed) can be manipulated to generate a protective 

immune response against a variety of clades (e.g., the clades to which a patient 

is most likely to be exposed; with the proportions of the components of the vaccine 

tailored to the extent of the patient’s risk to a particular clade or clades).
[52] US Class: 
[51] Int’l Class: C12N0015863 A61K003921 A61K003576 C12N001509 C12N000704 
A61K004800 A61P003118 C07K001416 
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The invention relates to methods and materials useful for targeting antigenic 

determinants of mutable pathogens for somatic hypermutation. These methods and 

materials can be used to induce an immune response against antigenic variants of 

mutable pathogens. 
[52] US Class: 
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The invention relates to methods and materials useful for targeting antigenic 

determinants of mutable pathogens for somatic hypermutation. These methods and 

materials can be used to induce an immune response against antigenic variants of 

mutable pathogens.
[52] US Class: 
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The invention provides a nucleotide sequence that encodes an HIV-1 gag protein or 

fragment thereof containing a gag epitope and a second HIV antigen or a fragment 

encoding an epitope of said second HIV antigen, operably linked to a heterologous 

promoter. Preferred polynucleotide sequences further encodes nef or a fragment 

thereof and RT or a fragment thereof. 
[52] US Class: 
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The invention provides a nucleotide sequence that encodes an HIV-1 gag protein or 

fragment thereof containing a gag epitope and a second HIV antigen or a fragment 

encoding an epitope of said second HIV antigen, operably linked to a heterologous 

promoter. Preferred polynucleotide sequences further encodes nef or a fragment 

thereof and RT or a fragment thereof.
[52] US Class: 
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The present invention relates to polynucleotides encoding immunogenic HIV 

polypeptides. Uses of the polynucleotides in applications including immunization, 

generation of packaging cell lines, and production of HIV polypeptides are also 

described. Polynucleotides encoding antigenic HIV polypeptides are described, as 

are uses of these polynucleotides and polypeptide products therefrom, including 

formulations of immunogenic compositions and uses thereof.
[52] US Class: 
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The invention describes HIV-1 subtype isolate regulatory/accessory genes, and 

modifications and derivatives thereof. The genes which are described are the tat, 

nef and rev genes. Consensus amino acid sequences are also disclosed. The invention 

also relates to a vaccine including two or more of the nucleotide sequences, and 

nucleotide sequences from the pol and/or gag genes of HIV-1. 
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The invention describes HIV-1 subtype isolate regulatory/accessory genes, and 

modifications and derivatives thereof. The genes which are described are the tat, 

nef and rev genes. Consensus amino acid sequences are also disclosed. The invention 

also relates to a vaccine including two or more of the nucleotide sequences, and 

nucleotide sequences from the pol and/or gag genes of HIV-1.
[52] US Class: 
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[21] Application No.: NA
[22] Filed:  20020726 
[43] Published:  20030213 






Use of a) an HIV Tat protein or polynucleotide; or b) an HIV Nef protein or 

polynucleotide; or c) an HIV Tat protein or polynucleotide linked to an HIV Nef 

protein or polynucleotide; and an HIV gp 120 protein or polynucleotide in the 

manufacture of a vaccine suitable for a prime-boost delivery for the prophylactic 

or therapeutic immunisation of humans against HIV, wherein the protein or 

polynucleotide is delivered via a bombardment approach.
[52] US Class: 
[51] Int’l Class: A61K003921 A61K00317088 A61K000900 C12N001589 A61P003118 
A61P003704 C12N001509 C12N001549 A61K003900 A61K0031711 A61K004800 
C07K001416 A61K004702 A61K003576 A61K003800 
[52] ECLA: A61K003921 C07K001416D C07K001416F C12N001589B K61K003953 

M07K031900
169            © 2008 MicroPatent, LLC
MicroPatent ReportWO2002099101A1
MOLECULAR CLONES WITH MUTATED HIV GAG/POL, SIV 

GAG AND SIV ENV GENES

[71] Applicant: US GOVERNMENT; 

PAVLAKIS GEORGE N
[72] Inventors: PAVLAKIS, George, 

N.
[21] Application No.: NA
[22] Filed:  20020531 
[43] Published:  20021212 






Nucleic acid constructs containing HIV-1 gag/pol and SIV  gag or SIV env genes 

which have been mutated to remove or reduce inhibitory/instability sequences are 

disclosed. Viral particles and host cells containing these constructs and/or viral 

particles are also disclosed. The exemplified constructs and viral particles of the 

invention may be useful in gene therapy for numerous disorders, including HIV 

infection, or as a vaccine for HIV-1 immunotherapy and immunoprophylaxis.
[52] US Class: 
[51] Int’l Class: C07K0014155 A61K00317052 C12N000510 C12N000700 C12N001509 
A61P003704 A61K003921 C12N000121 C12N0015867 C07K001416 A61K004800 
A61P003118 A61K003900 
[52] ECLA: C07K0014155 C07K001416B C12N000700 C12N0015867 K61K003900 

K61K003953 K61K004800 M07K020700 M12N083042 M12N083048 

M12N083050 M12N084010C M12N084020 K61K0039525C M12N074003F
170            © 2008 MicroPatent, LLC
MicroPatent ReportWO2002004493A2
POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C 

POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

[71] Applicant: CHIRON CORP; UNIV 

STELLENBOSCH; ZUR  MEGEDE 

JAN;  BARNETT SUSAN W;  
 . . .
[72] Inventors: ZUR MEGEDE, Jan; 

BARNETT, Susan, W.;  

ENGELBRECHT,  Susan; VAN  
 . . .
[21] Application No.: NA
[22] Filed:  20010705 
[43] Published:  20020117 






The present invention relates to polynucleotides encoding immunogenic HIV type C 

polypeptides. Uses of the polynucleotides in applications including DNA 

immunization, generation of packaging cell lines, and production of HIV Type C 

proteins are also described. 
[52] US Class: 
[51] Int’l Class: C07K001416 A61K003800 A61K003576 C12N000121 C12N000510 
C12N001509 A61P003118 A61K003900 C12N000119 C12N000115 A61K004800 
A61P003112 
[52] ECLA: C07K001416B C07K001416D C07K001416F K61K003900 M07K020700
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MicroPatent ReportWO2002004493A3
POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C 

POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

[71] Applicant: CHIRON CORP; UNIV 

STELLENBOSCH; ZUR  MEGEDE 

JAN;  BARNETT SUSAN W;  
 . . .
[72] Inventors: ZUR MEGEDE, Jan; 

BARNETT, Susan, W.;  

ENGELBRECHT,  Susan; VAN  
 . . .
[21] Application No.: NA
[22] Filed:  20010705 
[43] Published:  20030626 






The present invention relates to polynucleotides encoding immunogenic HIV type C 

polypeptides. Uses of the polynucleotides in applications including DNA 

immunization, generation of packaging cell lines, and production of HIV Type C 

proteins are also described.
[52] US Class: 
[51] Int’l Class: C07K001416 A61K003800 A61K003576 C12N000121 C12N000510 
C12N001509 A61P003118 A61K003900 C12N000119 C12N000115 A61K004800 
A61P003112 
[52] ECLA: C07K001416B C07K001416D C07K001416F K61K003900 M07K020700




[71] Applicant: SMITHKLINE BEECHAM 

BIOLOG; VOSS  GERALD
[72] Inventors: VOSS, Gerald
[21] Application No.: NA
[22] Filed:  20010129 
[43] Published:  20010802 






The invention provides the use of a) an HIV Tat protein or polynucleotide; or b) 

an HIV Nef protein or polynucleotide; or c) an HIV Tat protein or polynucleotide 

linked to an HIV Nef protein or polynucleotide (Nef-Tat); and an HIV gp120 

protein or polynucleotide in the manufacture of a vaccine for the prophylactic or 

therapeutic immunisation of humans against HIV. 
[52] US Class: 
[51] Int’l Class: C12N001549 A61K003912 C12N001509 C07K001416 A61K003939 
A61K004800 A61P003118 A61K003900 
[52] ECLA: C07K001416D C07K001416F K61K003900 K61K003953 

K61K0039555B7 K61K003957 M07K031900
173            © 2008 MicroPatent, LLC
MicroPatent ReportWO2001054719A3




[71] Applicant: SMITHKLINE BEECHAM 

BIOLOG; VOSS  GERALD
[72] Inventors: VOSS, Gerald
[21] Application No.: NA
[22] Filed:  20010129 
[43] Published:  20011220 






The invention provides the use of a) an HIV Tat protein or polynucleotide; or b) 

an HIV Nef protein or polynucleotide; or c) an HIV Tat protein or polynucleotide 

linked to an HIV Nef protein or polynucleotide (Nef-Tat); and an HIV gp120 

protein or polynucleotide in the manufacture of a vaccine for the prophylactic or 

therapeutic immunisation of humans against HIV.
[52] US Class: 
[51] Int’l Class: C12N001549 A61K003912 C12N001509 C07K001416 A61K003939 
A61K004800 A61P003118 A61K003900 
[52] ECLA: C07K001416D C07K001416F K61K003900 K61K003953 

K61K0039555B7 K61K003957 M07K031900
174            © 2008 MicroPatent, LLC
MicroPatent ReportWO2001045748A1
POLYNUCLEOTIDE VACCINES EXPRESSING CODON 

OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL

[71] Applicant: MERCK  CO INC; 

SHIVER JOHN W;  PERRY HELEN 

C;  CASIMIRO DANILO R;  FU 
 . . .
[72] Inventors: SHIVER, John, W.; 

PERRY, Helen, C.;  CASIMIRO, 

Danilo,  R.; FU, Tong-Ming
[21] Application No.: NA
[22] Filed:  20001221 
[43] Published:  20010628 






Pharmaceutical compositions which comprise HIV Pol DNA vaccines are disclosed, 

along with the production and use of these DNA vaccines. The pol-based DNA vaccines 

of the invention are administered directly introduced into living vertebrate tissue,

 preferably humans, and preferably express inactivated versions of the HIV Pol 

protein devoid of protease, reverse transcriptase activity, RNase H activity and 

integrase activity, inducing a cellular immune response which specifically 

recognizes human immunodeficiency virus-1 (HIV-1). The DNA molecules which 

comprise the open reading frame of these DNA vaccines are synthetic DNA molecules 

encoding codon optimized HIV-1 Pol and codon optimized inactive derivatives of 

optimized HIV-1 Pol, including DNA molecules which encode inactive Pol proteins 

which comprise an amino terminal leader peptide.
[52] US Class: 
[51] Int’l Class: A61K004800 A61K003900 C12N001509 A61P003118 C07K001416 
[52] ECLA: C07K001416B K61K0039525C
175            © 2008 MicroPatent, LLC
MicroPatent ReportWO2001082964A1
IMPROVED IMMUNOGENICITY USING A COMBINATION OF 

DNA AND VACCINIA VIRUS VECTOR VACCINES

[71] Applicant: US HEALTH; 

FRANCHINI  GENOVEFFA; HEL  

ZDENEK; PAVLAKIS  GEORGE; 
 . . .
[72] Inventors: FRANCHINI, 

Genoveffa; HEL,  Zdenek; 

PAVLAKIS,  George; TARTAGLIA,
 . . .
[21] Application No.: NA
[22] Filed:  20010430 
[43] Published:  20011108 






This invention relates to improved methods of inducing an immune response for the 

prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in 

conjunction with a recombinant viral vaccine, e.g. , a poxvirus vaccine, to 

potentiate and broaden the immune response. The present invention further provides 

a particularly effective vaccine regimen comprising a DNA vaccine used in 

combination with a poxvirus virus, especially NYVAC or ALVAC.
[52] US Class: 
[51] Int’l Class: A61K003921 A61K003900 C12N001509 A61K0039275 A61K003939 
A61P003118 
[52] ECLA: A61K003921 K61K0039525C K61K003953 K61K0039545
176            © 2008 MicroPatent, LLC
MicroPatent ReportWO2001082962A2
IMMUNIZING AGAINST HIV INFECTION

[71] Applicant: AVENTIS PASTEUR; 

ROVINSKI BENJAMIN;  

TARTAGLIA JAMES;  CAO SHI 
 . . .
[72] Inventors: ROVINSKI, Benjamin;

 TARTAGLIA, James;  CAO, Shi-

Xian;  PERSSON, Roy;  KLEIN, 
 . . .
[21] Application No.: NA
[22] Filed:  20010425 
[43] Published:  20011108 






A virus neutralizing level of antibodies to a primary HIV isolate is generated in a 

host by a prime-boost administration of antigents. The primary antigen is a DNA 

molecule encoding an envelop glycoprotein of a primary isolate of HIV-1 while the 

boosting antigen is either a non-infectious, non-replicating HIV-like particle 

having the envelope glycoprotein of a primary isolate of HIV-1 or an attenuated 

viral vector expressing an envelope glycoprotein of a primary isolate of HIV-1. 
[52] US Class: 
[51] Int’l Class: C07K001416 A61P003118 A61K003921 
[52] ECLA: A61K003921 C07K001416D K61K0039555A M07K022120
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IMMUNIZING AGAINST HIV INFECTION

[71] Applicant: AVENTIS PASTEUR; 

ROVINSKI BENJAMIN;  

TARTAGLIA JAMES;  CAO SHI 
 . . .
[72] Inventors: ROVINSKI, Benjamin;

 TARTAGLIA, James;  CAO, Shi-

Xian;  PERSSON, Roy;  KLEIN, 
 . . .
[21] Application No.: NA
[22] Filed:  20010425 
[43] Published:  20020321 






A virus neutralizing level of antibodies to a primary HIV isolate is generated in a 

host by a prime-boost administration of antigents. The primary antigen is a DNA 

molecule encoding an envelop glycoprotein of a primary isolate of HIV-1 while the 

boosting antigen is either a non-infectious, non-replicating HIV-like particle 

having the envelope glycoprotein of a primary isolate of HIV-1 or an attenuated 

viral vector expressing an envelope glycoprotein of a primary isolate of HIV-1.
[52] US Class: 
[51] Int’l Class: C07K001416 A61P003118 A61K003921 
[52] ECLA: A61K003921 C07K001416D K61K0039555A M07K022120
178            © 2008 MicroPatent, LLC
MicroPatent ReportWO2001046408A2
MOLECULAR CLONES WITH MUTATED HIV GAG/POL, SIV 

GAG AND SIV ENV GENES

[71] Applicant: US HEALTH; 

PAVLAKIS GEORGE N
[72] Inventors: PAVLAKIS, George, 

N.
[21] Application No.: NA
[22] Filed:  20001222 
[43] Published:  20010628 





Nucleic acid constructs containing HIV-1 GAG/POL and SIV gag or SIV env genes which 

have been mutated to remove or reduce inhibitory/instability sequences are 

disclosed. Viral particles and host cells containing these constructs and/or viral 

particles are also disclosed. The exemplified constructs and viral particles of the 

invention may be useful in gene therapy for numberous disorders, including HIV 

infection, or as a vaccine for HIV-1 immunotherapy and immunoprophylaxis. 
[52] US Class: 
[51] Int’l Class: C07K001416 A61K003900 A61K00317088 C12N0015867 C12N000121 
C12N000510 C12N001509 C12N000700 C07K0014155 A61K003921 C12N000119 
C12N000522 C12N000115 A61P003118 A61K004800 
[52] ECLA: A61K003921 C07K0014155 C07K001416B C12N000700 C12N0015867 

K61K003900 K61K003953 K61K004800 M07K020700 M12N074003F
179            © 2008 MicroPatent, LLC
MicroPatent ReportWO2001046408A3
MOLECULAR CLONES WITH MUTATED HIV GAG/POL, SIV 

GAG AND SIV ENV GENES

[71] Applicant: US HEALTH; 

PAVLAKIS GEORGE N
[72] Inventors: PAVLAKIS, George, 

N.
[21] Application No.: NA
[22] Filed:  20001222 
[43] Published:  20011213 





Nucleic acid constructs containing HIV-1 GAG/POL and SIV gag or SIV env genes which 

have been mutated to remove or reduce inhibitory/instability sequences are 

disclosed. Viral particles and host cells containing these constructs and/or viral 

particles are also disclosed. The exemplified constructs and viral particles of the 

invention may be useful in gene therapy for numberous disorders, including HIV 

infection, or as a vaccine for HIV-1 immunotherapy and immunoprophylaxis.
[52] US Class: 
[51] Int’l Class: C07K001416 A61K003900 A61K00317088 C12N0015867 C12N000121 
C12N000510 C12N001509 C12N000700 C07K0014155 A61K003921 C12N000119 
C12N000522 C12N000115 A61P003118 A61K004800 
[52] ECLA: A61K003921 C07K0014155 C07K001416B C12N000700 C12N0015867 

K61K003900 K61K003953 K61K004800 M07K020700 M12N074003F
180            © 2008 MicroPatent, LLC
MicroPatent ReportWO2001046408A9
MOLECULAR CLONES WITH MUTATED HIV GAG/POL, SIV 

GAG AND SIV ENV GENES

[71] Applicant: US GOVERNMENT; 

PAVLAKIS GEORGE N
[72] Inventors: PAVLAKIS GEORGE N
[21] Application No.: NA
[22] Filed:  20001222 
[43] Published:  20021107 





Nucleic acid constructs containing HIV-1    GAG/POL     and SIV    gag     or SIV   

 env     genes which have been mutated to remove or reduce inhibitory/instability 

sequences are disclosed. Viral particles and host cells containing these constructs 

and/or viral particles are also disclosed. The exemplified constructs and viral 

particles of the invention may be useful in gene therapy for numberous disorders, 

including HIV infection, or as a vaccine for HIV-1 immunotherapy and 

immunoprophylaxis.
[52] US Class: 
[51] Int’l Class: C07K001416 A61K003900 A61K00317088 C12N0015867 C12N000121 
C12N000510 C12N001509 C12N000700 C07K0014155 A61K003921 C12N000119 
C12N000522 C12N000115 A61P003118 A61K004800 
[52] ECLA: A61K003921 C07K0014155 C07K001416B C12N000700 C12N0015867 

K61K003900 K61K003953 K61K004800 M07K020700 M12N074003F
181            © 2008 MicroPatent, LLC
MicroPatent ReportWO2001043693A2
POLYNUCLEOTIDE VACCINES EXPRESSING CODON 

OPTIMIZED HIV-1 NEF AND MODIFIED HIV-1 NEF

[71] Applicant: MERCK  CO INC; 

SHIVER JOHN W;  LIANG 

XIAOPING; FU  TONG MING
[72] Inventors: SHIVER, John, W.; 

LIANG, Xiaoping;  FU, Tong-

Ming
[21] Application No.: NA
[22] Filed:  20001215 
[43] Published:  20010621 





Pharmaceutical compositions which comprise HIV Nef DNA vaccines are disclosed, 

along with the production and use of these DNA vaccines. The nef-based DNA vaccines 

of the invention are administered directly introduced into living vertebrate tissue,

 preferably humans, and express the HIV Nef protein or biologically relevant 

portions thereof, inducing a cellular immune response which specifically recognizes 

human immunodeficiency virus-1 (HIV-1). The DNA molecules which comprise the open 

reading frame of these DNA vaccines are synthetic DNA molecules encoding codon 

optimized HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef 

modifications comprising amino terminal leader peptides, removal of the amino 

terminal myristylation site, and/or modification of the Nef dileucine motif. These 

modifications may effect wild type characteristics of Nef, such as myristylation 

and down regulation of host CD4. 
[52] US Class: 
[51] Int’l Class: A61K003939 A61K003900 C12N001509 A61P003118 C07K001416 
[52] ECLA: C07K001416F K61K003953 K61K0039555B K61K003957
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POLYNUCLEOTIDE VACCINES EXPRESSING CODON 

OPTIMIZED HIV-1 NEF AND MODIFIED HIV-1 NEF

[71] Applicant: MERCK  CO INC; 

SHIVER JOHN W;  LIANG 

XIAOPING; FU  TONG MING
[72] Inventors: SHIVER, John, W.; 

LIANG, Xiaoping;  FU, Tong-

Ming
[21] Application No.: NA
[22] Filed:  20001215 
[43] Published:  20020221 





Pharmaceutical compositions which comprise HIV Nef DNA vaccines are disclosed, 

along with the production and use of these DNA vaccines. The nef-based DNA vaccines 

of the invention are administered directly introduced into living vertebrate tissue,

 preferably humans, and express the HIV Nef protein or biologically relevant 

portions thereof, inducing a cellular immune response which specifically recognizes 

human immunodeficiency virus-1 (HIV-1). The DNA molecules which comprise the open 

reading frame of these DNA vaccines are synthetic DNA molecules encoding codon 

optimized HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef 

modifications comprising amino terminal leader peptides, removal of the amino 

terminal myristylation site, and/or modification of the Nef dileucine motif. These 

modifications may effect wild type characteristics of Nef, such as myristylation 

and down regulation of host CD4.
[52] US Class: 
[51] Int’l Class: A61K003939 A61K003900 C12N001509 A61P003118 C07K001416 
[52] ECLA: C07K001416F K61K003953 K61K0039555B K61K003957
183            © 2008 MicroPatent, LLC
MicroPatent ReportWO2001026608A2




[71] Applicant: LEDBETTER JEFFREY 

A; HAYDEN  LEDBETTER MARTHA S
[72] Inventors: HAYDEN-LEDBETTER, 

Martha, S.;  LEDBETTER, 

Jeffrey,  A.
[21] Application No.: NA
[22] Filed:  20001013 
[43] Published:  20010419 





Vaccines that target one or more antigens to a cell surface receptor improve the 

antigen-specific humoral and cellular immune response. Antigen(s) linked to a 

domain that binds to a cell surface receptor are internalized, carrying antigen(s)

 into an intracellular compartment where the antigen(s) are digested into 

peptides and loaded onto MHC molecules. T cells specific for the peptide antigens 

are activated, leading to an enhanced immune response. The vaccine may comprise 

antigen(s) linked to a domain that binds at least one receptor or a DNA plasmid 

encoding antigen(s) linked to a domain that binds at least one receptor. A 

preferred embodiment of the invention targets HIV-1 env antigen to the CD40 

receptor, resulting in delivery of antigen to CD40 positive cells, and selective 

activation of the CD40 receptor on cells presenting HIV-1 env antigens to T cells. 
[52] US Class: 
[51] Int’l Class: C12P002104 A61K0039385 A61K003921 C12N001552 C07K001416 
C07K001646 C07K001900 A61K003900 
[52] ECLA: A61K003921 C07K001416D K61K003953 K61K003957 K61K003960P 

M07K020700 M07K031900
184            © 2008 MicroPatent, LLC
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[71] Applicant: LEDBETTER JEFFREY 

A; HAYDEN  LEDBETTER MARTHA S
[72] Inventors: LEDBETTER, Jeffrey,

 A.; HAYDEN- LEDBETTER, 

Martha,  S.
[21] Application No.: NA
[22] Filed:  20001013 
[43] Published:  20011018 





Vaccines that target one or more antigens to a cell surface receptor improve the 

antigen-specific humoral and cellular immune response. Antigen(s) linked to a 

domain that binds to a cell surface receptor are internalized, carrying antigen(s)

 into an intracellular compartment where the antigen(s) are digested into 

peptides and loaded onto MHC molecules. T cells specific for the peptide antigens 

are activated, leading to an enhanced immune response. The vaccine may comprise 

antigen(s) linked to a domain that binds at least one receptor or a DNA plasmid 

encoding antigen(s) linked to a domain that binds at least one receptor. A 

preferred embodiment of the invention targets HIV-1 env antigen to the CD40 

receptor, resulting in delivery of antigen to CD40 positive cells, and selective 

activation of the CD40 receptor on cells presenting HIV-1 env antigens to T cells.
[52] US Class: 
[51] Int’l Class: C12P002104 A61K0039385 A61K003921 C12N001552 C07K001416 
C07K001646 C07K001900 A61K003900 
[52] ECLA: A61K003921 C07K001416D K61K003953 K61K003957 K61K003960P 

M07K020700 M07K031900
185            © 2008 MicroPatent, LLC
MicroPatent ReportWO2001000648A1




[71] Applicant: PROGENICS PHARM 

INC; AARON DIAMOND  AIDS RES 

CT
[72] Inventors: BINLEY, James, M.; 

SCHUELKE, Norbert;  OLSON, 

William, C.;  MADDON, Paul, 
 . . .
[21] Application No.: NA
[22] Filed:  20000623 
[43] Published:  20010104 






This invention provides an isolated nucleic acid which comprises a nucleotide 

segment having a sequence encoding a viral envelope protein comprising a viral 

surface protein and a corresponding viral transmembrane protein wherein the viral 

envelope protein contains one or more mutations in amino acid sequence that enhance 

the stability of the complex formed between the viral surface protein and 

transmembrane protein. This invention also provide a viral envelope protein 

comprising a viral surface protein and a corresponding viral transmembrane protein 

wherein the viral envelope protein contains one or more mutations in amino acid 

sequence that enhance the stability of the complex formed between the viral surface 

protein and transmembrane protein. This invention further provides methods of 

treating HIV-1 infection.
[52] US Class: 
[51] Int’l Class: C07K001610 A61K0031711 C12P002108 C12N000119 C12N000121 
C12N001509 C12N000700 C07K001416 A61K0039395 C12N000115 C12N000510 
C07K001900 A61K004500 A61P003118 A61K003900 
[52] ECLA: C07K001610K1D K61K003900 K61K003953 M07K020302
186            © 2008 MicroPatent, LLC
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STABILIZED SOLUBLE GLYCOPROTEIN TRIMERS

[71] Applicant: DANA FARBER CANCER 

INST INC; UNIV  COLUMBIA; 

SODROSKI  JOSEPH G; WYATT  
 . . .
[72] Inventors: SODROSKI, Joseph, 

G.; WYATT, Richard;  YANG, 

Xinzhen;  FARZAN, Michael;  
 . . .
[21] Application No.: NA
[22] Filed:  20000918 
[43] Published:  20010322 






The present application is directed to stabilize HIV envelope glycoprotein trimers. 

The trimers are stabilized by introducing trimeric motifs, preferably the GCN4 

coiled coil or the fibritin trimeric domain, at certain sites, for example in the 

gp41 ectodomain. These stabilized trimers or DNA molecules encoding such trimers 

can be used to generate an immunogenic reaction. The trimers can also be used in 

assays to screen for molecules that interact with them - and to identify molecules 

that interact with specific sites. 
[52] US Class: 
[51] Int’l Class: C07K001416 C07K001401 C07K001447 A61K003900 
[52] ECLA: C07K001401 C07K001416D C07K001447A1B K61K003900 K61K003964 

M07K020300 M07K020700 M07K031935 M07K031973
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[71] Applicant: DANA FARBER CANCER 

INST INC; UNIV  COLUMBIA; 

SODROSKI  JOSEPH G; WYATT  
 . . .
[72] Inventors: SODROSKI, Joseph, 

G.; WYATT, Richard;  YANG, 

Xinzhen;  FARZAN, Michael;  
 . . .
[21] Application No.: NA
[22] Filed:  20000918 
[43] Published:  20011108 






The present application is directed to stabilize HIV envelope glycoprotein trimers. 

The trimers are stabilized by introducing trimeric motifs, preferably the GCN4 

coiled coil or the fibritin trimeric domain, at certain sites, for example in the 

gp41 ectodomain. These stabilized trimers or DNA molecules encoding such trimers 

can be used to generate an immunogenic reaction. The trimers can also be used in 

assays to screen for molecules that interact with them-and to identify molecules 

that interact with specific sites.
[52] US Class: 
[51] Int’l Class: C07K001416 C07K001401 C07K001447 A61K003900 
[52] ECLA: C07K001401 C07K001416D C07K001447A1B K61K003900 K61K003964 

M07K020300 M07K020700 M07K031935 M07K031973
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[71] Applicant: DANA FARBER CANCER 
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[72] Inventors: SODROSKI JOSEPH G; 

WYATT RICHARD;  YANG XINZHEN;
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[21] Application No.: NA
[22] Filed:  20000918 
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The present application is directed to stabilize HIV envelope glycoprotein trimers. 

The trimers are stabilized by introducing trimeric motifs, preferably the GCN4 

coiled coil or the fibritin trimeric domain, at certain sites, for example in the 

gp41 ectodomain. These stabilized trimers or DNA molecules encoding such trimers 

can be used to generate an immunogenic reaction. The trimers can also be used in 

assays to screen for molecules that interact with them - and to identify molecules 

that interact with specific sites.
[52] US Class: 
[51] Int’l Class: C07K001416 C07K001401 C07K001447 A61K003900 
[52] ECLA: C07K001401 C07K001416D C07K001447A1B K61K003900 K61K003964 

M07K020300 M07K020700 M07K031935 M07K031973
189            © 2008 MicroPatent, LLC
MicroPatent ReportWO2001002607A1
ADENOVIRUS CARRYING GAG GENE HIV VACCINE

[71] Applicant: MERCK  CO INC; 

CHEN LING; SHIVER  JOHN; 

BETT ANDREW  J; CASIMIRO 
 . . .
[72] Inventors: CHEN, Ling; SHIVER,

 John; BETT,  Andrew, J.;  

CASIMIRO, Danilo,  Riguera; 
 . . .
[21] Application No.: NA
[22] Filed:  20000703 
[43] Published:  20010111 





An adenoviral vector is described which carries a codon-optimized gag gene, along 

with a heterologous promoter and transcription terminator. This viral vaccine can 

effectively prevent HIV infection when administered to humans either alone or as 

part of a prime and boost regime also with a vaccine plasmid.
[52] US Class: 
[51] Int’l Class: C12N0015861 A61K003921 A61K003576 C12N001509 C12N000510 
A61K004800 C12Q000170 C12P002104 A61P003118 C07K001416 
[52] ECLA: C07K001416B C12N0015861 C12Q000170B2B K61K0039525C 

K61K003953 M07K022104
190            © 2008 MicroPatent, LLC
MicroPatent ReportWO2000071561A1




[71] Applicant: UNIV PENNSYLVANIA
[72] Inventors: HOFFMAN, Trevor, L.
[21] Application No.: NA
[22] Filed:  20000516 
[43] Published:  20001130 






The invention relates to novel CD4-independent HIV Envelope proteins and uses 

therefor.
[52] US Class: 
[51] Int’l Class: C12N001548 A61P003118 G01N0033569 C12N000701 A61K003800 
A61K003152 C12N001500 C12N000700 G01N003368 G01N003315 C12N001533 
C12N000502 C12N001574 C12N000115 C12N000119 C12N001563 G01N003350 
C12N001570 C12N000500 A61K004800 A61K003821 C07K001416 C12N000121 
C12N000510 C07H002102 A61K003921 C12N001509 A61K004500 
[52] ECLA: C07K001416D C12N000700 M12N074003F
191            © 2008 MicroPatent, LLC
MicroPatent ReportWO2000071561A9




[71] Applicant: TRUSTEES OF THE 

UNIVERSITY OF
[72] Inventors: HOXIE JAMES A; 

LABRANCHE CELIA C;  DOMS 

ROBERT W;  HOFFMAN TREVOR L
[21] Application No.: NA
[22] Filed:  20000516 
[43] Published:  20020627 






The invention relates to novel CD4-independent HIV Envelope proteins and uses 

therefor.
[52] US Class: 
[51] Int’l Class: C12N001548 A61P003118 G01N0033569 C12N000701 A61K003800 
A61K003152 C12N001500 C12N000700 G01N003368 G01N003315 C12N001533 
C12N000502 C12N001574 C12N000115 C12N000119 C12N001563 G01N003350 
C12N001570 C12N000500 A61K004800 A61K003821 C07K001416 C12N000121 
C12N000510 C07H002102 A61K003921 C12N001509 A61K004500 
[52] ECLA: C07K001416D C12N000700 M12N074003F
192            © 2008 MicroPatent, LLC
MicroPatent ReportWO2000039303A2
MODIFIED HIV ENV POLYPEPTIDES

[71] Applicant: CHIRON CORP
[72] Inventors: BARNETT, Susan; 

HARTOG, Karin;  MARTIN, Eric
[21] Application No.: NA
[22] Filed:  19991230 
[43] Published:  20000706 






Polynucleotide encoding modified HIV Env polypeptides are disclosed. The Env 

polypeptides are modified so as to expose at least part of the CD4 binding region. 

Methods of diagnosis, treatment and prevention using the polynucleotides and 

polypeptides are also provided.
[52] US Class: 
[51] Int’l Class: C07K0014155 A61K003912 C12N000704 C12N001549 C12N001509 
A61P003702 A61K003942 C07K001418 C12N0015867 C07K001416 A61K004800 
A61P003118 A61K003900 
[52] ECLA: C07K001416B C07K001416D C07K001416F C07K001418F4 

C12N000704A C12N0015867P K61K003900 K61K0039515C 

K61K0039525C K61K0039525D K61K003953 K61K003954 K61K004800 

M07K020300 M07K020700 M07K021500
193            © 2008 MicroPatent, LLC
MicroPatent ReportWO2000039303A3
MODIFIED HIV ENV POLYPEPTIDES

[71] Applicant: CHIRON CORP
[72] Inventors: BARNETT SUSAN; 

HARTOG KARIN;  MARTIN ERIC
[21] Application No.: NA
[22] Filed:  19991230 
[43] Published:  20000921 






Polynucleotide encoding modified HIV Env polypeptides are disclosed. The Env 

polypeptides are modified so as to expose at least part of the CD4 binding region. 

Methods of diagnosis, treatment and prevention using the polynucleotides and 

polypeptides are also provided.
[52] US Class: 
[51] Int’l Class: C07K0014155 A61K003912 C12N000704 C12N001549 C12N001509 
A61P003702 A61K003942 C07K001418 C12N0015867 C07K001416 A61K004800 
A61P003118 A61K003900 
[52] ECLA: C07K001416B C07K001416D C07K001416F C07K001418F4 

C12N000704A C12N0015867P K61K003900 K61K0039515C 

K61K0039525C K61K0039525D K61K003953 K61K003954 K61K004800 

M07K020300 M07K020700 M07K021500




[71] Applicant: STRATHMANN AG  CO;

 SCHREIBER MICHAEL
[72] Inventors: SCHREIBER, Michael
[21] Application No.: NA
[22] Filed:  19991203 
[43] Published:  20000817 





The invention relates to a pharmaceutical composition or vaccine containing a 

mixture of viral protein molecules which are sequence variants of a single viral 

protein or of part of such a protein. The invention also relates to a DNA vaccine 

coding for a mixture of structurally different virus proteins. Said vaccine 

contains a mixture of sequence variants of a viral DNA molecule or of a part 

thereof which code for sequence variants of a viral protein or of a part thereof. 

According to a preferred embodiment of the invention the viral proteins are 

sequence variants of the GP120 protein of the human immunodeficiency virus (HIV) 

which differ from each other in terms of the amino acid sequence in the area of the 

V2-loop and/or the V3-loop, preferably both the V2-and V3-loop. The invention also 

relates to the production of said viral vaccines, including the related 

intermediate stages and constructs, as well as to their methods of production and 

their uses.
[52] US Class: 
[51] Int’l Class: A61P003112 A61K003800 A61K003576 C12P002102 C07K001416 
C12N000510 C12N001509 C12N001549 A61K004800 A61K003900 C07K0014155 
C12N001534 A61P003118 A61K003912 A61K003921 
[52] ECLA: C07K001416D A61K003921 K61K0039505 K61K003953 M07K020700




[71] Applicant: STRATHMANN AG  CO;

 SCHREIBER MICHAEL
[72] Inventors: SCHREIBER MICHAEL
[21] Application No.: NA
[22] Filed:  19991203 
[43] Published:  20001116 





The invention relates to a pharmaceutical composition or vaccine containing a 

mixture of viral protein molecules which are sequence variants of a single viral 

protein or of part of such a protein. The invention also relates to a DNA vaccine 

coding for a mixture of structurally different virus proteins. Said vaccine 

contains a mixture of sequence variants of a viral DNA molecule or of a part 

thereof which code for sequence variants of a viral protein or of a part thereof. 

According to a preferred embodiment of the invention the viral proteins are 

sequence variants of the GP120 protein of the human immunodeficiency virus (HIV) 

which differ from each other in terms of the amino acid sequence in the area of the 

V2-loop and/or the V3-loop, preferably both the V2- and V3-loop. The invention also 

relates to the production of said viral vaccines, including the related 

intermediate stages and constructs, as well as to their methods of production and 

their uses.
[52] US Class: 
[51] Int’l Class: A61P003112 A61K003800 A61K003576 C12P002102 C07K001416 
C12N000510 C12N001509 C12N001549 A61K004800 A61K003900 C07K0014155 
C12N001534 A61P003118 A61K003912 A61K003921 
[52] ECLA: C07K001416D A61K003921 K61K0039505 K61K003953 M07K020700
196            © 2008 MicroPatent, LLC
MicroPatent ReportWO2000034494A1
A RECOMBINANT VECTOR EXPRESSING MULTIPLE 

COSTIMULATORY MOLECULES AND USES THEREOF

[71] Applicant: US HEALTH; THERION 

BIOLOG CORP;  SCHLOM JEFFREY;

  HODGE JAMES;  PANICALI 
 . . .
[72] Inventors: SCHLOM, Jeffrey; 

HODGE, James;  PANICALI, 

Dennis
[21] Application No.: NA
[22] Filed:  19991112 
[43] Published:  20000615 





The present invention is a recombinant vector encoding and expressing at least 

three or more costimulatory molecules. The recombinant vector may additionally 

contain a gene encoding one or more target antigens or immunological epitope 

thereof. The synergistic effect of these costimulatory molecules on the enhanced 

activation of T cells is demonstrated. The degree of T-cell activation using 

recombinant vectors containing genes encoding three costimulatory molecules was far 

greater than the sum of recombinant vector constructs containing one costimulatory 

molecule and greater than the use of two costimulatory molecules. Results employing 

the triple costimulatory vectors were most dramatic under conditions of either low 

levels of first signal or low stimulator to T-cell ratios. This phenomenon was 

observed with both isolated CD4+ and CD8+ T cells. The recombinant vectors of 

the present invention are useful as immunogenes and vaccines against cancer and 

pathogenic micro-organisms, and in providing host cells, including dendritic cells 

and splenocytes with enhanced antigen-presenting functions.
[52] US Class: 
[51] Int’l Class: C07K0014705 A61K0039125 C12N000700 A61P003112 A61K003574 
A61K003512 A61P003500 A61P003110 C12N001502 C12N000510 C12N0015863 
A61P003706 A61P000104 C12N000121 A61K0039245 A61K0039275 C12N000115 
G01N003353 C12N000119 A61K004800 C12Q000102 A61K003912 A61K003576 
A61K0039235 A61K003929 A61P003104 A61K003921 A61K003800 A61P003702 
A61K003900 
[52] ECLA: C07K0014705B C07K0014705B20 C07K0014705B22 C07K0014705B24 

C12N0015863 K61K003512 K61K003900 K61K003957 K61K004800 

M07K020700 M07K022100 197            © 2008 MicroPatent, LLC
MicroPatent ReportWO2000039304A2
POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C 

POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

[71] Applicant: CHIRON CORP
[72] Inventors: BARNETT, Susan; 

ZUR MEGEDE, Jan
[21] Application No.: NA
[22] Filed:  19991230 
[43] Published:  20000706 






The present invention relates to polynucleotides encoding immunogenic HIV type C 

Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in 

applications including DNA immunization, generation of packaging cell lines, and 

production of Gag- and/or Env-containing proteins are also described. 
[52] US Class: 
[51] Int’l Class: A61P003118 A61K003576 A61K0009127 C12N0015867 C07K001418 
C12N000510 C12N001509 C12N001549 A61K004800 A61K003800 C07K001416 
C12N000704 C12P002102 A61P003702 A61K003939 A61K003900 
[52] ECLA: C07K001416B C07K001416D C07K001416F C07K001418F4 

C12N000704A C12N0015867P K61K003900 K61K0039515C 

K61K0039525C K61K0039525D K61K003953 K61K003954 K61K004800 

M07K020300 M07K020700 M07K021500 M12N080010E M12N084020A
198            © 2008 MicroPatent, LLC
MicroPatent ReportWO2000039304A3
POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C 

POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

[71] Applicant: CHIRON CORP
[72] Inventors: BARNETT, Susan; 

ZUR MEGEDE, Jan
[21] Application No.: NA
[22] Filed:  19991230 
[43] Published:  20010118 






The present invention relates to polynucleotides encoding immunogenic HIV type C 

Gag-and/or Env-containing polypeptides. Uses of the polynucleotides in applications 

including DNA immunization, generation of packaging cell lines, and production of 

Gag-and/or Env-containing proteins are also described.
[52] US Class: 
[51] Int’l Class: A61P003118 A61K003576 A61K0009127 C12N0015867 C07K001418 
C12N000510 C12N001509 C12N001549 A61K004800 A61K003800 C07K001416 
C12N000704 C12P002102 A61P003702 A61K003939 A61K003900 
[52] ECLA: C07K001416B C07K001416D C07K001416F C07K001418F4 

C12N000704A C12N0015867P K61K003900 K61K0039515C 

K61K0039525C K61K0039525D K61K003953 K61K003954 K61K004800 

M07K020300 M07K020700 M07K021500 M12N080010E M12N084020A
199            © 2008 MicroPatent, LLC
MicroPatent ReportWO2000039304A9
POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C 

POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

[71] Applicant: CHIRON CORP
[72] Inventors: BARNETT SUSAN; ZUR 

MEGEDE JAN
[21] Application No.: NA
[22] Filed:  19991230 
[43] Published:  20001207 






The present invention relates to polynucleotides encoding immunogenic HIV type C 

Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in 

applications including DNA immunization, generation of packaging cell lines, and 

production of Gag- and/or Env-containing proteins are also described.
[52] US Class: 
[51] Int’l Class: A61P003118 A61K003576 A61K0009127 C12N0015867 C07K001418 
C12N000510 C12N001509 C12N001549 A61K004800 A61K003800 C07K001416 
C12N000704 C12P002102 A61P003702 A61K003939 A61K003900 
[52] ECLA: C07K001416B C07K001416D C07K001416F C07K001418F4 

C12N000704A C12N0015867P K61K003900 K61K0039515C 

K61K0039525C K61K0039525D K61K003953 K61K003954 K61K004800 

M07K020300 M07K020700 M07K021500 M12N080010E M12N084020A
200            © 2008 MicroPatent, LLC
MicroPatent ReportWO2000029561A2
METHOD FOR PRODUCING A NUCLEOTIDE CONSTRUCT WITH 

OPTIMISED CODONS FOR AN HIV GENETIC VACCINE 

BASED ON A PRIMARY, EARLY HIV ISOLATE AND 

[71] Applicant: STATENS 

SERUMINSTITUT;  FOMSGAARD 

ANDERS
[72] Inventors: FOMSGAARD, Anders
[21] Application No.: NA
[22] Filed:  20000327 
[43] Published:  20000525 





The present invention relates to a method for producing a nucleotide sequence 

construct with optimized codons for an HIV genetic vaccine based on a primary, 

early HIV isolate. Specific such nucleotide sequence construct are the synthetic 

envelope BX08 constructs. The invention further relates to the medical use of such 

constructs for the treatment and prophylaxis of HIV through DNA vaccine and for 

diagnostics. 
[52] US Class: 
[51] Int’l Class: C12N001549 C07K001416 
[52] ECLA: C07K001416D K61K0039525 M07K020500 M07K020700
201            © 2008 MicroPatent, LLC
MicroPatent ReportWO2000029561A3
NUCLEOTIDE CONSTRUCT WITH OPTIMISED CODONS FOR 

AN HIV GENETIC VACCINE BASED ON A PRIMARY, EARLY 

HIV ISOLATE AND SYNTHETIC ENVELOPE

[71] Applicant: STATENS 

SERUMINSTITUT;  FOMSGAARD 

ANDERS
[72] Inventors: FOMSGAARD, Anders
[21] Application No.: NA
[22] Filed:  20000327 
[43] Published:  20000817 





The present invention relates to a method for producing a nucleotide sequence 

construct with optimized codons for an HIV genetic vaccine based on a primary, 

early HIV isolate. Specific such nucleotide sequence construct are the synthetic 

envelope BX08 constructs. The invention further relates to the medical use of such 

constructs for the treatment and prophylaxis of HIV through DNA vaccine and for 

diagnostics.
[52] US Class: 
[51] Int’l Class: C12N001549 C07K001416 
[52] ECLA: C07K001416D K61K0039525 M07K020500 M07K020700
202            © 2008 MicroPatent, LLC
MicroPatent ReportWO2000029561A8
METHOD FOR PRODUCING A NUCLEOTIDE SEQUENCE 

CONSTRUCT WITH OPTIMISED CODONS FOR AN HIV 

GENETIC VACCINE BASED ON A PRIMARY, EARLY HIV 

[71] Applicant: STATENS 

SERUMINSTITUT;  FOMSGAARD 

ANDERS
[72] Inventors: FOMSGAARD ANDERS
[21] Application No.: NA
[22] Filed:  20000327 
[43] Published:  20000817 





The present invention relates to a method for producing a nucleotide sequence 

construct with optimized codons for an HIV genetic vaccine based on a primary, 

early HIV isolate. Specific such nucleotide sequence construct are the synthetic 

envelope BX08 constructs. The invention further relates to the medical use of such 

constructs for the treatment and prophylaxis of HIV through DNA vaccine and for 

diagnostics.
[52] US Class: 
[51] Int’l Class: C12N001549 C07K001416 
[52] ECLA: C07K001416D K61K0039525 M07K020500 M07K020700




[71] Applicant: MERCK  CO INC; 

VOLKIN DAVID B;  EVANS 

ROBERT K;  ULMER JEFFREY B;  
 . . .
[72] Inventors: VOLKIN, David, B.; 

EVANS, Robert, K.;  ULMER, 

Jeffrey, B.;  CAULFIELD,  
 . . .
[21] Application No.: NA
[22] Filed:  19990708 
[43] Published:  20000120 






The present invention relates to a novel vaccine formulation comprising nucleic 

acid molecules and a mineral-based adjuvant provided in a biologically effective 

concentration so as to improve induction of an immune response subsequent to 

vaccination which correlates to expression of one or more specific antigens encoded 

by the nucleic acid molecule.
[52] US Class: 
[51] Int’l Class: A61K003921 A61K0039145 A61K004800 A61K0039245 A61K003929 
A61K003939 
[52] ECLA: A61K0039145 A61K003921 A61K0039245 A61K003929B A61K003939 

K61K003953 K61K0039555A
204            © 2008 MicroPatent, LLC
MicroPatent ReportWO1999027958A2
HIV-1 TAT, OR DERIVATIVES THEREOF FOR 

PROPHYLACTIC AND THERAPEUTIC VACCINATION

[71] Applicant: IST SUPERIORE 

SANITA; ENSOLI  BARBARA
[72] Inventors: ENSOLI, Barbara
[21] Application No.: NA
[22] Filed:  19981130 
[43] Published:  19990610 






The present invention refers to Tat as the active principale for a prophylactic 

and/or therapeutic vaccine against HIV infection, the progression towards AIDS and 

the development of tumors and other syndromes and symptoms in subjects infected by 

HIV. Tat is in biologically active form either as recombinant protein or peptide or 

as DNA. More particularly, the invention refers to a vaccine based on HIV-1 Tat as 

immunogen, inoculated as DNA and/or recombinant protein or as peptides, alone or in 

combination with other genes or viral gene products (Nef, Rev, Gag) or parts 

thereof, or in combination with various immuno modulant cytokines (IL-12, IL-15) 

or with the gene coding for an immuno modulant cytokine or part thereof. Tat, Nef, 

Rev, Gag and the immuno modulant cytokines are administrated both as a mixture of 

recombinant proteins, peptides or fusion proteins (Tat/Nef, Tat/Rev, Tat/Gag, 

Tat/IL-12, Tat/IL-15) or as plasmid DNA.
[52] US Class: 
[51] Int’l Class: A61P003704 A61K003900 A61K003800 C12Q000168 C12N000510 
C12N001549 C12N001509 C12P002108 A61P003500 A61K003921 C07K001416 
C12P002102 C07K000708 A61K004800 A61P003118 C12R000191 
[52] ECLA: A61K003921 C07K001416F K61K003800 K61K003900 K61K0039525 

M07K020700 M12N022100
205            © 2008 MicroPatent, LLC
MicroPatent ReportWO1999027958A3
HIV-1 TAT, OR DERIVATIVES THEREOF FOR 

PROPHYLACTIC AND THERAPEUTIC VACCINATION

[71] Applicant: IST SUPERIORE 

SANITA; ENSOLI  BARBARA
[72] Inventors: ENSOLI BARBARA
[21] Application No.: NA
[22] Filed:  19981130 
[43] Published:  19990722 






The present invention refers to Tat as the active principale for a prophylactic 

and/or therapeutic vaccine against HIV infection, the progression towards AIDS and 

the development of tumors and other syndromes and symptoms in subjects infected by 

HIV. Tat is in biologically active form either as recombinant protein or peptide or 

as DNA. More particularly, the invention refers to a vaccine based on HIV-1 Tat as 

immunogen, inoculated as DNA and/or recombinant protein or as peptides, alone or in 

combination with other genes or viral gene products (Nef, Rev, Gag) or parts 

thereof, or in combination with various immuno modulant cytokines (IL-12, IL-15) 

or with the gene coding for an immuno modulant cytokine or part thereof. Tat, Nef, 

Rev, Gag and the immuno modulant cytokines are administrated both as a mixture of 

recombinant proteins, peptides or fusion proteins (Tat/Nef, Tat/Rev, Tat/Gag, 

Tat/IL-12, Tat/IL-15) or as plasmid DNA.
[52] US Class: 
[51] Int’l Class: A61P003704 A61K003900 A61K003800 C12Q000168 C12N000510 
C12N001549 C12N001509 C12P002108 A61P003500 A61K003921 C07K001416 
C12P002102 C07K000708 A61K004800 A61P003118 C12R000191 
[52] ECLA: A61K003921 C07K001416F K61K003800 K61K003900 K61K0039525 

M07K020700 M12N022100
206            © 2008 MicroPatent, LLC
MicroPatent ReportWO1999027958A9
HIV-1 TAT, OR DERIVATIVES THEREOF FOR 

PROPHYLACTIC AND THERAPEUTIC VACCINATION

[71] Applicant: IST SUPERIORE 

SANITA; ENSOLI  BARBARA
[72] Inventors: ENSOLI BARBARA
[21] Application No.: NA
[22] Filed:  19981130 
[43] Published:  19990910 






The present invention refers to Tat as the active principale for a prophylactic 

and/or therapeutic vaccine against HIV infection, the progression towards AIDS and 

the development of tumors and other syndromes and symptoms in subjects infected by 

HIV. Tat is in biologically active form either as recombinant protein or peptide or 

as DNA. More particularly, the invention refers to a vaccine based on HIV-1 Tat as 

immunogen, inoculated as DNA and/or recombinant protein or as peptides, alone or in 

combination with other genes or viral gene products (Nef, Rev, Gag) or parts 

thereof, or in combination with various immuno modulant cytokines (IL-12, IL-15) 

or with the gene coding for an immuno modulant cytokine or part thereof. Tat, Nef, 

Rev, Gag and the immuno modulant cytokines are administrated both as a mixture of 

recombinant proteins, peptides or fusion proteins (Tat/Nef, Tat/Rev, Tat/Gag, 

Tat/IL-12, Tat/IL-15) or as plasmid DNA.
[52] US Class: 
[51] Int’l Class: A61P003704 A61K003900 A61K003800 C12Q000168 C12N000510 
C12N001549 C12N001509 C12P002108 A61P003500 A61K003921 C07K001416 
C12P002102 C07K000708 A61K004800 A61P003118 C12R000191 
[52] ECLA: A61K003921 C07K001416F K61K003800 K61K003900 K61K0039525 

M07K020700 M12N022100




[71] Applicant: MERCK  CO INC; 

VOLKIN DAVID B;  EVANS 

ROBERT K;  ULMER JEFFREY B;  
 . . .
[72] Inventors: VOLKIN, David, B.; 

EVANS, Robert, K.;  ULMER, 

Jeffrey, B.;  CAULFIELD,  
 . . .
[21] Application No.: NA
[22] Filed:  19980213 
[43] Published:  19980820 






The present invention relates to a novel vaccine formulation comprising nucleic 

acid molecules and a mineral-based adjuvant provided in a biologically effective 

concentration so as to improve induction of an immune response subsequent to 

vaccination which correlates to expression of one or more specific antigens encoded 

by the nucleic acid molecule.
[52] US Class: 
[51] Int’l Class: A61K004800 A61K0039145 A61K0039102 A61P003702 A61K004702 
A61K003939 A61K003921 A61P003500 A61P003112 A61K0039245 A61K003929 
[52] ECLA: A61K0039102 A61K0039145 A61K003921 A61K0039245 A61K003929B 

A61K003939 K61K003953 K61K0039555A K61K004800




[71] Applicant: MERCK  CO INC; 

SHIVER JOHN W JR;  DAVIES 

MARY ELLEN  M; FREED DANIEL 
 . . .
[72] Inventors: SHIVER, John, W., 

Jr.; DAVIES, Mary- Ellen, M.;

 FREED,  Daniel, C.; LIU,  
 . . .
[21] Application No.: NA
[22] Filed:  19980203 
[43] Published:  19980813 






Synthetic DNA molecules encoding HIV gag and modifications of HIV gag are provided. 

The codons of the synthetic molecules are codons preferred by the projected host 

cell. The synthetic molecules may be used as a polynucleotide vaccine which 

provides effective immunoprophylaxis against HIV infection through stimulation of 

neutralizing antibody and cell-mediated immunity.
[52] US Class: 
[51] Int’l Class: C07K001416 A61K003900 A61K003800 C12N001509 A61P004300 
A61K004800 C12N000704 A61P003118 A61P003704 C12R000192 
[52] ECLA: C07K001416B K61K003900 M07K020300 M07K020700 M07K031902
209            © 2008 MicroPatent, LLC
MicroPatent ReportWO1998034640A3
SYNTHETIC HIV GAG GENES

[71] Applicant: MERCK  CO INC; 

SHIVER JOHN W JR;  DAVIES 

MARY ELLEN  M; FREED DANIEL 
 . . .
[72] Inventors: SHIVER JOHN W JR; 

DAVIES MARY-ELLEN  M; FREED 

DANIEL C;  LIU MARGARET A;  
 . . .
[21] Application No.: NA
[22] Filed:  19980203 
[43] Published:  19981119 




[52] US Class: 
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Synthetic polynucleotides comprising a DNA sequence encoding a peptide or protein 

are provided. The DNA sequence of the synthetic polynucleotides comprise codons 

optimized for expression in a nonhomologous host. The invention is exemplified by 

synthetic DNA molecules encoding HIV envas well as modifications of HIV env. The 

codons of the synthetic molecules include the projected host cell’s preferred 

codons. The synthetic molecules provide preferred forms of foreign genetic material.

 The synthetic molecules may be used as a polynucleotide vaccine which provides 

immunoprophylaxis against HIV infection through neutralizing antibody and cell-

mediated immunity. This invention provides polynucleotides which, when directly 

introduced into a vertebrate in vivo, including mammals such as primates and humans,

 induces the expression of encoded proteins within the animal.
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Synthetic DNA molecules encoding HIV genes and modifications of HIV genes are 

provided. The codons of the synthetic molecules use codons preferred by the 

projected host cell. The synthetic molecules may be used as a polynucleotide 

vaccine which provides effective immunoprophylaxis against HIV infection through 

neutralizing antibody and cell-mediated immunity.
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This invention relates to a method of immunizing a vertebrate, comprising 

introducing into the vertebrate a DNA transcription unit which comprises DNA 

encoding a desired antigen or antigens. The uptake of the DNA transcription unit by 

a host vertebrate results in the expression of the desired antigen or antigens, 

thereby eliciting humoral or cell-mediated immune responses or both humoral and 

cell-mediated responses. The elicited humoral and cell-mediated response can 

provide protection against infection by pathogenic agents, provide an anti-tumor 

response, or provide contraception. The host can be any vertebrate, avian or mammal,

 including humans. 
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This invention relates to a method of immunizing a vertebrate, comprising 

introducing into the vertebrate a DNA transcription unit which comprises DNA 

encoding a desired antigen or antigens. The uptake of the DNA transcription unit by 

a host vertebrate results in the expression of the desired antigen or antigens, 

thereby eliciting humoral or cell-mediated immune responses or both humoral and 

cell-mediated responses. The elicited humoral and cell- mediated response can 

provide protection against infection by pathogenic agents, provide an anti-tumor 

response, or provide contraception. The host can be any vertebrate, avian or mammal,

 including humans.
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The invention provides a recombinant nucleic acid molecule which encodes a mutant 

HIV-1 gp120 envelope glycoprotein, vaccines comprising the mutant HIV-1 envelope 

glycoprotein, antibodies and methods of treating individuals.
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The invention disclosed includes a method for the production of attenuated human 

immunodeficiency viruses (HIV). This method includes the production of a plasmid 

having a proviral HIV genome including the env, nef, vif, and vpr genes, and 

deleting from the plasmid significant portions of at least three, and preferably 

all four genes, such that the resulting plasmid encodes an attenuated virus that 

exhibits cell-free infectivity and reduced syncytium formation ability. Also 

disclosed is a method for the prophylactic prevention of infection of a person by 

HIV which comprises the administration of a prophylactically effective amount of 

attenuated virus, a vaccine for such prophylactic prevention, a method of 

therapeutic treatment comprising the administration of a therapeutically effective 

amount of attenuated virus and a vaccine for therapeutic treatment.
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